<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004073.pub4" GROUP_ID="PREG" ID="379801092709253538" MERGED_FROM="" MODIFIED="2016-05-05 14:11:03 +0100" MODIFIED_BY="Leanne Jones" REVIEW_NO="0374" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2016-05-05 14:11:03 +0100" MODIFIED_BY="Leanne Jones">
<TITLE>Vitamin supplementation for preventing miscarriage</TITLE>
<CONTACT MODIFIED="2016-05-05 14:11:03 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="16423166684790351955100216211632" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Erika</FIRST_NAME><LAST_NAME>Ota</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>e-i@umin.ac.jp</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Nursing</DEPARTMENT><ORGANISATION>St. Luke's International University, Graduate School of Nursing Sciences</ORGANISATION><ADDRESS_1>10-1 Akashi-cho</ADDRESS_1><ADDRESS_2>Chuo-Ku</ADDRESS_2><CITY>Tokyo</CITY><ZIP>104-0044</ZIP><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>81-3-5550-2374</PHONE_1><FAX_1>81-3-5565-1626</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-05-05 14:11:03 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="44751567398680865467101027135524" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Olukunmi</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Balogun</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>omobolanle_balogun@yahoo.com</EMAIL_1><EMAIL_2>balogun-o@ncchd.go.jp</EMAIL_2><ADDRESS><DEPARTMENT>Department of Health Policy</DEPARTMENT><ORGANISATION>National Center for Child Health and Development</ORGANISATION><ADDRESS_1>Medical Building No. 2, Hongo Campus</ADDRESS_1><ADDRESS_2>2-10-1 Okura</ADDRESS_2><CITY>Tokyo</CITY><ZIP>157-8535</ZIP><REGION>Tokyo</REGION><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>+81 3 34160181</PHONE_1><FAX_1>+81 3 34172694</FAX_1></ADDRESS></PERSON><PERSON ID="z1506081438286289018552673476843" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katharina</FIRST_NAME><LAST_NAME>da Silva Lopes</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>katharina.dslopes@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Health Policy</DEPARTMENT><ORGANISATION>National Center for Child Health and Development</ORGANISATION><ADDRESS_1>2-10-1 Okura</ADDRESS_1><CITY>Tokyo</CITY><ZIP>157-8535</ZIP><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>+81 3 34160181</PHONE_1><FAX_1>+81 3 34172694</FAX_1></ADDRESS></PERSON><PERSON ID="16423166684790351955100216211632" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Erika</FIRST_NAME><LAST_NAME>Ota</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>e-i@umin.ac.jp</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Nursing</DEPARTMENT><ORGANISATION>St. Luke's International University, Graduate School of Nursing Sciences</ORGANISATION><ADDRESS_1>10-1 Akashi-cho</ADDRESS_1><ADDRESS_2>Chuo-Ku</ADDRESS_2><CITY>Tokyo</CITY><ZIP>104-0044</ZIP><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>81-3-5550-2374</PHONE_1><FAX_1>81-3-5565-1626</FAX_1></ADDRESS></PERSON><PERSON ID="z1505081418470244423350888149854" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yo</FIRST_NAME><LAST_NAME>Takemoto</LAST_NAME><POSITION>Clinical researcher</POSITION><EMAIL_1>yotakemoto0402@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>National Research Institute for Child Health and Development</ORGANISATION><ADDRESS_1>2-10-1 Okura, Setagaya-ku</ADDRESS_1><CITY>Tokyo</CITY><REGION>157-8535</REGION><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>81-3-3416-0181</PHONE_1></ADDRESS></PERSON><PERSON ID="16009" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alice</FIRST_NAME><LAST_NAME>Rumbold</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>alice.rumbold@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>The Robinson Research Institute</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Ground Floor, Norwich Centre</ADDRESS_1><ADDRESS_2>55 King William Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>SA 5006</ZIP><REGION>NT</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 8313 0136</PHONE_1><FAX_1>+61 8 8313 0427</FAX_1></ADDRESS></PERSON><PERSON ID="z1602011407360785807077808661797" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mizuki</FIRST_NAME><LAST_NAME>Takegata</LAST_NAME><POSITION>Researcher</POSITION><ADDRESS><DEPARTMENT>Department of Health Policy</DEPARTMENT><ORGANISATION>National Center for Child Health and Development</ORGANISATION><ADDRESS_1>2-10-1 Okura, Setagaya-ku</ADDRESS_1><CITY>Tokyo</CITY><ZIP>157-8535</ZIP><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>+81 3 3416018</PHONE_1><FAX_1>+81 3 34162222</FAX_1></ADDRESS></PERSON><PERSON ID="97A61E5482E26AA2012C734C90F3913F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rintaro</FIRST_NAME><LAST_NAME>Mori</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>rintaromori@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Health Policy</DEPARTMENT><ORGANISATION>National Center for Child Health and Development</ORGANISATION><ADDRESS_1>2-10-1 Okura</ADDRESS_1><ADDRESS_2>Setagaya-ku</ADDRESS_2><CITY>Tokyo</CITY><ZIP>157-0074</ZIP><REGION>Tokyo</REGION><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>+81 3 3416 0181</PHONE_1><PHONE_2>+81 90 9991 4823</PHONE_2><FAX_1>+81 3 3417 2694</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-02-19 09:27:35 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="11" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="6" MONTH="11" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-28 10:00:00 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-02-04 04:42:49 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>Conclusion unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-04-28 10:00:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>Search updated and 15 new trials included (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>, <LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK> ;<LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>); an additional nine trials have been excluded (<LINK REF="STD-Christian-2003" TYPE="STUDY">Christian 2003</LINK>; <LINK REF="STD-Chelchowska-2004" TYPE="STUDY">Chelchowska 2004</LINK>; <LINK REF="STD-Correia-1982" TYPE="STUDY">Correia 1982</LINK>; <LINK REF="STD-Hekmatdoost-2011" TYPE="STUDY">Hekmatdoost 2011</LINK>; <LINK REF="STD-Kaestel-2005" TYPE="STUDY">Kaestel 2005</LINK>; <LINK REF="STD-Potdar-2014" TYPE="STUDY">Potdar 2014</LINK>; <LINK REF="STD-Taylor-1982" TYPE="STUDY">Taylor 1982</LINK>; <LINK REF="STD-Wehby-2012" TYPE="STUDY">Wehby 2012</LINK>; <LINK REF="STD-Young-2015" TYPE="STUDY">Young 2015</LINK>). Three trials are awaiting classification (<LINK REF="STD-Adu_x002d_Afarwuah-2015" TYPE="STUDY">Adu-Afarwuah 2015</LINK>; <LINK REF="STD-Agarwal-2012a" TYPE="STUDY">Agarwal 2012a</LINK>; <LINK REF="STD-Prado-2015" TYPE="STUDY">Prado 2015</LINK>) and one is ongoing. (<LINK REF="STD-Johns-2004" TYPE="STUDY">Johns 2004</LINK>).</P>
<P>We have revised the outcomes to restrict the scope of the current update to look at miscarriage and miscarriage-related outcomes (<LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>).</P>
<P>Six new authors joined the team for the 2015/2016 update: Erika Ota, Olukunmi Balogun, Katharina da Silva Lopes, Yo Takemoto, Mizuki Takegata and Rintaro Mori. Three authors who contributed to previous versions of this review stepped down for this update: Ning Pan, Caroline Crowther and Philippa Middleton.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-03-11 14:02:47 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-11-16 11:07:12 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Substantive amendment and addition of a new author. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-11 14:02:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. 11 new studied included (<LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; Taylor 1982a; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>), 3 studies excluded (<LINK REF="STD-Feyi_x002d_Waboso-2005" TYPE="STUDY">Feyi-Waboso 2005</LINK>; <LINK REF="STD-Huybregts-2009" TYPE="STUDY">Huybregts 2009</LINK>; <LINK REF="STD-Shu-2002" TYPE="STUDY">Shu 2002</LINK>). Two new studies are awaiting classification (Chelchowska 2004b; Kubik 2004b) and two new ongoing trials were identified (Fall 2007b; <LINK REF="STD-Johns-2004" TYPE="STUDY">Johns 2004</LINK>; Sezikawa 2007).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-05 15:34:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-04-07 13:55:31 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-02-04 13:25:33 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-02-04 13:23:28 +0000" MODIFIED_BY="[Empty name]">
<NAME>The Grant of National Center for Child Health and Development 27B-10, 26A-5</NAME>
<COUNTRY CODE="JP">Japan</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-04-07 13:55:31 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-04-07 13:55:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>Japan Agency for Medical Research and Development</NAME>
<COUNTRY CODE="JP">Japan</COUNTRY>
<DESCRIPTION>
<P>The National Research Center for Child Health and Development, Japan receives government funding (AMED No.27300101) from the Clinical Research Program for Child Health and Development, AMED, Japan to support the Cochrane Pregnancy and Childbirth Satellite in Japan</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-05-05 12:04:55 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-04-20 19:23:51 +0100" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2016-02-02 05:57:58 +0000" MODIFIED_BY="[Empty name]">Vitamin supplementation for preventing miscarriage</TITLE>
<SUMMARY_BODY MODIFIED="2016-04-20 19:23:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>
<B>What is the issue?</B>
</P>
<P>Miscarriage occurs frequently among pregnant women but it is often difficult to know the factors responsible. Poor diet, without enough vitamins, has been associated with an increased risk of women losing their baby in early pregnancy. Does vitamin supplementation taken by women before pregnancy and during pregnancy decrease the risk of spontaneous miscarriage? Does supplementation improve maternal, birth and infant outcomes, and are there any side effects?</P>
<P>
<B>Why is this important?</B>
</P>
<P>Vitamin supplementation is commonly recommended for pregnant women and women planning to conceive. Considering the widespread use of vitamin supplementation before and during pregnancy, it is important to study the relation between vitamin supplementation and early pregnancy outcomes, particularly since the causes of miscarriage are unknown and the nutritional status of a mother can affect her baby&#8217;s development.</P>
<P>
<B>What evidence did we find?</B>
</P>
<P>This review included 40 randomised controlled trials involving 276,820 women and 278,413 pregnancies. Supplementing women with any vitamins does not reduce the number of women who have miscarriages. However, the risk for stillbirth was reduced among women receiving multivitamins plus iron and folic acid compared with iron and folate only groups. Although total fetal loss was lower in women who were given multivitamins without folic acid and multivitamins with or without vitamin A, these findings included one trial each with small numbers of women involved. Also, they include studies where the comparison groups included women receiving either vitamin A or placebo, and thus require caution in interpretation.</P>
<P>
<B>What does this mean?</B>
</P>
<P>Taking vitamin supplements before pregnancy or in early pregnancy may be beneficial; but this review did not show sufficient evidence that taking vitamin supplements prevents miscarriage.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-05-05 11:51:29 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-02-03 14:29:46 +0000" MODIFIED_BY="[Empty name]">
<P>Miscarriage is a common complication of pregnancy that can be caused by a wide range of factors. Poor dietary intake of vitamins has been associated with an increased risk of miscarriage, therefore supplementing women with vitamins either prior to or in early pregnancy may help prevent miscarriage.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-01 18:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>The objectives of this review were to determine the effectiveness and safety of any vitamin supplementation, on the risk of spontaneous miscarriage.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-02-08 11:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group Trials Register (6 November 2015) and reference lists of retrieved studies.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-04-20 10:54:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>All randomised and quasi-randomised trials comparing supplementation during pregnancy with one or more vitamins with either placebo, other vitamins, no vitamins or other interventions. We have included supplementation that started prior to conception, periconceptionally or in early pregnancy (less than 20 weeks' gestation).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-04-20 19:23:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>Three review authors independently assessed trials for inclusion, extracted data and assessed trial quality. We assessed the quality of the evidence using the GRADE approach. The quality of evidence is included for numerical results of outcomes included in the 'Summary of findings' tables.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-05-05 11:51:29 +0100" MODIFIED_BY="[Empty name]">
<P>We included a total of 40 trials (involving 276,820 women and 278,413 pregnancies) assessing supplementation with any vitamin(s) starting prior to 20 weeks' gestation and reporting at least one primary outcome that was eligible for the review. Eight trials were cluster-randomised and contributed data for 217,726 women and 219,267 pregnancies in total.</P>
<P>Approximately half of the included trials were assessed to have a low risk of bias for both random sequence generation and adequate concealment of participants to treatment and control groups.</P>
<P>
<B>Vitamin C supplementation</B>
</P>
<P>There was no difference in the risk of total fetal loss (risk ratio (RR) 1.14, 95% confidence interval (CI) 0.92 to 1.40, seven trials, 18,949 women; <I>high-quality evidence</I>); early or late miscarriage (RR 0.90, 95% CI 0.65 to 1.26, four trials, 13,346 women; <I>moderate-quality evidence</I>); stillbirth (RR 1.31, 95% CI 0.97 to 1.76, seven trials, 21,442 women; <I>moderate-quality evidence</I>) or adverse effects of vitamin supplementation (RR 1.16, 95% CI 0.39 to 3.41, one trial, 739 women; <I>moderate-quality evidence</I>) between women receiving vitamin C with vitamin E compared with placebo or no vitamin C groups. No clear differences were seen in the risk of total fetal loss or miscarriage between women receiving any other combination of vitamin C compared with placebo or no vitamin C groups.</P>
<P>
<B>Vitamin A supplementation</B>
</P>
<P>No difference was found in the risk of total fetal loss (RR 1.01, 95% CI 0.61 to 1.66, three trials, 1640 women; <I>low-quality evidence</I>); early or late miscarriage (RR 0.86, 95% CI 0.46 to 1.62, two trials, 1397 women; <I>low-quality evidence</I>) or stillbirth (RR 1.29, 95% CI 0.57 to 2.91, three trials, 1640 women; <I>low-quality evidence</I>) between women receiving vitamin A plus iron and folate compared with placebo or no vitamin A groups. There was no evidence of differences in the risk of total fetal loss or miscarriage between women receiving any other combination of vitamin A compared with placebo or no vitamin A groups.</P>
<P>
<B>Multivitamin supplementation</B>
</P>
<P>There was evidence of a decrease in the risk for stillbirth among women receiving multivitamins plus iron and folic acid compared iron and folate only groups (RR 0.92, 95% CI 0.85 to 0.99, 10 trials, 79,851 women; <I>high-quality evidence</I>). Although total fetal loss was lower in women who were given multivitamins without folic acid (RR 0.49, 95% CI 0.34 to 0.70, one trial, 907 women); and multivitamins with or without vitamin A (RR 0.60, 95% CI 0.39 to 0.92, one trial, 1074 women), these findings included one trial each with small numbers of women involved. Also, they include studies where the comparison groups included women receiving either vitamin A or placebo, and thus require caution in interpretation.</P>
<P>We found no difference in the risk of total fetal loss (RR 0.96, 95% CI 0.93 to 1.00, 10 trials, 94,948 women; <I>high-quality evidence</I>) or early or late miscarriage (RR 0.98, 95% CI 0.94 to 1.03, 10 trials, 94,948 women; <I>moderate-quality evidence</I>) between women receiving multivitamins plus iron and folic acid compared with iron and folate only groups.</P>
<P>There was no evidence of differences in the risk of total fetal loss or miscarriage between women receiving any other combination of multivitamins compared with placebo, folic acid or vitamin A groups.</P>
<P>
<B>Folic acid supplementation</B>
</P>
<P>There was no evidence of any difference in the risk of total fetal loss, early or late miscarriage, stillbirth or congenital malformations between women supplemented with folic acid with or without multivitamins and/or iron compared with no folic acid groups.</P>
<P>
<B>Antioxidant vitamins supplementation</B>
</P>
<P>There was no evidence of differences in early or late miscarriage between women given antioxidant compared with the low antioxidant group (RR 1.12, 95% CI 0.24 to 5.29, one trial, 110 women).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-04-20 19:23:42 +0100" MODIFIED_BY="Heather Maxwell">
<P>Taking any vitamin supplements prior to pregnancy or in early pregnancy does not prevent women experiencing miscarriage. However, evidence showed that women receiving multivitamins plus iron and folic acid had reduced risk for stillbirth. There is insufficient evidence to examine the effects of different combinations of vitamins on miscarriage and miscarriage-related outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-05-05 12:04:55 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-04-20 19:24:40 +0100" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2016-04-20 19:24:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Miscarriage can be caused by a wide range of factors, and determining the aetiology is often difficult given the variety of underlying mechanisms potentially responsible. Consideration of the timing of the miscarriage is also important, as diverse causes of miscarriage manifest at different periods of gestation. The most common causes include abnormal chromosomal rearrangements, endocrinological disorders and uterine abnormalities (<LINK REF="REF-Garrido_x002d_Gimenez-2015" TYPE="REFERENCE">Garrido-Gimenez 2015</LINK>). Early miscarriages are mostly associated with chromosomal abnormalities, defective placental development and maternal disease conditions; while late miscarriages are more likely due to structural problems of the uterus and/or cervix such as cervical incompetence. Women experiencing recurrent miscarriage often have an underlying medical condition such as autoimmune disease, i.e. systemic lupus erythematosus and antiphospholipid syndrome, or other blood clotting disorders such as hyperhomocysteinaemia (high levels of homocysteine in the blood) or another thrombophilia (<LINK REF="REF-Preston-1996" TYPE="REFERENCE">Preston 1996</LINK>). Other risk factors for miscarriage include higher maternal age at conception, multiple pregnancies and a history of previous miscarriage (Baba 2011; <LINK REF="REF-Garc_x0131_a_x002d_Engu_x0131_danos-2002" TYPE="REFERENCE">Garc&#305;a-Engu&#305;danos 2002</LINK>; <LINK REF="REF-Hure-2012" TYPE="REFERENCE">Hure 2012</LINK>). Behavioural factors including alcohol consumption (<LINK REF="REF-Maconochie-2007" TYPE="REFERENCE">Maconochie 2007</LINK>), smoking (Baba 2011; <LINK REF="REF-Hure-2012" TYPE="REFERENCE">Hure 2012</LINK>), use of illicit drugs (<LINK REF="REF-Garc_x0131_a_x002d_Engu_x0131_danos-2002" TYPE="REFERENCE">Garc&#305;a-Engu&#305;danos 2002</LINK>), and exposure to non-steroidal anti-inflammatory drugs (NSAIDs) around the time of conception are also suggested causes of miscarriage (<LINK REF="REF-Li-2003" TYPE="REFERENCE">Li 2003</LINK>; <LINK REF="REF-Nielsen-2001" TYPE="REFERENCE">Nielsen 2001</LINK>). While several factors may promote miscarriage, for a great proportion of women, no cause can be found.</P>
<P>In clinical practice, surgical and non-surgical interventions are used in the management of miscarriage. Bed rest, commonly prescribed for preventing miscarriage, is lacking proven benefit (Aleman 2005). Similarly, there is currently insufficient evidence on the benefit provided from the use of uterine muscle relaxant drugs (<LINK REF="REF-Lede-2005" TYPE="REFERENCE">Lede 2005</LINK>), Chinese herbal medicine (<LINK REF="REF-Li-2012" TYPE="REFERENCE">Li 2012</LINK>), hormones (<LINK REF="REF-Devaseelan-2010" TYPE="REFERENCE">Devaseelan 2010</LINK>; <LINK REF="REF-Haas-2013" TYPE="REFERENCE">Haas 2013</LINK>; <LINK REF="REF-Lim-1013" TYPE="REFERENCE">Lim 1013</LINK>; <LINK REF="REF-Morley-2013" TYPE="REFERENCE">Morley 2013</LINK>), and immunotherapy (<LINK REF="REF-Wong-2014" TYPE="REFERENCE">Wong 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-04-02 14:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>Vitamins are essential nutrients required in the body for numerous functions such as to ensure normal metabolism, physical growth and development as well as to prevent diseases. Based on evidence from observational studies, vitamin supplementation has been advocated for the prevention of miscarriage (<LINK REF="REF-Hasan-2009" TYPE="REFERENCE">Hasan 2009</LINK>; <LINK REF="REF-Maconochie-2007" TYPE="REFERENCE">Maconochie 2007</LINK>), most commonly folate and B vitamins. Due to consistent associations between pregnancy complications and decreased antioxidant defence and infections, it has been suggested that vitamin supplementation during pregnancy might provide protection against adverse pregnancy outcomes and may influence the risk of spontaneous miscarriage in women.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-04-20 19:24:40 +0100" MODIFIED_BY="Heather Maxwell">
<P>Vitamins are either water soluble &#8211; such as vitamin C and the B group vitamins (including folate) or fat soluble such as vitamins A, D, E and K. They may be obtained directly from the diet or in the form of dietary supplements of either individual vitamin or multivitamin preparations. Multivitamins contain a range of vitamins and minerals, usually in doses similar to the recommended dietary intakes.</P>
<P>The rationale for vitamin supplementation for the prevention of miscarriage is based on epidemiological studies linking healthy dietary patterns with reduced risk for miscarriage (<LINK REF="REF-Hasan-2009" TYPE="REFERENCE">Hasan 2009</LINK>; <LINK REF="REF-Maconochie-2007" TYPE="REFERENCE">Maconochie 2007</LINK>). Several studies have reported an association between certain vitamin deficiencies and adverse reproductive outcomes (<LINK REF="REF-George-2002" TYPE="REFERENCE">George 2002</LINK>; <LINK REF="REF-Guerra_x002d_Shinohara-2010" TYPE="REFERENCE">Guerra-Shinohara 2010</LINK>; <LINK REF="REF-H_x00fc_bner-2008" TYPE="REFERENCE">Hübner 2008</LINK>; <LINK REF="REF-Reznikoff_x002d_Eti_x00e9_vant-2002" TYPE="REFERENCE">Reznikoff-Etiévant 2002</LINK>). Nutritional mechanisms underlying this association include homocysteine metabolism and oxidative stress.</P>
<P>Homocysteine is an amino acid that is involved in several key metabolic processes, vital to ongoing cellular activity of the living organism. The metabolism of homocysteine is facilitated by B vitamins and folate. The concentration of homocysteine in the blood is determined by various dietary factors, including folate, vitamin B6 and vitamin B12. Disturbance of maternal and fetal homocysteine metabolism has been associated with various obstetric conditions including miscarriage (<LINK REF="REF-Hague-2003" TYPE="REFERENCE">Hague 2003</LINK>; <LINK REF="REF-Nelen-2000" TYPE="REFERENCE">Nelen 2000</LINK>), and hyperhomocysteinaemia is considered a risk factor for recurrent early pregnancy loss. Therefore, supplementation with B vitamins and folate may influence the risk of spontaneous miscarriage in women with recurrent miscarriage. Moreover, low serum vitamin B12 concentrations have been reported in women with recurrent miscarriage (<LINK REF="REF-H_x00fc_bner-2008" TYPE="REFERENCE">Hübner 2008</LINK>). Evidence on the effect of vitamin supplementation, particularly folic acid, on risk of miscarriage is still conflicting; however the few studies that have adjusted for confounding support a protective effect.</P>
<P>Oxidative stress is caused by an imbalance between pro-oxidants and antioxidants. Pro-oxidants act either by generating reactive oxygen species (ROS) or by inhibiting antioxidant systems. In living cells, ROS are formed continuously both from biochemical processes occurring in the body and in reaction to external factors. Excessive ROS production may however, overpower the body&#8217;s natural antioxidant defence system, creating an environment unsuitable for normal female reproductive processes (<LINK REF="REF-Al_x002d_Gubory-2010" TYPE="REFERENCE">Al-Gubory 2010</LINK>). A recent review of evidence from experimental and observational studies suggests that oxidative stress is an important cause in spontaneous and recurrent miscarriage (<LINK REF="REF-Agarwal-2012b" TYPE="REFERENCE">Agarwal 2012b</LINK>; <LINK REF="REF-Al_x002d_Gubory-2010" TYPE="REFERENCE">Al-Gubory 2010</LINK>; <LINK REF="REF-Gupta-2007" TYPE="REFERENCE">Gupta 2007</LINK>). Adequate maternal antioxidant status before and during pregnancy could prevent and control oxidative stress. Therefore, intake of antioxidant vitamins such as vitamin C and vitamin E may be an important factor to reduce the risk of miscarriage. In a population-based case-control study, vitamin supplementation (including vitamin C), and eating fresh fruits and vegetables daily were associated with reduced risk of miscarriage (<LINK REF="REF-Maconochie-2007" TYPE="REFERENCE">Maconochie 2007</LINK>). Another observational study demonstrated an association between the risk of spontaneous early miscarriage and dietary factors; poor intake of green vegetables, fruit and dairy products coupled with a high intake of fat was associated with a high risk of spontaneous miscarriage (<LINK REF="REF-Di-Cintio-2001" TYPE="REFERENCE">Di Cintio 2001</LINK>). There is limited information available about the impact of vitamins on the risk of early versus late miscarriage. However, dietary factors could theoretically influence structural abnormalities such as cervical incompetence. There is a growing body of research investigating the relationship between nutrition and placental development, fetal growth, pregnancy outcomes and adult diseases (<LINK REF="REF-McMillen-2008" TYPE="REFERENCE">McMillen 2008</LINK>; <LINK REF="REF-Meher-2015" TYPE="REFERENCE">Meher 2015</LINK>; <LINK REF="REF-Wu-2004" TYPE="REFERENCE">Wu 2004</LINK>). Therefore, adequate maternal nutrition, particularly vitamin intake, may be an important factor in preventing spontaneous miscarriage. Currently, little information is available about the most appropriate vitamin type or combination. Similarly, many commercially available vitamin preparations contain a range of combinations of vitamins. Therefore, this review will cover all vitamin types.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-04-07 11:58:35 +0100" MODIFIED_BY="[Empty name]">
<P>Vitamin supplementation is frequently recommended for pregnant women and women planning to conceive. The documented benefits of supplementation relate mainly to the lowered risk of congenital anomalies such as neural tube defects (<LINK REF="REF-Hovdenak-2012" TYPE="REFERENCE">Hovdenak 2012</LINK>; <LINK REF="REF-MRC-Vitamin-Study-Research-Group-1991" TYPE="REFERENCE">MRC Vitamin Study Research Group 1991</LINK>). Given the widespread vitamin supplementation before and during pregnancy, studying the relationship between this common exposure and early pregnancy outcomes is of great value, particularly since the causes of miscarriage are unknown and this exposure is known to affect specific developmental processes.</P>
<P>This is an update of a Cochrane review first published in 2005 and previously updated in 2011. The previously updated review included 28 trials involving 96,674 women (98,267 pregnancies (<LINK REF="REF-Rumbold-2011" TYPE="REFERENCE">Rumbold 2011</LINK>)). Based on available evidence, <LINK REF="REF-Rumbold-2011" TYPE="REFERENCE">Rumbold 2011</LINK> concluded that taking any vitamin supplements prior to pregnancy or in early pregnancy does not prevent women from experiencing miscarriage or stillbirth. However, there is insufficient evidence to examine the effects of different combinations of vitamins on miscarriage. In the current review, we examined the effect of different vitamin combinations on the risk of miscarriage. The scope of the current update has been restricted to look at miscarriage and miscarriage-related outcomes.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-04-20 19:25:02 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>To determine the effectiveness and safety of any vitamin supplementation taken by women prior to conception, periconceptionally and in early pregnancy on the risk of spontaneous miscarriage.</LI>
<LI>If vitamins are effective, to determine which of these agents are best and to compare vitamins with other interventions.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2016-04-20 19:27:05 +0100" MODIFIED_BY="Heather Maxwell">
<SELECTION_CRITERIA MODIFIED="2016-04-20 19:25:11 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2016-04-20 19:25:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>All randomised trials (including individual- and cluster-randomised) and quasi-randomised trials comparing one or more vitamins with either placebo, other vitamins, no vitamins or other interventions, prior to conception, periconceptionally or in early to mid pregnancy. Cross-over trials were not included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-04-20 19:25:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pregnant women (less than 20 weeks' gestation) or women in the reproductive age group planning on becoming pregnant in the near future, regardless of whether they are at low or high risk of having a miscarriage. No restrictions were placed on the age of participants or past obstetric history.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-04-20 19:25:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>Comparisons of specific vitamin(s), alone or in combination with other agents with either placebo, other vitamin(s), no vitamin(s) or other interventions for the prevention of miscarriage, either in areas where there is an inadequate dietary intake or where there is a presumed adequate intake of that vitamin(s).</P>
<P>The review authors deemed it important to include any supplementation trials, where supplementation began prior to 20 weeks' gestation, and where at least one miscarriage-related outcome as specified in the review was reported, even if the intervention was not specifically for the prevention of miscarriage. We excluded trials where the onset of supplementation occurred definitely after 20 weeks' gestation or where it was reported that the majority of women commenced supplementation after 20 weeks' gestation. We included trials where the onset of supplementation occurred both prior to and after 20 weeks' gestation, and when it could not be established whether the majority of the women started supplementation prior to 20 weeks' gestation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-04-07 12:00:08 +0100" MODIFIED_BY="[Empty name]">
<P>The scope of the current update has been restricted to look at miscarriage and miscarriage-related outcomes.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-04-02 14:47:06 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total fetal loss, defined as the combined numbers of early miscarriage (spontaneous pregnancy loss less than 12 weeks' gestation), late miscarriage (spontaneous pregnancy loss greater than or equal to 12 and less than 24 weeks), and stillbirth (pregnancy loss at greater than or equal to 24 weeks).</LI>
<LI>Early or late miscarriage.</LI>
</OL>
<P>To overcome wide variation in the definitions of miscarriage and stillbirth between studies, we included the combined outcome 'total fetal loss' in the review.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-04-02 14:47:06 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Stillbirth.</LI>
<LI>Congenital malformations.</LI>
<LI>Adverse effects of vitamin supplementation sufficient to stop supplementation, such as manifestations of hypervitaminosis, headache, nausea, vomiting, diarrhoea</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-04-13 10:01:35 +0100" MODIFIED_BY="[Empty name]">
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-04-13 10:01:35 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (6 November 2015).</P>
<P>The Register is a database containing over 21,000 reports of controlled trials in the field of pregnancy and childbirth. For full search methods used to populate the Pregnancy and Childbirth Group's Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this link to the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A> in <I>The Cochrane Library</I> and select the &#8216;<I>
<B>Specialized Register</B> </I>&#8217; section from the options on the left side of the screen.</P>
<P>Briefly, the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE (Ovid);</LI>
<LI>weekly searches of Embase (Ovid);</LI>
<LI>monthly searches of CINAHL (EBSCO);</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth Group review topic (or topics), and is then added to the Register. The Trials Search Co-ordinator searches the Register for each review using this topic number rather than keywords. This results in a more specific search set which has been fully accounted for in the relevant review sections (<LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK>; <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK>; <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>; <LINK TAG="ONGOING_STUDIES" TYPE="SECTION">Ongoing studies</LINK>).</P>
<P>[We carried out additional author searching in an earlier version of this review (<LINK REF="REF-Rumbold-2005" TYPE="REFERENCE">Rumbold 2005</LINK>), <I>see </I>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details]</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-02-08 11:46:48 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of retrieved studies.</P>
<P>We did not apply any language or date restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-04-20 19:27:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>For methods used in the previous version of this review, see <LINK REF="REF-Rumbold-2011" TYPE="REFERENCE">Rumbold 2011</LINK>.</P>
<P>For this update, the following methods were used for assessing the 90 reports that were identified as a result of the updated search.</P>
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<STUDY_SELECTION MODIFIED="2016-04-19 11:16:26 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently assessed all the potential studies identified as a result of the search strategy for inclusion. Disagreements were resolved through discussion and, when required, we consulted a third person. We created a study flow diagram to map out the number of records identified, included and excluded.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-04-20 19:25:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>We collected data from the selected studies using a pre-designed data extraction form. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion. If discrepancies could not be resolved, we consulted a third review author. We entered data into Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and checked for accuracy. When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-04-20 19:26:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreement by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We describe for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or supplied by the trial authors, we re-included missing data in the analyses which we undertook.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We describe for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook </I>(<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1510061244164197642741724712694&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of the quality of the evidence using the GRADE approach</HEADING>
<P>For this update, we assessed the quality of the evidence using the GRADE approach as outlined in the <A HREF="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html">GRADE handbook</A> in order to assess the quality of the body of evidence relating to the following outcomes in the comparisons: 1) vitamin C and vitamin E versus placebo, 2) vitamin A plus iron plus folate versus iron plus folate and 3) multivitamin plus iron plus folate versus iron plus folate.</P>
<OL>
<LI>Total fetal loss, defined as the combined numbers of early miscarriage (spontaneous pregnancy loss less than 12 weeks&#8217; gestation), late miscarriage (spontaneous pregnancy loss greater than or equal to 12 and less than 24 weeks), and stillbirth (pregnancy loss at greater than or equal to 24 weeks).</LI>
<LI>Early or late miscarriage.</LI>
<LI>Stillbirth.</LI>
<LI>Adverse effects of vitamin supplementation sufficient to stop supplementation.</LI>
</OL>
<P>We used the <A HREF="http://www.guidelinedevelopment.org/">GRADEpro</A> Guideline Development Tool to import data from Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) in order to create &#8217;Summary of findings&#8217; tables. A summary of the intervention effect and a measure of quality for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence was downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-04-20 19:26:23 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as summary risk ratio (RR) with 95% confidence intervals (CI).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we planned to use the mean difference (MD) if outcomes were measured in the same way between trials and, if appropriate, the standardised mean difference (SMD) to combine trials that measured the same outcome, but used different methods.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-04-20 19:26:33 +0100" MODIFIED_BY="Heather Maxwell">
<P>Where trials recruited women prior to becoming pregnant, we reported the denominators for each trial as all women randomised; or where there was accurate information about the number of women in each trial who became pregnant, we reported the denominators as the number of women randomised with confirmed pregnancy.</P>
<P>We included all included trials in the initial analysis which we performed by any vitamin to include all vitamin combinations and then by individual vitamin type.</P>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We included cluster-randomised trials in the analyses along with individually-randomised trials. We used the effect estimates and uncertainty range from the cluster trials to perform the meta-analysis using the generic inverse variance approach for the meta-analysis of dichotomous outcomes where trials using cluster-randomisation techniques were included (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>).</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-04-20 19:26:40 +0100" MODIFIED_BY="Heather Maxwell">
<P>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-04-20 19:26:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>We applied tests of heterogeneity between trials to assess the significance of any differences between trials in the analyses. We regarded heterogeneity as substantial if the I² was greater than 30% and either the Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. 
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-02-03 14:59:12 +0000" MODIFIED_BY="[Empty name]">
<P>We investigated reporting biases (such as publication bias) using funnel plots. We assessed funnel plot asymmetry visually. If asymmetry was suggested by a visual assessment, we performed exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-04-20 19:26:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. We treated the random-effects summary as the average of the range of possible treatment effects and we discuss the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. Where we used random-effects analyses, we have presented the results as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-04-20 19:26:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Had we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses and to consider whether an overall summary was meaningful, and if it was, to use random-effects analysis to produce it.</P>
<P>In this update, we were not able to carry out the following subgroup analyses:</P>
<OL>
<LI>the dose of vitamin(s) (below or above the recommended dietary intake); and the duration of vitamin usage, based on time of trial entry: before pregnancy, &lt; 12 weeks&#8217; gestation, between 12-20 weeks&#8217; gestation or &#8217;mixed&#8217;, which included women enrolled before and after 20 weeks&#8217; gestation;</LI>
<LI>their risk of spontaneous miscarriage (high risk defined as the presence of medical conditions associated with miscarriage such as hyperhomocysteinaemia, thrombophilia, antiphospholipid syndrome, systemic lupus erythematosus; low risk defined as none of the above conditions); their risk of recurrent miscarriage (high risk defined as two or more previous consecutive spontaneous miscarriages, and/or the presence of medical conditions associated with miscarriage such as hyperhomocysteinaemia, thrombophilia, antiphospholipid syndrome, systemic lupus erythematosus; low risk defined as none of the above conditions);</LI>
<LI>low or adequate dietary vitamin intake at trial entry (low intake defined as less than the recommended daily intake for each vitamin in that setting, as measured by dietary questionnaire).</LI>
</OL>
<P>We would have included all outcomes in the subgroup analysis.</P>
<P>We planned to assess subgroup differences by interaction tests available within RevMan (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1510061244164197642741724712694&amp;format=REVMAN#REF-RevMan-2014">RevMan 2014</A>) and to report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-04-20 19:27:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out sensitivity analysis to explore the effects of trial quality and type of randomisation on the primary outcomes related to fetal loss (total fetal loss and early or late miscarriage). We included only trials with 'adequate' rating on allocation concealment, We considered these trials to be of high quality. We also carried out sensitivity analysis by excluding cluster-randomised trials and comparing the results of cluster-randomised trials with the individually-randomised trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-05-05 11:59:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-04-20 19:27:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>
<I>See</I> tables <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details of individual studies.</P>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-04-20 19:27:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>For the 2016 update, we included a total of 40 trials (involving 276,820 women) assessing supplementation with specific vitamin(s) starting prior to 20 weeks' gestation. Many of the trials assessed interventions not specifically for the prevention of miscarriage, however, the authors included any supplementation trials, where supplementation began prior to 20 weeks' gestation, and where at least one miscarriage-related outcome as specified in the review was reported.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The demographic and obstetric characteristics of the women varied widely between the trials (see table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The 40 included trials contributed data for analysis from 276,820 women. Eight of the 40 included studies were cluster-randomised trials including 217,726 women (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). Two of the trials from the previous version of this review (one cluster (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>), and one small trial (<LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>)) included women who were pregnant more than once in the study period; resulting in data contributing to 59,146 pregnancies for the individual trials and 219,267 pregnancies from the cluster trials. Five trials enrolled women prior to conception (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>) and asked women to continue taking the supplements up until the second or third missed menstrual period. One trial (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>) supplemented women from before conception, through pregnancy and postpartum for a total of 3.5 years postpartum. Another eight trials enrolled women in the first trimester (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>), and 24 trials in early to mid pregnancy (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). Some of the trials enrolling women in early to mid pregnancy included women enrolled at or after 20 weeks' gestation (<LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). One trial (<LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>), enrolled 41,839 women at 'any gestational age', although more than 70% of the women were enrolled in the first or second trimester.</P>
<P>Two trials (<LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>) involved vitamin A supplementation in women seropositive for the Human Immunodeficiency Virus (HIV); one trial (<LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>) involved only women with clinical risk factors for pre-eclampsia, while one trial (<LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>), limited the eligibility to women with type1 diabetes. <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK> involved only nulliparous women.</P>
<P>Baseline characteristics of women enrolled in the intervention group and control group were comparable in all the trials except two (<LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>). In <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>, there was a slightly higher proportion of women with multiple pregnancies in the placebo group; while in <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>, women in the control group tended to be poorer and less educated, while women in the intervention group had larger households and used more preventive measures against malaria.</P>
<P>The trials were conducted in both resource-rich and resource-poor countries including the United States (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>), Canada (<LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>), the United Kingdom (<LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>), Hungary (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>), Tanzania (<LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>), Nigeria (<LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>), Burkino Faso (<LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>), Japan (<LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>), India (<LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>), Nepal (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>), the Republic of Ireland (<LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>), Uganda (<LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>), Bangladesh (<LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>, <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>), China (<LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>), Niger (<LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>), Pakistan (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>), Australia (<LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>), Brazil (<LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>), Mexico (<LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>), Malawi (<LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>), Indonesia (<LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>), and South Africa (<LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>). One trial involved 33 international centres (<LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>) and another trial was a multi-country study involving India, Peru, South Africa and Vietnam (<LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The 40 trials assessed a range of vitamin supplements, alone or in combination with other supplements. The vitamins included vitamin A, alone or with iron, folic acid, multivitamins, or &#946;-carotene (<LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>); vitamin C with or without multivitamins or vitamin E (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>); folic acid with or without multivitamins and/or iron (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>); antioxidant vitamins (<LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>); multivitamins with/without folic acid, vitamin A, vitamin E or iron and folic acid (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>); and multivitamins alone (<LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>). The doses of vitamins were similar for the vitamin C supplementation trials (range 400 mg to 1000 mg). However, they varied widely between trials for the folic acid (range 0.3 mg to 10 mg), multivitamins and vitamin A trials (range 5000 international units (IU) to 23,300 IU). The components of MMN supplementation were different among the trials but all of them contained iron and folate in the MMN supplements. All supplements were taken orally from the enrolment until delivery or up to 3.5 years postpartum.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Main outcomes</HEADING>
<P>Thirty-six trials reported pregnancy loss as miscarriage or stillbirth. The outcome 'total fetal loss' included both miscarriage or stillbirth, and overcame problems with different definitions of miscarriage and stillbirth. There was no consistency amongst trials with regards to the definition of miscarriage. For some trials, miscarriage was considered to occur up until 26 or 28 weeks' gestation, while other studies reported miscarriage as pregnancy loss prior to 20 weeks' gestation. Other studies did not specify their definition of miscarriage or stillbirth.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>There was no consistency amongst trials with regards to the definition of stillbirth. In some trials, stillbirth was considered as pregnancy loss greater than or equal to 20 weeks' gestation, while some trials considered stillbirth as pregnancy loss beyond 24 weeks' gestation. Thirty trials reported stillbirth as an outcome. Only one trial (<LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>) reported on adverse effects of vitamin sufficient to stop supplementation, while congenital malformations was reported in nine trials (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-04-20 19:27:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>We excluded 48 trials, of which 16 trials reported no clinically relevant data, or data in a format suitable for inclusion (<LINK REF="STD-Christian-2003" TYPE="STUDY">Christian 2003</LINK>; <LINK REF="STD-Chelchowska-2004" TYPE="STUDY">Chelchowska 2004</LINK>; <LINK REF="STD-Correia-1982" TYPE="STUDY">Correia 1982</LINK>; <LINK REF="STD-Hibbard-1969" TYPE="STUDY">Hibbard 1969</LINK>; <LINK REF="STD-Laurence-1981" TYPE="STUDY">Laurence 1981</LINK>; <LINK REF="STD-Lira-1989" TYPE="STUDY">Lira 1989</LINK>; <LINK REF="STD-Meirinho-1987" TYPE="STUDY">Meirinho 1987</LINK>; <LINK REF="STD-Mock-2002" TYPE="STUDY">Mock 2002</LINK>; <LINK REF="STD-Moldenhauer-2002" TYPE="STUDY">Moldenhauer 2002</LINK>; <LINK REF="STD-Semba-2001" TYPE="STUDY">Semba 2001</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Tanumihardjo-2002" TYPE="STUDY">Tanumihardjo 2002</LINK>; <LINK REF="STD-Taylor-1982" TYPE="STUDY">Taylor 1982</LINK>; <LINK REF="STD-Thauvin-1992" TYPE="STUDY">Thauvin 1992</LINK>; <LINK REF="STD-Villamor-2002" TYPE="STUDY">Villamor 2002</LINK>; <LINK REF="STD-Vutyavanich-1995" TYPE="STUDY">Vutyavanich 1995</LINK>). Seven trials did not clearly report the gestational age when supplementation was started (<LINK REF="STD-Biswas-1984" TYPE="STUDY">Biswas 1984</LINK>; <LINK REF="STD-Fletcher-1971" TYPE="STUDY">Fletcher 1971</LINK>; <LINK REF="STD-Hampel-1974" TYPE="STUDY">Hampel 1974</LINK>; <LINK REF="STD-Lumeng-1976" TYPE="STUDY">Lumeng 1976</LINK>; <LINK REF="STD-Schuster-1984" TYPE="STUDY">Schuster 1984</LINK>; <LINK REF="STD-Trigg-1976" TYPE="STUDY">Trigg 1976</LINK>; <LINK REF="STD-Young-2015" TYPE="STUDY">Young 2015</LINK>), and for two trials, the majority of women were enrolled after 20 weeks and did not report outcomes separately for women starting supplementation prior to 20 weeks (<LINK REF="STD-Ferguson-1955" TYPE="STUDY">Ferguson 1955</LINK>; <LINK REF="STD-Giles-1971" TYPE="STUDY">Giles 1971</LINK>). Thirteen trials (<LINK REF="STD-Baumslag-1970" TYPE="STUDY">Baumslag 1970</LINK>; <LINK REF="STD-Blot-1981" TYPE="STUDY">Blot 1981</LINK>; <LINK REF="STD-Chanarin-1968" TYPE="STUDY">Chanarin 1968</LINK>; <LINK REF="STD-Colman-1974" TYPE="STUDY">Colman 1974</LINK>; <LINK REF="STD-Coutsoudis-1999" TYPE="STUDY">Coutsoudis 1999</LINK>; <LINK REF="STD-Dawson-1962" TYPE="STUDY">Dawson 1962</LINK>; <LINK REF="STD-Edelstein-1968" TYPE="STUDY">Edelstein 1968</LINK>; <LINK REF="STD-Feyi_x002d_Waboso-2005" TYPE="STUDY">Feyi-Waboso 2005</LINK>; <LINK REF="STD-Hankin-1966" TYPE="STUDY">Hankin 1966</LINK>; <LINK REF="STD-Kaestel-2005" TYPE="STUDY">Kaestel 2005</LINK>; <LINK REF="STD-Marya-1981" TYPE="STUDY">Marya 1981</LINK>; <LINK REF="STD-Metz-1965" TYPE="STUDY">Metz 1965</LINK>; <LINK REF="STD-Owen-1966" TYPE="STUDY">Owen 1966</LINK>) reported supplementation after 20 weeks' gestation. One trial (<LINK REF="STD-Ross-1985" TYPE="STUDY">Ross 1985</LINK>) did not specify the contents of the supplements; in five trials all women were given a vitamin supplement (<LINK REF="STD-Hekmatdoost-2011" TYPE="STUDY">Hekmatdoost 2011</LINK>; <LINK REF="STD-Hunt-1984" TYPE="STUDY">Hunt 1984</LINK>; <LINK REF="STD-Huybregts-2009" TYPE="STUDY">Huybregts 2009</LINK>; <LINK REF="STD-Shu-2002" TYPE="STUDY">Shu 2002</LINK>; <LINK REF="STD-Wehby-2012" TYPE="STUDY">Wehby 2012</LINK>); one trial was a food intervention (<LINK REF="STD-Potdar-2014" TYPE="STUDY">Potdar 2014</LINK>) and two were non-randomised (<LINK REF="STD-Smithells-1981" TYPE="STUDY">Smithells 1981</LINK>; <LINK REF="STD-Ulrich-1999" TYPE="STUDY">Ulrich 1999</LINK>).</P>
<P>Three other trials (<LINK REF="REF-Beazley-2005" TYPE="REFERENCE">Beazley 2005</LINK>; <LINK REF="REF-Chaudhuri-1969" TYPE="REFERENCE">Chaudhuri 1969</LINK>; <LINK REF="REF-Rivas_x002d_Echeverria-2000" TYPE="REFERENCE">Rivas-Echeverria 2000</LINK>) supplemented women for the prevention of pre-eclampsia, and did not report any outcomes related to pregnancy loss. These trials are covered in the Cochrane review '<I>Antioxidants for preventing pre-eclampsia</I>' (<LINK REF="REF-Rumbold-2008" TYPE="REFERENCE">Rumbold 2008</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-04-20 19:28:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> illustrate that the trials were of variable quality. Two trials (<LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>) used quasi-random allocation methods involving alternate allocation of participants. Similarly, eight trials (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>) used cluster randomisation.</P>
<ALLOCATION MODIFIED="2016-04-07 12:45:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Sequence generation:</I> 25 trials adequately randomised the participants to the intervention and control groups and were judged to be of low risk of bias (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). The method used for random sequence generation was unclear in 13 trials (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>), because methodological details were not reported or not clearly described. The remaining two trials <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK> and <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK> used quasi-randomised methods and were rated as high risk of bias for sequence generation.</P>
<P>
<I>Allocation concealment: </I>20 trials were assessed to have a low risk of bias for adequate concealment of participants to treatment and control groups (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). In 18 trials the method for allocation concealment was not described or not clearly described (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>). In two trials, allocation was not concealed and therefore judged as high risk of bias (<LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-04-07 12:46:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Participants and personnel: </I>28 trials were assessed as having a low risk of performance bias and reported blinding of participants and personnel to the treatment allocation (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). Another 11 trials were judged to have an unclear risk of bias because no or not enough information were provided (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>). <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK> was rated as high risk of bias as personnel (but not participants) were aware of participants' allocation due to the different appearance of the supplements.</P>
<P>
<I>Outcome assessment:</I> blinding of outcome assessors was clearly stated in 14 trials (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>) and unclear in 23 trials (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). In <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK> and <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK> outcome assessors were not blinded to the allocation code and the trials were rated as high risk of detection bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-04-07 12:47:20 +0100" MODIFIED_BY="[Empty name]">
<P>Loss to follow-up ranged from no loss at all in <LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK> to over 20% in <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK> and <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>. Incomplete outcome data was judged low risk of bias in 21 trials and high in nine trials. Ten trials were rated as unclear risk of bias due to missing information about loss of follow-up.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-04-03 01:10:13 +0100" MODIFIED_BY="[Empty name]">
<P>Eighteen trials were considered to have a low risk of reporting bias. Another 20 trials were assessed as unclear risk of bias because of unavailability of trial registration or protocol (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>), variations between the protocol and the publication (<LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>), due to insufficient details provided about methods or selective reporting (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>; <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>), variations of information between serial publications (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>), or the trial was stopped before completion (<LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>). The remaining two trials were at high risk of reporting bias; in <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>, not all outcomes were reported for all treatment groups and in <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>, fewer outcomes were stated in the trial registration compared with the report.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-04-20 19:28:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>In 18 trials, other sources of bias were not detected and these trials were rated as low risk of bias. Fourteen trials provided only limited methodological details to exclude other sources of bias and were judged as unclear (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>) as well as <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>, were participants in the control and intervention group slightly differed in systolic blood pressure at baseline. Additionally, <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK> was rated as unclear due to an imbalanced number of excluded clusters across the intervention groups, which may have been due to important baseline differences. The remaining eight trials were at high risk of bias. In <LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>, the distribution of study participants across the urban and rural areas is unclear from the text and no adjustments were made for cluster design. In <LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>, no placebo was used in the control group. Two trials (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>) used the total number of pregnancies during the study period as dominator and not the total number or randomised women. In <LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK> and <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>, the trials were terminated at an earlier stage and in <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK> the outcomes resulted from an interim analysis. In <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>, the participants in the control and interventions groups differed substantially in their baseline characteristics.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-05-05 11:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> for each of the main comparisons. The quality of evidence is included for numerical results of outcomes included in the 'Summary of findings' tables. We have included 40 trials, involving 276,820 women and 278,413 pregnancies. One trial (<LINK REF="STD-Jauniaux-2004" TYPE="STUDY">Jauniaux 2004</LINK>) contributed no outcome data because it was stopped early and withdrawn. Thus, 39 trials contributed data to our analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin C supplementation</HEADING>
<P>The trials involving vitamin C supplementation included the following interventions: vitamin C plus multivitamins versus placebo plus multivitamins (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>; <LINK REF="STD-Hans-2010" TYPE="STUDY">Hans 2010</LINK>), vitamin C and vitamin E supplementation versus placebo (<LINK REF="STD-Chappell-1999" TYPE="STUDY">Chappell 1999</LINK>; <LINK REF="STD-McCance-2010" TYPE="STUDY">McCance 2010</LINK>; <LINK REF="STD-Poston-2006" TYPE="STUDY">Poston 2006</LINK>; <LINK REF="STD-Roberts-2010" TYPE="STUDY">Roberts 2010</LINK>; <LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>; <LINK REF="STD-Spinnato-2007" TYPE="STUDY">Spinnato 2007</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>), and vitamin C alone versus no supplement or placebo (<LINK REF="STD-Hemmi-2003" TYPE="STUDY">Hemmi 2003</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>There was no difference in the risk of <B>total fetal loss</B> between women receiving:</P>
<OL>
<LI>vitamin C with vitamin E (risk ratio (RR) 1.14, 95% confidence interval (CI) 0.92 to 1.40, seven trials, 18,949 women; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <I>high-quality evidence</I>);</LI>
<LI>vitamin C alone (RR 1.28, 95% CI 0.58 to 2.83, two trials, 224 women; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>);</LI>
<LI>vitamin C with multivitamins (RR 1.32, 95% CI 0.63 to 2.77, one trial, 406 women; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>);</LI>
</OL>
<P>compared with placebo or no vitamin C groups.</P>
<P>Similarly, we found no overall difference in the risk for <B>early or late miscarriage</B> between women receiving:</P>
<OL>
<LI>vitamin C with vitamin E (RR 0.97, 95% CI 0.70 to 1.34, five trials, 15,882 women; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <I>moderate-quality evidence</I>);</LI>
<LI>vitamin C alone (RR 1.17, 95% CI 0.52 to 2.65, two trials, 224 women; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>);</LI>
<LI>vitamin C with multivitamins (RR 1.19, 95% CI 0.79 to 1.79, two trials, 790 women; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>There was no difference in the risk of <B>stillbirth</B> for women receiving:</P>
<OL>
<LI>vitamin C with vitamin E (RR 1.24, 95% CI 0.92 to 1.68, seven trials, 18,906 women; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <I>moderate-quality evidence</I>);</LI>
<LI>vitamin C alone (RR 3.00, 95% CI 0.12 to 72.77, one trial, 200 women; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>);</LI>
</OL>
<P>compared with placebo or no vitamin C groups. We found no difference in the risk of <B>congenital malformations</B> (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) or <B>adverse effects of vitamin supplementation </B>(RR 1.16, 95% CI 0.39 to 3.41, one trial, 739 women; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <I>moderate-quality evidence</I>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vitamin A supplementation</HEADING>
<P>The trials involving vitamin A supplementation included the following interventions: vitamin A and/or beta-carotene versus placebo (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>), vitamin A with or without multivitamins versus multivitamins (excluding vitamin A) or placebo (<LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>), and vitamin A plus iron and folic acid versus iron and folic acid (<LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Van-den-Broek-2006" TYPE="STUDY">Van den Broek 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>We found no difference in the risk of <B>total fetal loss</B> between women receiving:</P>
<OL>
<LI>vitamin A plus iron and folate (RR 1.01, 95% CI 0.61 to 1.66, three trials, 1640 women; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <I>low-quality evidence</I>);</LI>
<LI>vitamin A alone (RR 1.05, 95% CI 0.90 to 1.23, three trials, 52,480 women; Tau² = 0.01, I² = 73% <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>);</LI>
<LI>beta-carotene alone (RR 1.02, 95% CI 0.98 to 1.07, two trials, 51,163 women; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>);</LI>
<LI>vitamin A or beta-carotene (RR 1.05, 95% CI 0.91 to 1.21, one trial, 17,373 women; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>);</LI>
<LI>vitamin A with or without multivitamin (RR 0.80, 95% CI 0.53 to 1.21, one trial, 1074 women; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>);</LI>
</OL>
<P>compared with placebo or no vitamin A groups.</P>
<P>The heterogeneity in <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> seemed to have been contributed by combining two cluster-randomised trials and one individually-randomised trial. Heterogeniety was no longer present when the individually-randomised trial was excluded. However, this did not change the conclusion of no significant difference between vitamin A and no vitamin A groups.</P>
<P>There was no evidence of a difference in the risk for <B>early or late miscarriage</B> between women receiving:</P>
<OL>
<LI>vitamin A plus iron and folate (RR 0.86, 95% CI 0.46 to 1.62, two trials, 1397 women; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <I>low-quality evidence</I>);</LI>
<LI>vitamin A alone (RR 0.98, 95% CI 0.92 to 1.04, one trial, 39,668 women; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>);</LI>
<LI>beta-carotene alone (RR 1.00, 95% CI 0.94 to 1.06, one trial, 39,860 women; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>);</LI>
<LI>vitamin A with or without multivitamin (RR 0.76, 95% CI 0.37 to 1.55, one trial, 1075 women; <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>);</LI>
</OL>
<P>compared with placebo or no vitamin A groups.</P>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>There was no difference in the risk for <B>stillbirth</B> for the following supplementation treatments:</P>
<OL>
<LI>vitamin A plus iron and folate (RR 1.29, 95% CI 0.57 to 2.91, three trials, 1640 women; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <I>low-quality evidence</I>);</LI>
<LI>vitamin A alone (RR 0.95, 95% CI 0.86 to 1.06, one trial, 39,668 women; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>);</LI>
<LI>beta-carotene alone (RR 1.09, 95% CI 0.98 to 1.20, one trial, 39,860 women; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>);</LI>
<LI>vitamin A with or without multivitamin (RR 1.04, 95% CI 0.60 to 1.79, one trial, 1075 women; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>);</LI>
</OL>
<P>compared with placebo or no vitamin A groups. <B>Congenital malformations</B> and <B>adverse effects of vitamin supplementation</B> were not reported by trials included in these analyses.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Multivitamin supplementation</HEADING>
<P>The trials involving multivitamin supplementation included the following interventions: multivitamins with or without folic acid versus no multivitamins or folic acid (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>); multivitamins with or without folic acid versus folic acid (<LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>); multivitamins with or without vitamin A versus vitamin A or placebo (<LINK REF="STD-Fawzi-1998" TYPE="STUDY">Fawzi 1998</LINK>); multivitamins versus control (<LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>); multivitamins with vitamin E versus multivitamins without vitamin E or control (<LINK REF="STD-Rush-1980" TYPE="STUDY">Rush 1980</LINK>); multivitamins with iron and folic acid versus iron and folic acid (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Fawzi-2007" TYPE="STUDY">Fawzi 2007</LINK>; <LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Tofail-2008" TYPE="STUDY">Tofail 2008</LINK>; <LINK REF="STD-West-2014" TYPE="STUDY">West 2014</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The risk for <B>total fetal loss</B> was reduced in women supplemented with:</P>
<OL>
<LI>multivitamin without folic acid (RR 0.49, 95% CI 0.34 to 0.70, one trial, 907 women; <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>);</LI>
<LI>multivitamin with/without vitamin A (RR 0.60, 95% CI 0.39 to 0.92, one trial, 1074 women; <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>);</LI>
</OL>
<P>compared with placebo or no multivitamin groups.</P>
<P>There was no difference in the risk of <B>total fetal loss</B> for the following interventions:</P>
<OL>
<LI>multivitamin plus iron and folic acid compared iron and folate only groups (RR 0.96, 95% CI 0.93 to 1.00, 10 trials, 94,948 women; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <I>high-quality evidence</I>);</LI>
<LI>multivitamins alone or in combination with other vitamins or micronutrients compared with placebo or no multivitamins groups (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>; <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>; <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>; <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>; <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>; <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK> (random effects; three trials)).</LI>
</OL>
<P>Similarly, we found no difference in the risk for <B>early or late miscarriage</B> between women receiving the following interventions:</P>
<OL>
<LI>multivitamin plus iron and folic acid compared iron and folate only groups (RR 0.98, 95% CI 0.94 to 1.03, 10 trials, 94,948 women; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>; <I>moderate-quality evidence</I>);</LI>
<LI>multivitamins alone or in combination with other vitamins or micronutrients compared with placebo or no multivitamins groups (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>; <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>; <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>; <LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>; <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>; <LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK> (random effects; three trials)).</LI>
</OL>
<P>The heterogeneity in <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK> and <LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK> seemed to have been contributed by <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>, which included women who had previously given birth to a child with an open neural tube defect. When this trial was excluded, the heterogeneity was no longer present.</P>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>There was evidence of a decrease in the risk for <B>stillbirth</B> among women receiving multivitamin plus iron and folic acid compared iron and folate only groups (RR 0.92, 95% CI 0.85 to 0.99, 10 trials, 79,851 women; <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>; <I>high-quality evidence</I>).</P>
<P>There was no difference in the risk of:</P>
<OL>
<LI>
<B>stillbirth</B> (<LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>; <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>; <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>; <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>; <LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK>; <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>; <LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>; <LINK REF="CMP-018.03" TYPE="ANALYSIS">Analysis 18.3</LINK>); or</LI>
<LI>
<B>congenital malformation</B> (<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>; <LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>; <LINK REF="CMP-012.04" TYPE="ANALYSIS">Analysis 12.4</LINK>; <LINK REF="CMP-013.04" TYPE="ANALYSIS">Analysis 13.4</LINK>; <LINK REF="CMP-014.04" TYPE="ANALYSIS">Analysis 14.4</LINK>; <LINK REF="CMP-018.04" TYPE="ANALYSIS">Analysis 18.4</LINK>) between women receiving multivitamins alone or in combination with other vitamins or micronutrients compared with placebo or no multivitamins groups.</LI>
</OL>
<P>There were no data available to conduct any analysis for <B>adverse effects of vitamin supplementation</B>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Folic acid supplementation</HEADING>
<P>The trials involving folic acid supplementation included the following interventions: folic acid with or without multivitamins compared with no folic acid or multivitamins (<LINK REF="STD-Czeizel-1994" TYPE="STUDY">Czeizel 1994</LINK>; <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>); folic acid with or without multivitamins compared with multivitamins (<LINK REF="STD-Kirke-1992" TYPE="STUDY">Kirke 1992</LINK>; <LINK REF="STD-MRC-1991" TYPE="STUDY">MRC 1991</LINK>); folic acid and iron compared with iron (<LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>); folic acid and iron compared with no iron or folic acid (<LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>We found no difference in the risk of:</P>
<OL>
<LI>
<B>total fetal loss</B> (<LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK> (random effects; three trials); <LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>; <LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>; <LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>; <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>; <LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>; <LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>; <LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>); or</LI>
<LI>
<B>early or late miscarriage</B> (<LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK> (random effects; three trials); <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>; <LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>; <LINK REF="CMP-022.02" TYPE="ANALYSIS">Analysis 22.2</LINK>; <LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>; <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>; <LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>; <LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>);</LI>
</OL>
<P>between women supplemented with folic acid with or without multivitamins and/or iron compared with no folic acid groups. The heterogeneity found seemed to have been contributed by <LINK REF="STD-ICMR-2000" TYPE="STUDY">ICMR 2000</LINK>, which included women who had previously given birth to a child with an open neural tube defect. Excluding this trial removed the heterogeneity but did not change the conclusion of no difference between the treatment groups.</P>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>There was no difference in the risk of:</P>
<OL>
<LI>
<B>stillbirth</B> (<LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>; <LINK REF="CMP-020.03" TYPE="ANALYSIS">Analysis 20.3</LINK>; <LINK REF="CMP-021.03" TYPE="ANALYSIS">Analysis 21.3</LINK>; <LINK REF="CMP-022.03" TYPE="ANALYSIS">Analysis 22.3</LINK> (random effects); <LINK REF="CMP-023.03" TYPE="ANALYSIS">Analysis 23.3</LINK>; <LINK REF="CMP-024.03" TYPE="ANALYSIS">Analysis 24.3</LINK> (random effects); <LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>); or</LI>
<LI>
<B>congenital malformations</B> (<LINK REF="CMP-019.04" TYPE="ANALYSIS">Analysis 19.4</LINK>; <LINK REF="CMP-020.04" TYPE="ANALYSIS">Analysis 20.4</LINK>; <LINK REF="CMP-021.04" TYPE="ANALYSIS">Analysis 21.4</LINK>; <LINK REF="CMP-022.04" TYPE="ANALYSIS">Analysis 22.4</LINK> (random effects); <LINK REF="CMP-023.04" TYPE="ANALYSIS">Analysis 23.4</LINK>; <LINK REF="CMP-024.04" TYPE="ANALYSIS">Analysis 24.4</LINK> (random effects)) between women supplemented with folic acid with or without multivitamins and/or iron;</LI>
</OL>
<P>compared no folic acid groups. There were no data available to conduct any analysis for <B>adverse effects of vitamin supplementation</B>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antioxidant vitamins supplementation</HEADING>
<P>The trial involving antioxidant vitamins supplementation included the following interventions: antioxidant with multivitamins compared multivitamins with low antioxidant content (<LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>).</P>
<P>
<B>Primary outcomes</B>
</P>
<P>In the one trial involving 110 women (<LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>), there was no evidence of differences between women given antioxidant with multivitamins compared multivitamins with low antioxidant group on <B>early or late miscarriage</B> (RR 1.12, 95% CI 0.24 to 5.29, one trial, 110 women, <LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>). No other primary or secondary outcomes were reported by this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses by dose of vitamins and duration of vitamin usage</HEADING>
<P>Subgroup analyses by dose of vitamin(s) (below or above the recommended dietary intake) were complicated by the limited number of studies in each vitamin group, and by the use of multivitamin supplements. For many of the vitamin types and for those reporting pregnancy loss outcomes, all of the trials supplemented women with amounts that were above the recommended dietary intake. Similarly, the duration of vitamin usage was complicated by the fact that many of the trials had wide recruitment periods, and one trial (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>) supplemented women up until three years postpartum. We have not performed subgroup analyses based on vitamin dosage or time of trial entry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses by women's risk of spontaneous or recurrent miscarriage</HEADING>
<P>Information enabling women to be classified at high or low risk of either spontaneous miscarriage or recurrent miscarriage was not clearly stated in any of the trials included in this update. Based on the inclusion criteria, one trial (<LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>) included women at low risk of miscarriage. One trial (<LINK REF="STD-Briscoe-1959" TYPE="STUDY">Briscoe 1959</LINK>) included women who had experienced recurrent miscarriage as well as women at high risk of miscarriage (more than two previous miscarriages and/or bleeding in the pregnancy) and low-risk women (two or less previous miscarriages and no bleeding in the pregnancy). After classifying women into these groups, the number of women in the high-risk group was too small to permit any meaningful comparisons and we have therefore not performed subgroup analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses by dietary intake of vitamins</HEADING>
<P>Seven trials (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Fleming-1968" TYPE="STUDY">Fleming 1968</LINK>; <LINK REF="STD-Kumwenda-2002" TYPE="STUDY">Kumwenda 2002</LINK>; <LINK REF="STD-People_x0027_s-League-1942" TYPE="STUDY">People's League 1942</LINK>; <LINK REF="STD-Schmidt-2001" TYPE="STUDY">Schmidt 2001</LINK>; <LINK REF="STD-Steyn-2003" TYPE="STUDY">Steyn 2003</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>) reported information about women's nutritional status or the percentage of women who were dietary deficient at trial entry for the vitamin of interest. Other trials reported that they were being undertaken in countries where the population was at high risk of multiple micronutrient deficiencies (<LINK REF="STD-Osrin-2005" TYPE="STUDY">Osrin 2005</LINK>; <LINK REF="STD-Prawirohartono-2011" TYPE="STUDY">Prawirohartono 2011</LINK>; <LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>; <LINK REF="STD-Summit-2008" TYPE="STUDY">Summit 2008</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>), or there was a high prevalence of anaemia (<LINK REF="STD-Bhutta-2009" TYPE="STUDY">Bhutta 2009</LINK>; <LINK REF="STD-Fleming-1986" TYPE="STUDY">Fleming 1986</LINK>; <LINK REF="STD-Sunawang-2009" TYPE="STUDY">Sunawang 2009</LINK>; <LINK REF="STD-Zagre-2007" TYPE="STUDY">Zagre 2007</LINK>; <LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>), but provided no specific information on nutritional status of participants. Two trials (<LINK REF="STD-Rumiris-2006" TYPE="STUDY">Rumiris 2006</LINK>; <LINK REF="STD-Wibowo-2012" TYPE="STUDY">Wibowo 2012</LINK>) included women with 'low antioxidant status'. There were not enough trials within each vitamin group to assess the role of supplementation in women with dietary deficient intakes of the individual vitamins and results were not reported separately for women with a low dietary vitamin intake; therefore, we could not perform subgroup analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>We carried out sensitivity analysis to explore the effects of trial quality and type of randomisation on the primary outcomes related to fetal loss (total fetal loss and early or late miscarriage). We included only trials with 'adequate' rating on allocation concealment, but found that restricting to only trials with adequate allocation concealment made very little difference to the results for the primary outcomes. Effect of type of randomisation was explored by excluding cluster-randomised trials and restricting the analyses to individually-randomised trials. We found no difference between women supplemented with multivitamins compared with controls for total fetal loss or early or late miscarriage when the analyses were restricted to individually-randomised trials only. These sensitivity analyses indicate that the analyses for the effects of multivitamins on outcomes related to fetal loss and early or late miscarriage are no different when only individually-randomised trials are included.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-05-05 12:04:55 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-04-20 19:29:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>The purpose of this review was to determine the effectiveness and safety of any vitamin supplementation taken by women pre- or periconceptionally on the risk of miscarriage. In this updated version of the review, we included 40 studies involving 59,094 women from individually-randomised trials plus a further 217,726 women from eight cluster-randomised controlled trials. The results did not provide sufficient evidence to support the use of single vitamin supplementation for preventing total fetal loss or early or late miscarriage. However, stillbirth was significantly lower in women given multivitamin supplementation plus iron and folic acid compared to iron and folic acid alone. Although there was evidence of decreased risk for total fetal loss among women receiving multivitamins without folic acid compared with no multivitamin/folic acid and multivitamin supplementation with/without vitamin A compared with vitamin A or placebo; these findings occurred in analyses involving one trial each with small numbers of women involved. Also, they include studies where the comparison groups included women receiving either vitamin A or placebo, and thus require caution in interpretation.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-04-20 19:30:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>There was considerable consistency in reported total fetal loss (including miscarriages or combined miscarriages and stillbirths) among included studies with no difference in the rates of miscarriage and stillbirth across treatment groups. While this may suggest the true effect of vitamin supplementation on risk of miscarriage, most of the studies included in this review did not originally set out to examine the effect of vitamin supplementation on the risk of miscarriage.</P>
<P>Our review included trials that randomised women prior to conception; however, in some cases, not all women enrolled in these trials fell pregnant during the study period. Some of the trials reported outcomes only for women falling pregnant, whereas other trials did not distinguish between women who were never pregnant and women who may have been pregnant but were lost to follow-up. The outcomes in this review relating to pregnancy outcomes are not relevant for the women who never became pregnant during the study period. In this review, where trials provided accurate information about the number of women who joined the study and became pregnant in the time period, we included this number in the totals, rather than the number of women who may have been randomised. Where it was not clear about the exact number of women with a confirmed pregnancy, we included all women who had been randomised. This may therefore mean that a certain proportion of women in the denominator were never pregnant during the study period. By including these women who were never pregnant in the totals, the review assumes that if these women had become pregnant, they would not have had a miscarriage, which is unlikely to be entirely correct. Including these women creates the potential to underestimate any treatment effects observed.</P>
<P>Similarly, for one large trial (<LINK REF="STD-Katz-2000" TYPE="STUDY">Katz 2000</LINK>) and one smaller trial (<LINK REF="STD-Roberfroid-2008" TYPE="STUDY">Roberfroid 2008</LINK>), some women were pregnant more than once during the study period. In these trials, the denominators reported are the total number of pregnancies during the study period, not the total number of women randomised, which incorrectly assumes that each data point included is independent from the next. This has the potential to either underestimate or overestimate the results, depending on whether the women contributing data for more than one pregnancy may be more or less susceptible to experiencing miscarriage or stillbirth. One way to overcome this may be to summarise the data for each woman so that there is only one set of data points for each woman; however, we were unable to do this for these particular studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-04-20 19:31:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>Some of the trials included in the review were at high risk of bias, either due to poor or unclear allocation concealment or large losses to follow-up. The data were also complicated by differing definitions of miscarriage. For some trials, miscarriage was considered to occur up until 26 or 28 weeks' gestation, while other studies reported miscarriage as pregnancy loss prior to 20 weeks' gestation, and stillbirth as pregnancy loss greater or equal to 20 weeks' gestation. Other studies did not specify their definition of miscarriage or stillbirth. In addition to the problems with differing definitions, the timing of the onset of vitamin supplementation for some of the included trials occurred in mid-pregnancy, which may limit the impact of supplementation on the risk of miscarriage. The review attempted to overcome these issues by using the outcome 'total fetal loss', which included either miscarriage or stillbirth.</P>
<P>We assessed the quality of the evidence using GRADE and judged the evidence for vitamin C and vitamin E compared with control as high quality for total fetal loss, and moderate quality for early or late miscarriage, stillbirth, and adverse effects, which was downgraded due to wide 95% confidence intervals (CIs) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). For vitamin A plus iron plus folate versus iron plus folate trials were judged to have low quality of evidence for total fetal loss, early or late miscarriage, and stillbirth due to design limitation and wide 95% CI (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). No studies reported any adverse effects for this comparison. For multivitamin plus iron plus folate versus iron plus folate trials were judged to be high quality for total fetal death and stillbirth, moderate quality for early or late miscarriage, downgraded due to publication bias suspected by funnel plot, or wide CI crossing the line of no effect (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). No studies reported any adverse effects for this comparison.</P>
<P>In order to determine the effect of publication bias, we undertook funnel plots for comparisons with 10 or more studies (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) for the comparisons of multivitamins plus iron and folic acid versus iron and folic acid. Asymmetry was suggested by visual assessment of <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> for early or late miscarriage.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-05-05 12:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>We took steps to minimise the introduction of bias during the review process. All relevant trials were identified including published abstracts from conference proceedings, English and non-English publications. A pro forma translation sheet was used to extract relevant information from non-English articles. At least two review authors independently assessed each trial, performed data extraction, and assessment of risk of bias for each of the included trials. Our assessment of previously identified ongoing trials that remained unpublished were limited to trial published protocols or the records of the initial communication between our authors and the authors of the unpublished trials.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-05-05 12:04:18 +0100" MODIFIED_BY="[Empty name]">
<P>There are several Cochrane reviews evaluating the effect of single vitamin supplementation during pregnancy on maternal, fetal, neonatal and infant outcomes. Benefits or hazards of vitamin supplementation in pregnancy on total fetal loss and miscarriage have not been or insufficiently investigated. However, our results on secondary outcomes are consistent with finding in the particular publications.</P>
<P>In the analysis by vitamin type, vitamin C supplementation alone or in combination with vitamin E or multivitamins did not show any effect on total fetal loss, miscarriage, or the secondary outcomes stillbirth, congenital malformation and adverse effects. A review focusing on vitamin C supplementation alone or in combination with other separate supplements on pregnancy outcomes, did not observe effects on stillbirth or congenital malformations which is consistent with our results (<LINK REF="REF-Rumbold-2015" TYPE="REFERENCE">Rumbold 2015</LINK>).</P>
<P>Supplementing women with vitamin A alone or in combination with iron and folic acid or multivitamins was not associated with changes in fetal loss or miscarriage as well as stillbirth. These findings are consistent with the Cochrane review '<I>Vitamin A supplementation during pregnancy for maternal and newborn outcomes</I>' (<LINK REF="REF-McCauley-2015" TYPE="REFERENCE">McCauley 2015</LINK>), which found no difference in the rate of stillbirth for women receiving vitamin A alone compared with placebo/no treatment or vitamin A with other micronutrients compared with micronutrient supplementation without vitamin A.</P>
<P>In the analysis comparing multivitamin alone or in combination with other vitamins, we found a positive effect of multivitamin supplementation without folic acid compared with no multivitamin/folic acid as well as multivitamin with/without vitamin A compared with vitamin A alone or placebo on total fetal loss. However, these findings resulted from only one study, respectively. Stillbirth was significantly reduced for women receiving multivitamin plus iron and folic acid. This result is consistent with findings in a review assessing the effect of multiple-micronutrient supplementation during pregnancy on maternal, fetal and infant health outcomes (<LINK REF="REF-Haider-2015" TYPE="REFERENCE">Haider 2015</LINK>). Here they also reported a significant reduction in the risk of stillbirth. Miscarriage (loss before 28 weeks) was not effected by this intervention.</P>
<P>Folic acid supplementation with or without multivitamin compared to no folic acid/multivitamin or multivitamin alone did not reduce the risk of total fetal loss, miscarriage, stillbirth or congenital malformations. This in accordance with a review evaluating the effectiveness of oral folic acid supplementation during pregnancy on maternal health and pregnancy outcomes (<LINK REF="REF-Lassi-2013" TYPE="REFERENCE">Lassi 2013</LINK>). The authors did not observe any effect of folic acid supplementation on stillbirth. Even though miscarriage was included as a secondary outcome, none of the included studies reported on miscarriage. In addition, another review assessed the effects and safety of periconceptional oral folate supplementation for preventing birth defects (<LINK REF="REF-De_x002d_Regil-2015" TYPE="REFERENCE">De-Regil 2015</LINK>). There was no effect of folate versus no intervention, placebo or other micronutrients without folate on miscarriage or stillbirth. They investigated the effect of folate supplementation on several congenital malformations and found a 69% reduction in the risk of neural tube defects.</P>
<P>Antioxidant vitamin supplementation had no effect on early or late miscarriage. The effectiveness and safety of any antioxidant supplementation during pregnancy on the risk of various pregnancy outcomes is explored in the Cochrane review '<I>Antioxidants for preventing pre-eclampsia</I>' (<LINK REF="REF-Rumbold-2008" TYPE="REFERENCE">Rumbold 2008</LINK>). Our results are in accordance with the results form this review where any antioxidant supplementation compared to control or placebo had no effect on miscarriage or stillbirth.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-04-20 19:32:18 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2016-04-20 19:32:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>There is no evidence to support the prophylactic use of single vitamins to prevent either early or late miscarriages. Supplementing women with multivitamin with or without iron and/or folic acid or vitamin A, may decrease the risk of total fetal loss and stillbirth, Even though there is a positive effect of multivitamin supplementation on pregnancy outcomes, there was insufficient evidence to examine the effect of different combinations of vitamins on miscarriage and miscarriage-related outcomes. Our findings suggest, that no particular vitamin decreases the risk of miscarriage or stillbirth, but the combination of various vitamins may have the potential to positively influence pregnancy outcomes. This could be due to an overall improvement in maternal nutrition and health status, making women more resistant to infections during pregnancy. However, this needs to be investigated further before recommendations on routine multivitamin supplementation to prevent miscarriage can be given.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-04-20 19:32:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>The impact of different combinations of vitamins (i.e. individual vitamins or multivitamin preparations with or without vitamin A and folic acid) on miscarriage and miscarriage-related outcomes is unclear. Any future studies of vitamin supplementation should be high quality and focus on women at high risk of miscarriage. Considerations should include timing of the intervention and trials should assess the most appropriate vitamin type and dosage; to see whether it is beneficial without causing any harms to the mother or fetus and include assessments of any psychological effects and long-term follow-up of mothers and infants. Further, the data in the current review were complicated by differing definitions of miscarriage and so this may be an important issue to consider in any future trials.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-04-28 09:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>For previous versions of the review, we thank Simon Gates for statistical advice regarding inclusion of cluster-randomised trials, Lelia Duley for helpful comments on the format of the review and Sonja Henderson for assisting with review administration.</P>
<P>We also thank Ning Pan, Caroline Crowther and Philippa Middleton for their contribution as authors on previous versions of the review.</P>
<P>We thank the following for their translation help: Izabella Brzostowicz and Agnieszke Kimball for <LINK REF="STD-Chelchowska-2004" TYPE="STUDY">Chelchowska 2004</LINK>; Rebecca Gainey and Kate Bartos for <LINK REF="STD-Lira-1989" TYPE="STUDY">Lira 1989</LINK>; and Lucia Bartos for <LINK REF="REF-M_x00e9_tneki-1996" TYPE="REFERENCE">Métneki 1996</LINK>.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team), a member of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
<P>Rintaro Mori's institution receives government funding from the Clinical Research Program for Child Health and Development, AMED, Japan to provide support for the PCG Satellite in Japan.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-04-28 14:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>Alice Rumbold is an investigator on the Australian Collaborative Trial of Supplements with vitamin C and vitamin E for the prevention of pre-eclampsia (<LINK REF="STD-Rumbold-2006" TYPE="STUDY">Rumbold 2006</LINK>). This trial is included in this review but its eligibility for inclusion, trial quality assessments and data extraction were carried out independently by two of the review authors not involved in the original trial.</P>
<P>Erika Ota: none known. </P>
<P>Olukunmi O Balogun: none known.</P>
<P>Katharina da Silva Lopes: none known.</P>
<P>Yo Takemoto: none known.</P>
<P>Mizuki Takegata: none known.</P>
<P>Rintaro Mori's institution receives government funding from the Clinical Research Program for Child Health and Development, AMED, Japan to provide support for the PCG Satellite in Japan.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-04-20 19:32:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Olukunmi Balogun: screened studies for inclusion/exclusion, data extraction, 'Risk of bias' assessment, data analysis, manuscript revision.</P>
<P>Kathrina da Silva Lopes: screened studies for inclusion/exclusion, data extraction, 'Risk of bias' assessment, manuscript revision.</P>
<P>Erika Ota: screened studies for inclusion/exclusion, statistical support, 'Summary of findings' tables, overall supervision.</P>
<P>Yo Takemoto: screened studies for inclusion/exclusion, data extraction, 'Risk of bias' assessment, manuscript revision.</P>
<P>Alice Rumbold: overall supervision.</P>
<P>Mizuki Takegata: data extraction, 'Risk of bias' assessment.</P>
<P>Rintaro Mori: statistical support, overall supervision.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-04-20 19:35:04 +0100" MODIFIED_BY="Heather Maxwell">
<P>2011 update</P>
<P>We now include trials where supplementation occurred in mid-pregnancy. This was not specified in the original protocol for this review, but this was amended to be in line with other miscarriage reviews such as 'Progestogen for preventing miscarriage' (<LINK REF="REF-Haas-2009" TYPE="REFERENCE">Haas 2009</LINK>). We included trials where the onset of supplementation occurred both prior to and after 20 weeks' gestation, and when it could not be established whether the majority of the women started supplementation prior to 20 weeks' gestation. To overcome differences in the definition of miscarriage and stillbirth, we have used a combined outcome of total fetal loss (early or late miscarriage or stillbirth). We have still reported early or late miscarriage and stillbirth separately in addition to this combined outcome. Similarly, we specified in the original protocol that we would exclude studies reporting greater than 20% losses to follow-up. In this review we have included studies that reported more than 20% losses to follow-up and undertaken further analyses based on trial quality.</P>
<P>2016 update<BR/>The methods section was updated to current Cochrane Pregnancy and Childbirth standard text.</P>
<P>The scope of the current update has been restricted to look at miscarriage and miscarriage-related outcomes. Comparison 1 (any vitamins) and comparison 2 (sensitivity analysis) have been deleted in this update. After discussion it was decided that it did not make sense to compare any vitamin supplementation with no supplementation from either a clinical or consumer perspective.</P>
<P>We deleted the following primary outcomes.<BR/>For the woman</P>
<OL>
<LI>Placental abruption.</LI>
<LI>Pre-eclampsia.</LI>
<LI>Psychological effects (anxiety and depression) (previously included as maternal outcomes)</LI>
</OL>
<P>For the infant</P>
<OL>
<LI>Preterm birth (defined as birth less than 37 weeks' gestation).</LI>
<LI>Birthweight.</LI>
<LI>Small-for-gestational age (birthweight less than the third centile or the most extreme centile reported) (previously included as infant outcomes)</LI>
</OL>
<P>and secondary outcomes:</P>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<OL>
<LI>Multiple pregnancy (including only trials supplementing women prior to or around the time of conception).</LI>
<LI>Very preterm birth (defined as less than 34 weeks' gestation).</LI>
<LI>Apgar score less than seven at five minutes.</LI>
<LI>Use of blood transfusion for the mother.</LI>
<LI>Anaemia (maternal and infant).</LI>
<LI>Placental weight.</LI>
<LI>Methods of feeding: breastfeeding, formula or both.</LI>
<LI>Subsequent fertility (subsequent pregnancy rate per couple or as defined by the authors).</LI>
<LI>Poor growth at childhood follow-up.</LI>
<LI>Disability at childhood follow-up.</LI>
<LI>Maternal views of care.</LI>
<LI>Gynaecological hospital admission.</LI>
<LI>Admission to neonatal intensive care unit.</LI>
<LI>Healthcare costs.</LI>
</OL>
<P>All subgroups have been deleted from any analysis.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-04-26 15:38:17 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2016-04-26 15:38:17 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-04-26 15:36:29 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bhutta-2009" MODIFIED="2016-02-03 06:28:40 +0000" MODIFIED_BY="[Empty name]" NAME="Bhutta 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-12-29 17:21:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhutta ZA, Rizvi A, Raza F, Hotwani S, Zaidi S, Moazzam Hossain S, et al</AU>
<TI>A comparative evaluation of multiple micronutrient and iron-folic acid supplementation during pregnancy in Pakistan: impact on pregnancy outcomes</TI>
<SO>Food &amp; Nutrition Bulletin</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>4</NO>
<PG>S496-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briscoe-1959" NAME="Briscoe 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briscoe CC</AU>
<TI>The role of vitamin C-hesperidin in the prevention of abortion</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1959</YR>
<VL>14</VL>
<NO>3</NO>
<PG>288-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chappell-1999" MODIFIED="2016-04-18 09:28:09 +0100" MODIFIED_BY="Heather Maxwell" NAME="Chappell 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-04-18 09:28:09 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chappell LC, Seed PT, Briely AL, Kelly FJ, Lee R, Hunt BJ, et al</AU>
<TI>Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>810-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czeizel-1994" MODIFIED="2016-04-26 15:29:21 +0100" MODIFIED_BY="[Empty name]" NAME="Czeizel 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel A, Rode K</AU>
<TI>Trial to prevent first occurrence of neural tube defects by periconceptional multivitamin supplementation [letter]</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>2</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:30:45 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Dudás I, Frotz G, Técsöi A, Hanck A, Kunovits G</AU>
<TI>The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>1992</YR>
<VL>251</VL>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Dudás I, Metneki J</AU>
<TI>Pregnancy outcomes in a randomised controlled trial of periconceptional multivitamin supplementation. Final report</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>1994</YR>
<VL>255</VL>
<PG>131-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Dudás I</AU>
<TI>Prevention of the first occurrence of anencephaly and spina bifida with periconceptional multivitamin supplementation (conclusion)</TI>
<SO>Orvosi Hetilap</SO>
<YR>1994</YR>
<VL>135</VL>
<PG>2313-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Dudás I</AU>
<TI>Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>1832-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Fritz G</AU>
<TI>Randomized trial of periconceptional vitamins [letter]</TI>
<SO>JAMA</SO>
<YR>1989</YR>
<VL>262</VL>
<PG>1634</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Métneki J, Dudás I</AU>
<TI>Higher rate of multiple births after periconceptional vitamin supplementation [letter]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>1687-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Métneki J, Dudás I</AU>
<TI>The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes</TI>
<SO>Acta Geneticae Medicae et Gemellologiae (Roma)</SO>
<YR>1994</YR>
<VL>43</VL>
<PG>175-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE, Rockenbauer M, Susánsky E</AU>
<TI>No change in sexual activity during preconceptional multivitamin supplementation</TI>
<SO>British Journal of Obstetrics &amp; Gynaecology</SO>
<YR>1996</YR>
<VL>103</VL>
<PG>569-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE</AU>
<TI>Controlled studies of multivitamin supplementation on pregnancy outcomes</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>1993</YR>
<VL>678</VL>
<PG>266-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE</AU>
<TI>Limb reduction defects and folic acid supplementation [letter]</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<PG>932</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE</AU>
<TI>Nutritional supplementation and prevention of congenital abnormalities</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>7</VL>
<PG>88-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czeizel AE</AU>
<TI>Prevention of congenital abnormalities by periconceptional multivitamin supplementation</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>1645-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dudás I, Rockenbauer M, Czeizel AE</AU>
<TI>The effect of preconceptional multivitamin supplementation on the menstrual cycle</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>1995</YR>
<VL>256</VL>
<PG>115-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eros E, Geher P, Gomor B, Czeizel AE</AU>
<TI>Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1998</YR>
<VL>80</VL>
<PG>75-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-28 19:34:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Métneki J, Dudás I, Czeizel AE</AU>
<TI>Periconceptional multivitamin administration may result in higher frequency of twin pregnancies</TI>
<SO>Orvosi Hetilap</SO>
<YR>1996</YR>
<VL>137</VL>
<PG>2401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawzi-1998" MODIFIED="2016-04-18 09:38:37 +0100" MODIFIED_BY="Heather Maxwell" NAME="Fawzi 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-21 08:52:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baylin A, Villamor E, Rifai N, Msamanga G, Fawzi WW</AU>
<TI>Effect of vitamin supplementation to HIV-infected pregnant women on the micronutrient status of their infants</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>8</NO>
<PG>960-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:37:43 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi W, Msamanga G, Renjifo B, Spiegelman D, Urassa E, Hashemi L, et al</AU>
<TI>Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women</TI>
<SO>AIDS</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>9</NO>
<PG>1157-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:38:08 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga G, Hunter D, Urassa E, Renjifo B, Mwakagile D, et al</AU>
<TI>Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>246-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 08:55:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga GI, Kupka R, Spiegelman D, Villamor E, Mugusi F, et al</AU>
<TI>Multivitamin supplementation improves hematologic status in HIV-infected women and their children in Tanzania</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>85</VL>
<NO>5</NO>
<PG>1335-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:38:37 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga GI, Spielgelman D, Urassa EJN, McGrath N, Mwakagile D, et al</AU>
<TI>Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1 infected women in Tanzania</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>1477-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 09:02:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villamor E, Msamanga G, Saathoff E, Manji K, Fawzi WW</AU>
<TI>Effect of vitamin supplements on the incidence of malaria among children born to HIV-infected Women</TI>
<SO>FASEB Journal</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4 Pt 1</NO>
<PG>A125</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawzi-2007" MODIFIED="2016-04-18 09:39:10 +0100" MODIFIED_BY="Heather Maxwell" NAME="Fawzi 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-04-18 09:39:10 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga GI, Urassa W, Hertzmark E, Petraro P, Willett WC, et al</AU>
<TI>Vitamins and perinatal outcomes among HIV-negative women in Tanzania</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<NO>14</NO>
<PG>1423-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleming-1968" NAME="Fleming 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleming AF, Hendrickse JP, Allan NC</AU>
<TI>The prevention of megaloblastic anaemia in pregnancy in Nigeria</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1968</YR>
<VL>75</VL>
<PG>425-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleming-1986" MODIFIED="2016-04-18 09:45:02 +0100" MODIFIED_BY="Heather Maxwell" NAME="Fleming 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-04-18 09:45:02 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fleming AF, Ghatoura GBS, Harrison KA, Briggs ND, Dunn DT</AU>
<TI>The prevention of anaemia in pregnancy in primigravidae in the guinea savanna of Nigeria</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>2</NO>
<PG>211-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 08:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison KA, Fleming AF, Briggs ND, Rossiter CE</AU>
<TI>Growth during pregnancy in Nigerian teenage primigravidae</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1985</YR>
<VL>Suppl 5</VL>
<PG>32-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hans-2010" MODIFIED="2015-12-29 17:23:16 +0000" MODIFIED_BY="[Empty name]" NAME="Hans 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-12-29 17:23:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hans U, Edward B</AU>
<TI>Regular vitamin C supplementation during pregnancy reduces hospitalization: outcomes of a Ugandan rural cohort study</TI>
<SO>Pan African Medical Journal</SO>
<YR>2010</YR>
<VL>5</VL>
<PG>15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hemmi-2003" NAME="Hemmi 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hemmi H, Endo T, Kitajima Y, Manase K, Hata H, Kudo R</AU>
<TI>Effects of ascorbic acid supplementation on serum progesterone levels in patients with a luteal phase defects</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>2003</YR>
<VL>80</VL>
<NO>2</NO>
<PG>456-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ICMR-2000" NAME="ICMR 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ICMR Collaborating Centres and Central Technical Co-ordinating Unit</AU>
<TI>Multicentric study of efficacy of periconceptional folic acid containing vitamin supplementation in prevention of open neural tube defects from India</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>2000</YR>
<VL>112</VL>
<PG>206-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jauniaux-2004" MODIFIED="2016-03-16 06:01:01 +0000" MODIFIED_BY="[Empty name]" NAME="Jauniaux 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-03-16 06:01:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jauniaux E</AU>
<TI>The effect of vitamin C and E supplementation in women with a history of two early pregnancy failures - a randomised controlled trial</TI>
<SO>ISRCTN Registry (http://www.isrctn.com/) [accessed 28 October 2015]</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="ISRCTN" VALUE="ISRCTN61737241"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-2000" MODIFIED="2016-04-18 09:49:39 +0100" MODIFIED_BY="Heather Maxwell" NAME="Katz 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-04-18 09:46:21 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Khatry SK, Yamini S, Stallings R, LeClerq SC, Shrestha SR, et al</AU>
<TI>Zinc supplementation might potentiate the effect of vitamin A in restoring night vision in pregnant Nepalese women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2001</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1045-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:46:37 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, West KP Jr, Khatry SK, Katz J, LeClerq SC, Kimbrough-Pradhan E, et al</AU>
<TI>Vitamin A or beta-carotene supplementation reduces symptoms of illness in pregnant and lactating Nepali women</TI>
<SO>Journal of Nutrition</SO>
<YR>2000</YR>
<VL>130</VL>
<NO>11</NO>
<PG>2675-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:46:57 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, West KP Jr, Khatry SK, Katz J, Shrestha SR, Pradhan EK, et al</AU>
<TI>Night blindness of pregnancy in rural Nepal--nutritional and health risk</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>2</NO>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:47:24 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, West KP Jr, Khatry SK, Kimbrough-Pradhan E, LeClerq SC, Shrestha SR, et al</AU>
<TI>Night blindness during pregnancy and subsequent mortality among women in Nepal: effects of vitamin A and beta-carotene supplementation</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2000</YR>
<VL>152</VL>
<NO>6</NO>
<PG>542-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:48:10 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katz J, West KP Jr, Khatry S, Pradhan EK, LeClerq SC, Christian P, et al</AU>
<TI>Maternal low-dose vitamin A or beta-carotene supplementation has no effect on fetal loss and early infant mortality: a randomized cluster trial in Nepal</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>1570-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:48:56 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz J, West KP Jr, Khatry SK, LeClerq SC, Christian P, Pradhan EK, et al</AU>
<TI>Twinning rates and survival of twins in rural Nepal</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>4</NO>
<PG>802-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-21 15:55:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmer AC, Schulze KJ, Khatry SK, De Luca LM, West KP</AU>
<TI>Maternal vitamin A supplementation increases natural antibody concentrations of preadolescent offspring in rural Nepal</TI>
<SO>Nutrition (Burbank, Los Angeles County, Calif.)</SO>
<YR>2015</YR>
<VL>31</VL>
<NO>6</NO>
<PG>813-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 04:55:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart CP, Christian P, Katz J, Schulze KJ, Wu LSF, LeClerq SC, et al</AU>
<TI>Maternal supplementation with vitamin A or B-carotene and cardiovascular risk factors among pre-adolescent children in rural Nepal</TI>
<SO>Journal of Developmental Origins of Health and Disease</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>4</NO>
<PG>262-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 09:49:39 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West KP Jr, Katz J, Khatry SK, LeClerq SC, Pradhan EK, Shrestha SR, et al</AU>
<TI>Double blind, cluster randomised trial of low dose supplementation with vitamin A or beta carotene on mortality related to pregnancy in Nepal. The NNIPS-2 Study Group</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<PG>570-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirke-1992" NAME="Kirke 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirke PN, Daly LE, Elwood JH for the Irish Vitamin Study Group</AU>
<TI>A randomised trial of low dose folic acid to prevent neural tube defects</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>1442-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumwenda-2002" MODIFIED="2016-04-18 09:52:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kumwenda 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-04-18 09:52:28 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumwenda N, Miotti PG, Taha TE, Broadhead R, Biggar RJ, Brookes Jackson JB, et al</AU>
<TI>Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>5</NO>
<PG>618-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCance-2010" MODIFIED="2016-04-18 09:57:13 +0100" MODIFIED_BY="Heather Maxwell" NAME="McCance 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-04-18 09:57:13 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, et al; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group</AU>
<TI>Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes(DAPIT): a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9737</NO>
<PG>259-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 01:44:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissgerber T, Gandley R</AU>
<TI>Risk of types of pregnancy associated hypertension according to haptoglobin phenotype</TI>
<SO>Reproductive Sciences</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>3 Suppl 1</NO>
<PG>69A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 01:44:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissgerber TL, Gandley RE, McGee PL, Spong CY, Myatt L, Leveno KJ, et al</AU>
<TI>Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population</TI>
<SO>PLoS ONE [Electronic Resource]</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>4</NO>
<PG>e60479</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 01:44:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissgerber TL, Gandley RE, Roberts JM, Patterson CC, Holmes VA, Young IS, et al</AU>
<TI>Haptoglobin phenotype, pre-eclampsia, and response to supplementation with vitamins C and E in pregnant women with type-1 diabetes</TI>
<SO>BJOG : an International Journal of Obstetrics and Gynaecology</SO>
<YR>2013</YR>
<VL>120</VL>
<NO>10</NO>
<PG>1192-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 01:44:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissgerber TL, Gandley RE, Roberts JM, Patterson CC, Holmes VA, Young IS, et al</AU>
<TI>Haptoglobin phenotype, preeclampsia risk and response to vitamin C and E supplementation in pregnant women with type 1 diabetes</TI>
<SO>Reproductive Sciences (Thousand Oaks, Calif.)</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>3 Suppl</NO>
<PG>268A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1991" MODIFIED="2016-02-08 11:37:04 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MRC Vitamin Study Research Group</AU>
<TI>Prevention of neural tube defects: results of the Medical Research Council vitamin study</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-08 11:37:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathews F, Murphy M, Wald NJ, Hackshaw A</AU>
<TI>Twinning and folic acid use</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>291-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osrin-2005" MODIFIED="2016-04-18 10:00:03 +0100" MODIFIED_BY="Heather Maxwell" NAME="Osrin 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-02-03 05:56:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devakumar D, Chaube SS, Wells JC, Saville NM, Ayres JG, Manandhar DS, et al</AU>
<TI>Effect of antenatal multiple micronutrient supplementation on anthropometry and blood pressure in mid-childhood in Nepal: follow-up of a double-blind randomised controlled trial</TI>
<SO>The Lancet. Global Health</SO>
<YR>2014</YR>
<VL>2</VL>
<NO>11</NO>
<PG>e654-63</PG>
<EN>ISRCTN88625934</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:56:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devakumar D, Stocks J, Ayres JG, Kirkby J, Yadav SK, Saville NM, et al</AU>
<TI>Effects of antenatal multiple micronutrient supplementation on lung function in mid-childhood: follow-up of a double-blind randomised controlled trial in Nepal</TI>
<SO>European Respiratory Journal</SO>
<YR>2015</YR>
<VL>45</VL>
<NO>6</NO>
<PG>1566-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:56:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devakumar D, Wells JCK, Chaube SS, Saville NM, Manandhar DS, Costello A, et al</AU>
<TI>The phenotypic effects of antenatal multiple micronutrient supplementation in Nepalese children</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2014</YR>
<VL>99</VL>
<NO>Suppl 1</NO>
<PG>A2, Abstract no: P04</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:05:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hindle LJ, Gitau R, Filteau SM, Newens KJ, Osrin D, Costello AM, et al</AU>
<TI>Effect of multiple micronutrient supplementation during pregnancy on inflammatory markers in Nepalese women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>5</NO>
<PG>1086-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:56:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>MIRA (Mother Infant Research Unit)</AU>
<TI>MIRA Janakpur. Multiple micronutrient supplementation study. The effects of multiple micronutrient supplementation on birthweight, gestation and infection: a double blind, randomised controlled trial conducted in Nepal</TI>
<SO>Personal communication</SO>
<YR>2003</YR>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:00:03 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Osrin D, Vaidya A, Shrestha Y, Baniya RB, Manandhar DS, Adhikari RK, et al</AU>
<TI>Effects of antenatal multiple micronutrient supplementation on birthweight and gestational duration in Nepal: double-blind, randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>955-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:56:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaidya A, Saville N, Shrestha BP, Costello AM, Manandhar DS, Osrin D</AU>
<TI>Effects of antenatal multiple micronutrient supplementation on children's weight and size at 2 years of age in Nepal: follow-up of a double-blind randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9611</NO>
<PG>492-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-People_x0027_s-League-1942" NAME="People's League 1942" YEAR="1942">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>People's League of Health</AU>
<TI>Nutrition of expectant and nursing mothers: interim report</TI>
<SO>Lancet</SO>
<YR>1942</YR>
<VL>2</VL>
<PG>10-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>People's League of Health</AU>
<TI>The nutrition of expectant and nursing mothers in relation to maternal and infant mortality and morbidity</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Empire</SO>
<YR>1946</YR>
<VL>53</VL>
<PG>498-509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poston-2006" MODIFIED="2016-04-03 01:16:24 +0100" MODIFIED_BY="[Empty name]" NAME="Poston 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-04-03 01:16:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH, for the Vitamins in Pre-eclampsia (VIP) Trial Consortium</AU>
<TI>Vitamin C and vitamin E in pregnant women at risk forpre-eclampsia (VIP trial): randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<PG>1145&#8211;54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prawirohartono-2011" MODIFIED="2016-03-22 01:13:59 +0000" MODIFIED_BY="[Empty name]" NAME="Prawirohartono 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-03-22 00:37:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prawirohartono EP, Nystrom L, Ivarsson A, Stenlund H, Lind T</AU>
<TI>The impact of prenatal vitamin A and zinc supplementation on growth of children up to 2 years of age in rural Java, Indonesia</TI>
<SO>Public Health Nutrition</SO>
<YR>2011</YR>
<VL>14</VL>
<NO>12</NO>
<PG>2197-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-22 01:13:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prawirohartono EP, Nystrom L, Nurdiati DS, Hakimi M, Lind T</AU>
<TI>The impact of prenatal vitamin A and zinc supplementation on birth size and neonatal survival - a double-blind, randomized controlled trial in a rural area of Indonesia</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>2013</YR>
<VL>83</VL>
<NO>1</NO>
<PG>14-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberfroid-2008" MODIFIED="2016-04-18 10:01:48 +0100" MODIFIED_BY="Heather Maxwell" NAME="Roberfroid 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-02-03 05:27:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberfroid D, Huybregts L, Habicht JP, Lanou H, Henry MC, Meda N, et al</AU>
<TI>Randomized controlled trial of 2 prenatal iron supplements: is there a dose-response relation with maternal hemoglobin?</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>93</VL>
<NO>5</NO>
<PG>1012-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:27:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberfroid D, Huybregts L, Lanou H, Habicht JP, Henry MC, Meda N, et al</AU>
<TI>Prenatal micronutrient supplements cumulatively increase fetal growth</TI>
<SO>Journal of Nutrition</SO>
<YR>2012</YR>
<VL>142</VL>
<NO>3</NO>
<PG>548-54</PG>
<EN>NCT00642408</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:01:30 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberfroid D, Huybregts L, Lanou H, Henry MC, Meda N, Kolsteren FP, et al</AU>
<TI>Effect of maternal multiple micronutrient supplements on cord blood hormones: a randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>91</VL>
<NO>6</NO>
<PG>1649-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:01:48 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roberfroid D, Huybregts L, Lanou H, Henry MC, Meda N, Menten J, et al</AU>
<TI>Effects of maternal multiple micronutrient supplementation on fetal growth: a double-blind randomized controlled trial in rural Burkina Faso</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2008</YR>
<VL>88</VL>
<NO>5</NO>
<PG>1330-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 05:27:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberfroid D, Huybregts L, Lanou H, Ouedraogo L, Henry MC, Meda N, et al</AU>
<TI>Impact of prenatal multiple micronutrients on survival and growth during infancy: a randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2012</YR>
<VL>95</VL>
<NO>4</NO>
<PG>916-24</PG>
<EN>NCT00642408</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-2010" MODIFIED="2016-03-16 01:44:00 +0000" MODIFIED_BY="[Empty name]" NAME="Roberts 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gandley R, Abramovici A</AU>
<TI>Prenatal vitamin C and e supplementation is associated with a reduction in placental abruption and preterm birth in smokers</TI>
<SO>Pregnancy Hypertension</SO>
<YR>2012</YR>
<VL>2</VL>
<NO>3</NO>
<PG>331-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-08 11:34:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauth J; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network</AU>
<TI>Vitamin C and E supplementation to prevent preterm premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2009</YR>
<VL>201</VL>
<NO>6 Suppl 1</NO>
<PG>S175-S176</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauth JC, Clifton RG, Roberts JM, Myatt L, Spong CY, Leveno KJ, et al</AU>
<TI>Maternal insulin resistance and preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2011</YR>
<VL>204</VL>
<NO>4</NO>
<PG>327.e1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauth JC, Clifton RG, Roberts JM, Spong CY, Myatt L, Leveno KJ, et al</AU>
<TI>Vitamin C and E supplementation to prevent spontaneous preterm birth: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>3</NO>
<PG>653-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauth JC</AU>
<TI>Maternal insulin resistance and preeclampsia</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2011</YR>
<VL>204</VL>
<NO>1 Suppl</NO>
<PG>S12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NICHD MFMUMFMUN</AU>
<TI>Combined antioxidants and preeclampsia prediction studies</TI>
<SO>Biostatistics Center - George Washington University (http://www.bsc.gwu.edu.mfmu/projects/capps.cgi) (accessed September 1 2004)</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Child Health and Human Development (NICHD)</AU>
<TI>Antioxidant therapy to prevent preeclampsia</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 14 June 2005)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-29 06:17:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al</AU>
<TI>Vitamins C and E to prevent complications of pregnancy-associated hypertension</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<NO>14</NO>
<PG>1282-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JM, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</AU>
<TI>A randomized controlled trial of antioxidant vitamins to prevent serious complications associated with pregnancy related hypertension in low risk, nulliparous women</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2008</YR>
<VL>199</VL>
<NO>6 Suppl 1</NO>
<PG>S4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumbold-2006" MODIFIED="2016-02-10 09:35:10 +0000" MODIFIED_BY="[Empty name]" NAME="Rumbold 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-02-10 09:35:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS, for the ACTS Study Group</AU>
<TI>Vitamins C and E and the risks of preeclampsia and perinatal complications</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>17</NO>
<PG>1796-806</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-10 09:34:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS</AU>
<TI>Australian collaborative trial of supplements (ACTS) with vitamin C and E for the prevention of pre-eclampsia - a randomised controlled trial</TI>
<SO>Perinatal Society of Australia and New Zealand 10th Annual Congress; 2006 April 3-6; Perth, Australia</SO>
<YR>2006</YR>
<PG>180</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumiris-2006" MODIFIED="2010-09-28 19:55:57 +0100" MODIFIED_BY="[Empty name]" NAME="Rumiris 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-28 19:55:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rumiris D, Purwosunu Y, Wibowo N, Farina A, Sekizawa A</AU>
<TI>Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>3</NO>
<PG>241-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rush-1980" MODIFIED="2016-04-18 10:04:00 +0100" MODIFIED_BY="Heather Maxwell" NAME="Rush 1980" YEAR="1980">
<REFERENCE MODIFIED="2016-04-18 10:04:00 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rush D, Kristal A, Navarro C, Chaunhan P, Blanc W, Naeye R, et al</AU>
<TI>The effects of dietary supplementation during pregnancy on placental morphology, pathology and histomorphometry</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1984</YR>
<VL>39</VL>
<PG>863-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rush D, Stein Z, Susser M</AU>
<TI>A randomized trial of prenatal nutritional supplementation in New York City</TI>
<SO>Pediatrics</SO>
<YR>1980</YR>
<VL>65</VL>
<NO>4</NO>
<PG>683-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2001" MODIFIED="2016-04-18 10:04:34 +0100" MODIFIED_BY="Heather Maxwell" NAME="Schmidt 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-04-18 10:04:34 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muslimatun S, Schmidt MK, Schultink W, West CE, Hautvast JA, Gross R, et al</AU>
<TI>Weekly supplementation with iron and vitamin A during pregnancy increases hemoglobin concentration but decreases serum ferritin concentration in Indonesian pregnant women</TI>
<SO>Journal of Nutrition</SO>
<YR>2001</YR>
<VL>131</VL>
<NO>1</NO>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muslimatun S, Schmidt MK, West CE, Schultink W, Gross R, Hautvast JG</AU>
<TI>Determinants of weight and length of Indonesian neonates</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>10</NO>
<PG>947-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muslimatun S, Schmidt MK, West CE, Schultink W, Hautvast JG, Karyadi D</AU>
<TI>Weekly vitamin A and iron supplementation during pregnancy increases vitamin A concentration of breast milk but not iron status in Indonesian lactating women</TI>
<SO>Journal of Nutrition</SO>
<YR>2001</YR>
<VL>131</VL>
<NO>10</NO>
<PG>2664-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt MK, Muslimatun S, West CE, Schultink W, Hautvast JG</AU>
<TI>Randomised double-blind trial of the effect of vitamin A supplementation of Indonesian pregnant women on morbidity and growth of their infants during the first year of life</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>56</VL>
<PG>338-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt MK, Muslimatun S, West CE, Schultink W, Hautvast JG</AU>
<TI>Vitamin A and iron supplementation of Indonesian pregnant women benefits vitamin A status of their infants</TI>
<SO>British Journal of Nutrition</SO>
<YR>2001</YR>
<VL>86</VL>
<PG>607-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spinnato-2007" MODIFIED="2010-09-28 19:55:43 +0100" MODIFIED_BY="[Empty name]" NAME="Spinnato 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-28 19:55:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spinnato II JA, Freire S, Silva JL, Cunha Rudge MV, Martins-Costa S, Koch MA, et al</AU>
<TI>Antioxidant therapy to prevent preeclampsia: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1311-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steyn-2003" MODIFIED="2016-01-13 01:52:05 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Steyn 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-21 08:59:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoeman J, Steyn PS, Odendaal HJ, Grove D</AU>
<TI>Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>8</NO>
<PG>751-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-13 01:52:05 +0000" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steyn PS, Odendaal HJ, Schoeman J, Grove D</AU>
<TI>Vitamin c, pre-eclampsia and preterm labour: a randomized, placebo-controlled, double blind trial [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-07 03:57:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steyn PS, Odendaal HJ, Schoeman J, Stander C, Fanie N, Grove D</AU>
<TI>A randomised, double blind placebo-controlled trial of ascorbic acid supplementation for the prevention of preterm labour</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>2</NO>
<PG>150-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Summit-2008" MODIFIED="2016-02-10 10:39:18 +0000" MODIFIED_BY="[Empty name]" NAME="Summit 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-02-03 05:47:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prado E, Sebayang S, Apriatni M, Hidayati N, Adawiyah S, Islamiyah A, et al</AU>
<TI>Maternal multiple micronutrient supplementation and children's cognition at age 9-12 years in Indonesia</TI>
<SO>FASEB Journal</SO>
<YR>2015</YR>
<VL>29</VL>
<NO>1 Suppl</NO>
<PG>[28.7]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-10 10:39:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prado EL, Alcock KJ, Muadz H, Ullman MT, Shankar AH; for the SUMMIT Study Group</AU>
<TI>Maternal multiple micronutrient supplements and child cognition: a randomized trial in Indonesia</TI>
<SO>Pediatrics</SO>
<YR>2012</YR>
<VL>130</VL>
<NO>3</NO>
<PG>e536-e546</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 04:51:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prado EL, Ullman MT, Muadz H, Alcock KJ, Shankar AH</AU>
<TI>The effect of maternal multiple micronutrient supplementation on cognition and mood during pregnancy and postpartum in indonesia: A randomized trial</TI>
<SO>PLoS ONE</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>3</NO>
<PG>e32519</PG>
<EN>ISRCTN34151616</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 04:51:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sebayang SK, Dibley MJ, Kelly P, Shankar AV, Shankar AH</AU>
<TI>Modifying effect of maternal nutritional status on the impact of maternal multiple micronutrient supplementation on birthweight in Indonesia</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>65</VL>
<NO>10</NO>
<PG>1110-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 04:51:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shankar AV, Asrilla Z, Kadha JK, Sebayang S, Apriatni M, Sulastri A, et al</AU>
<TI>Programmatic effects of a large-scale multiple-micronutrient supplementation trial in Indonesia: using community facilitators as intermediaries for behavior change</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>2 Suppl</NO>
<PG>S207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-10 09:32:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Supplementation with Multiple Micronutrients Intervention Trial (SUMMIT) Study Group, Shankar AH, Jahari AB, Sebayang SK, Aditiawarman, Apriatni M, et al</AU>
<TI>Effect of maternal multiple micronutrient supplementation on fetal loss and infant death in Indonesia: a double-blind cluster-randomised trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9608</NO>
<PG>215-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-02-10 10:38:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-02-10 10:38:07 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN34151616"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunawang-2009" MODIFIED="2016-01-22 01:54:09 +0000" MODIFIED_BY="[Empty name]" NAME="Sunawang 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-12-29 17:49:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunawang, Utomo B, Hidayat A, Kusharisupeni, Subarkah</AU>
<TI>Preventing low birthweight through maternal multiple micronutrient supplementation: a cluster-randomized, controlled trial in Indramayu, West Java</TI>
<SO>Food &amp; Nutrition Bulletin</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>4</NO>
<PG>S488-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tofail-2008" MODIFIED="2016-01-29 11:48:53 +0000" MODIFIED_BY="[Empty name]" NAME="Tofail 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekstrom EC, Eneroth H, Arifeen SE, Persson L</AU>
<TI>Efficacy of micronutrient supplement intake in increasing hemoglobin in pregnancy: Dose-effect comparisons with multiple micronutrient in the MINIMat trial in rural Bangladesh</TI>
<SO>FASEB Journal</SO>
<YR>2013</YR>
<VL>27 Suppl</VL>
<PG>Abstract no: 845.25</PG>
<EN>ISRCTN16581394</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eneroth H, El Arifeen S, Persson LA, Lonnerdal B, Hossain MB, Stephensen CB, et al</AU>
<TI>Maternal multiple micronutrient supplementation has limited impact on micronutrient status of Bangladeshi infants compared with standard iron and folic acid supplementation</TI>
<SO>Journal of Nutrition</SO>
<YR>2010</YR>
<VL>140</VL>
<NO>3</NO>
<PG>618-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eneroth H, Persson LA, El Arifeen S, Ekstrom EC</AU>
<TI>Infant anaemia is associated with infection, low birthweight and iron deficiency in rural Bangladesh</TI>
<SO>Acta Paediatrica</SO>
<YR>2011</YR>
<VL>100</VL>
<NO>2</NO>
<PG>220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkesworth S, Wagatsuma Y, Kahn AI, Hawlader MD, Fulford AJ, Arifeen SE, et al</AU>
<TI>Combined food and micronutrient supplements during pregnancy have limited impact on child blood pressure and kidney function in rural Bangladesh</TI>
<SO>Journal of Nutrition</SO>
<YR>2013</YR>
<VL>143</VL>
<NO>5</NO>
<PG>728-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan A, Kabir I, Ekstrom EC, Asling-Monemi K, Alam D, Frongillo EA, et al</AU>
<TI>Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: A randomized trial in Bangladesh</TI>
<SO>Nutrition Journal</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>1</NO>
<PG>134</PG>
<EN>ISRCTN16581394</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan AI, Hawkesworth S, Ekstrom EC, Arifeen S, Moore SE, Frongillo EA, et al</AU>
<TI>Effects of exclusive breastfeeding intervention on child growth and body composition: The MINIMat trial, Bangladesh</TI>
<SO>Acta Paediatrica</SO>
<YR>2013</YR>
<VL>102</VL>
<NO>8</NO>
<PG>815-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan AI</AU>
<TI>Effects of pre- and postnatal nutrition interventions on child growth and body composition: the MINIMat trial in rural Bangladesh</TI>
<SO>Global Health Action</SO>
<YR>2013</YR>
<VL>6</VL>
<PG>22476</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindström E, Hossain MB, Lönnerdal B, Raqib R, El Arifeen S, Ekström EC</AU>
<TI>Prevalence of anemia and micronutrient deficiencies in early pregnancy in rural Bangladesh, the MINIMat trial</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2011</YR>
<VL>90</VL>
<NO>1</NO>
<PG>47-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore SE, Fulford AJ, Wagatsuma Y, Persson LA, Arifeen SE, Prentice AM</AU>
<TI>Thymus development and infant and child mortality in rural Bangladesh</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2014</YR>
<VL>43</VL>
<PG>216-23</PG>
<EN>ISRCTN16581394</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Persson LA, Arifeen S, Ekstrom EC, Rasmussen KM, Frongillo EA, Yunus M</AU>
<TI>Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: The MINIMat randomized trial</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>307</VL>
<NO>19</NO>
<PG>2050-9</PG>
<EN>ISRCTN16581394</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaheen R, Persson LA, Ahmed S, Lindholm L</AU>
<TI>Early invitation to prenatal food combined with multiple micronutrients is cost-effective compared to iron-folic acid supplementations: Results from MINIMat trial</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>Suppl 1</NO>
<PG>88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaheen R, Persson LA, Ahmed S, Streatfield PK, Lindholm L</AU>
<TI>Cost-effectiveness of invitation to food supplementation early in pregnancy combined with multiple micronutrients on infant survival: analysis of data from MINIMat randomized trial, Bangladesh</TI>
<SO>BMC Pregnancy and Childbirth</SO>
<YR>2015</YR>
<VL>15</VL>
<NO>1</NO>
<PG>125</PG>
<EN>ISRCTN16581394</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaheen R, Streatfield PK, Naved RT, Lindholm L, Persson LA</AU>
<TI>Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh</TI>
<SO>BMC Public Health</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>5</PG>
<EN>ISRCTN16581394</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-29 11:48:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tofail F, Persson LA, El Arifeen S, Hamadani JD, Mehrin F, Ridout D, et al</AU>
<TI>Effects of prenatal food and micronutrient supplementation on infant development: a randomized trial from the maternal and infant nutrition interventions, Matlab (MIMIMat) study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2008</YR>
<VL>87</VL>
<NO>3</NO>
<PG>704-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-den-Broek-2006" MODIFIED="2016-04-26 15:35:46 +0100" MODIFIED_BY="[Empty name]" NAME="Van den Broek 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-04-26 15:35:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trial not published to date, but recruitment expected to be completed April 1999. Primary outcome listed as Hb at term.&lt;/p&gt;" NOTES_MODIFIED="2016-04-26 15:35:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Van den Broek N</AU>
<TI>Vitamin A supplementation for anaemia in pregnancy</TI>
<SO>Personal communication 1998</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-26 15:35:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van den Broek NR, White SA, Flowers C, Cook JD, Letsky EA, Tanumihardjo SA, et al</AU>
<TI>Randomised trial of vitamin A supplementation in pregnant women in rural Malawi found to be anaemic on screening by HemoCue</TI>
<SO>BJOG: an International Journal of Obstetrics and Gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>5</NO>
<PG>569-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villar-2009" MODIFIED="2016-04-26 15:36:29 +0100" MODIFIED_BY="[Empty name]" NAME="Villar 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-04-26 15:36:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Purwar M, Merialdi M, Zavaleta N, Ngoc N, Anthony J et al</AU>
<TI>Effect of vitamin C &amp; E supplementation of pregnant women at risk of preeclampsia plus low nutritional status: the WHO trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>4</NO>
<PG>501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-26 15:36:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J et al</AU>
<TI>World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2009</YR>
<VL>116</VL>
<NO>6</NO>
<PG>780-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-03 06:25:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villar J, Purwar M, Merialdi M, Zavaleta N, Tien NN, Anthony J</AU>
<TI>WHO randomized trial of vitamin C and E supplementation among women at high risk for preeclampsia and nutritional deficiency</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>197</VL>
<NO>6 Suppl 1</NO>
<PG>S4, Abstract no: 8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-West-2011" MODIFIED="2016-04-18 10:26:38 +0100" MODIFIED_BY="Heather Maxwell" NAME="West 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-06 05:56:27 +0000" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Klemm R, Shamim AA, Ali H, Rashid M, Shaikh S, et al</AU>
<TI>Effects of vitamin A and beta-carotene supplementation on birth size and length of gestation in rural Bangladesh: a cluster-randomized trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2013</YR>
<VL>97</VL>
<NO>1</NO>
<PG>188-94</PG>
<EN>NCT00198822</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-06 05:54:48 +0000" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Labrique AB, Ali H, Richman MJ, Wu L, Rashid M, et al</AU>
<TI>Maternal vitamin A and beta-carotene supplementation and risk of bacterial vaginosis: a randomized controlled trial in rural Bangladesh</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>94</VL>
<NO>6</NO>
<PG>1643-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-06 05:55:46 +0000" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labrique AB, Christian P, Klemm RDW, Rashid M, Shamim AA, Massie A, et al</AU>
<TI>A cluster-randomized, placebo-controlled, maternal vitamin A or beta-carotene supplementation trial in Bangladesh: design and methods</TI>
<SO>Trials</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:26:38 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>West KPJ, Christian P, Labrique AB, Rashid M, Shamim AA, Klemm RD, et al</AU>
<TI>Effects of vitamin A or beta carotene supplementation on pregnancy-related mortality and infant mortality in rural Bangladesh: a cluster randomized trial</TI>
<SO>JAMA</SO>
<YR>2011</YR>
<VL>305</VL>
<NO>19</NO>
<PG>1986-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-West-2014" MODIFIED="2016-04-18 10:27:55 +0100" MODIFIED_BY="Heather Maxwell" NAME="West 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-13 01:40:39 +0000" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gernand AD, Schulze KJ, Nanayakkara-Bind A, Arguello M, Shamim AA, Ali H, et al</AU>
<TI>Effects of prenatal multiple micronutrient supplementation on fetal growth factors: a cluster-randomized, controlled trial in rural Bangladesh</TI>
<SO>Plos One</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>10</NO>
<PG>e0137269</PG>
<EN>NCT00860470</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:39:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West KP, Shamim AA, Labrique AB, Ali H, Shaikh S, Mehra S, et al</AU>
<TI>Efficacy of antenatal multiple micronutrient (MM) vs iron-folic acid (IFA) supplementation in improving gestational and postnatal viability in rural Bangladesh: The JiVitA-3 trial</TI>
<SO>FASEB Journal</SO>
<YR>2013</YR>
<VL>27 Suppl</VL>
<PG>Abstract no: 358.6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:39:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>West KP</AU>
<TI>Antenatal micronutrient supplementation and infant survival (JiVitA-3)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov) (accessed 8 July 2011)</SO>
<YR>2011</YR>
<EN>NCT00860470</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:27:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>West KPJ, Shamim AA, Mehra S, Labrique AB, Ali H, Shaikh S, et al</AU>
<TI>Effect of maternal multiple micronutrient vs iron-folic acid supplementation on infant mortality and adverse birth outcomes in rural Bangladesh: the JiVitA-3 randomized trial</TI>
<SO>JAMA</SO>
<YR>2014</YR>
<VL>312</VL>
<NO>24</NO>
<PG>2649-58</PG>
<EN>NCT00860470</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wibowo-2012" MODIFIED="2016-04-18 10:28:12 +0100" MODIFIED_BY="Heather Maxwell" NAME="Wibowo 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-03-11 12:47:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sezikawa A</AU>
<TI>Antioxidant supplementation in pregnant women with low antioxidant status</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 June 2007)</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:28:12 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wibowo N, Purwosunu Y, Sekizawa A, Farina A, Idriansyah L, Fitriana I</AU>
<TI>Antioxidant supplementation in pregnant women with low antioxidant status</TI>
<SO>Journal of Obstetrics &amp; Gynaecology Research</SO>
<YR>2012</YR>
<VL>38</VL>
<NO>9</NO>
<PG>1152-61</PG>
<EN>NCT01232205</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2010" MODIFIED="2016-04-18 10:29:31 +0100" MODIFIED_BY="Heather Maxwell" NAME="Xu 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-04-18 10:29:31 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu H, Perez-Cuevas R, Xiong X, Reyes H, Roy C, Julien P, et al</AU>
<TI>An international trial of antioxidants in the prevention of preeclampsia (INTAPP)</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2010</YR>
<VL>202</VL>
<NO>3</NO>
<PG>239.e1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zagre-2007" MODIFIED="2015-12-29 17:50:23 +0000" MODIFIED_BY="[Empty name]" NAME="Zagre 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-12-29 17:50:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zagre NM, Desplats G, Adou P, Mamadoultaibou A, Aguayo VM</AU>
<TI>Prenatal multiple micronutrient supplementation has greater impact on birthweight than supplementation with iron and folic acid: a cluster-randomized, double-blind, controlled programmatic study in rural Niger</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>3</NO>
<PG>317-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2008" MODIFIED="2016-03-11 12:40:11 +0000" MODIFIED_BY="[Empty name]" NAME="Zeng 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao Y, Wang T, Zeng L</AU>
<TI>Risk of childhood malnutrition at 24 months related to small for gestational age and low birth weight in rural Western China</TI>
<SO>Annals of Nutrition &amp; Metabolism</SO>
<YR>2013</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>556, Abstract no: PO619</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang S, Zeng L, Brouwer ID, Kok FJ, Yan H</AU>
<TI>Effect of iron deficiency anemia in pregnancy on child mental development in rural China</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>131</VL>
<NO>3</NO>
<PG>e755-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Yan H, Zeng L, Cheng Y, Liang W, Dang S, et al</AU>
<TI>Effects of maternal multimicronutrient supplementation on the mental development of infants in rural western China: follow-up evaluation of a double-blind, randomized, controlled trial</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>4</NO>
<PG>e685-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang W, Yan H, Zeng L, Cheng Y, Wang D, Li Q</AU>
<TI>No effect of maternal micronutrient supplementation on early childhood growth in rural western China: 30 month follow-up evaluation of a double blind, cluster randomized controlled trial</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>2</NO>
<PG>261-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-11 12:40:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yan H</AU>
<TI>Impact of iron/folate versus multi-micronutrient supplementation during pregnancy on birth weight: a randomised controlled trial in rural Western China</TI>
<SO>ISRCTN Registry (http://www.isrctn.com/) [accessed 15 February 2007]</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-10 10:16:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zeng L, Dibley MJ, Cheng Y, Dang S, Chang S, Kong L, et al</AU>
<TI>Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>337</VL>
<PG>a2001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng L, Yan H, Cheng Y, Dang S, Dibley MJ</AU>
<TI>Adherence and costs of micronutrient supplementation in pregnancy in a double-blind, randomized, controlled trial in rural western China</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>4</NO>
<PG>S480-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng L, Yan H, Cheng Y, Dibley M</AU>
<TI>Modifying effects of maternal nutrition status on the response to multiple micronutrients supplementation on preterm and neonatal mortatility in China</TI>
<SO>Annals of Nutrition &amp; Metabolism</SO>
<YR>2013</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>859-60, Abstract no: PO1241</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-29 17:50:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng L, Yan H, Cheng Y, Dibley MJ</AU>
<TI>Modifying effects of wealth on the response to nutrient supplementation in pregnancy on birth weight, duration of gestation and perinatal mortality in rural western China: double-blind cluster randomized controlled trial</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2011</YR>
<VL>40</VL>
<NO>2</NO>
<PG>350-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-04-26 15:38:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baumslag-1970" MODIFIED="2010-12-07 03:59:13 +0000" MODIFIED_BY="[Empty name]" NAME="Baumslag 1970" YEAR="1970">
<REFERENCE MODIFIED="2010-12-07 03:59:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumslag N, Edelstein T, Metz J</AU>
<TI>Reduction of incidence of prematurity by folic acid supplementation in pregnancy</TI>
<SO>British Medical Journal</SO>
<YR>1970</YR>
<VL>1</VL>
<PG>16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biswas-1984" NAME="Biswas 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biswas MK, Pernoll MJ, Mabie WC</AU>
<TI>A placebo-controlled comparative trial of various prenatal vitamin formulations in pregnant women</TI>
<SO>Clinical Therapeutics</SO>
<YR>1984</YR>
<VL>6</VL>
<NO>6</NO>
<PG>763-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blot-1981" NAME="Blot 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blot I, Papiernik E, Kaltwasser JP, Werner E, Tchernia G</AU>
<TI>Influence of routine administration of folic acid and iron during pregnancy</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1981</YR>
<VL>12</VL>
<PG>294-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chanarin-1968" MODIFIED="2010-12-07 03:59:34 +0000" MODIFIED_BY="[Empty name]" NAME="Chanarin 1968" YEAR="1968">
<REFERENCE MODIFIED="2010-12-07 03:59:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chanarin I, Rothman D, Perry J, Stratfull D</AU>
<TI>Normal dietary folate, iron and protein intake, with particular reference to pregnancy</TI>
<SO>British Medical Journal</SO>
<YR>1968</YR>
<VL>2</VL>
<PG>394-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-07 03:59:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chanarin I, Rothman D, Ward A, Perry J</AU>
<TI>Folate status and requirement in pregnancy</TI>
<SO>British Medical Journal</SO>
<YR>1968</YR>
<VL>2</VL>
<PG>390-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chelchowska-2004" MODIFIED="2016-04-18 10:33:55 +0100" MODIFIED_BY="Heather Maxwell" NAME="Chelchowska 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-04-18 10:33:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chelchowska M, Laskowska-Klita T, Kubik P, Leibschang J</AU>
<TI>The effect of vitamin-mineral supplementation on the level of MDA and activity of glutathione peroxidase and superoxide dismutase in blood of matched maternal-cord pairs</TI>
<TO>Wplyw suplementacji witaminowo-mineralnej na poziom MDA oraz aktywnosc peroksydazy glutationowej i dysmutazy ponadtlenkowej w krwi kobiet ciezarnych i krwi pepowinowej ich dzieci</TO>
<SO>Przeglad Lekarski</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>7</NO>
<PG>760-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-11 12:36:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kubik P, Kowalska B, Laskowska-Klita T, Chelchowska M, Leibschang J</AU>
<TI>Effect of vitamin-mineral supplementation on the status of some microelements in pregnant women</TI>
<TO>Wplyw suplementacji preparatem witaminowo-mineralnym na status wybranych mikroelementow u kobiet ciezarnych</TO>
<SO>Przeglad Lekarski</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>7</NO>
<PG>764-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christian-2003" MODIFIED="2016-04-18 10:39:45 +0100" MODIFIED_BY="Heather Maxwell" NAME="Christian 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-04-18 10:35:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Khatry SK, Katz J, Pradhan EK, LeClerq SC, Shrestha SR, et al</AU>
<TI>Effects of alternative maternal micronutrient supplements on low birth weight in rural Nepal: double blind randomised community trial</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7389</NO>
<PG>571</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-11 12:17:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Murray-Kolb LE, Khatry SK, Katz J, Schaefer BA, Cole PM, et al</AU>
<TI>Prenatal micronutrient supplementation and intellectual and motor function in early school-aged children in Nepal</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>304</VL>
<NO>24</NO>
<PG>2716-23</PG>
<EN>NCT00115271</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:36:19 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Shrestha J, LeClerq S, Khatry SK, Jiang T, Wagner T, et al</AU>
<TI>Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal</TI>
<SO>Journal of Nutrition</SO>
<YR>2003</YR>
<VL>133</VL>
<PG>3492-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:36:48 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, Stewart CP, LeClerq SC, Wu L, Katz J, West KP Jr, et al</AU>
<TI>Antenatal and postnatal iron supplementation and childhood mortality in rural Nepal: a prospective follow-up in a randomized, controlled community trial</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>170</VL>
<NO>9</NO>
<PG>1127-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:39:45 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christian P, West KP, Khatry SK, Leclerq SC, Pradhan EK, Katz J, et al</AU>
<TI>Effects of maternal micronutrient supplementation on fetal loss and infant mortality</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>78</VL>
<NO>6</NO>
<PG>1194-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-11 12:17:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kulkarni B, Christian P, LeClerq SC, Khatry SK</AU>
<TI>Determinants of compliance to antenatal micronutrient supplementation and women's perceptions of supplement use in rural Nepal</TI>
<SO>Public Health Nutrition</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>1</NO>
<PG>82-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-11 12:17:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart CP, Christian P, LeClerq SC, West KP Jr, Khatry SK</AU>
<TI>Antenatal supplementation with folic acid + iron + zinc improves linear growth and reduces peripheral adiposity in school-age children in rural Nepal</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>90</VL>
<NO>1</NO>
<PG>132-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-11 12:17:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart CP, Christian P, Schulze KJ, Arguello M, Leclerq SC, Khatry SK, et al</AU>
<TI>Low maternal vitamin B-12 status is associated with offspring insulin resistance regardless of antenatal micronutrient supplementation in rural Nepal</TI>
<SO>Journal of Nutrition</SO>
<YR>2011</YR>
<VL>141</VL>
<NO>10</NO>
<PG>1912-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colman-1974" NAME="Colman 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colman N, Barker M, Green R, Metz J</AU>
<TI>Prevention of folate deficiency in pregnancy by food fortification</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1974</YR>
<VL>27</VL>
<PG>339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colman N, Larsen JV, Barker M, Barker A, Green R, Metz J</AU>
<TI>Prevention of folate deficiency by food fortification. III. Effect in pregnant subjects of varying amounts of added folic acid</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1975</YR>
<VL>28</VL>
<PG>465-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Correia-1982" MODIFIED="2016-03-24 01:34:18 +0000" MODIFIED_BY="[Empty name]" NAME="Correia 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-03-24 01:34:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Correia JM, Silva Cruz A, Silva Meirinho M</AU>
<TI>The importance of the contribution of folic acid in gestation</TI>
<TO>Importancia del aporte de acido folico en las gestacion</TO>
<SO>Progresos de Obstetricia y Ginecologia</SO>
<YR>1982</YR>
<VL>25</VL>
<NO>6</NO>
<PG>381-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coutsoudis-1999" NAME="Coutsoudis 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM</AU>
<TI>Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African vitamin A study group</TI>
<SO>AIDS</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dawson-1962" MODIFIED="2016-04-18 10:41:33 +0100" MODIFIED_BY="Heather Maxwell" NAME="Dawson 1962" YEAR="1962">
<REFERENCE MODIFIED="2016-04-18 10:41:33 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawson DW, More JR, Aird DC</AU>
<TI>Prevention of megalo-blastic anaemia in pregnancy by folic acid</TI>
<SO>Lancet</SO>
<YR>1962</YR>
<VL>2</VL>
<NO>7264</NO>
<PG>1015-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edelstein-1968" NAME="Edelstein 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edelstein T, Stevens K, Baumslag N, Metz J</AU>
<TI>Folic acid and vitamin B12 supplementation during pregnancy in a population subsisting on a suboptimal diet</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1968</YR>
<VL>75</VL>
<NO>2</NO>
<PG>133-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferguson-1955" NAME="Ferguson 1955" YEAR="1955">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson JH</AU>
<TI>Methionine-vitamin B therapy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1955</YR>
<VL>6</VL>
<NO>2</NO>
<PG>221-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feyi_x002d_Waboso-2005" MODIFIED="2010-07-21 08:56:09 +0100" MODIFIED_BY="[Empty name]" NAME="Feyi-Waboso 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-21 08:56:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feyi-Waboso PA, Chris A, Nwaogu GC, Archibong EI, Ejikem EC</AU>
<TI>The role of parenteral multivitamin preparation (Eldervit-12) in the prevention of anaemia in pregnancy</TI>
<SO>Tropical Journal of Obstetrics and Gynaecology</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>2</NO>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fletcher-1971" NAME="Fletcher 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fletcher J, Gurr A, Fellingham FR, Prankerd TAJ, Brant HA, Menzies DN</AU>
<TI>The value of folic acid supplements in pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1971</YR>
<VL>78</VL>
<PG>781-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giles-1971" NAME="Giles 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giles PFH, Harcourt AG, Whiteside MG</AU>
<TI>The effect of prescribing folic acid during pregnancy on birth weight and duration of pregnancy, a double blind trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>1971</YR>
<VL>5</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampel-1974" NAME="Hampel 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampel KP, Roetz R</AU>
<TI>Influence of a long term substitution with a folate-iron preparation on serum folate, serum iron and haematological data during pregnancy: result of a prospective study</TI>
<SO>Geburtshilfe und Frauenheilkd</SO>
<YR>1974</YR>
<VL>34</VL>
<PG>409-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hankin-1966" NAME="Hankin 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hankin ME, Cellier KM</AU>
<TI>Studies of nutrition in pregnancy V: ascorbic acid levels of blood and milk in pregnancy and lactation</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1966</YR>
<VL>6</VL>
<PG>153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hekmatdoost-2011" MODIFIED="2016-04-26 15:37:18 +0100" MODIFIED_BY="[Empty name]" NAME="Hekmatdoost 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-04-26 15:37:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hekmatdoost A, Vahid F, Yari Z, Sadeghi M, Eini-Zinab H, Lakpour Niknam, et al</AU>
<TI>Methyltetrahydrofolate vs folic acid supplementation in idiopathic recurrent miscarriage with respect to methylenetetrahydrofolate reductase C677T and A1298C polymorphisms: a randomized controlled trial</TI>
<SO>PLoS ONE</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>12</NO>
<PG>e0143569</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-28 06:14:09 +0100" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="OTHER">
<AU>Hekmatdoost A</AU>
<TI>Comparison of the effect of folic acid and 5-methyltetrahydrofolate (5MTHF) on serum folate and homocysteine levels, and abortion rates in women suffering from recurrent abortion</TI>
<SO>IRCT Iranian Registry of Clinical Trials (www.irct.ir) (accessed 8 July 2011)</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hibbard-1969" MODIFIED="2016-02-03 05:02:50 +0000" MODIFIED_BY="[Empty name]" NAME="Hibbard 1969" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hibbard BM, Hibbard ED</AU>
<TI>The prophylaxis of folate deficiency in pregnancy</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1969</YR>
<VL>48</VL>
<PG>339-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hibbard BM, Hibbard ED</AU>
<TI>The treatment of folate deficiency in pregnancy</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1969</YR>
<VL>48</VL>
<PG>349-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunt-1984" MODIFIED="2016-04-18 10:45:00 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hunt 1984" YEAR="1984">
<REFERENCE MODIFIED="2016-04-18 10:45:00 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunt IF, Murphy NJ, Cleaver AE, Faraji B, Swendseid ME, Coulson AH, et al</AU>
<TI>Zinc supplementation during pregnancy: effects on selected blood constituents and on progress and outcome of pregnancy in low-income women of Mexican descent</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1984</YR>
<VL>40</VL>
<PG>508-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huybregts-2009" MODIFIED="2016-02-08 11:33:11 +0000" MODIFIED_BY="[Empty name]" NAME="Huybregts 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-02-08 11:27:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huybregts L, Roberfroid D, Lanou H, Kolsteren P, Camp J</AU>
<TI>Prenatal lipid-based nutrient supplements increase cord leptin concentration in pregnant women from rural Burkina Faso</TI>
<SO>Annals of Nutrition &amp; Metabolism</SO>
<YR>2013</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>799, Abstract no: PO1134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-08 11:29:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huybregts L, Roberfroid D, Lanou H, Meda N, Taes Y, Valea I, et al</AU>
<TI>Prenatal lipid-based nutrient supplements increase cord leptin concentration in pregnant women from rural Burkina Faso</TI>
<SO>Journal of Nutrition</SO>
<YR>2013</YR>
<VL>143</VL>
<NO>5</NO>
<PG>576-83</PG>
<EN>NCT00909974</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-08 11:33:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huybregts L, Roberfroid D, Lanou H, Menten J, Meda N, Van Camp J, et al</AU>
<TI>Prenatal food supplementation fortified with multiple micronutrients increases birth length: a randomized controlled trial in rural Burkina Faso</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>90</VL>
<NO>6</NO>
<PG>1593-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-08 11:29:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanou H, Huybregts L, Roberfroid D, Kolsteren P</AU>
<TI>Effect of prenatal lipid-based nutrient supplementation on gestational weight gain</TI>
<SO>Annals of Nutrition &amp; Metabolism</SO>
<YR>2013</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>783, Abstract no: PO1099</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-08 11:30:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanou H, Huybregts L, Roberfroid D, Nikiema L, Kouanda S, Van Camp J, et al</AU>
<TI>Prenatal nutrient supplementation and postnatal growth in a developing nation: an RCT</TI>
<SO>Pediatrics</SO>
<YR>2014</YR>
<VL>133</VL>
<NO>4</NO>
<PG>e1001-8</PG>
<EN>NCT00909974</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaestel-2005" MODIFIED="2016-04-18 10:46:59 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kaestel 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-02-02 02:23:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen GS, Friis H, Michaelsen KF, Rodrigues A, Benn CS, Aaby P, et al</AU>
<TI>Effects of maternal micronutrient supplementation on fetal loss and under-2-years child mortality: long-term follow-up of a randomised controlled trial from Guinea-Bissau</TI>
<SO>African Journal of Reproductive Health</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>2</NO>
<PG>17-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:46:59 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaestel P, Michaelsen KF, Aaby P, Friis H</AU>
<TI>Effects of prenatal multimicronutrient supplements on birth weight and perinatal mortality: a randomised, controlled trial in Guinea-Bissau</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>9</NO>
<PG>1081-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurence-1981" MODIFIED="2010-12-07 04:02:07 +0000" MODIFIED_BY="[Empty name]" NAME="Laurence 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-12-07 04:02:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laurence KM, James N, Miller MH, Tennant GB, Campbell H</AU>
<TI>Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects</TI>
<SO>British Medical Journal (Clinical Research Edition)</SO>
<YR>1981</YR>
<VL>282</VL>
<PG>1509-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurence KM</AU>
<TI>Prevention of neural tube defects by improvement in maternal diet and preconceptional folic acid supplementation</TI>
<SO>Progress in Clincial and Biological Research</SO>
<YR>1985</YR>
<VL>163</VL>
<PG>383-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2010" MODIFIED="2016-01-06 00:03:07 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Lin 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-06 00:03:07 +0000" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin JH, Yang YK, Liu H, Lin QD, Zhang WY</AU>
<TI>Effect of antioxidants on amelioration of high-risk factors inducing hypertensive disorders in pregnancy</TI>
<SO>Chinese Medical Journal</SO>
<YR>2010</YR>
<VL>123</VL>
<NO>18</NO>
<PG>2548-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lira-1989" NAME="Lira 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lira P, Barrena N, Foradori A, Gormaz G, Grebe G</AU>
<TI>Folate deficiency in pregnancy: effect of supplemental folate</TI>
<TO>Deficiencia de folatos en el embarazo: Efecto de una suplementacion con acido folico</TO>
<SO>Sangre</SO>
<YR>1989</YR>
<VL>34</VL>
<NO>1</NO>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lumeng-1976" NAME="Lumeng 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lumeng L, Cleary RE, Wagner R, Pao-Lo Y, Ting-Kai L</AU>
<TI>Adequacy of vitamin B6 supplementation during pregnancy: a prospective study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1976</YR>
<VL>29</VL>
<PG>1379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marya-1981" NAME="Marya 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marya RK, Rathee S, Lata V, Mudgil S</AU>
<TI>Effects of vitamin D supplementation in pregnancy</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1981</YR>
<VL>12</VL>
<PG>155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meirinho-1987" NAME="Meirinho 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meirinho M, Correia JM, Silva Cruz A</AU>
<TI>Administration of folic acid during pregnancy and trophoblastic disease</TI>
<TO>Administracion de acido folico en la gestacion y actividad trofoblastica</TO>
<SO>Progresos de Obstetricia y Ginecologia</SO>
<YR>1987</YR>
<VL>30</VL>
<NO>2</NO>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metz-1965" NAME="Metz 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metz J, Festenstein H, Welch P</AU>
<TI>Effect of folic acid and vitamin B12 supplementation on tests of folate and vitamin B12 nutrition in pregnancy</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1965</YR>
<VL>16</VL>
<PG>472-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mock-2002" MODIFIED="2010-09-28 19:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Mock 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-28 19:54:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mock DM, Quirk JG, Mock NI</AU>
<TI>Marginal biotin deficiency during normal pregnancy</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>75</VL>
<PG>295-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moldenhauer-2002" NAME="Moldenhauer 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moldenhauer J, Guo S, Liang R, Prada J</AU>
<TI>Dietary intake levels of the antioxidants vitamin C and vitamin E are adequately achieved with standard prenatal vitamin supplementation in high risk pregnancy groups [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owen-1966" MODIFIED="2016-02-03 05:51:39 +0000" MODIFIED_BY="[Empty name]" NAME="Owen 1966" YEAR="1967">
<REFERENCE MODIFIED="2016-02-03 05:51:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen GM, Nelsen CE, Baker GL, Connor WE, Jacobs JP</AU>
<TI>Use of vitamin K1 in pregnancy: effect of serum bilirubin and plasma prothrombin in the newborn</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1967</YR>
<VL>99</VL>
<NO>3</NO>
<PG>368-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Owen GM, Nelsen CE, Baker GL, Connor WE, Jacobs JP</AU>
<TI>Use of vitamin K1 in pregnancy: effect on bilirubin metabolism and coagulation mechanism in the newborn</TI>
<SO>Pediatrics</SO>
<YR>1966</YR>
<VL>68</VL>
<NO>5</NO>
<PG>850</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potdar-2014" MODIFIED="2016-04-26 15:38:17 +0100" MODIFIED_BY="[Empty name]" NAME="Potdar 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-02 02:13:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fall C</AU>
<TI>Mumbai maternal nutrition project</TI>
<SO>Current Controlled Trials (www.controlled-trials.com)</SO>
<YR>(accessed 15 February 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-26 15:38:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Potdar RD, Sahariah SA, Gandhi M, Kehoe SH, Brown N, Sane H, et al</AU>
<TI>Improving women's diet quality preconceptionally and during gestation: effects on birth weight and prevalence of low birth weight&#8212;a randomized controlled efficacy trial in India (Mumbai Maternal Nutrition Project)</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2014</YR>
<VL>100</VL>
<NO>5</NO>
<PG>1257-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-28 07:00:18 +0100" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Potdar RD, Sahariah SA, Gandhi M, Sane H, Brown NB, Fall C, et al</AU>
<TI>Preconceptual nutrition and weight gain in a) women during pregnancy and b) in babies at birth in Mumbai Maternal Nutrition Project (a RCT)</TI>
<SO>The Power of Programming 2014: International Conference on Developmental Origins of Adiposity and Long-Term Health</SO>
<YR>March 2014</YR>
<VL>61</VL>
<PG>13-15</PG>
<CY>Munich, Germany</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-1985" NAME="Ross 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross SM, Nel E, Naeye RL</AU>
<TI>Differing effects of low and high bulk maternal dietary supplements during pregnancy</TI>
<SO>Early Human Development</SO>
<YR>1985</YR>
<VL>10</VL>
<PG>298-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuster-1984" NAME="Schuster 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuster K, Bailey LB, Mahan CS</AU>
<TI>Effect of maternal pyridoxine-HCl supplementation on the vitamin B-6 status of mother and infant and on pregnancy outcomes</TI>
<SO>Journal of Nutrition</SO>
<YR>1984</YR>
<VL>114</VL>
<PG>977-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semba-2001" MODIFIED="2016-04-18 10:51:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Semba 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-04-18 10:51:06 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Kumwenda N, Taha TE, Mtimavalye L, Broadhead R, Garrett E, et al</AU>
<TI>Impact of vitamin A supplementation on anaemia and plasma erthryopoietin concentrations in pregnant women: a controlled clinical trial</TI>
<SO>European Journal of Haematology</SO>
<YR>2001</YR>
<VL>66</VL>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shu-2002" MODIFIED="2010-07-21 09:00:17 +0100" MODIFIED_BY="[Empty name]" NAME="Shu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-07-21 09:00:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shu J, Miao P, Wang RJ</AU>
<TI>Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion. [Chinese]</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional &amp; Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>6</NO>
<PG>414-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smithells-1981" MODIFIED="2016-04-18 10:51:27 +0100" MODIFIED_BY="Heather Maxwell" NAME="Smithells 1981" YEAR="1981">
<REFERENCE MODIFIED="2016-04-18 10:51:27 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smithells RW, Sheppard S, Schorah CJ, Sellar MJ, Nevin NC, Harris R, et al</AU>
<TI>Apparent prevention of neural tube defects by periconceptional vitamin supplementation</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1981</YR>
<VL>56</VL>
<PG>911-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suharno-1993" NAME="Suharno 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suharno D, West CE, Muhilal, Karyadi D, Hautvast JG</AU>
<TI>Supplementation with vitamin A and iron for nutritional anaemia in pregnant women in West Java, Indonesia</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<PG>1325-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanumihardjo-2002" MODIFIED="2010-12-07 04:18:38 +0000" MODIFIED_BY="[Empty name]" NAME="Tanumihardjo 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-12-07 04:18:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanumihardjo SA</AU>
<TI>Vitamin A and iron status are improved by vitamin A and iron supplementation in pregnant Indonesian women</TI>
<SO>Journal of Nutrition</SO>
<YR>2002</YR>
<VL>132</VL>
<PG>1909-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1982" MODIFIED="2016-03-11 12:18:01 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-03-11 12:18:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This trial was identified from the iron and folate supplementation in pregnancy Cochrane review. In the paper, the only clinical outcome reported  was birthweight,  however the review states that the trial reports PIH and stillbirth/neonatal death. To clarify with the reviewers.&lt;/p&gt;" NOTES_MODIFIED="2016-03-11 12:18:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor DJ, Mallen C, McDougall N, Lind T</AU>
<TI>Effect of iron supplementation on serum ferritin levels during and after pregnancy</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1982</YR>
<VL>89</VL>
<PG>1011-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thauvin-1992" MODIFIED="2016-04-18 10:52:16 +0100" MODIFIED_BY="Heather Maxwell" NAME="Thauvin 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-04-18 10:52:16 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thauvin E, Fusselier M, Arnaud J, Faure H, Favier H, Coudray C, et al</AU>
<TI>Effects of a multivitamin mineral supplement on zinc and copper status during pregnancy</TI>
<SO>Biological Trace Elements Research</SO>
<YR>1992</YR>
<VL>32</VL>
<PG>405-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trigg-1976" MODIFIED="2016-02-03 06:37:57 +0000" MODIFIED_BY="[Empty name]" NAME="Trigg 1976" YEAR="1976">
<REFERENCE MODIFIED="2016-02-03 06:37:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trigg KH, Rendall EJC, Johnson A, Fellingham FR, Prankerd TAJ</AU>
<TI>Folate supplements during pregnancy</TI>
<SO>Journal of the Royal College of General Practitioners</SO>
<YR>1976</YR>
<VL>26</VL>
<PG>228-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulrich-1999" NAME="Ulrich 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rolschau J, Kristoffersen K, Ulrich M, Grinsted P, Schaumburg E, Foged N</AU>
<TI>The influence of folic acid supplement on the outcome of pregnancies in the county of Funen in Denmark. Part I</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1999</YR>
<VL>87</VL>
<NO>2</NO>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich M, Kristoffersen K, Rolschau J, Grinsted P, Schaumburg E, Foged N</AU>
<TI>The influence of folic acid supplement on the outcome of pregnancies in the county of Funen in Denmark. Part II. Congenital anomalies. A randomised study</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1999</YR>
<VL>87</VL>
<NO>2</NO>
<PG>111-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich M, Kristoffersen K, Rolschau J, Grinsted P, Schaumburg E, Foged N</AU>
<TI>The influence of folic acid supplement on the outcome of pregnancies in the county of Funen in Denmark. Part III. Congenital anomalies. An observational study</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1999</YR>
<VL>87</VL>
<NO>2</NO>
<PG>115-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villamor-2002" MODIFIED="2016-04-18 10:53:04 +0100" MODIFIED_BY="Heather Maxwell" NAME="Villamor 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-04-18 10:53:04 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villamor E, Msamanga G, Spielgelman D, Antelman G, Peterson KE, Hunter DJ, et al</AU>
<TI>Effect of multivitamin and vitamin A supplements on weight gain during pregnancy among HIV-1-infected women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>76</VL>
<PG>1082-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vutyavanich-1995" NAME="Vutyavanich 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vutyavanich T, Wongtra-ngan S, Ruangsri R</AU>
<TI>Pyroxidone for nausea and vomiting of pregnancy: a randomized, double-blind, placebo controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<NO>3</NO>
<PG>881-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wehby-2012" MODIFIED="2016-04-18 10:56:13 +0100" MODIFIED_BY="Heather Maxwell" NAME="Wehby 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-04-02 13:42:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Javois L</AU>
<TI>Birth defects treatment and prevention program: oral cleft prevention program (ongoing trial)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006)</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:55:35 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vila-Nova C, Wehby GL, Queiros FC, Chakraborty H, Felix TM, Goco N, et al</AU>
<TI>Periconceptional use of folic acid and risk of miscarriage - findings of the Oral Cleft Prevention Program in Brazil</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2013</YR>
<VL>41</VL>
<NO>4</NO>
<PG>461-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:55:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wehby GL, Felix TM, Goco N, Richieri-Costa A, Chakraborty H, Souza J, et al</AU>
<TI>High dosage folic acid supplementation, oral cleft recurrence and fetal growth</TI>
<SO>International Journal of Environmental Research and Public Health</SO>
<YR>2013</YR>
<VL>10</VL>
<NO>2</NO>
<PG>590-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-18 10:56:13 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wehby GL, Goco N, Moretti-Ferreira D, Felix T, Richieri-Costa A, Padovani C, et al</AU>
<TI>Oral cleft prevention program (OCPP)</TI>
<SO>BMC Pediatrics</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>184</NO>
<PG>1-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-2015" MODIFIED="2016-03-28 07:35:18 +0100" MODIFIED_BY="Olukunmi Balogun" NAME="Young 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-03-28 07:35:18 +0100" MODIFIED_BY="Olukunmi Balogun" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramakrishnan U, DiGirolamo A, Nguyen P, Gonzalez-Casanova I, Nguyen H, Pham H, et al</AU>
<TI>Effects of preconceptual micronutrient supplementation on maternal depression in Vietnamese women</TI>
<SO>FASEB Journal</SO>
<YR>2015</YR>
<VL>29</VL>
<NO>1 Suppl</NO>
<PG>28.1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-28 07:35:18 +0100" MODIFIED_BY="Olukunmi Balogun" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Young MF, Nguyen PH, Addo OY, Hao W, Nguyen H, Pham H, et al</AU>
<TI>The relative influence of maternal nutritional status before and during pregnancy on birth outcomes in Vietnam</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2015</YR>
<VL>194</VL>
<PG>223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01665378"/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-04-13 10:25:28 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adu_x002d_Afarwuah-2015" MODIFIED="2015-11-13 14:08:28 +0000" MODIFIED_BY="[Empty name]" NAME="Adu-Afarwuah 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-11-13 14:08:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adu-Afarwuah S, Lartey A, Okronipa H, Peerson J, Ashorn P, Dewey K</AU>
<TI>Effects of small-quantity lipid-based nutrient supplement on hemoglobin and iron status of pregnant Ghanaian women</TI>
<SO>FASEB Journal</SO>
<YR>2015</YR>
<VL>29</VL>
<NO>1 Suppl</NO>
<PG>[39.5]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agarwal-2012a" MODIFIED="2016-04-13 10:25:28 +0100" MODIFIED_BY="[Empty name]" NAME="Agarwal 2012a" YEAR="2012">
<REFERENCE MODIFIED="2015-11-13 14:08:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal N, Dora S, Kriplani A, Garg P, Vivekanandhan S, Kulshrestha V</AU>
<TI>Response of therapy with vitamin B6, B12 and folic acid on homocysteine level and pregnancy outcome in hyperhomocysteinemia with unexplained recurrent abortions</TI>
<SO>International Journal of Gynecology and Obstetrics</SO>
<YR>2012</YR>
<VL>119</VL>
<NO>Suppl 3</NO>
<PG>S759</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frenzel-1956" MODIFIED="2010-09-24 05:41:28 +0100" MODIFIED_BY="[Empty name]" NAME="Frenzel 1956" YEAR="1956">
<REFERENCE MODIFIED="2010-09-24 05:41:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frenzel KH, Geissler R</AU>
<TI>The importance of prophylaxis with multivitamin preparations during pregnancy, childbirth and nursing period</TI>
<TO>Die Bedeutung der Prophylaxe mit Multivitaminpraparaten wahrend Schwangerschaft, Wochenbett und Stillperiode</TO>
<SO>Die Medizinsche Welt</SO>
<YR>1956</YR>
<VL>7</VL>
<NO>20</NO>
<PG>767-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prado-2015" MODIFIED="2016-02-03 06:23:51 +0000" MODIFIED_BY="[Empty name]" NAME="Prado 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-03 06:23:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Prado E, Abbeddou S, Adu-Afarwuah S, Arimond M, Ashorn P, Ashorn U, et al</AU>
<TI>Associations between linear growth and language development in Ghana, Malawi, and Burkina Faso</TI>
<SO>FASEB Journal</SO>
<YR>2015</YR>
<VL>29</VL>
<NO>1 Suppl</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-03-16 06:01:01 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Johns-2004" MODIFIED="2016-02-10 10:13:51 +0000" MODIFIED_BY="[Empty name]" NAME="Johns 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-02-03 06:31:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Johns J</AU>
<TI>The effect of antioxidant supplementation on women with threatened miscarriage</TI>
<SO>ISRCTN Registry (http://www.isrctn.com/) [accessed 28 October 2015]</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-02-10 10:13:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-02-10 10:13:51 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN68958618"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-26 14:20:51 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-04-26 14:20:51 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Agarwal-2012b" MODIFIED="2016-04-13 10:25:23 +0100" MODIFIED_BY="[Empty name]" NAME="Agarwal 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S</AU>
<TI>The effects of oxidative stress on female reproduction: a review</TI>
<SO>Reproductive Biology and Endocrinology</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>1</NO>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Gubory-2010" MODIFIED="2016-04-13 10:06:46 +0100" MODIFIED_BY="[Empty name]" NAME="Al-Gubory 2010" TYPE="JOURNAL_ARTICLE">
<AU>Al-Gubory KH, Fowler PA, Garrel C</AU>
<TI>The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes</TI>
<SO>International Journal of Biochemistry &amp; Cell Biology</SO>
<YR>2010</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1634-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2016-02-03 14:57:36 +0000" MODIFIED_BY="[Empty name]" NAME="Alderson 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins JPT, editors</AU>
<TI>Cochrane Reviewers&#8217; Handbook 4.2.2 [updated December 2003]</TI>
<SO>In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beazley-2005" MODIFIED="2016-04-13 10:05:38 +0100" MODIFIED_BY="[Empty name]" NAME="Beazley 2005" TYPE="JOURNAL_ARTICLE">
<AU>Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM</AU>
<TI>Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>2</NO>
<PG>520-1</PG>
<IDENTIFIERS MODIFIED="2016-04-01 07:55:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15695996"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chaudhuri-1969" NAME="Chaudhuri 1969" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhuri SK</AU>
<TI>Effect of nutrient supplementation on the incidence of toxaemia of pregnancy</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>1969</YR>
<VL>19</VL>
<PG>156-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De_x002d_Regil-2015" MODIFIED="2016-04-13 10:13:44 +0100" MODIFIED_BY="[Empty name]" NAME="De-Regil 2015" TYPE="COCHRANE_REVIEW">
<AU>De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P</AU>
<TI>Effects and safety of periconceptional oral folate supplementation for preventing birth defects</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2016-04-13 10:13:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-04-13 10:13:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007950.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Devaseelan-2010" MODIFIED="2016-01-25 00:43:41 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Devaseelan 2010" TYPE="COCHRANE_REVIEW">
<AU>Devaseelan P, Fogarty PP, Regan L</AU>
<TI>Human chorionic gonadotrophin for threatened miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:43:41 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:43:41 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD007422.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Di-Cintio-2001" MODIFIED="2016-04-18 11:14:14 +0100" MODIFIED_BY="Heather Maxwell" NAME="Di Cintio 2001" TYPE="JOURNAL_ARTICLE">
<AU>Di Cintio E, Parazzini F, Chatenoud L, Surace M, Benzi G, Zanconato G, et al</AU>
<TI>Dietary factors and risk of spontaneous abortion</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2001</YR>
<VL>95</VL>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garc_x0131_a_x002d_Engu_x0131_danos-2002" MODIFIED="2016-01-25 01:32:48 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Garc&#305;a-Engu&#305;danos 2002" TYPE="JOURNAL_ARTICLE">
<AU>Garc&#305;a-Engu&#305;danos A, Calle M, Valero J, Luna S, Dom&#305;nguez-Rojas V</AU>
<TI>Risk factors in miscarriage: a review</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2002</YR>
<VL>102</VL>
<NO>2</NO>
<PG>111-119</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garrido_x002d_Gimenez-2015" MODIFIED="2016-04-13 10:06:05 +0100" MODIFIED_BY="[Empty name]" NAME="Garrido-Gimenez 2015" TYPE="JOURNAL_ARTICLE">
<AU>Garrido-Gimenez C, Alijotas-Reig J</AU>
<TI>Recurrent miscarriage: causes, evaluation and management</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2015</YR>
<VL>91</VL>
<NO>1073</NO>
<PG>151-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-George-2002" MODIFIED="2016-04-13 10:14:14 +0100" MODIFIED_BY="[Empty name]" NAME="George 2002" TYPE="JOURNAL_ARTICLE">
<AU>George L, Mills JL, Johansson AL, Nordmark A, Olander B, Granath F, Cnattingius S</AU>
<TI>Plasma folate levels and risk of spontaneous abortion</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>15</NO>
<PG>1867-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guerra_x002d_Shinohara-2010" MODIFIED="2016-04-18 11:14:41 +0100" MODIFIED_BY="Heather Maxwell" NAME="Guerra-Shinohara 2010" TYPE="JOURNAL_ARTICLE">
<AU>Guerra-Shinohara EM, Pereira PM, Kubota AM, Silva TA, Reis JL, Miyashita GS, et al</AU>
<TI>Increased MMA concentration and body mass index are associated with spontaneous abortion in Brazilian women: a pilot study</TI>
<SO>Clinica Chimica Acta</SO>
<YR>2010</YR>
<VL>411</VL>
<NO>5</NO>
<PG>423-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2007" MODIFIED="2016-04-13 10:06:31 +0100" MODIFIED_BY="[Empty name]" NAME="Gupta 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gupta S, Agarwal A, BanerjeeJ, Alvarez JG</AU>
<TI>The role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: a systematic review</TI>
<SO>Obstetrical &amp; Gynecological Survey</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>5</NO>
<PG>335-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haas-2009" MODIFIED="2010-09-28 19:26:06 +0100" MODIFIED_BY="[Empty name]" NAME="Haas 2009" TYPE="COCHRANE_REVIEW">
<AU>Haas DM, Ramsey PS</AU>
<TI>Progestogen for preventing miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-09-28 19:25:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-28 19:25:42 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003511.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haas-2013" MODIFIED="2016-01-25 00:45:20 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Haas 2013" TYPE="COCHRANE_REVIEW">
<AU>Haas DM, Ramsey PS</AU>
<TI>Progestogen for preventing miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:45:20 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:45:20 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD003511.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hague-2003" MODIFIED="2016-04-13 10:07:20 +0100" MODIFIED_BY="[Empty name]" NAME="Hague 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hague WM</AU>
<TI>Homocysteine and pregnancy</TI>
<SO>Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>3</NO>
<PG>459-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haider-2015" MODIFIED="2016-04-13 10:10:05 +0100" MODIFIED_BY="[Empty name]" NAME="Haider 2015" TYPE="COCHRANE_REVIEW">
<AU>Haider BA, Bhutta ZA</AU>
<TI>Multiple-micronutrient supplementation for women during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2016-04-13 10:09:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-04-13 10:09:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004905.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hasan-2009" MODIFIED="2016-03-28 06:48:44 +0100" MODIFIED_BY="Olukunmi Balogun" NAME="Hasan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hasan R, Olshan AF, Herring AH, Savitz DA, Siega-Riz AM, Hartmann KE</AU>
<TI>Self-reported vitamin supplementation in early pregnancy and risk of miscarriage</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>11</NO>
<PG>1312-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-02-03 13:45:19 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hovdenak-2012" MODIFIED="2016-04-18 11:15:30 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hovdenak 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hovdenak N, Haram K</AU>
<TI>Influence of mineral and vitamin supplements on pregnancy outcome</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2012</YR>
<VL>164</VL>
<NO>2</NO>
<PG>127-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hure-2012" MODIFIED="2016-03-28 06:49:12 +0100" MODIFIED_BY="Olukunmi Balogun" NAME="Hure 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hure AJ, Powers JR, Mishra GD, Herbert DL, Byles JE, Loxton D</AU>
<TI>Miscarriage, preterm delivery, and stillbirth: large variations in rates within a cohort of Australian women</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>5</NO>
<PG>37109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00fc_bner-2008" MODIFIED="2016-04-18 11:15:53 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hübner 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hübner U, Alwan A, Jouma M, Tabbaa M, Schorr H, Herrmann W</AU>
<TI>Low serum vitamin B12 is associated with recurrent pregnancy loss in Syrian women</TI>
<SO>Clinical Chemistry and Laboratory Medicine</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>9</NO>
<PG>1265-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lassi-2013" MODIFIED="2016-04-13 10:19:48 +0100" MODIFIED_BY="[Empty name]" NAME="Lassi 2013" TYPE="COCHRANE_REVIEW">
<AU>Lassi ZS, Salam RA, Haider BA, Bhutta ZA</AU>
<TI>Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-04-13 10:19:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-04-13 10:19:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006896.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lede-2005" MODIFIED="2016-01-25 00:39:10 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Lede 2005" TYPE="COCHRANE_REVIEW">
<AU>Lede RL, Duley L</AU>
<TI>Uterine muscle relaxant drugs for threatened miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:36:50 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:36:50 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD002857.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li-2003" MODIFIED="2016-01-25 00:26:27 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Li 2003" TYPE="JOURNAL_ARTICLE">
<AU>Li DK, Liu L, Odouli R</AU>
<TI>Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7411</NO>
<PG>368</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2012" MODIFIED="2016-01-25 00:41:36 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Li 2012" TYPE="COCHRANE_REVIEW">
<AU>Li L, Dou L, Leung PC, Wang CC</AU>
<TI>Chinese herbal medicines for threatened miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:41:36 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:41:36 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD008510.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lim-1013" MODIFIED="2016-01-25 00:47:43 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Lim 1013" TYPE="COCHRANE_REVIEW">
<AU>Lim CED, Ho KK, Cheng NCL, Wong FW</AU>
<TI>Combined oestrogen and progesterone for preventing miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:47:43 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:47:43 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD009278.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maconochie-2007" MODIFIED="2016-04-13 10:20:06 +0100" MODIFIED_BY="[Empty name]" NAME="Maconochie 2007" TYPE="JOURNAL_ARTICLE">
<AU>Maconochie N, Doyle P, Prior S, Simmons R</AU>
<TI>Risk factors for first trimester miscarriage&#8212;results from a UK&#8208;population&#8208;based case&#8211;control study</TI>
<SO>BJOG: An International Journal of Obstetrics &amp; Gynaecology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>2</NO>
<PG>170-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCauley-2015" MODIFIED="2016-04-13 10:21:38 +0100" MODIFIED_BY="[Empty name]" NAME="McCauley 2015" TYPE="COCHRANE_REVIEW">
<AU>McCauley ME, van den Broek N, Dou L, Othman M</AU>
<TI>Vitamin A supplementation during pregnancy for maternal and newborn outcomes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2016-04-13 10:21:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-04-13 10:21:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008666.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McMillen-2008" MODIFIED="2016-04-18 11:16:46 +0100" MODIFIED_BY="Heather Maxwell" NAME="McMillen 2008" TYPE="JOURNAL_ARTICLE">
<AU>McMillen IC, MacLaughlin SM, Muhlhausler BS, Gentili S, Duffield JL, Morrison JL</AU>
<TI>Developmental origins of adult health and disease: the role of periconceptional and foetal nutrition</TI>
<SO>Basic &amp; Clinical Pharmacology &amp; Toxicology</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>2</NO>
<PG>82-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meher-2015" MODIFIED="2016-04-13 10:21:56 +0100" MODIFIED_BY="[Empty name]" NAME="Meher 2015" TYPE="JOURNAL_ARTICLE">
<AU>Meher A, Sundrani D, Joshi, S</AU>
<TI>Maternal nutrition influences angiogenesis in the placenta through peroxisome proliferator activated receptors: A novel hypothesis</TI>
<SO>Molecular Reproduction and Development</SO>
<YR>2015</YR>
<VL>82</VL>
<NO>10</NO>
<PG>726-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morley-2013" MODIFIED="2016-01-25 00:49:42 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Morley 2013" TYPE="COCHRANE_REVIEW">
<AU>Morley LC, Simpson N, Tang T</AU>
<TI>Human chorionic gonadotrophin (hCG) for preventing miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:49:42 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:49:42 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD008611.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MRC-Vitamin-Study-Research-Group-1991" MODIFIED="2016-04-13 10:22:08 +0100" MODIFIED_BY="[Empty name]" NAME="MRC Vitamin Study Research Group 1991" TYPE="JOURNAL_ARTICLE">
<AU>MRC Vitamin Study Research Group</AU>
<TI>Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<NO>8760</NO>
<PG>131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00e9_tneki-1996" MODIFIED="2016-02-10 11:09:43 +0000" MODIFIED_BY="[Empty name]" NAME="Métneki 1996" TYPE="JOURNAL_ARTICLE">
<AU>Métneki J, Dudás I, Czeizel AE</AU>
<TI>Periconceptional multivitamin administration may result in higher frequency of twin pregnancies</TI>
<SO>Orvosi Hetilap</SO>
<YR>1996</YR>
<VL>137</VL>
<PG>2401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelen-2000" MODIFIED="2016-04-13 10:22:28 +0100" MODIFIED_BY="[Empty name]" NAME="Nelen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nelen WL, Blom HJ, Steegers EA, den Heijer M, Thomas CM, Eskes TK</AU>
<TI>Homocysteine and folate levels as risk factors for recurrent early pregnancy loss</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>4</NO>
<PG>519-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nielsen-2001" MODIFIED="2016-04-13 10:22:37 +0100" MODIFIED_BY="[Empty name]" NAME="Nielsen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen GL, Sorensen HT, Larsen H, Pedersen L</AU>
<TI>Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>322</VL>
<NO>7281</NO>
<PG>266-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preston-1996" MODIFIED="2016-04-19 10:35:35 +0100" MODIFIED_BY="Heather Maxwell" NAME="Preston 1996" TYPE="JOURNAL_ARTICLE">
<AU>Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, Conard J, et al</AU>
<TI>Increased fetal loss in women with heritable thrombophilia</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9032</NO>
<PG>913-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-11-13 14:14:20 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reznikoff_x002d_Eti_x00e9_vant-2002" MODIFIED="2016-04-13 10:22:45 +0100" MODIFIED_BY="[Empty name]" NAME="Reznikoff-Etiévant 2002" TYPE="JOURNAL_ARTICLE">
<AU>Reznikoff-Etiévant MF, Zittoun J, Vaylet C, Pernet P, Milliez J</AU>
<TI>Low vitamin B 12 level as a risk factor for very early recurrent abortion</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2002</YR>
<VL>104</VL>
<NO>2</NO>
<PG>156-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rivas_x002d_Echeverria-2000" MODIFIED="2016-04-18 11:18:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Rivas-Echeverria 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rivas-Echeverria CA, Echeverria Y, Molina L, Novoa D</AU>
<TI>Synergic use of aspirin, fish oil and vitamins C and E for the prevention of preeclampsia [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>19</YR>
<VL>Suppl 1</VL>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rumbold-2008" MODIFIED="2010-10-06 10:58:15 +0100" MODIFIED_BY="[Empty name]" NAME="Rumbold 2008" TYPE="COCHRANE_REVIEW">
<AU>Rumbold A, Duley L, Crowther C, Haslam RR</AU>
<TI>Antioxidants for preventing pre-eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-10-06 10:58:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-06 10:58:03 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004227.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rumbold-2015" MODIFIED="2016-04-13 10:24:28 +0100" MODIFIED_BY="[Empty name]" NAME="Rumbold 2015" TYPE="COCHRANE_REVIEW">
<AU>Rumbold A, Ota E, Nagata C, Shahrook S, Crowther CA</AU>
<TI>Vitamin C supplementation in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2016-04-13 10:24:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-04-13 10:24:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004072.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wong-2014" MODIFIED="2016-01-25 00:51:44 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Wong 2014" TYPE="COCHRANE_REVIEW">
<AU>Wong LF, Porter TF, Scott JR</AU>
<TI>Immunotherapy for recurrent miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2016-01-25 00:51:44 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 00:51:44 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD000112.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wu-2004" MODIFIED="2016-04-13 10:24:38 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wu G, Bazer FW, Cudd TA, Meininger CJ, Spencer TE</AU>
<TI>Maternal nutrition and fetal development</TI>
<SO>Journal of Nutrition</SO>
<YR>2004</YR>
<VL>134</VL>
<NO>9</NO>
<PG>2169-72</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-04-18 11:10:56 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Rumbold-2005" MODIFIED="2016-01-25 01:52:53 +0000" MODIFIED_BY="Olukunmi Balogun" NAME="Rumbold 2005" TYPE="COCHRANE_REVIEW">
<AU>Rumbold A, Middleton P, Crowther CA</AU>
<TI>Vitamin supplementation for preventing miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-01-25 01:52:53 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 01:52:53 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD004073.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rumbold-2011" MODIFIED="2016-04-18 11:10:56 +0100" MODIFIED_BY="Heather Maxwell" NAME="Rumbold 2011" TYPE="COCHRANE_REVIEW">
<AU>Rumbold A, Middleton P, Pan N, Crowther CA</AU>
<TI>Vitamin supplementation for preventing miscarriage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-01-25 01:54:28 +0000" MODIFIED_BY="Olukunmi Balogun">
<IDENTIFIER MODIFIED="2016-01-25 01:54:28 +0000" MODIFIED_BY="Olukunmi Balogun" TYPE="DOI" VALUE="10.1002/14651858.CD004073.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-04-20 19:50:47 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-04-20 19:50:47 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-04-20 19:12:47 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bhutta-2009">
<CHAR_METHODS MODIFIED="2016-04-18 18:25:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: random allocation of the entire population of the urban and rural areas (population, 110,000; 20,400 households) into 28 discrete clusters (16 rural and 12 urban) on the basis of household characteristics, socioeconomic criteria, and geographic location. Each cluster was allocated to a community health worker who distributed the supplements on a cluster-based allocation strategy of supplements ("either iron&#8211;folic acid or multiple micronutrients"). Distribution of the sealed, coded supplement bottles were independently controlled by the pharmacy at Aga Khan University.</P>
<P>Blinding of outcome assessment: medical officers, community health workers, social scientists, and data collection team remained blinded to the supplementation allocation.</P>
<P>Documentation of exclusion: 373 women (16.5%) were excluded.</P>
<P>Use of placebo control: no placebo given, women in the control group were given IFA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 13:42:36 +0000" MODIFIED_BY="[Empty name]">
<P>2378 women from community settings in urban and rural Sindh (Pakistan) less than 16 weeks of gestation. Eligible women were women with a confirmed pregnancy at less than 16 weeks of gestation. Women who did not have a confirmed pregnancy on ultrasound scanning or women who were clearly advanced beyond 24 weeks of gestation were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-20 19:12:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Multiple micronutrients comprised 30 mg of iron (ferrous fumarate) and 400 mcg of folic acid along with 800 mcg of retinol (retinyl acetate), 200 IU of vitamin D (ergocalciferol), 10 mg of vitamin E (&#945;-tocopherol acetate), 70 mg of ascorbic acid, 1.4 mg of vitamin B1 (thiamine mononitrate), 18 mg of niacin (niacinamide) 1.4 mg of vitamin B2, 1.9 mg of vitamin B6 (pyridoxine), 2.6 mcg of vitamin B12 (cyanocobalamin), 15 mg of zinc (zinc gluconate), 2 mg of copper, 65 mcg of selenium, and 150 mcg of iodine. Intervention was timed to start at less than 16 weeks' gestation. Comparison was iron (60 mg) and folic acid (400 mcg).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:23:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>Maternal outcomes:</P>
<OL>
<LI>Blood Hb level as well as serum ferritin, zinc, and vitamin A.</LI>
<LI>Physical and clinical examination, including a morbidity assessment and measurement of fundal height.</LI>
<LI>Height, weight, and mid-upper-arm circumference.</LI>
</OL>
<P>Infant outcomes:</P>
<OL>
<LI>Birthweight.</LI>
<LI>Gestational age.</LI>
<LI>Neonatal death and cause of death.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 18:23:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear.</P>
<P>Womens' BMI, Hb, ferritin, zinc, and serum retinol at admission are reported.</P>
<P>Sample-size calculation reported by 2 methods: 1. based on a potential 5% gain in birthweight, 2. based to estimate a difference in birthweight of 150 g between the 2 groups.</P>
<P>No intention-to-treat analyses performed.</P>
<P>Compliance: community health worker performed a tablet count every fourth nightly visit. Proportion of tablets consumed 75.65 in the intervention group and 76.7% in the control group.</P>
<P>Location: urban population (Bilal Colony, Karachi) and rural villages (Kot Diji district, rural Sindh), Pakistan.</P>
<P>Timeframe: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 16:58:19 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Briscoe-1959">
<CHAR_METHODS>
<P>Randomisation and allocation concealment: unclear, no methodological details given, dubious as the number of women allocated to the treatment group was more than double that allocated to the placebo group. "Unselected patients were each given 200 capsules... these were given a code, unknown to us and contained either an inert powder or 100 mg each of ascorbic acid and hesperidin."</P>
<P>Blinding of outcome assessment: women and study investigators did not know the treatment codes. </P>
<P>Documentation of exclusion: none reported. </P>
<P>Use of placebo control: placebo given; however, all women received an additional multivitamin supplement.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 16:58:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>406 women were recruited in the study. Eligible women were "unselected patients" in private obstetrics care, who were less than or equal to 10 weeks' pregnant, and were eligible regardless of whether they were currently bleeding or the number of previous pregnancies. Women greater than 10 weeks' gestation were excluded. 406 women were randomised to either vitamin C (n = 303) or placebo (n = 103), no losses to follow-up were reported. 77 women in the study had more than 2 previous miscarriages and/or bleeding in the pregnancy, and 329 had 2 or fewer miscarriages and no bleeding in the pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 14:35:34 +0000" MODIFIED_BY="[Empty name]">
<P>All women were given 200 tablets, containing either 100 mg each of ascorbic acid and hesperidin or placebo (an inert powder).<BR/>The study lasted for 7 weeks. For the first 2 weeks, women were asked to take 8 tablets daily (i.e. daily 800 mg each of vitamin C and hesperidin or placebo). For the following 5 weeks, women took 4 tablets daily (i.e. daily 400 mg each of vitamin C and hesperidin or placebo). All women received a multiple vitamin supplement containing 50 mg vitamin C.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 11:04:45 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Spontaneous miscarriage.</LI>
<LI>Spontaneous miscarriage in women with 2 or fewer previous miscarriages and no bleeding in the current pregnancy.</LI>
<LI>Spontaneous miscarriage in women with more than 2 previous miscarriages and/or bleeding in the current pregnancy.</LI>
<LI>Spontaneous miscarriage in women who experienced recurrent miscarriage.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 02:35:29 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear, as there is no information about concurrent medical conditions or other risk factors for miscarriage. 9 of the 406 women were classified as experiencing recurrent miscarriage.<BR/>No information is available about women's nutritional status.<BR/>No sample-size calculation reported.<BR/>Intention-to-treat analyses performed (no losses to follow-up reported).<BR/>Compliance: no compliance information reported.<BR/>Location: Philadelphia, USA.<BR/>Timeframe: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-20 19:40:33 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Chappell-1999">
<CHAR_METHODS MODIFIED="2010-12-07 02:35:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: a computer-generated randomisation list using blocks of 10 was given to the hospital pharmacy departments. Researchers allocated the next available number to participants and women collected the trial tablets from the pharmacy department.</P>
<P>Blinding of outcome assessment: women, caregivers and researchers were blinded to the treatment allocation until recruitment, data collection and laboratory analyses were complete.</P>
<P>Documentation of exclusion: 123 (43.5%) women were excluded, of which 70 women were withdrawn because their second Doppler scan was normal. Pregnancy outcome data were reported for all women randomised.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>283 women were recruited into the study. Inclusion criteria: abnormal Doppler waveform in either uterine artery at 18-22 weeks' gestation or a history in the preceding pregnancy of pre-eclampsia necessitating delivery before 37 weeks' gestation, eclampsia or the syndrome of HELLP. <BR/>Exclusion criteria: heparin or warfarin treatment, abnormal fetal-anomaly scan or multiple pregnancy. <BR/>Women were randomised at 18-22 weeks' gestation; however, women with a previous history who were identified at an earlier stage were randomised at 16 weeks' gestation. Women with abnormal Doppler waveform analysis returned for a second scan at 24 weeks' gestation, those with a normal waveform at this time stopped treatment and were withdrawn from the study. The remaining women who had persistently abnormal waveforms, and those with a previous history or pre-eclampsia remained in the study and were seen every 4 weeks through the rest of pregnancy. 1512 women underwent Doppler screening, 273 women had abnormal waveforms and of these, 242 women consented to the study. An additional 41 women who had a history of pre-eclampsia consented. 283 women were randomised to either the vitamin C and E group (n = 141) or the placebo group (n = 142), 72 women had normal Doppler scans at 24 weeks' gestation and 24 women did not return for a second scan and were withdrawn. A further 27 women withdrew from the trial after 24 weeks' gestation for various reasons. In total, 160 women completed the trial protocol until delivery, 79 in the vitamin C and E group and 81 in the placebo group. Pregnancy outcome data were presented for all women randomised (n = 283) as well as only for those women completing the trial protocol (n = 160).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-20 19:40:33 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women randomised to the vitamin C and E group received tablets containing 1000 mg vitamin C daily and capsules containing 400 IU vitamin E daily.<BR/>Women randomised to the placebo group received tablets containing microcrystalline cellulose and soyabean oil, that were identical in appearance to the vitamin C tablets and vitamin E capsules. After 24 weeks' gestation women were seen every 4 weeks, and blood samples were taken at each visit.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 11:10:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Ratio of PAI-1 to PAI-2.</LI>
<LI>Incidence of pre-eclampsia.</LI>
<LI>Placental abruption.</LI>
<LI>Spontaneous preterm delivery (&lt; 37 weeks).</LI>
<LI>Intrauterine death.</LI>
<LI>Small-for-gestational-age infants (on or below the 10th centile).</LI>
<LI>Mean systolic and diastolic blood pressure before delivery.</LI>
<LI>Gestational age at delivery (median, IQR).</LI>
<LI>Birthweight (median, IQR).</LI>
<LI>Birthweight centile (median, IQR).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Women's risk of spontaneous and recurrent miscarriage is unclear, women were at high risk of pre-eclampsia.<BR/>No information is available about women's nutritional status. <BR/>Sample-size calculation reported, based on a 30% reduction in PAI-1. <BR/>Intention-to-treat analyses performed. <BR/>Compliance: "within the treated group, plasma ascorbic acid concentration increased by 32% from baseline values and plasma alpha-tocopherol increased by 54%". <BR/>Location: London, UK. <BR/>Timeframe: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-10 15:13:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czeizel-1994">
<CHAR_METHODS MODIFIED="2010-12-07 02:40:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: unclear, "women agreed to their allocation on the basis of a random table".</P>
<P>Blinding of outcome assessment: unclear, women were aware of the "blind use of one of two kinds of tablets", but no other details given.</P>
<P>Documentation of exclusion: 49 women (1%) were lost to follow-up and excluded.</P>
<P>Use of placebo control: "trace element control" given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 14:35:39 +0000" MODIFIED_BY="[Empty name]">
<P>7765 women were recruited into the study. Women participating in the HOFPP who volunteered to take part, were not currently pregnant, and who conceived within 12 months of ceasing contraception. In the first 2 years of the HOFPP, women were also required to be aged &lt; 35 years, and not to have had a previous pregnancy except a prior induced abortion. 7905 women were approached, of which 140 refused participation, 7765 were randomised and 5502 women had a confirmed pregnancy and were allocated to either multivitamins (n = 2819) or control (n = 2683). 49 women of the 5502 confirmed pregnancies were lost to follow-up.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-24 09:16:08 +0100" MODIFIED_BY="[Empty name]">
<P>Women were provided with multivitamin or trace element 'control' from at least 28 days before conception continuing until at least the second missed menstrual period.<BR/>The multivitamin with folic acid contained 6000 IU vitamin A, 1.6 mg vitamin B1, 1.8 mg vitamin B2, 2.6 mg vitamin B6, 4.0 mcg vitamin B12, 100 mg vitamin C, 500 IU vitamin D, 15 mg vitamin E, 19 mg nicotinamide, 10 mg calcium pantothenate, 0.2 mg biotin, 0.8 mg folic acid, 125 mg calcium, 125 mg phosphorus, 100 mg magnesium, 60 mg iron, 1 mg copper, 1 mg manganese, 7.5 mg zinc.<BR/>The trace element control contained 7.5 mg vitamin C, 1 mg copper, 1 mg manganese and 7.5 mg zinc.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:13:42 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>NTDs and other birth defects.</LI>
<LI>Miscarriage.</LI>
<LI>Ectopic pregnancy.</LI>
<LI>Termination of pregnancy.</LI>
<LI>Live births.</LI>
<LI>Stillbirths.</LI>
<LI>Multiple gestation.</LI>
<LI>Subgroup data are available on menstrual cycle, first trimester symptoms and sexual activity.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-06 11:16:13 +0100" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear.<BR/>Information on their dietary status is unknown.<BR/>No sample-size calculation reported.<BR/>Partial intention-to-treat analyses performed.<BR/>Compliance: compliance was assessed by questioning, checking the tick-off on the basal temperature chart and counting of unused tablets. 70% of women in the multivitamin group and 71% in the control group took the full course of the supplements, with an additional 20% and 21% in the multivitamin and control groups respectively receiving a partial course of supplementation.<BR/>Location: Hungary.<BR/>Time frame: 1 February 1984 to 30 April 1992.<BR/>The denominators used for this trial are the number of women randomised and with a confirmed pregnancy (i.e. 2819 for the multivitamin group and 2683 for the control group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:06:56 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fawzi-1998">
<CHAR_METHODS MODIFIED="2010-12-07 02:41:42 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: block randomisation using blocks of 20, eligible women were "assigned the next numbered bottle of regimen". The study used a 2 by 2 factorial design and women were randomised to 1 of 4 groups. Tablets were indistinguishable and packaged in identically coded bottles.</P>
<P>Blinding of outcome assessment: women and study investigators were unaware of the treatment allocation, no information given about blinding of outcome assessors.</P>
<P>Documentation of exclusion: 64 women (6%) were lost to follow-up and excluded.</P>
<P>Use of placebo control: placebo given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 14:33:50 +0000" MODIFIED_BY="[Empty name]">
<P>1085 women were recruited into the study. Pregnant women between 12 and 27 weeks' gestation who were HIV-1 infected, living in Dar es Salaam and intended to stay there for at least 1 year were eligible for the study. Women not HIV-1 positive or moving out of Dar es Salaam were excluded. 13,879 pregnant women consented to be HIV-1 tested, of which 1806 were positive, and 1085 were randomised. Of these, 3 women were not pregnant and 7 women died before delivery and were excluded from the trial. Of the remaining 1075 women, 54 women (5%) were lost to follow-up by the time of delivery, leaving birth outcomes reported for 1021 women. Women were randomised to 1 of 4 groups: vitamin A (n = 269), multivitamins excluding vitamin A (n = 269); multivitamins including vitamin A (n = 270) or placebo (n = 267).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-06 11:17:27 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to 1 of 4 groups:</P>
<OL>
<LI>vitamin A (30 mg beta-carotene plus 5000 IU preformed vitamin A);</LI>
<LI>multivitamins excluding vitamin A (20 mg vitamin B1, 20 mg vitamin B2, 25 mg vitamin B6, 100 mg niacin, 50 mcg vitamin B12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid);</LI>
<LI>multivitamins including vitamin A, all formulated in 2 tablets; or</LI>
<LI>placebo.</LI>
</OL>
<P>All women received 400 mg ferrous sulphate and 5 mg folic acid daily, as well as 500 mg chloroquine phosphate weekly. At delivery, all women taking vitamin A were to receive an additional oral dose of 200,000 IU vitamin A and the others an extra dose of a placebo. Pill counts were conducted at each visit and new tablets were given out at each visit.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 08:44:45 +0000" MODIFIED_BY="Denise Atherton">
<OL>
<LI>Miscarriage, defined as delivery before 28 weeks' gestation.</LI>
<LI>Stillbirth, defined as delivery of a dead baby at or after 28 weeks' gestation.</LI>
<LI>Fetal death, defined as either miscarriage or stillbirth.</LI>
<LI>Low birthweight, defined as birthweight less than 2500 g.</LI>
<LI>Very low birthweight, defined as birthweight less than 2000 g.</LI>
<LI>Preterm delivery, defined as delivery before 37 weeks.</LI>
<LI>Severe preterm birth, defined as delivery before 34 weeks.</LI>
<LI>Small-for-gestational age, defined as birthweight less than the 10th percentile for gestational age.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:06:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear, although may be increased due to their HIV-1 positive status.<BR/>Women's nutritional status is also unclear.<BR/>Figures change with serial publications, particularly for secondary outcomes, and results are not reported separately for the individual 4 groups. Results are reported as: any multivitamins, multivitamin, any vitamin A or no vitamin A.<BR/>Sample-size calculation performed allowing for 20% loss to follow-up.<BR/>Intention-to-treat analyses performed.<BR/>Compliance: compliance assessed by the percentage of prescribed tablets absent from the returned bottles, and in plasma vitamin A concentrations in a subset of 100 women. Median compliance assessed using pill counts was 90% by the time of delivery.<BR/>Location: Tanzania.<BR/>Timeframe: April 1995 to July 1997.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-20 19:38:51 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fawzi-2007">
<CHAR_METHODS MODIFIED="2016-02-01 02:38:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: unclear about sequence generation.</P>
<P>Allocation concealment: states a list was prepared according to the randomisation sequence in blocks of 20, tablets were bottled in identical coded bottles, eligible women were given the next numbered bottle.</P>
<P>Blinding of outcome assessment: women and research assistants who assessed the study outcomes were unaware of the intervention groups.</P>
<P>Documentation of exclusion: 49 women lost to follow-up (multivitamin group: 23, placebo group: 26), no post-randomisation exclusions.</P>
<P>Use of placebo control: placebo given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-20 19:38:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>8428 women were randomised in the study. Pregnant women between 12 and 27 weeks who had a negative test for HIV infection and planned to stay in the city until delivery and for 1 year thereafter recruited through antenatal clinics in Dar es Salaam. 8468 women were enrolled, however 40 women were then found to be ineligible. 8428 women were randomly assigned to receive either a multivitamin (n = 4214) or placebo (n = 4214) from the time of enrolment until 6 weeks after delivery. 6 women died before delivery and 43 were lost to follow-up by the time of delivery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 17:08:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>The supplements included 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 mcg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid.</P>
<P>The active tablets and placebo were similar in shape, size, and colour.</P>
<P>All women, irrespective of the assigned study regimen, were given daily doses of iron (60 mg of elemental iron) and folic acid (0.25 mg). They were also given malaria prophylaxis in the form of sulfadoxine-pyrimethamine tablets at 20 weeks and 30 weeks of gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 08:46:27 +0000" MODIFIED_BY="Denise Atherton">
<OL>
<LI>Low birthweight (&lt; 2500 g).</LI>
<LI>Preterm delivery (before 37 weeks' gestation).</LI>
<LI>Fetal death.</LI>
<LI>Birthweight below 2000 g.</LI>
<LI>Extremely preterm delivery (before 34 weeks).</LI>
<LI>Small-for-gestational age (birthweight below the 10th percentile for gestational age).</LI>
<LI>Fetal death and death in the first 6 weeks of life.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:20:43 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is also unclear.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: average compliance was 88%, no difference in compliances between the 2 groups.</P>
<P>Location: Tanzania.</P>
<P>Timeframe: August 2001 and July 2004.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:11:43 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fleming-1968">
<CHAR_METHODS>
<P>Randomisation and allocation concealment: quasi-randomised, alternate women were allocated to receive folic acid or placebo according to the order in which they attended antenatal clinic. No other methodological details were given.</P>
<P>Blinding of outcome assessment: women and investigators were blinded to the treatment allocation, until after the completion of the trial.</P>
<P>Documentation of exclusion: 21 women (28%) excluded from the analysis.</P>
<P>Use of placebo control: control tablet containing iron given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 17:10:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>75 women were recruited into the trial. Women were eligible if they were primigravida, less than 26 weeks' pregnant (range of gestation 10 to 26 weeks'), with haematocrit value (PCV) 27% or more, and who had not received treatment so far as was known. Women with Hb SC, Hb SS, Hb CC were excluded. Alternate patients were allocated to group A (placebo) or B (folic acid). 75 women were included (40 in group A and 35 in group B) initially; however, only 26 in group A and 28 in group B completed the trial. 16 women (10 in group A and 8 in group B) defaulted from the trial, 3 (2 in group A and 1 in group B) were anaemic on the second visit warranting folic acid treatment, 1 in group A self-medicated with folic acid and 1 in group A 'aborted'.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 13:56:28 +0000" MODIFIED_BY="[Empty name]">
<P>All women received antimalarials and iron supplements as per the standard antenatal care at the hospital.<BR/>Women in group B received 5 mg folic acid tablets on each attendance, which was fortnightly initially and weekly in the last trimester.<BR/>Group A received "one tablet of lactose base and colouring matter in the same manner".</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 11:23:15 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>PCV and reticulocyte index.</LI>
<LI>Serum folic acid concentration and 'megaloblastic score'.</LI>
<LI>Malarial infection.</LI>
<LI>Maternal morbidity (pyelonephritis, pre-eclamptic toxaemia, septicaemia, puerperal psychosis).</LI>
<LI>Prematurity.</LI>
<LI>Birthweight (mean birthweight but no standard deviation).</LI>
<LI>Fetal mortality.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:11:43 +0100" MODIFIED_BY="Heather Maxwell">
<P>Results not reported as intention-to-treat; however, where possible, the review authors included data in the review as intention-to-treat.<BR/>Unclear of women's risk of spontaneous and recurrent miscarriage.<BR/>16 women in the trial showed evidence of folic acid deficiency at trial entry.<BR/>Sample-size calculation: none reported.<BR/>No intention-to-treat analyses performed.<BR/>Compliance: no compliance information reported specifically; however, women were "seen to swallow" the tablets at their fortnightly and weekly visits.<BR/>Location: Nigeria.<BR/>Time frame: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:14:57 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fleming-1986">
<CHAR_METHODS MODIFIED="2016-02-10 13:57:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: women were "randomly allocated to one of five groups using a random number table", no other details given.</P>
<P>Blinding of outcome assessment: women and investigators were blinded to the treatment allocation, until after the completion of the trial.</P>
<P>Documentation of exclusion: 18 women (9%) were excluded due to anaemia at enrolment, 'defaulting', or being 'mentally subnormal', these women were replaced by other women chosen by an investigator. A further 42 women were excluded before delivery and another 30 failed to attend the postnatal clinic, birth outcomes were available for 160 women (80%).</P>
<P>Use of placebo control: no placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 17:13:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>228 women met the eligibility criteria; however 200 pregnant women were recruited into the study. Women were allocated to 1 of 5 groups; 40 women were allocated to each group.</P>
<P>Eligible women included:</P>
<OL>
<LI>Hausa women living in Zaria and planning to deliver in Zaria;</LI>
<LI>pregnant for the first time;</LI>
<LI>at less than 24 weeks' gestation, as estimated by the height of the fundus uteri;</LI>
<LI>the wives of unskilled or semiskilled men.</LI>
</OL>
<P>Women were excluded if they had already taken any antimalarial treatment or haematinics during the pregnancy, or had the following complications: hydatiform mole, Hb SC disease, overt anaemia or proteinuria.</P>
<P>The mean gestational age of women at enrolment was 18.5 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 13:58:10 +0000" MODIFIED_BY="[Empty name]">
<P>Women were allocated to 1 of 5 groups:</P>
<UL>
<LI>group 1: no active treatment (control);</LI>
<LI>group 2: antimalarials only (600 mg chloroquine/day + 100 mg proguanil/day);</LI>
<LI>group 3: iron + antimalarials (60 mg iron/day + 600 mg chloroquine/day + 100 mg proguanil/day);</LI>
<LI>group 4: folic acid + antimalarials (1 mg folic acid/day + 600 mg chloroquine/day + 100 mg proguanil/day);</LI>
<LI>group 5: iron + folic acid + antimalarials (1 mg folic acid/day + 60 mg iron/day + 600 mg chloroquine/day + 100 mg proguanil/day).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 13:58:30 +0000" MODIFIED_BY="[Empty name]">
<P>Maternal outcomes</P>
<OL>
<LI>Anaemia (severe and mild/moderate) before 28 weeks', between 28-36 weeks', and after 36 weeks' gestation.</LI>
<LI>Gestation age.</LI>
<LI>Mode of delivery.</LI>
<LI>Complications of pregnancy (abortion, hypertension, pre-eclampsia or eclampsia, hydramnios, abdominal pain).</LI>
</OL>
<P>Infant outcomes</P>
<OL>
<LI>Fetal distress.</LI>
<LI>Birthweight.</LI>
<LI>Apgar score at 2 minutes.</LI>
<LI>Fetal complications.</LI>
</OL>
<P>Laboratory outcomes</P>
<OL>
<LI>Hb concentration, red cell indices and WBC at first attendance, 28 weeks, 36 weeks, at delivery (form mother and infant) and 6 weeks postpartum.</LI>
</OL>
<P>Not all outcomes were reported for each individual treatment group. Miscarriage was reported for the combined groups 4 and 5, therefore for the purpose of this review the groups 4 and 5 are combined (folic acid + iron) and compared with group 2 and group 3 (iron + antimalarials). The authors reported that 8 women had hypertension without other signs, 21 women had pre-eclampsia and 6 developed eclampsia, with no association between these outcomes and treatment group. No other details were provided, including the breakdown of these outcomes by treatment group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:14:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women were at high risk of anaemia. Information about other nutritional indices was not provided.</P>
<P>Intention-to-treat analyses not performed, however, where possible, the review authors included data in the review as intention-to-treat.</P>
<P>Compliance: 72 women (36%) were classed as defaulters.</P>
<P>Location: Nigeria.</P>
<P>Timeframe: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:18:22 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hans-2010">
<CHAR_METHODS MODIFIED="2016-02-05 14:43:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: women were randomly assigned to receive either 400 mg of vitamin C daily or not in addition to their standard antenatal vitamin. Randomisation was obtained by a computer-generated, block design sequence to receive vitamin C or not in a 1:1 ratio. No other methodological details given.</P>
<P>Blinding of outcome assessment: unclear, no details given.</P>
<P>Documentation of exclusion: 16 women (4%) did not complete the trial after randomisation.</P>
<P>Use of placebo control: no placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 14:10:07 +0000" MODIFIED_BY="[Empty name]">
<P>400 women 4 to 12 gestational weeks of pregnancy confirmed serologically by B-HCG reagent test along with referred last menstrual period not exceeding the past 3 months, aged at least 18. Women with referred pregnancy of more than 3 months by last menstrual period, concomitant HIV infection status, active or recent (&lt; 2 weeks) sexually transmitted disease infection, medical record of any severe organ disease such as heart, liver or renal failure at the time of assessment, diagnosis of pregnancy during inpatient admission for any other reason, recent history of multivitamin supplementation (&lt; 12 weeks) for any reason, except for pregnancy, and patients incapable to read and write.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 14:10:15 +0000" MODIFIED_BY="[Empty name]">
<P>Chewable tablet of synthetic form of L-ascorbic acid or vitamin C 400 mg administered daily 2 tablet 2 times a day, from first trimester until delivery. Comparison received no vitamin C in addition to their standard antenatal vitamin.</P>
<P>All women received ferrous sulphate 200 mg, folic acid 5 mg and vitamin B-complex 60 mg once daily tablets. Nutritional counselling was provided to all women.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 14:10:31 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Prevention of hospitalisations during pregnancy.</LI>
<LI>Overall hospitalisations rate.</LI>
<LI>Weight gain during pregnancy (normal &lt; 16 kg).</LI>
<LI>Term pregnancy (&#8805; 37 gestational weeks).</LI>
<LI>Preterm delivery.</LI>
<LI>miscarriage (&lt; 24 gestational weeks).</LI>
<LI>Low birthweight (&lt; 2500 g).</LI>
<LI>Gestational systolic blood pressure.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:18:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous or recurrent miscarriage is unclear, as is their dietary intake.</P>
<P>Sample-size calculation based on at least 30% of women not hospitalised during pregnancy in the control group and at least 50% of women not hospitalised in the intervention group.</P>
<P>Analyses were not based on intention-to-treat.</P>
<P>Compliance: no details of any compliance assessments were given.</P>
<P>Location: Kyeibuza, Uganda.</P>
<P>Timeframe: August 2007 and January 2009.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 14:35:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hemmi-2003">
<CHAR_METHODS MODIFIED="2010-12-07 02:59:49 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: unclear, "patients were randomly assigned to the control group or the study group". No other methodological details given.</P>
<P>Blinding of outcome assessment: unclear, no details given.</P>
<P>Documentation of exclusion: 28 women (19%) in the control group were excluded, no details given for the exclusion.</P>
<P>Use of placebo control: no placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 14:35:49 +0000" MODIFIED_BY="[Empty name]">
<P>150 women were recruited into the study. Women with a luteal phase defect, as described by a peak serum P level &lt; 120 mg/mL in the mid-luteal phase measured at 3 time points, were eligible and invited to participate. Luteal phase defects were ascertained in 2 consecutive menstrual cycles, and the third cycle was the intervention cycle. Women receiving IVF-ET treatment were excluded. 313 women were considered for enrolment in the study, 150 (48%) were randomised. 28 women were withdrawn from the control group, leaving 122 women in the study, who were allocated to vitamin C (n = 76) or control (n = 46). 5 women in the control group and 19 women in the vitamin C group became pregnant during the study period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Women in the intervention group took 750 mg vitamin C per day from the first day of the third menstrual cycle until a urinary pregnancy test was positive. Pregnancy rate was checked up until 6 months after the study cycle was started. Women in the control group received no supplementation and no treatment was given in the third cycle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 11:29:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Serum P concentrations.</LI>
<LI>Serum E2 (oestrogen) concentrations.</LI>
<LI>Pregnancy rate.</LI>
<LI>Miscarriage.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-06 11:29:50 +0100" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous or recurrent miscarriage was unclear according to criteria specified in the review.<BR/>Their dietary intake of vitamin C is unknown.<BR/>No sample-size calculation was reported.<BR/>Analyses were not based on intention to treat.<BR/>Compliance: no details of any compliance assessments were given.<BR/>Country: Japan.<BR/>Time frame: January 1997 to December 2000.<BR/>The denominators used for this trials are the number of women randomised and with a confirmed pregnancy (i.e. 19 for the vitamin group and 5 for the control group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:21:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-ICMR-2000">
<CHAR_METHODS>
<P>Randomisation and allocation concealment: unclear, "containers of vitamin or placebo capsules were given a random number" and "the key to random numbers was kept at the ICMR Headquarters". No other methodological details were given.</P>
<P>Blinding of outcome assessment: "double blind" mentioned in the text, but no details given. </P>
<P>Documentation of exclusion: 187 women (40%) were excluded from the analysis.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 16:50:24 +0100" MODIFIED_BY="Heather Maxwell">
<P>466 women were recruited into the study. Women who had previously given birth to a child with an open NTD, and planned to have another child were eligible and invited to participate. This was regardless of their parity, number of previous births with an NTD, age, consanguinity, and socioeconomic status. Women who had previously given birth to a child with closed spina bifida, or with a history of diabetes or abnormal fasting and post-prandial blood sugar, history of epilepsy, congenital anomalies indicative of a genetic syndrome in the previous NTD, history of vitamin intake in the 3 months prior to enrolment, and pregnancy were excluded. 466 women were enrolled and randomised to either vitamin (n = 231) or placebo (n = 235), of these women, 90 were lost to follow-up immediately and 71 did not conceive until the final follow-up. Of the remaining 305 women who were known to become pregnant (vitamin n = 152, placebo n = 153), pregnancy outcomes were unknown for 26 women. In the paper, 279 of the initial 466 women were included in the analysis; however, in this review results are presented for main outcomes on an intention-to-treat basis (i.e. n = 466).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The folic acid containing multivitamin included 120 mg ferrous sulphate, 240 mg calcium phosphate, 4000 IU vitamin A, 400 IU vitamin D, 2.5 mg vitamin B1, 2.5 mg vitamin B2, 2 mg vitamin B6, 15 mg nicotinamide, 40 mg vitamin C, 4 mg folic acid, 10 mg zinc.<BR/>The placebo tablets contained the following trace elements: 120 mg ferrous sulphate and 240 mg calcium phosphate. Both capsules were identical in appearance and women were provided with the tablets from at least 28 days before conception and continuing until at least the second missed menstrual period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:13:45 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Recurrence of NTDs.</LI>
<LI>Live births.</LI>
<LI>Stillbirths.</LI>
<LI>Spontaneous and induced abortion.</LI>
<LI>Multiple birth.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:21:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>The risk profile of women in the trial for spontaneous and recurrent miscarriage is unclear, as is the dietary intake of participants.<BR/>Sample-size calculation performed, assuming a 20% drop out rate. The trial was terminated after publication of the MRC trial in 1991.<BR/>Compliance: compliance was assessed at 3-monthly visits, by checking a diary card maintained by the woman and the number of capsules returned. If the total number of missed days in 3 months did not exceed 10 days, and the total number of missed days at a stretch did not exceed 3, compliance was taken as satisfactory. Women not meeting the above criteria were excluded if they became pregnant in that particular quarter. No compliance data are specifically reported.<BR/>Analyses not based on intention-to-treat.<BR/>Country: India.<BR/>Time frame: 1988 to 1991.<BR/>The denominators used for this trial are based on the number of women randomised (i.e. 231 for the vitamin group and 235 for the placebo group). There was not enough information to accurately confirm the number of women that did or did not become pregnant due to the large number of losses to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-03 01:53:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jauniaux-2004">
<CHAR_METHODS MODIFIED="2016-04-03 01:53:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: randomised controlled trial, but no other information provided.</P>
<P>Blinding of outcome assessment: unclear.</P>
<P>Documentation of exclusions: unclear, no information provided.</P>
<P>Use of placebo: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-16 06:01:01 +0000" MODIFIED_BY="[Empty name]">
<P>Women with a history of 2 or more early pregnancy losses, with no identifiable cause for the losses.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-16 06:01:01 +0000" MODIFIED_BY="[Empty name]">
<P>Vitamin C 1000 mg and vitamin E 400 IU versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-16 06:01:01 +0000" MODIFIED_BY="[Empty name]">
<P>Miscarriage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-03 01:53:53 +0100" MODIFIED_BY="[Empty name]">
<P>Updated 27/11/2013: the trial was stopped in October 2009 due to poor recruitment and lack of funding.</P>
<P>Women's risk of spontaneous and recurrent miscarriage is unclear.<BR/>Sample-size calculation: not done.<BR/>No intention-to-treat analyses: not done.<BR/>Compliance: unclear.<BR/>Location: UK.<BR/>Timeframe: recruitment planned from 2000 to 2001, but trial stopped in 2009.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-20 19:50:47 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Katz-2000">
<CHAR_METHODS MODIFIED="2016-02-10 14:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: cluster-randomised. 270 centres in the Salarhi district, Nepal, were involved which included 30 subdistricts each with 9 wards. Each ward was assigned to 1 of 3 treatment groups. "Wards were assigned by a random draw of numbered chits, blocked on subdistrict."</P>
<P>Blinding of outcome assessment: women and study investigators were not aware of the treatment codes. Maternal mortality was assessed by study investigators blinded to treatment allocation, no details were given for other outcomes.</P>
<P>Documentation of exclusions: 157 (1%) women were lost to follow-up and excluded.</P>
<P>Use of placebo: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 03:03:54 +0000" MODIFIED_BY="[Empty name]">
<P>15,832 women were recruited into the study. All married women of child bearing age in the Salarhi district, Nepal, were eligible and invited to participate in the study. Women migrating into the study area, or women that were never pregnant or refused participation, or women who migrated before being pregnant, were excluded from the analysis. Eligible women were identified from census data and marriage registers. 44,646 women were recruited, of which 1136 (2.5%) were excluded as they either emigrated before becoming pregnant, died or refused consent. During the study period 15,832 women identified themselves as being pregnant, and 157 women were lost to follow-up in the postpartum period. Results are reported for 17,373 pregnancies, allocated to the following groups: vitamin A (n = 6070), beta-carotene (n = 5650) or placebo (n = 5653). Denominators for the treatment groups vary for the measures of early infant mortality, due to losses to follow-up after birth.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 14:36:28 +0000" MODIFIED_BY="[Empty name]">
<P>The 3 treatment groups consisted of a weekly single oral supplement of either:</P>
<OL>
<LI>23,300 IU preformed vitamin A as retinyl palmitate;</LI>
<LI>42 mg of all trans beta-carotene;</LI>
<LI>placebo.</LI>
</OL>
<P>All capsules contained mg dl-alpha-tocopherol as an antioxidant. Women took the tablets prior to conception, during pregnancy and postpartum, for a total of 3.5 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 17:23:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Fetal loss, defined as any reported miscarriage, stillbirth or maternal death during pregnancy. The outcomes were based on self-reports, and women who reported to be pregnant for &gt;= 6 weeks but then no longer reported being pregnant were considered to have had a miscarriage.<BR/>Serial publications also reported neonatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-20 19:50:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk profile for spontaneous or recurrent miscarriage was unclear, as was their dietary intake of vitamin A.<BR/>Compliance: women were distributed the capsules in their home on a weekly basis, receipt of capsules was noted only if the distributor observed the woman swallowing the capsule. Over half of the women who became pregnant during the study received over 80% of their intended supplements, and 75% of pregnant women received at least half of their eligible doses.<BR/>There were serial publications of this study causing the study numerators and denominators to vary between published versions, and multiple pregnancy figures reported did not include higher order pregnancies.<BR/>Sample-size calculation performed.<BR/>Partial intention-to-treat analyses, and the risk ratios and confidence intervals were adjusted to account for any cluster-design effect.<BR/>Country: Nepal.<BR/>Timeframe: April 1994 to September 1997.<BR/>The denominators used for this trial are the number of women randomised who identified themselves as pregnant (i.e. 6070 for the vitamin A group, 5650 for the beta-carotene group and 5653 for the placebo group).<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-03 01:10:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirke-1992">
<CHAR_METHODS MODIFIED="2010-12-07 03:05:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: block randomisation, stratified by hospital, using "consecutively numbered, opaque, sealed envelopes".</P>
<P>Blinding of outcome assessment: women and study investigators were initially blinded to the treatment allocation, however the tablet preparations were changed after 55 women were randomised and after this only participants were blinded.</P>
<P>Documentation of exclusion: 3 women (1%) were lost to follow-up and excluded.</P>
<P>Use of placebo control: 3 treatment regimens were assessed, no placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 15:13:49 +0000" MODIFIED_BY="[Empty name]">
<P>354 women were recruited into the study. Women with a previous NTD defined as anencephalus, iniencephalus, encephalocoele, and spina bifida aperta, who were not pregnant when contacted but were planning a future pregnancy, were eligible and invited to participate. Women were identified from case registers at the participating hospitals. Women with conditions likely to result in impaired absorption from the gastrointestinal tract were excluded.<BR/>435 women were approached, of which 354 (84%) consented and were randomised to either F (n = 115 ), MV (n = 119) or MF (n = 120). 16 women did not become pregnant, and 75 women withdrew; however, their pregnancy outcome status was known, and 18 of these women subsequently became pregnant after withdrawing. 3 women were lost to follow-up. 281 women (93 in the F group, 93 in the MF group and 95 in the MV group) became pregnant in the study period and their pregnancy outcome was known.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 14:36:29 +0000" MODIFIED_BY="[Empty name]">
<P>Indistinguishable trial tablets were initially made by Beecham and Glaxo, however Beecham withdrew their support after 55 women had been randomised. After this time a commercially available pregnavite Forte F was used (MF tablet) and Antigen Pharmaceuticals produced a white multivitamin tablet without folic acid. This was associated with a loss of blinding. Women were randomised to 1 of 3 treatments:</P>
<OL>
<LI>folic acid alone (F);</LI>
<LI>multivitamin with folic acid (MF);</LI>
<LI>multivitamin with no folic acid (MV).</LI>
</OL>
<P>The F and MF resulted in a daily dose of 0.3 mg folic acid. The MF and MV resulted in a daily dose of 4000 IU vitamin A, 400 IU calciferol, 1.5 mg thiamine hydrochloride, 1.5 mg riboflavine, 1 mg pyridoxine hydrochloride, 15 mg nicotinamide, 40 mg ascorbic acid, 480 mg calcium phosphate, and 252 mg ferrous sulphate. Women took the tablets for at least 2 months prior to conception and until the date of the 3rd missed period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:13:55 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Recurrence risk of NTDs.</LI>
<LI>Spontaneous abortion.</LI>
<LI>Ectopic pregnancy.</LI>
<LI>Livebirth.</LI>
<LI>Stillbirth.</LI>
<LI>Congenital malformations excluding NTDs.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-03 01:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>The trial was stopped after there were poor recruitment rates and birth rates. A sample-size calculation required 462 women to show a reduction in NTDs from 5% to 1%. Data from 106 women who were already pregnant at time of recruitment are also included.<BR/>The risk profile of women in the trial for spontaneous and recurrent miscarriage is unclear, as is their dietary intake.<BR/>Compliance: compliance was assessed on tablet counts and blood tests; however, the results are not presented.<BR/>Intention-to-treat analyses were performed.<BR/>Location: Republic of Ireland.<BR/>Timeframe: December 1981 to January 1988.<BR/>The denominators used for this trial are the number of women randomised who became pregnant in the study period and their pregnancy outcome was known (i.e. 93 in the F group, 93 in the MF group and 95 in the MV group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:27:00 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kumwenda-2002">
<CHAR_METHODS MODIFIED="2010-12-07 03:07:03 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial of vitamin A, iron and folic acid supplementation versus iron and folic acid only, during pregnancy, to improve infant outcomes born to women infected with HIV in Malawi.</P>
<P>Randomisation and allocation concealment: "treatment assignment was determined by use of a computer's random-number generator" and "mothers were assigned an original study identification number at enrolment and were given the next sequentially numbered opaque bottle with supplements". "Treatment assignment was concealed by pre packing study supplements in sequentially numbered series assigned to study identification numbers."</P>
<P>Blinding of outcome assessment: unclear, not specifically stated, but participants were blind to their treatment allocation.</P>
<P>Documentation of exclusion: 63 (9%) women were lost to follow-up and 14 (2%) pairs of twins were excluded.</P>
<P>Use of placebo control: control tablets containing iron and folic acid were given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 03:07:20 +0000" MODIFIED_BY="[Empty name]">
<P>Pregnant women between 18 and 29 weeks' gestation and infected with HIV. The average gestation of participants was 23 weeks. 693 women were enrolled and allocated to either vitamin A (n = 340) or control (n = 357), of which pregnancy outcomes were known for 623 women. 63 women were lost to follow-up and 14 sets of twins were excluded due to their higher risk of low birthweight and infant mortality.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-24 09:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>All women received orally administered daily doses of 30 mg iron and 400 mcg folic acid during the study. Women in the intervention group received 10,000 IU vitamin A (3 mg retinol equivalent) orally, in addition to the iron and folic acid supplements. Women were asked to take the tablets from enrolments until delivery. Tablet counts were conducted every 4 weeks. All women received 30 mg retinol equivalents at 6 weeks postpartum, according to standard postpartum care in Malawi.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 17:27:00 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Infant Hb level at 6 weeks and 12 months of age.</LI>
<LI>Percentage of infants with anaemia at 6 weeks of age and at 12 months, defined as a Hb level of &lt; 110 g/L.</LI>
<LI>Birthweight.</LI>
<LI>Percentage of infants &lt; 2500 g at birth.</LI>
<LI>Weight and length at 6 weeks, 14 weeks and 6 months of age.</LI>
<LI>Transmission of HIV to the infant, infant mortality at &lt; 6 weeks of age, at 12 months and at 24 months.</LI>
<LI>Stillbirth and spontaneous abortion (undefined).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-01 03:11:56 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear, although may be increased due to their HIV status.<BR/>50% of women in the vitamin A group and 51% of women in the control group had deficient levels of vitamin A (defined as plasma vitamin A &lt; 0.70 umol/L) at trial entry.<BR/>Sample-size calculation performed.<BR/>No intention-to-treat analyses were performed.<BR/>Compliance: more than 95% of women in both groups took &gt; 90% of study supplements, as ascertained by tablet counts.<BR/>Location: Malawi.<BR/>Timeframe: November 1995 to December 1996.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:27:34 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-McCance-2010">
<CHAR_METHODS MODIFIED="2016-04-18 17:27:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: participants were randomly allocated in a 1:1 ratio to receive 1000 mg vitamin C and 400 IU vitamin E. A randomisation sequence generated in advance by Victoria Pharmaceuticals using PRISYM ID software (version1.0009) was used. The randomisation sequence was stratified by centre with balanced blocks of 8 patients and was held by Victoria Pharmaceuticals. Individual sealed envelopes containing treatment allocations were given to trial pharmacists in every centre allowing treatment groups to be revealed in a clinical emergency.</P>
<P>Blinding of outcome assessment: diagnosis was independently confirmed by 3 senior clinicians, who were unaware of treatment allocation.</P>
<P>Documentation of exclusion: only 1 loss to follow-up was reported.</P>
<P>Use of placebo control: matched placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:21:17 +0000" MODIFIED_BY="[Empty name]">
<P>762 pregnant women between 8 and 22 weeks' gestation with type-1 diabetes attending 25 antenatal metabolic clinics across Northern Ireland, Scotland, and northwest England. Participants were women with type 1 diabetes preceding pregnancy, presentation between 8 weeks' and 22 weeks' gestation, singleton pregnancy, and age 16 years or older. Women with chronic hypertension were included in the trial.</P>
<P>Women were excluded if they did not give consent, were enrolled in another research study, were being treated with warfarin, or were known to misuse drugs Women taking vitamin supplements were excluded only if these contained 500 mg or more vitamin C or 200 IU or more vitamin E daily.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-01 03:13:05 +0000" MODIFIED_BY="[Empty name]">
<P>1000 mg vitamin C and 400 IU vitamin E versus matched placebo started between 8 and 22 weeks' gestation and taken until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-01 03:15:55 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pre-eclampsia.</LI>
<LI>Placental and endothelial function (established by PAI-1 to PAI-2 ratio).</LI>
<LI>Gestational hypertension.</LI>
<LI>Birthweight (centile as calculated from customised birthweight charts).</LI>
<LI>Miscarriage.</LI>
<LI>Maternal death.</LI>
<LI>Obstetric complications and other adverse outcomes.</LI>
<LI>Fetal malformation.</LI>
<LI>Gestational age at delivery.</LI>
<LI>Admission to a neonatal care unit.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:17:22 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk profile for spontaneous and recurrent miscarriage: women with chronic hypertension were included.</P>
<P>Multivitamin supplementation at randomisation was reported at trial entry. Other information about nutrition status are not provided.</P>
<P>Sample-size calculation: based on 40% reduction in pre-eclampsia.</P>
<P>Modified intention to treat was used for analysis of the primary endpoint.</P>
<P>Compliance: unused tablets and capsules were collected during delivery admission or at the 6-week postnatal trial visit, or were returned in postage prepaid envelopes.</P>
<P>Location: Northern Ireland, Scotland, northwest England.</P>
<P>Tiimeframe: April 2003 to June 2008.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:30:01 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-MRC-1991">
<CHAR_METHODS>
<P>Randomisation and allocation concealment: third party randomisation, "randomisation was carried out through the Clinical Trials Service Unit in Oxford". Randomisation was stratified by centre. </P>
<P>Blinding of outcome assessment: women, caregivers and study investigators were blinded to the treatment allocation. </P>
<P>Documentation of exclusion: 164 women (9%) excluded. </P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 15:14:03 +0000" MODIFIED_BY="[Empty name]">
<P>1817 women were recruited into the study. Women who had a previous pregnancy affected by a NTD, and were planning another pregnancy and not already taking supplements were eligible for the study. Women whose affected child had Meckel's syndrome and those women with epilepsy were excluded. 1817 women were randomised to either F (n = 449), MV (n = 453), MF (n = 461) or P (n = 454), of which, 1195 were informative pregnancies that is, where the outcome of NTD or not was definitely known (F n = 298, MV n = 302, MF n = 295, P n = 300). Results for pregnancy loss are reported for both informative and not informative pregnancies. 164 women were excluded as they may have been pregnant at the time of randomisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-06 11:34:29 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised into 1 of 4 groups:</P>
<OL>
<LI>4 mg, 240 mg di-calcium phosphate and 120 mg ferrous sulphate (F);</LI>
<LI>4000 IU vitamin A, 400 IU calciferol, 1.5 mg thiamine hydrochloride, 1.5 mg riboflavine, 1 mg pyridoxine hydrochloride, 15 mg nicotinamide, 40 mg ascorbic acid, 240 mg di-calcium phosphate and 120 mg ferrous sulphate (MV);</LI>
<LI>folic acid combined with the multivitamins specified above (MF);</LI>
<LI>placebo containing 240 mg di-calcium phosphate and 120 mg ferrous sulphate only (P).</LI>
</OL>
<P>Women took the tablets prior to conception and attended the site every 3 months to collect additional supplies and again during the 12th week of pregnancy. No special dietary advice was given to women.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:14:07 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>NTD and other birth defects.</LI>
<LI>Spontaneous abortions.</LI>
<LI>Ectopic pregnancy.</LI>
<LI>Termination or pregnancy.</LI>
<LI>Livebirth.</LI>
<LI>Stillbirth.</LI>
<LI>Multiple pregnancy.</LI>
<LI>Subsequent publications report on blood folic acid and zinc concentrations.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:30:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial was stopped early after there were 1195 informative pregnancies, according to prespecified stopping rules. The aim of the study was to obtain information on at least 2000 informative pregnancies unless a sufficiently clear result emerged sooner.<BR/>Women's risk profile for spontaneous and recurrent miscarriage was unclear, as was their nutritional status.<BR/>Compliance: compliance based on self-reports, and data were available for women with an informative pregnancy only, where 79 (6%) women reported they stopped taking their capsules before their last scheduled visit.<BR/>Intention-to-treat analyses are reported in this review including not informative pregnancies (i.e. n = 1817).<BR/>Location: multi-national study co-ordinated from the UK.<BR/>Timeframe: July 1983 to April 1991.<BR/>The denominators used for this trial are the number of women randomised, i.e. (449 for the F group, 453 for the MV group, 461 for the MF and 454 for the P group). There was no information provided about any women randomised that did not become pregnant in the study period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:30:38 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Osrin-2005">
<CHAR_METHODS MODIFIED="2016-04-18 17:30:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: 1 of the authors 'randomly allocated 1200 participant numbers by computer into 2 groups in permuted blocks of 50'. Every identification number was allocated a supplement container, which was then packed by a team member not otherwise involved in the trial. After enrolment, another author allocated participants sequential identification numbers with the corresponding supplement containers.</P>
<P>Blinding of outcome assessment: double-blind stated but no other details given.</P>
<P>Documentation of exclusion: 61 women (5%) withdrew or were lost to follow-up, however data on miscarriage were reported for those who withdrew due to miscarriage.</P>
<P>Use of placebo control: control of iron and folic acid supplements given which looked identical to the intervention supplements.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-14 03:16:20 +0100" MODIFIED_BY="[Empty name]">
<P>1200 women were recruited into the study. Women were eligible if they were: less than 20 completed weeks, had a singleton pregnancy, no notable fetal abnormality, no existing maternal illness of a severity that could compromise the outcome of pregnancy, and lived in an area of Dhanusha or the adjoining district of Mahottari accessible for home visits. </P>
<P>Maternal illnesses that led to exclusion were: recently treated recurrent cysticercosis, need for chlorpromazine or anticoagulant drugs with changing doses, and symptomatic mitral stenosis or multivalvular heart disease. Fetal exclusions were: twin pregnancies, anencephaly, occipital meningocele, encephalocele, duodenal atresia and a grossly dilated pelvicalyceal system.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-02 05:49:41 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group: vitamin A 800 mcg, vitamin E 10 mg, vitamin D 5 mcg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 mcg, folic acid 400 mcg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 mcg, and iodine 150 mcg.</P>
<P>Control group: iron 60 mg and folic acid 400 mcg.</P>
<P>Supplementation began at a minimum of 12 weeks&#8217; gestation and continued until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 08:44:59 +0000" MODIFIED_BY="Denise Atherton">
<OL>
<LI>Birthweight.</LI>
<LI>Gestational duration.</LI>
<LI>Infant length and head circumference.</LI>
<LI>Miscarriage defined as cessation of confirmed pregnancy before 23 weeks&#8217; gestation.</LI>
<LI>Stillbirth defined as delivery of an infant showing no signs of life (movement, breathing, or heartbeat) after 23 weeks&#8217; gestation.</LI>
<LI>Early neonatal death defined as death of a live born infant in the first 7 days after birth.</LI>
<LI>Late neonatal death as death of a live born infant after 7 but within 28 days.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:19:27 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is also unclear, however, women are presumable at high risk of under-nutrition as the paper states that in Nepal 'deficiencies of several micronutrients have been well described in individual studies and in a national sample'.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: median 'adherence' was 98% in the control group and 97% in the intervention group.</P>
<P>Location: Nepal.</P>
<P>Timeframe: August 2002 to October 2003.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-03 01:10:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-People_x0027_s-League-1942">
<CHAR_METHODS MODIFIED="2016-04-03 01:10:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: "women enrolled at the antenatal clinic were divided into two main groups by placing them alternatively on separate lists".</P>
<P>Blinding of outcome assessment: unclear, no information given on blinding of participants, carers or outcome assessors.</P>
<P>Documentation of exclusion: 622 women (11%) were excluded.</P>
<P>Use of placebo control: no placebo given.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 03:13:20 +0000" MODIFIED_BY="[Empty name]">
<P>5644 women were recruited into the study. All women attending the antenatal clinics and who were less than or equal to 24 weeks' gestation and who were in 'good health' were eligible for the study. Women who were more than 24 weeks' gestation and women who suffered from any disease or physical abnormality were excluded from the study. After enrolment, women who had twin births and who miscarried at an early stage were also excluded.<BR/>5644 women were initially enrolled in the study of which 5022 (89%) remained in the study. Of the 622 (11%) women withdrawn from the trial, 494 were evacuated from the London area (due to World War 2), 39 women had twin births and 89 women miscarried at an early stage. 5022 women remained in the study and were allocated to either multivitamins (n = 2510) or control (n = 2512). Women were further divided into primiparae and multiparae, and various age groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Women allocated to the treatment group were given daily vitamin C 100 mg, ferrous iron 0.26 g, calcium 0.26 g, minute quantities of iodine, manganese and copper, adsorbate of vitamin B1 containing all factors of the B complex and halibut liver oil 0.36 g containing vitamin A (52,000 IU per g) and vitamin D (2500 IU per g). <BR/>Women allocated to the control group received no placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 11:35:50 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Toxaemia classified into subgroups based on: hypertension only, albuminuria with or without hypertension, or hypertension with albuminuria (pre-eclampsia).</LI>
<LI>Maternal sepsis.</LI>
<LI>Length of gestation (categorised as less than 40 weeks, 40 weeks, and greater than 40 weeks).</LI>
<LI>Percentage of women breastfeeding.</LI>
<LI>Stillbirth.</LI>
<LI>Neonatal mortality (defined as death before 8 days).</LI>
<LI>Birthweight (pounds) (only reported for primiparae and multiparae separately).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-06 11:35:57 +0100" MODIFIED_BY="[Empty name]">
<P>Women risk status for spontaneous and recurrent miscarriage is unclear.<BR/>Dietary intake at trial entry: "vitamin C shortage affected about half the women".<BR/>Intention-to-treat analyses: not performed.<BR/>Compliance: unclear, no information provided.<BR/>Sample-size calculation: unclear. "It was decided that the investigation should include a minimum of 5000 pregnant women". No other details given.<BR/>Location: England.<BR/>Timeframe: 1938 to 1939.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:39:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Poston-2006">
<CHAR_METHODS MODIFIED="2016-04-18 17:35:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: the randomisation (computer-generated sequence) was blocked&#8212;i.e., balanced&#8212;by centre in groups of 2 to 10 individuals.</P>
<P>Blinding of outcome assessment: none of the trial staff or any other person involved in the trial knew the allocated treatment of any woman until after completion of the study.</P>
<P>Documentation of exclusion: 9 (0.4%) women were excluded.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 17:38:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>2404 women with clinical risk factors for pre-eclampsia</P>
<P>Inclusion criteria:</P>
<P>gestational age 14+&#8304;&#8211;21+&#8310; weeks; one or more of the following risk factors: pre-eclampsia in the pregnancy preceding the index pregnancy, requiring delivery before 37 completed weeks&#8217; gestation, diagnosis of HELLP syndrome in any previous pregnancy, eclampsia in any previous pregnancy; essential hypertension requiring medication, type 1 or type 2 diabetes, multiple pregnancy; abnormal uterine artery doppler waveform primiparity with BMI at first antenatal appointment of 30 kg/m² or more.</P>
<P>Exclusion criteria:</P>
<P>women unable or unwilling to give written informed consent or women who were being treated with warfarin. Women taking vitamin supplements that contained doses of vitamin C of 200 mg or more or of vitamin E of 40 IU or more daily were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 17:38:40 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were assigned to 1000 mg vitamin C and 400 IU vitamin E (RRR &#945; tocopherol; n = 1199) or matched placebo (n = 1205) daily from the second trimester of pregnancy until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 17:39:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>Primary outcomes</P>
<OL>
<LI>Pre-eclampsia,</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>Low birthweight (&lt;2·5 kg).</LI>
<LI>Small size for gestational age.</LI>
<LI>Preterm birth (&#8804;37+&#8304; weeks&#8217; gestation).</LI>
<LI>Gestational age at delivery.</LI>
<LI>Smaller than 10<SUP>th</SUP> centile for gestation.</LI>
<LI>Use of health-care resources.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:39:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women risk status for spontaneous and recurrent miscarriage: history of chronic hypertension, BMI, pre-eclampsia, multiple pregnancy, diabetes, and other risk factors reported.<BR/>Dietary intake at trial entry: use of supplements reported.<BR/>Intention-to-treat analyses: not performed.<BR/>Compliance: 80% (n = 1653) of women took at least 50% of their tablets, 65% (n = 1345) took 80% or more, and 32% (n = 661) took all of their tablets; 6% (n = 125) did not take any tablets.<BR/>Sample-size calculation: expected incidence of pre-eclampsia in the placebo group of at least 15% and in the treatment group of at least 30%<BR/>
<BR/>Location: 25 hospitals, UK.<BR/>Timeframe: August 2003 to June 2005.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:48:18 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Prawirohartono-2011">
<CHAR_METHODS MODIFIED="2016-04-18 17:40:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: community-based, individually-randomised, placebo-controlled and double-blinded study. Pregnat women were randomly allocated in a 1:1:1:1 ratio in blocks of 12 based on a list of treatment numbers derived from a pseudo-random number generated with SAS software.</P>
<P>Blinding of outcome assessment: all investigators, field and laboratory staff and participants were blinded to the treatment code until all field data had been collected and preliminary data analysis by coded groups had been completed.</P>
<P>Documentation of exclusions: 75 women (3.5%) were excluded.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-03 01:11:40 +0100" MODIFIED_BY="[Empty name]">
<P>2173 women at a gestational age of ,17 weeks were included in the study. Women at a gestational age of &gt;=17 weeks were not eligible.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 17:48:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were allocated to one of the three intervention groups:</P>
<OL>
<LI>2400 retinol equivalents of vitamin A as retinyl palmitate,</LI>
<LI>20 mg of zinc sulfate, or</LI>
<LI>the same dose of vitamin A and zinc sulfate.</LI>
</OL>
<P>Comparison group: placebo.</P>
<P>All capsules also contained 2mg dl-alpha-tocopherol as antioxidant and 350 mg of soyabean oil, 20 mg of beeswax and 8 mg of lecithin as capsule filler.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-03 01:11:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Birthweigh.</LI>
<LI>Birth length.</LI>
<LI>Neonatal morbidity.</LI>
<LI>Infant mortality.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-03 01:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is unclear</P>
<P>Intention-to-treat analyses not performed.</P>
<P>Sample-size calculation not performed</P>
<P>Compliance: consumption of 70% of supplements.</P>
<P>Location: Indonesia.</P>
<P>Timeframe: September 1995 to December 1999.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-20 19:11:41 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Roberfroid-2008">
<CHAR_METHODS MODIFIED="2016-04-20 19:11:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: the randomisation scheme was generated by a computer program in permuted blocks of 4. Randomisation numbers were sealed in opaque envelopes. At each inclusion, the consulting physician opened the next sealed envelope and transmitted the randomisation number to a pharmacist managing the allocation sequence and the packaging of drugs at a central location.</P>
<P>Blinding of outcome assessment: the consulting physicians, pharmacist and women were blinded to allocation.</P>
<P>Documentation of exclusions: 107 women were lost to follow-up (however their pregnancy outcome was reported). Post randomisation 26 twins were excluded (multivitamin group: 15; iron/folic acid group: 11 twins (including 1 set of triplets). Only singleton pregnancies were included in the analysis because fetal loss and anthropometric measures at birth in multiple pregnancies are not primarily nutrition-related. 3 women died before delivery and 1 woman underwent a therapeutic abortion.</P>
<P>Use of placebo control: no placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 13:42:45 +0000" MODIFIED_BY="[Empty name]">
<P>1374 women were recruited to participate, however 52 women were randomly assigned twice for consecutive pregnancies, resulting in data for 1426 pregnancies. Women had a pregnancy confirmed by urine testing and were randomly assigned to receive either IFA (n = 712) or UNIMMAP (n = 714) daily until 3 months after delivery. Women were recruited between 5 to 36 weeks&#8217; gestation; 34.6% (n = 493) of the participants were recruited in the first trimester of pregnancy, mean gestational age at enrolment was 17.3 weeks (SD 7.8 weeks).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 17:44:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>UNIMMAP: vitamin A 800 mcg, vitamin D 200 IU, vitamin E 10 mg, vitamin B-1 1.4 mg, vitamin B-2 1.4 mg, niacin 18 mg, folic acid 400 mcg, vitamin B-6 1.9 mg, vitamin B-12 2.6 mcg, vitamin C 70 mg, zinc 15 mg, iron 30 mg, copper 2 mg, selenium 65 mcg, iodine 150 mcg.</P>
<P>IFA (control): folic acid 400 mcg, Iron 60 mg.</P>
<P>In a case of maternal illness, appropriate treatments were provided according to national guidelines. Severely anaemic women (Hb &lt; 70 g/L, without dyspnoea) received ferrous sulphate (200 mg) + folic acid (0.25 mg) twice daily, for 3 months, regardless of their allocation group. All participants also received 400 mg albendazole in the second and third trimesters. If malaria occurred despite chemoprophylaxis, quinine (300 mg, 3 times/day) was given for 5 days. Vitamin A (200,000 IU) was given to all women after delivery, in accordance with national recommendations.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 17:44:38 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Gestational duration.</LI>
<LI>Birthweight, birth length, and Rohrer ponderal index at birth (weight(g)X100/length3(cm)).</LI>
<LI>Low birthweight (&lt; 2500 g).</LI>
<LI>Small-for-gestational age (birthweight below the 10th percentile).</LI>
<LI>Large-for-gestational age (birthweight above the 90th percentile of the study population).</LI>
<LI>Thoracic circumference, head circumference, mid upper arm circumference.</LI>
<LI>Hb concentration in mothers during the third trimester, Hb and sTfR concentrations in cord blood.</LI>
<LI>Preterm birth (&lt; 37 weeks&#8217; gestation).</LI>
<LI>Stillbirth (delivery of an infant showing no sign of life after a gestational age of 28 weeks).</LI>
<LI>Perinatal death.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:48:27 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear. 18% of women in each group had experienced a previous fetal loss.</P>
<P>Women's nutritional status is unclear, although women are presumable at risk as the purpose of the trial is to correct MMN deficiencies.</P>
<P>Intention-to-treat analyses not performed, however the review included details of losses to follow-up where the outcome was known.</P>
<P>Compliance: unclear, states that there was no difference in compliance between the 2 groups.</P>
<P>Location: Burkino Faso.</P>
<P>Timeframe: March 2004 to October 2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:49:59 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Roberts-2010">
<CHAR_METHODS MODIFIED="2016-02-10 14:49:11 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: women were randomly assigned to receive capsules containing a combination of 1000 mg of vitamin C (ascorbic acid) and 400 IU of vitamin E (RRR-alpha-tocopherol acetate) or matching placebo (mineral oil). The simple urn method, with stratification according to clinical centre, was used by the data co-ordinating centre to create a randomisation sequence. No further methodological details are provided.</P>
<P>Blinding of outcome assessment: medical charts were reviewed by at least 3 reviewers who were unaware of the treatment assignments.</P>
<P>Documentation of exclusions: 183 women (1.8%) were lost to follow-up and for 2 women had been removed after randomisation.</P>
<P>Use of placebo control: placebo given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 17:49:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>10,154 pregnant women who had a singleton fetus with a gestational age of less than 16 weeks 0 days at the time of screening attending 16 clinical centres and the independent data coordinating centre of the MFMU Network. Women were eligible for inclusion if they had not had a previous pregnancy that lasted beyond 19 weeks 6 days.</P>
<P>Women were not eligible if they had elevated systolic or diastolic blood pressure, proteinuria, were taking or had taken antihypertensive medication, or were taking more than 150 mg of vitamin C or more than 75 IU of vitamin E daily. Other exclusion criteria were diabetes that was present before the pregnancy, treatment with antiplatelet drugs or non-steroidal anti-inflammatory agents, uterine bleeding within the week before recruitment, uterine malformation, serious medical condition, known fetal anomaly or aneuploidy, in vitro fertilisation resulting in the current pregnancy, or abuse of illicit drugs or alcohol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-29 06:15:24 +0000" MODIFIED_BY="[Empty name]">
<P>A combination of 1000 mg of vitamin C (ascorbic acid) and 400 IU of vitamin E daily administered from enrolment until delivery. The control group received placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-01 04:00:23 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pregnancy-associated hypertension.</LI>
<LI>Serious adverse outcomes in the mother or her fetus or neonate. Pre-eclampsia.</LI>
<LI>Other maternal and neonatal outcomes.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-01 04:04:02 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Use of prenatal vitamins or multivitamins, daily dose of vitamin C and E were reported at trial entry.</P>
<P>Sample size calculation was based on a 30% reduction in the rate of the primary outcome.</P>
<P>Intention-to-treat analysis was performed.</P>
<P>Compliance: monthly, participants returned unused study drugs from the previous month.</P>
<P>Location: UK.</P>
<P>Timeframe: July 2003 to February 2008.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:51:40 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rumbold-2006">
<CHAR_METHODS MODIFIED="2016-02-10 14:50:31 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: computer-generated random number list with balanced variable blocks and stratification for collaborating centre and gestational age (&lt; 18 weeks versus 18 weeks or more), allocation occurred via a central telephone randomisation service. The treatment packs contained 4 sealed, opaque, white plastic bottles of either the antioxidants vitamin C and vitamin E or the placebo and were prepared by a researcher not involved in recruitment or clinical care.</P>
<P>Blinding of outcome assessment: women, caregivers and investigators were blinded to allocation.</P>
<P>Documentation of exclusion: no losses to follow-up.</P>
<P>Use of placebo control: placebo given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 03:19:39 +0000" MODIFIED_BY="[Empty name]">
<P>1877 women were recruited into the study. Eligible women included those: with a nulliparous singleton pregnancy, between 14 and 22 weeks of gestation and with normal blood pressure at the first measurement in pregnancy and again at trial entry.</P>
<P>Women who had any of the following were excluded: known multiple pregnancy, known potentially lethal fetal anomaly, known thrombophilia, chronic renal failure, antihypertensive therapy, or specific contraindications to vitamin C or E therapy such as haemochromatosis or anticoagulant therapy.</P>
<P>Women were allocated to the vitamin C and E group (n = 935) or placebo (n = 935).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 14:37:02 +0000" MODIFIED_BY="[Empty name]">
<P>Women allocated to the vitamin C and E group took 4 coated tablets of a combination of 250 mg of vitamin C (as ascorbic acid) and 100 IU of vitamin E (as <I>d</I>-alpha-tocopherol succinate) each day from trial entry until delivery (total daily dose of vitamin C: 1000 mg; vitamin E: 400 IU).</P>
<P>Women were advised not to take any other antioxidant supplements, although a multivitamin preparation that provided a daily intake of no more than 200 mg of vitamin C or 50 IU of vitamin E was permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 17:51:40 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Pre-eclampsia.</LI>
<LI>A composite measure of death or serious outcomes in the infant.</LI>
<LI>Small-for-gestational age.</LI>
<LI>Serious infant complications occurring before hospital discharge.</LI>
<LI>For women included a composite of any of the following until 6 weeks postpartum: death, pulmonary edema, eclampsia, stroke, thrombocytopenia, renal insufficiency, respiratory distress syndrome, cardiac arrest, respiratory arrest, placental abruption, abnormal liver function, preterm prelabour rupture of membranes, major postpartum haemorrhage, postpartum pyrexia, pneumonia, deep-vein thrombosis, or pulmonary embolus requiring anticoagulant therapy.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:51:32 +0000" MODIFIED_BY="[Empty name]">
<P>Women were at low risk of spontaneous and recurrent miscarriage based on the review criteria.</P>
<P>The majority of women participating had a baseline dietary intake of vitamin C and E above the Australian recommended daily amount.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: there was no difference in compliance between the vitamin group (67%) and the placebo group (70%).</P>
<P>Location: Australia.</P>
<P>Timeframe: December 2001 and January 2005.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:53:34 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rumiris-2006">
<CHAR_METHODS MODIFIED="2016-02-05 14:42:39 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: a computer-generated random number sequence.</P>
<P>Randomisation and allocation concealment: central allocation (randomisation by an independent third party who had no conflict of interest in the study).</P>
<P>Blinding of outcome assessment: treatment allocations were blinded to both the investigator and the patient until the study was finished.</P>
<P>Documentation of exclusion: none reported.</P>
<P>Use of placebo control: no, comparisons were between antioxidants versus iron and folic acid.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 14:52:14 +0000" MODIFIED_BY="[Empty name]">
<P>60 women between 8 and 12 weeks' gestation were eligible for randomisation (supplementation group: n = 29; folic acid group: n = 31).</P>
<P>Setting: at the antenatal clinic of the Department of Obstetrics and Gynecology, University of Indonesia between March 2003 and June 2004.</P>
<P>Eligibility criteria: pregnant women with low antioxidant status.</P>
<P>Exclusion criteria:</P>
<OL>
<LI>history or current use of anti-hypertensive medication or diuretics;</LI>
<LI>use of vitamins C &gt; 150 mg and/or E &gt; 75 IU per day;</LI>
<LI>known placental abnormalities;</LI>
<LI>current pregnancy as a result of in vitro fertilisation;</LI>
<LI>regular use of platelet active drugs or non-steroidal anti-inflammatory drugs;</LI>
<LI>known fetal abnormalities;</LI>
<LI>documented uterine bleeding within a week of screening;</LI>
<LI>uterine malformations;</LI>
<LI>history of medical complications.</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-01 04:05:20 +0000" MODIFIED_BY="[Empty name]">
<P>Supplementation group: received antioxidant supplements daily - vitamins A (1000 IU), B6 (2.2 mg), B12 (2.2 mcg), C (200 mg), E (400 IU), folic acid (400 mcg), <I>N</I>-acetylcysteine (200 mg), Cu (2 mg), Zn (15 mg), Mn (0.5 mg), Fe (30 mg), calcium (800 mg), and selenium (100 mcg).</P>
<P>Folic acid group: received Fe 30 mg and folic acid 400 mcg daily.</P>
<P>Timing of the intervention: early pregnancy (8 to 12 weeks).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 03:21:50 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pre-eclampsia.</LI>
<LI>Abortion.</LI>
<LI>Hypertension.</LI>
<LI>Intrauterine growth restriction.</LI>
<LI>Intrauterine fetal death.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 17:53:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Participating women had low antioxidant status at enrolment, as defined as superoxide dismutase level below 164U/mL. No nutritional information provided.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: unclear, no information reported.</P>
<P>Location: Indonesia.</P>
<P>Timeframe: March 2003 and June 2004.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 14:36:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rush-1980">
<CHAR_METHODS>
<P>Randomisation and allocation concealment: unclear, women were allocated to groups based on "random assignment". Randomisation was stratified on pre-pregnancy weight, weight gain during pregnancy, previous low birthweight infant and protein intake. No other methodological details given. </P>
<P>Blinding of outcome assessment: unclear, women were allocated to 2 forms of treatment or control, where both treatments were given as a canned beverage and the control group were given standard oral multivitamins. No information is given on blinding of outcome assessors. </P>
<P>Documentation of exclusion: 237 women (22%) were excluded. </P>
<P>Use of placebo control: no placebo, the control group received standard prenatal multivitamin supplements.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 14:36:38 +0000" MODIFIED_BY="[Empty name]">
<P>1051 women were recruited into the study. Women eligible were black, English speaking, and not greater than 30 weeks' gestation. They also had 1 of the following criteria: low pre-pregnant weight (under 110 pounds at conception); low weight gain at the time of recruitment; at least 1 previous low birthweight infant; a history of protein intake of less than 50 g in the 24 hours preceding recruitment. Women were not eligible if they were known to be seeking a termination, had specific chronic health disorders, if they admitted to recent use of narcotics or heavy use of alcohol, or weighed &gt;= 140 pounds at conception.<BR/>The mean gestation at enrolment ranged from 16-18 weeks for the treatment groups.<BR/>1225 women were invited to join the study, of which 1051 (84%) consented. Of these, 237 (22%) were excluded and 814 women (77%) remained active in the study until delivery and were allocated to 1 of 3 groups: supplement (n = 263), complement (n = 272) or control (n = 279).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-06 11:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised to 1 of 3 groups:</P>
<OL>
<LI>high protein supplement (daily 40 g animal protein, 470 calories, 1000 mg calcium, 100 mg magnesium, 60 mg iron, 4 mg zinc, 2 mg copper, 150 mcg iodine, 6000 IU vitamin A, 400 IU vitamin D, 30 USPU vitamin E, 60 mg vitamin C, 3 mg vitamin B1, 15 mg vitamin B2, 15 mg niacin, 2.5 mg vitamin B6, 1 mg pantothenic acid, 200 mcg biotin, 350 mcg folic acid, 8 mcg vitamin B12);</LI>
<LI>balanced protein-energy complement (6 g animal protein, 250 mg calcium, 12 mg magnesium, 40 mg iron, 0.084 mg zinc, 0.15 mg copper, 100 mcg iodine, 4000 IU vitamin A, 400 IU vitamin D, 60 mg vitamin C, 3 mg vitamin B1, 15 mg vitamin B2, 10 mg niacin, 3 mg vitamin B6, 1 mg pantothenic acid, 350 mcg folic acid, 3 mcg vitamin B12);</LI>
<LI>control (250 mg calcium, 0.15 mg magnesium, 117 mg iron, 0.85 mg zinc, 0.15 mg copper, 100 mcg iodine, 4000 IU vitamin A, 400 IU vitamin D, 60 mg vitamin C, 3 mg vitamin B1, 2 mg vitamin B2, 10 mg niacin, 3 mg vitamin B6, 1 mg pantothenic acid, 350 mcg folic acid, 3 mcg vitamin B12).</LI>
</OL>
<P>Women received the high protein or balanced protein-energy supplements in the format of a drink. Women in the control group received a standard oral prenatal multivitamin supplement.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 03:23:55 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total weight gain, average weight gain and early weight gain during pregnancy.</LI>
<LI>Duration of gestation (presented as cumulative rates of delivery from life tables for each treatment group).</LI>
<LI>Preterm birth &lt; 37 weeks.</LI>
<LI>Fetal death (before &lt; 20 weeks' gestation and &gt;= 20 weeks' gestation).</LI>
<LI>Neonatal death (according to gestation at delivery).</LI>
<LI>Birthweight (mean).</LI>
<LI>Somatic measures of infant growth at 1 year of age.</LI>
<LI>Psychological measures at 1 year of age.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 14:36:39 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear, as there is no information about concurrent medical conditions or other risk factors for miscarriage. Women in the trial had a low caloric intake at trial entry, and unexpectedly, an adequate protein intake. No other specific nutritional information is reported.<BR/>Sample-size calculation reported: 250 women were required in each treatment group to show a 125 g difference in birthweight. A 25% loss to follow-up was incorporated into the sample size.<BR/>Intention-to-treat analyses not performed.<BR/>There were 9 sets of twins amongst the 3 treatment groups.<BR/>Compliance: "on average, about three quarters of the prescribed amount of beverage was probably ingested".<BR/>Location: New York City, USA.<BR/>Timeframe: 1969 to 1976.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:23:54 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Schmidt-2001">
<CHAR_METHODS MODIFIED="2016-04-18 17:55:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation and allocation concealment: unclear, women were "randomly assigned on an individual basis, to double-blind, weekly supplementation until delivery".</P>
<P>Blinding of outcome assessment: unclear, double-blind stated in text but no details given.</P>
<P>Documentation of exclusion: 42 women (17%) were lost to follow-up and excluded.</P>
<P>Use of placebo control: control tablets containing iron and folic acid were given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 17:56:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>243 women were recruited into this study. Pregnant women between 16 and 20 weeks' gestation, aged between 17 and 35 years old, with a parity &lt; 6 and Hb level between 80-140 g/L, were eligible for this study. Women were randomised to receive either vitamin A plus iron and folic acid (n = 122) or iron and folic acid only (n = 121). Of these 22 (18%) and 20 (17%) women in vitamin A plus iron and folic acid and the iron and folic acid groups respectively, dropped out between enrolment and the follow-up at 4 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Women were randomised to a weekly supplementation with 120 mg ferrous sulfate and 500 mcg folic acid, with or without vitamin A (2400 retinol equivalents). Women were asked to take the trial tablets from between 16 and 20 weeks' gestation until birth.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:23:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Stillbirth.<BR/>2. Concentrations of Hb, serum ferritin and serum transferrin receptors, at or near term.<BR/>3. Concentrations of iron and vitamin A in breast milk.<BR/>4. Hb and serum vitamin A concentrations in the mother and infant at 4 months postpartum.<BR/>5. General health, growth and development measures in the first year of life.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 03:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>Women risk status for spontaneous and recurrent miscarriage is unclear.<BR/>At baseline, between 13% and 17% of women had marginal vitamin A deficiency 44% to 50% of women were anaemic.<BR/>Sample-size calculation performed allowing for a 50% drop-out during the study period.<BR/>Intention-to-treat analyses were not performed.<BR/>Compliance: adherence to the tablet intake was assessed through interview during a postnatal home visit, which revealed that the median tablet intake was 50 tablets (i.e. 25 weeks), while only 17% of the subjects took more than 90 tablets.<BR/>Location: Indonesia.<BR/>Serial publications of this data report different denominators.<BR/>Time frame: November 1997 to May 1998.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:57:32 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Spinnato-2007">
<CHAR_METHODS MODIFIED="2016-04-18 17:57:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Generation of random number sequence: the randomisation sequence was constructed by the data co-ordinating centre (DCC) as permuted blocks of random size, stratified by clinical centre, and implemented via a program residing on the clinical centres study computer.</P>
<P>Randomisation and allocation concealment: central allocation.</P>
<P>Blinding of outcome assessment: all clinicians and clinical investigators were blinded to group assignment.</P>
<P>Documentation of exclusion: none reported.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 14:37:03 +0000" MODIFIED_BY="[Empty name]">
<P>739 eligible women between 12<SUP>0/7</SUP> and 19<SUP>6/7 </SUP>weeks of gestation were enrolled in the study (treatment: 371; placebo: 368).</P>
<P>Setting: 4 Brazilian clinical centres: 1 primary clinical centre (Recife) and 3 additional clinical sites (Campinas, Botucatu, and Porto Alegre); each site&#8217;s major teaching hospital serves a primarily urban low-income population.</P>
<P>Eligibility criteria: women between 12<SUP>0/7</SUP> and 19<SUP>6/7 </SUP>weeks of gestation and diagnosed with nonproteinuric chronic hypertension or a prior history of pre-eclampsia in their most recent pregnancy that progressed beyond 20 weeks' gestation.</P>
<P>Exclusion criteria:multifetal gestation, allergy to vitamin C or vitamin E, requirement for aspirin or anticoagulant medication, 24-hour urinary protein &#8805; 300 mg, pre-pregnancy diabetes mellitus, known fetal anomaly incompatible with life.</P>
<P>Loss to follow-up: 32 women (treatment 16; placebo 16).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 03:27:45 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group: daily treatment with both vitamin C (1000 mg) and E (400 IU) until delivery or until the diagnosis of pre-eclampsia.</P>
<P>Control group: daily placebo until delivery or until the diagnosis of pre-eclampsia.</P>
<P>Timing of the intervention: between 12<SUP>0/7</SUP> and 19<SUP>6/7 </SUP>weeks of gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 08:45:30 +0000" MODIFIED_BY="Denise Atherton">
<OL>
<LI>Pre-eclampsia (women were followed through the 14th day postpartum for the occurrence of pre-eclampsia).</LI>
<LI>Severity of pre-eclampsia.</LI>
<LI>Gestational hypertension.</LI>
<LI>Abruptio placentae.</LI>
<LI>Premature rupture of membranes.</LI>
<LI>Preterm birth.</LI>
<LI>Small-for-gestational age.</LI>
<LI>Low birthweight infant.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:21:38 +0000" MODIFIED_BY="[Empty name]">
<P>25 inclusion/exclusion criteria violations (23 enrolled outside 12-19 weeks&#8217; gestation; 2 twin gestations - 1 lost to spontaneous abortions, 1 delivered liveborn in treatment group); all 25 women remained in their assigned study groups.</P>
<P>26 women had early treatment terminations (treatment 19; placebo 7), but remained in follow-up.</P>
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is also unclear.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: average compliance was 85%, and similar between treatment groups.</P>
<P>Location: Brazil.</P>
<P>Timeframe: July 2, 2003 and November 23, 2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 17:59:26 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Steyn-2003">
<CHAR_METHODS>
<P>Randomisation and allocation concealment: "randomisation was undertaken by computer-generated numbers". Roche Pharmaceutical supplied numbered containers with either vitamin C or matching placebo, and they retained the study code until completion of the study. No other methodological details given. </P>
<P>Blinding of outcome assessment: "double blind" stated, Roche Pharmaceuticals retained the code until completion of the study. </P>
<P>Documentation of exclusion: none reported. </P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 03:29:32 +0000" MODIFIED_BY="[Empty name]">
<P>200 women were recruited into the study. Women with a history of a previous mid-trimester abortion (defined as spontaneous expulsion of the uterine contents between 13 and 26 weeks' gestational age), or previous preterm labour, and less than 26 weeks' gestation were eligible and invited to participate. Women with iatrogenic causes of their previous preterm labour such as previous induction of labour before term for severe pre-eclampsia, were excluded. 203 consecutive women were approached, of which 200 (98.5%) consented and were randomised to either vitamin C (n = 100) or placebo (n = 100). No losses to follow-up were reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 17:59:26 +0100" MODIFIED_BY="Heather Maxwell">
<P>Twice daily tablet of either 250 mg vitamin C or placebo, from trial entry until 34 weeks' gestation. All women were tested for bacterial vaginosis and all women with positive cultures for <I>Mycoplasma hominis</I> (and between 22 and 32 weeks' gestation) were treated with erythromycin for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 11:39:58 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Preterm labour, defined as spontaneous onset of labour and delivery before 37 completed weeks.</LI>
<LI>The secondary outcome was perinatal outcome, a composite endpoint including birthweight, gestational age at delivery, perinatal mortality, duration of admission in the neonatal intensive care unit and neonatal complications.</LI>
</OL>
<P>The age of fetal viability was considered to be 28 weeks' gestation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 14:35:58 +0000" MODIFIED_BY="[Empty name]">
<P>Results are from an interim analysis performed when 100 participants were recruited into each arm. Recruitment was stopped after the interim analysis revealed few differences between the 2 groups. Unclear if there was a sample-size calculation performed. Women's risk profile spontaneous and recurrent miscarriage is unclear, although they are clearly at high risk of preterm birth. It is also unclear if multiple births were included.<BR/>6% of women had an inadequate dietary intake of vitamin C, defined as an intake &lt; 67% of the recommended dietary allowance (70 mg per day).<BR/>Compliance: women were requested to bring the containers to each visit and the remaining tablets were counted to improve and control compliance; however, no compliance data were reported.<BR/>Country: South Africa.<BR/>Timeframe: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:01:11 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Summit-2008">
<CHAR_METHODS MODIFIED="2016-02-01 04:11:26 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: computer-generated number; 262 clustered unit of randomisation (all pregnant women served by the same midwife received supplements with the same midwife identification number).</P>
<P>Randomisation and allocation concealment: central allocation.</P>
<P>Blinding of outcome assessment: all study scientists and personnel, government staff, and enrollees were unaware of the allocation.</P>
<P>Documentation of exclusion: 1748 loss to follow-up before delivery (IFA: 853; MMN: 895); 1128 loss to follow-up after delivery (IFA: 553; MMN: 575). 10,549 pregnant women excluded post-randomisation because of trial termination (IFA group: 5057; MMN group: 5492).</P>
<P>Use of placebo control: no placebo, comparisons were between multiple micronutrients and iron and folic acid.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 18:01:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>41,839 pregnant women of any gestational age living on Lombok, Nusa Tenggara Barat Province, Indonesia. Women were allocated to IFA (n = 20,543) or MMN (n = 21,296).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 14:34:41 +0000" MODIFIED_BY="[Empty name]">
<P>MMN group: the MMN was the UNIMMAP formulation containing 30 mg iron (ferrous fumarate) and 400 mcg folic acid along with 800 mcg retinol (retinyl acetate), 200 IU vitamin D (ergocalciferol), 10 mg vitamin E (alpha tocopherol acetate), 70 mg ascorbic acid, 1.4 mg vitamin B1 (thiamine mononitrate), 18 mg niacin (niacinanide), 1.9 mg vitamin B6 (pyridoxine), 2.6 mcg vitamin B12 (cyanocobalamin), 15 mg zinc (zinc gluconate), 2 mg copper, 65 mcg selenium, and 150 mcg iodine - 1 capsule daily up to 3 months after birth.</P>
<P>IFA group: the IFA contained 30 mg iron (ferrous fumarate) and 400 mcg folic acid - 1 capsule daily up to 3 months after birth.</P>
<P>Timing of the intervention: any time during pregnancy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-07 08:45:35 +0000" MODIFIED_BY="Denise Atherton">
<OL>
<LI>Early infant mortality (deaths until 90 days postpartum).</LI>
<LI>Neonatal mortality.</LI>
<LI>Fetal loss (abortions and stillbirths).</LI>
<LI>Low birthweight.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:21:44 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is also unclear. However, 30% of women in each group had an mid upper arm circumference &lt; 23.5cm, which was used as an indicator of women being undernourished.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: median compliance was 85%, there was no difference between treatment groups in compliance.</P>
<P>Location: Indonesia.</P>
<P>Timeframe: July 1, 2001 to April 1, 2004.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:02:58 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sunawang-2009">
<CHAR_METHODS MODIFIED="2016-02-05 14:36:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation and allocation concealment: 160 clusters were randomly assigned to 4 blocks of 40 clusters each. 2 of the 4 blocks received either MMN of IFA. No details of how blocks were selected. 432 women in 40 clusters were allocated to the group receiving multiple micronutrients and 411 in the other 40 clusters were allocated to the iron&#8211;folic acid group. No further details on how allocation was done.</P>
<P>Blinding of outcome assessment: single-blind design, no further details provided.</P>
<P>Documentation of exclusion: 93 women (11%) were excluded.</P>
<P>Use of placebo control: no placebo, the control group received iron-folic acid supplementation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-01 04:09:23 +0000" MODIFIED_BY="[Empty name]">
<P>843 women residing in Indramayu District in the West Java Province of Indonesia who were between 12 to 20 weeks of gestation. Only women intending to remain in the study location until giving birth were recruited. Women suffering from potentially confounding illnesses, including diabetes, coronary heart disease, and tuberculosis, were excluded from the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 18:02:45 +0100" MODIFIED_BY="Heather Maxwell">
<P>MMN supplements containing 15 micronutrients vs IFA (60 mg of elemental iron as ferrous sulfate and 0.25 mg of folic acid). Supplementation was from time of enrolment at 12 to 20 weeks of gestation and continued to 30 days postpartum.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:02:58 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Birthweight.</LI>
<LI>Anthropometry.</LI>
<LI>Hb, serum ferritin, serum zinc, and serum retinol.</LI>
<LI>Compliance.</LI>
<LI>Side effects of supplementation.</LI>
<LI>Morbidity.</LI>
<LI>Fetal loss.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-01 04:37:31 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear.</P>
<P>Women's nutritional status is also unclear.</P>
<P>Sample size calculation not done.</P>
<P>Intention-to-treat analysis performed.</P>
<P>Compliance: Data on compliance was collected from weekly visits. Mean adherence in the intervention group 68% and control group 71%.</P>
<P>Location: Indonesia.</P>
<P>Timeframe: May 2001 to December 2002.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:05:12 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Tofail-2008">
<CHAR_METHODS MODIFIED="2016-04-18 18:03:53 +0100" MODIFIED_BY="Heather Maxwell">
<P>Generation of random number sequence: a computer-generated register was used for randomisation. Randomisation was performed in blocks of 12 food supplementation was randomly allocated but not blinded. micronutrient capsules looked identical and women were allocated to 1 of 3 types of micronutrient supplements in a 2 by 3 design.</P>
<P>Blinding of outcome assessment: allocation code was not broken until after the analysis.</P>
<P>Documentation of exclusion: 845 losses to follow-up (19%).</P>
<P>Use of placebo control: no placebo, the control group received IFA (Fe30Fol) supplementation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 14:58:53 +0000" MODIFIED_BY="[Empty name]">
<P>4436 pregnant women from rural Bangladesh within 6-8 weeks of conception (not more than 14 weeks). Women with Hb &lt; 80 g/L were ineligible for participation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 18:04:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>MMNs containing 15 recommended micronutrients (30 mg of iron, 400 &#956;g of folic acid). The micronutrient supplements were offered to the enrolled pregnant women at the 14weeks&#8217; clinic visit up to 3 months after delivery. Intervention was divided into early or late food supplementation.</P>
<P>Early or usual food supplementation plus 1, 2 or 3:</P>
<P>1) 30 mg iron(fumarate) + 400 mcg folic acid (Fe30Fol)</P>
<P>2) 60 mg iron (fumarate) + 400 mcg folic acid (Fe60Fol)</P>
<P>3) 30 mg iron (fumarate), 400 mcg folic acid, 800 mcg RE vitamin A (retinyl acetate), 5 mcg vitamin D (cholecalciferol), 10 mg vitamin E (a-tocopherol acetate), 70 mg vitamin C, 1.4 mg thiamine (mononitrate), 1.4 mg riboflavin, 18 mg niacin, 1.9 mg vitamin B-6 (pyridoxine hydrochloride), 2.6 mcg vitamin B-12 (cyanocobalamin), 15 mg zinc (sulfate), 2 mg copper (sulfate), 65 mcg selenium (sodium selenite), and 150 mcg iodine (potassium iodide) (MMNs).</P>
<P>All women received food supplement which consisted of roasted rice powder, roasted pulse powder, molasses, and soybean oil and had a total energy content of 2500 kJ. Early (immediately after detection of pregnancy, around 9 weeks) enrolment in food supplementation or usual (at the time of their choosing, around 20 weeks).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:05:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Infant outcomes:</P>
<OL>
<LI>Blood Hb and plasma ferritin, zinc, retinol, vitamin B-12, and folate at 6 months.</LI>
<LI>Low birthweight.</LI>
<LI>Small-for-gestational age.</LI>
<LI>Morbidities (diarrhoea, lower acute respiratory infections).</LI>
<LI>Birth anthropometry.</LI>
<LI>Neonatal survival.</LI>
<LI>Blood pressure.</LI>
<LI>Kidney function</LI>
<LI>Child growth and body composition.</LI>
</OL>
<P>Maternal outcome:</P>
<OL>
<LI>Hb at 30 weeks.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:59:39 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is also unclear.</P>
<P>Sample size calculation: not done.</P>
<P>Intention-to-treat analysis performed.</P>
<P>Compliance: the number of micronutrient pills taken in the first 30 weeks of pregnancy was 79+/-34 in the Fe30 group, 78+/-34 in the Fe60 group, and 75+/-33 in the MM group.</P>
<P>Location: Bangladesh.</P>
<P>Timeframe: November 2001 to June 2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:07:06 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Van-den-Broek-2006">
<CHAR_METHODS MODIFIED="2010-12-07 03:34:55 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: using a random-generation procedure.</P>
<P>Randomisation and allocation concealment: the supplements in vitamin A and placebo treatments allocated were prepared in identical capsules and were packaged in bottles according to the randomisation schedule (sealed envelopes) by midwives who were not involved in the trial conduct.</P>
<P>Blinding of outcome assessment: neither the women nor the midwives involved in treatment allocation revealed the randomisation schedule to anyone involved in the conduct of the trial.</P>
<P>Documentation of exclusion: 77 loss to follow-up before assessment at 26-28 weeks (5000 IU vitamin A: 26; 10,000 IU vitamin A: 26; placebo: 25). Additional 93 loss to follow-up before assessment at 36-38 weeks (5000 IU vitamin A: 34; 10,000 IU vitamin A: 28; placebo: 31).</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 18:06:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>700 women with singleton pregnancies at 12-24 weeks' gestation measured by ultrasound scan (5000 IU vitamin A: 234; 10,000 IU vitamin A: 234; placebo: 232).</P>
<P>Setting: the antenatal clinic at the Namitambo rural Health Centre in southern Malawi, central Africa.</P>
<P>Eligibility criteria: (Hb) &lt; 11.0 g/dL by HemoCue screening method at first antenatal visit, singleton pregnancy with gestational age &gt; 12 weeks and &#8804; 24 weeks measured by ultrasound scan, no fetal abnormality detectable by ultrasound at time of booking, residing in the catchment area of the health centre.</P>
<P>Exclusion criteria: women &gt; 24 weeks' gestation, or twin pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 03:35:55 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Intervention group 1: 5000 IU vitamin A daily until delivery.</LI>
<LI>Intervention group 2: 10,000 IU vitamin A daily until delivery.</LI>
<LI>Comparison group: placebo daily until delivery.</LI>
</UL>
<P>Timing of the intervention: supplementation started as early as possible after 12 weeks of pregnancy.</P>
<P>All women received iron tablets daily (60 mg elemental iron as ferrous sulphate with 0.25 mg folic acid).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:07:06 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Anaemia status (no anaemia ([Hb] &#8805; 11.0 g/dL), anaemia ([Hb] &lt; 11.0 g/dL) or severe anaemia ([Hb] &lt; 8.0 g/dL).</LI>
<LI>Hb concentration (Coulter counter value), iron status (determined by serum ferritin and serum transferring receptor concentration).</LI>
<LI>Evidence of infection (assessed by serum CRP, peripheral malaria parasitaemia and HIV status).</LI>
<LI>Vitamin A status (determined by serum retinol and the MRDR).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 14:21:54 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status is also unclear.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: unclear, no information provided.</P>
<P>Location: Malawi.</P>
<P>Timeframe: April 1997 and July 1999.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:08:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Villar-2009">
<CHAR_METHODS MODIFIED="2010-12-07 03:37:34 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: no sequence generation details available.</P>
<P>Randomisation and allocation concealment: central allocation (randomisation was performed by the statisticians of the British VIP Trial).</P>
<P>Blinding of outcome assessment: "double blind" stated.</P>
<P>Documentation of exclusion: 10 women (treatment 6; placebo 4), and 29 infants (treatment 13, placebo 16) were lost to follow-up.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 18:08:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>1365 women between 14-22 gestational age agreed to participate and were randomised (vitamins group: 687; placebo group: 678).</P>
<P>Setting: antenatal clinics located in Nagpur, India; Lima and Trujillo, Peru; Cape Town, South Africa; and Ho Chi Minh City, Viet Nam which served populations with low social-economic status and had evidence of overall low nutritional status, between October 2004 and December 2006.</P>
<P>Eligibility criteria: pregnant women considered high risk for pre-eclampsia (chronic hypertension, renal disease, pre-eclampsia-eclampsia in the pregnancy preceding the index pregnancy requiring delivery before 37 weeks&#8217; gestation, HELLP syndrome in any previous pregnancy, pre-gestational diabetes, primiparous with a BMI &gt; 30 kg/m<SUP>2</SUP>, history of medically-indicated preterm delivery, abnormal uterine artery Doppler waveforms and women with antiphospholipid syndrome), multifetal gestation. Women ingesting medications with aspirin-like compounds were not excluded.</P>
<P>Exclusion criteria: women ingesting vitamin supplements that contained &#8805; 200 mg of vitamin C and/or &#8805; 50 IU of vitamin E and women receiving warfarin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 03:38:25 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group: received 1000 mg vitamin C and 400 IU of vitamin E daily until delivery.</P>
<P>Comparison group: received placebo daily until delivery.</P>
<P>Timing of the intervention: between 14 and 22 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:03:45 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pre-eclampsia.</LI>
<LI>Eclampsia.</LI>
<LI>Placental abruption.</LI>
<LI>Low birthweight (&lt; 2500 g).</LI>
<LI>Small-for-gestational age (&lt; 10th centile of the WHO recommended standard).</LI>
<LI>Intrauterine or neonatal death before hospital discharge.</LI>
<LI>Preterm delivery (&lt; 37 weeks).</LI>
<LI>Early preterm delivery (&lt; 34 weeks).</LI>
<LI>Very low birthweight (&lt; 1500 g).</LI>
<LI>&#8805; 7 days in the neonatal intensive care unit.</LI>
<LI>Congenital malformations.</LI>
</OL>
<P>Pre-eclampsia information was unavailable for 14 women in the vitamins and 9 in the placebo group.</P>
<P>There were data from 81 supplemented (11.8%) and 100 placebo-treated (14.7%) women with multiple pregnancies, for whom newborn outcomes were considered separately.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 15:04:03 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear. Women at high risk of pre-eclampsia were included but data on fetal loss was not reported separately for this group.</P>
<P>No specific information on women's nutritional status is included; however, the paper states that the trial was conducted in populations with 'documented low nutritional status'.</P>
<P>Intention-to-treat analyses performed.</P>
<P>Compliance: median compliance was 87%, and was similar between the treatment groups.</P>
<P>Location: Antenatal clinics in India, Peru, South Africa and Vietnam.</P>
<P>Timeframe: October 2004 and December 2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:12:37 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-West-2011">
<CHAR_METHODS MODIFIED="2016-02-05 14:43:43 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: sectors were used as the unit of randomisations for supplement allocation, 3 sets of 3 identical coins on which the numbers 1, 2 or 3 were written were placed into a container, mixed and removed randomly, without replacement, and the 3-digit code of each sector was read aloud sequentially. Study supplements were identical in colour, taste and external appearance. Treatment codes were assigned by the Nutrilite Health Institute and were kept in a sealed envelope in a locked cabinet at both Nutrilite and Johns Hopkins University. Masking was further ensured by having a senior administrative staff (not involved in field activities) recode the supplement bottles with sector-specific permanent stickers bearing codes from 001 to 596.</P>
<P>Blinding of outcome assessment: investigators were all blinded to the allocation codes until the end of the parent trial.</P>
<P>Documentation of exclusion: 628 women (1%) were excluded.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 18:12:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>102,769 women from 596 sectors (60,294 pregnancy identified and 59,666 pregnancies included) 19 rural unions in the northwest Districts of Gaibandha and Rangpur in rural Bangladesh. Women were recruited from the first trimester of pregnancy through 12 weeks (84th day) after pregnancy termination. Eligible women included pregnant or postpartum, lactationally amenorrhoeic women were placed on a 'waiting list', and only became eligible for pregnancy surveillance once their menses resumed. Married women, women entering the study area within 4 months of marriage were also eligible to join the cohort under pregnancy surveillance. And when identified as pregnant, enrolled. Women who never got pregnant during the study period, permanently moved from the study area, were sterilised, reported menopause, divorce or death of husband, refused to participate or participation status unknown, died before detecting a pregnancy , had a pregnancy outcome after October 12, 2006, reported a last menstrual period after January 5, 2006 or had an unknown date of a last menstrual cycle were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:05:26 +0000" MODIFIED_BY="[Empty name]">
<P>1. Vitamin A (consisting of 7000 mcg retinol equivalents, or 23,300 IU, of VA palmitate in soybean oil with a small amount of vitamin E as an antioxidant).</P>
<P>2. &#946;-carotene at 42 mg&#8212;an amount equivalent to 7000 mcg REs administered weekly from the time of pregnancy enrolment until 3 months postpartum.</P>
<P>3. Control group received placebo (consisting of soybean oil with a small amount of vitamin E as an antioxidant).</P>
<P>All 3 supplements contained 5 IU vitamin E in oil.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 14:36:47 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause pregnancy-related mortality.</LI>
<LI>Fetal loss due to miscarriage or stillbirth.</LI>
<LI>Infant mortality under 3 months of age.</LI>
<LI>Maternal obstetric and infectious morbidity.</LI>
<LI>Infant infectious morbidity.</LI>
<LI>Maternal and infant micronutrient status.</LI>
<LI>Fetal and infant growth.</LI>
<LI>Prematurity.</LI>
<LI>External birth defects.</LI>
<LI>Postnatal infant growth to 3 months of age.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 18:12:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage was unclear.</P>
<P>Women's nutritional status: a 1-week history of diet at trial entry and 12 weeks after pregnancy was reported.</P>
<P>Sample size estimation: based on a 35% or greater reduction in all-cause mortality.</P>
<P>Primary outcomes were compared on an intent-to-treat basis.</P>
<P>Compliance: adherence to supplementation was comparable across groups, with approximately 80% of women having directly consumed (under staff supervision) at least 64% of eligible supplements.</P>
<P>Location: Bangladesh.</P>
<P>Timeframe: August 2001 to January 2007.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:15:45 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-West-2014">
<CHAR_METHODS MODIFIED="2016-04-18 18:13:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Generation of random number sequence: 596 sectors of comparable size were used as units of randomisations. "We stratified the contiguous list of 596 sectors into 74 blocks of 8 each (for the first 592 sectors), plus a 75th block of 4 sectors. A sector-supplement code key with A or B was created by flip of a coin, reflecting assignment to iron&#8211;folic acid or MM supplementation, and duplicated, and each of 2 copies was sealed into an envelope by an uninvolved colleague at Johns Hopkins. Computer program randomised sectors within blocks to 1 of 2 codes such that each permutation had an equal probability of being chosen. The resulting 2 lists of sectors were securely transmitted to field headquarters. 1 envelope with the code key was securely transmitted to the supplement producer and the other sealed in an envelope and secured at Johns Hopkins. At no time during the trial did study investigators or field or data management staff have access to the key."</P>
<P>Blinding of outcome assessment: outcome assessors were blinded to the treatment allocation.</P>
<P>Documentation of exclusion: 1351 pregnant women (3%) were excluded.</P>
<P>Use of placebo control: no placebo, the control group received IFA supplementation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-18 18:14:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>Participants in the study included 44,567 pregnant women and 28,518 infants in rural setting in Bangladesh. Pregnant women were recruited around ~ 10 weeks' gestation. All women under 45 years of age who are married and living with their husbands as residents of the JiVitA study area at the time of an initial population enumeration, and those who enter the cohort as newlyweds, were eligible for pregnancy surveillance and, when identified as pregnant, enrolled. Women who permanently moved, were sterilised or menopausal, died, and did not get pregnant were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 18:14:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Weekly supplementation from enrolment (early pregnancy) to 3 months postpartum.</P>
<P>Multiple-micronutrient: vitamin A (770 mcg retinol equivalents), vitamin D (5 mcg), vitamin E (15 mg), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (1.4 mg), vitamin B12 (2.5 mg), vitamin B6 (1.9 mg), vitamin C (85 mg), zinc (12 mg), iodine (220 mcg), copper (1000 mcg), and selenium (60 mcg). The control group received IFA supplement (standard care).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:15:45 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Infant survival: determine the efficacy of a standard MMN supplement given to women daily during pregnancy through 12 weeks postpartum in lowering neonatal and infant mortality through 6 months of age by &gt; 15% compared to the mortality of infants whose mothers receive daily iron + folic acid.</P>
<P>2. Fetal and newborn outcomes: assess the efficacy of the MM intervention in reducing the:</P>
<P>a) stillbirth rate by 23% or more, from an expected 30 to 24 or fewer stillbirths per 1000 births (i.e. live + still births);</P>
<P>b) rate of preterm birth (live birth delivered &lt; 37 weeks&#8217; gestation) by 10% or more, from an expected 20% to 18% or fewer of all live births;</P>
<P>c) prevalence of low birthweight (&lt; 2500 g) by 5% or more, from an expected 40% to 38% or fewer of all live births; and</P>
<P>d) neonatal morbidity related to sepsis, birth asphyxia, hypothermia and diarrhoea.</P>
<P>3. Other infant outcomes (to 6 months of age): assess the efficacy of the MM supplement intervention in improving:</P>
<P>a) linear and ponderal growth, including its ability to protect lean body mass, that could lead to reduced prevalences of stunting, wasting and underweight status in infancy;</P>
<P>b) infant morbidity, including diarrhoea and acute lower respiratory infection, in the first 3 months of life;</P>
<P>c) micronutrient intake, represented by measured breast milk micronutrient concentrations;</P>
<P>d) micronutrient status, and reducing prevalences of multiple deficiencies.</P>
<P>4. Maternal outcomes: assess the efficacy of either MM supplement intervention in influencing among mothers the:</P>
<P>a) prevalence of infectious morbidity, based on history, testing and signs, during pregnancy and in the 1st 6 months postpartum;</P>
<P>b) rates of potentially fatal (&#8220;near miss&#8221;) obstetric complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 15:08:54 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage: previous fetal loss and infant death reported.</P>
<P>Women's nutritional status is unclear.</P>
<P>Sample size estimation: live-born infants based on a 15% or greater reduction in 6-month mortality; pregnancies based on a 30% loss from induced abortion, miscarriage, and stillbirth.</P>
<P>Intent-to-treat analysis of all outcomes.</P>
<P>Compliance: adherence was high, with half the women in both groups estimated to consume a median of approximately 95% of all distributed supplements; 80% in both groups consumed more than 80% of their intended tablets.</P>
<P>Location: Bangladesh.</P>
<P>Timeframe: 2008 to 2012.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-20 19:13:45 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wibowo-2012">
<CHAR_METHODS MODIFIED="2016-04-20 19:13:45 +0100" MODIFIED_BY="Heather Maxwell">
<P>Generation of random number sequence: participants were randomised according to a computer-generated random number sequence. "Participants were assigned on an individual basis to antioxidant or placebo supplementation and remained in the same allocation group throughout the pregnancy and 2 weeks postpartum." No details about how allocation concealment was done.</P>
<P>Blinding of outcome assessment: unclear.</P>
<P>Documentation of exclusion: 6 women (5.5%) were excluded.</P>
<P>Use of placebo control: no placebo, the control group received non-antioxidant multiple micronutrients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-01 06:26:51 +0000" MODIFIED_BY="[Empty name]">
<P>110 women residing in Cipto Mangunkusumo National Hospital, Jakarta, Indonesia between 8 and 12 weeks of gestation. To be eligible, women had to have normal blood pressure at their first visit in pregnancy and again at trial entry. Women with multiple pregnancy, fetal anomaly, thrombophilia, infections, mola hydatidosa, chronic renal failure, uncontrolled hypertension, placental abnormalities, documented uterine bleeding within a week of screening, uterine malformation and history of medical and metabolic complication, such as heart disease or diabetes were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:10:08 +0000" MODIFIED_BY="[Empty name]">
<P>Antioxidant multiple micronutrient (MMN) supplement mixed into milk administered from trial entry until 2 weeks postpartum. Control received non-antioxidant (MMN) supplement and all women received 40 g of milk powder.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-01 06:10:50 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pre-eclampsia.</LI>
<LI>Fetal growth restriction.</LI>
<LI>HELLP syndrome.</LI>
<LI>Biochemical markers.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-01 06:32:51 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage: history of pre-eclampsia reported.</P>
<P>Women's nutritional status is unclear.</P>
<P>Sample size calculation: based on an expected incidence of pre-eclampsia in the control group of at least 29% and in the treatment group of at least 30%.</P>
<P>Analyses were performed on an intention-to-treat basis.</P>
<P>Compliance: unclear, no information reported.</P>
<P>Location: Jakarta, Indonesia.</P>
<P>Timeframe: June 2001 to December 2009.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-19 10:28:52 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Xu-2010">
<CHAR_METHODS MODIFIED="2016-04-18 18:18:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>Generation of random number sequence: double-blinded, multicentre trial. Randomisation was performed through an electronic data management platform, which enabled randomisation and data entry over the Internet. They were randomly allocated at a ratio of 1:1</P>
<P>to antioxidant supplementation (vitamins C and E) group or to placebo group through an electronic data management platform.</P>
<P>Blinding of outcome assessment: outcome assessors were blinded to the treatment allocation.</P>
<P>Documentation of exclusion: 277 women (10.5%) were excluded.</P>
<P>Use of placebo control: placebo control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-03 01:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>2460 women participated in the study. Women were eligible for the trial if they were between 12 and 18 completed weeks of pregnancy on the basis of last menstrual period and confirmed by early ultrasound examination. The exclusion criteria were:</P>
<P>(1) women who regularly consumed supplements200 mg/day for vitamin C and/or 50 IU/day for vitamin E;</P>
<P>(2) women who took warfarin;</P>
<P>(3) women who had known fetal abnormalities,</P>
<P>(4) women who had a history of medical complications,</P>
<P>(5) women with repeated spontaneous abortion,</P>
<P>(6) women who used an illicit drug during the current pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-03 01:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>Women were provided either with vitamins C and E or placebo. Total daily dose of vitamin C was 1000 mg, and that of vitamin E was 400 IU.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-19 10:28:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>Primary outcomes:</P>
<OL>
<LI>Gestational hypertension and its adverse conditions.</LI>
</OL>
<P>Other maternal outcomes:</P>
<OL>
<LI>Death.</LI>
<LI>Severe gestational hypertension.</LI>
<LI>Severe pre-eclampsia.</LI>
<LI>Prelabour rupture of membranes (PROM).</LI>
<LI>Preterm PROM (PPROM).</LI>
<LI>Hospitalisation prior to giving birth.</LI>
</OL>
<P>Fetal and neonatal outcomes:</P>
<OL>
<LI>Fetal loss or perinatal death (defined as any fetal loss at 20 weeks),</LI>
<LI>Stillbirth.</LI>
<LI>Neonatal death.</LI>
<LI>Preterm birth (before 37 weeks of gestational age; gestational age corrected by early ultrasound scan).</LI>
<LI>Preterm birth (before 34 weeks of gestational age.</LI>
<LI>Small for gestational age (defined as 5th or 10th centile).</LI>
<LI>Perinatal mortality.</LI>
<LI>Spontaneous abortion.</LI>
<LI>Neonatal morbidity indicators.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 18:19:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage: history of pre-eclampsia and gestational hypertension reported as well as obstetric history (abortion, stillbirth, low birthweight, preterm birth).</P>
<P>Women's nutritional status: use of supplements reported .</P>
<P>Sample size calculation: based on an expected 4% and 15% incidence of the primary outcome in the low- and high-risk strata, respectively.</P>
<P>Analyses were performed on an intention-to-treat basis.</P>
<P>Compliance: 85.5% in the vitamin group, 86.5% in the placebo group.</P>
<P>Location: multicentre trial in Canada (17 centres) and Mexico (10 centres).</P>
<P>Timeframe: January 2004 to March 2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-10 15:11:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zagre-2007">
<CHAR_METHODS MODIFIED="2016-02-10 15:10:52 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: cluster-randomised study wherin villages-not individuals-were randomly assigned to 1 treatment group or the other. The 2 supplements looked different but a coding system was adopted. &#8220;&#8230;packaged the supplements in boxes with identical labelling except for the supplement code&#8221;&#8230; "the code letter did not distinguish which supplement was used".</P>
<P>Blinding of outcome assessment: unclear if outcome assessors were unaware of participants' allocation to treatment or control group.</P>
<P>Documentation of exclusion: 768 women (20.9%) were excluded.</P>
<P>Use of placebo control: no placebo, the control group received iron-folic acid supplementation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 14:34:59 +0000" MODIFIED_BY="[Empty name]">
<P>3670 women from Maradi, rural Niger. Women who lived in 1 of the selected villages and who had experienced amenorrhoea for less than 12 weeks were eligible for participation. Exclusion criteria included women with night blindness and/or clinical signs of severe anaemia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:11:05 +0000" MODIFIED_BY="[Empty name]">
<P>Daily multiple micronutrients consisting vitamin A 800 mcg,vitamin D 200 IU, vitamin E 10 mg, vitamin C 70 mg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, vitamin B3 18 mg, vitamin B6 1.9, vitamin B12 2.6 mg, folic acid 400 mcg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 mcg, and iodine 150 mcg from enrolment until delivery. The control group received iron/folic acid.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:11:17 +0000" MODIFIED_BY="[Empty name]">
<P>Maternal outcomes:</P>
<OL>
<LI>Birth assistance.</LI>
<LI>Conditions of delivery.</LI>
<LI>Breastfeeding practices.</LI>
<LI>Miscarriage.</LI>
<LI>Stillbirths.</LI>
<LI>Maternal deaths.</LI>
</OL>
<P>Infant outcome:</P>
<OL>
<LI>Birthweight.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-01 06:48:26 +0000" MODIFIED_BY="[Empty name]">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear.</P>
<P>Women's nutritional status is unclear.</P>
<P>Sample size calculation: based on reduction of 25% in low birthweight.</P>
<P>Intention-to-treat analysis not performed.</P>
<P>Compliance: at subsequent visits, the remaining capsules were counted, and the number of missing capsules was replenished for another month and noted in the particular booklet. Compliance with treatment in the intervention group was 79.2% ± 18.1% and in the control group 78.4% ± 18.5%.</P>
<P>Location: Maradi, Niger.</P>
<P>Timeframe: January 2004 to March 2005.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-18 18:22:57 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Zeng-2008">
<CHAR_METHODS MODIFIED="2016-02-10 15:11:51 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of random number sequence: randomisation of villages was stratified by county with a fixed ratio of treatments (1:1:1) and blocking of 15. The randomisation schedule was generated off site with a pseudo-random number generator. Allocation concealment was described &#8220;a treatment colour code was assigned to each village based on the treatment allocation schedule. The treatment codes were opened only once all data had been collected&#8221;.</P>
<P>Blinding of outcome assessment: unclear.</P>
<P>Documentation of exclusion: 133 women (2.3%) were lost to follow-up, 279 women (4.8%) stopped taking the supplement and refused to continue to participate, and 601 women (10.3%) experienced fetal loss.</P>
<P>Use of placebo control: no placebo, the control group received folic acid alone.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 15:12:16 +0000" MODIFIED_BY="[Empty name]">
<P>5828 women from Shaanxi Province of north west China between &lt; 12 &#8211; 28 weeks' gestational age. Eligibility included all women resident in the counties who became pregnant between August 2002 and January 2006.</P>
<P>Women were ineligible if they:</P>
<P>1. were already taking supplements;</P>
<P>2. had a serious illness;</P>
<P>3. had an abnormal reproductive history;</P>
<P>4. were planning;</P>
<P>5. to work outside the area; or</P>
<P>were more than 28 weeks pregnant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-18 18:22:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>Supplementation with MMN; IFA (60 mg of iron and 400 mcg of folic acid) or folic acid alone (400 mcg of folic acid) from enrolment until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 18:21:34 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Birthweight.</LI>
<LI>Duration of gestation.</LI>
<LI>Maternal Hb concentration.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-18 18:22:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women's risk of spontaneous and recurrent miscarriage is unclear.</P>
<P>Women's nutritional status is unclear.</P>
<P>Sample size calculation: based on a 25% reduction in low birthweight between either iron-folic acid or multiple micronutrient and folic acid (control) groups.</P>
<P>Compliance: the number of remaining capsules was reported by the village doctor who visited the women every 2 weeks. The level of compliance with the supplementation was high in all treatment groups.</P>
<P>Location: Shaanxi Province, China.</P>
<P>Timeframe: August 2002 to January 2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>B-HCG: Beta human chorionic gonadotropin<BR/>BMI: body mass index<BR/>F: folic acid<BR/>Hb: haemoglobin<BR/>HbCC: haemoglobin C disease<BR/>HbSC:haemoglobin SC disease<BR/>HbSS: haemoglobin sickle cell disease<BR/>HELLP syndrome: haemolysis, elevated liver enzymes, low platelet count syndrome<BR/>HIV-1: Human Immunodeficiency Virus-1<BR/>HOFPP: Hungarian Optimal Family Planning Programme<BR/>IQR: interquartile range<BR/>IFA: iron and folic acid<BR/>IU: international units<BR/>IVF-ET: in vitro fertilization and embryo transfer<BR/>mcg: micrograms<BR/>mg/mL: milligrams per millilitre<BR/>MF: multivitamins with folic acid<BR/>mg: milligrams<BR/>MMN: multiple micronutrient<BR/>MRDR: modified relative dose-response<BR/>MV: multivitamins without folic acid<BR/>MRC: Medical Research Council<BR/>NTD: neural tube defect<BR/>P: progesterone<BR/>PAI-1: plasminogen activator inhibitor-1<BR/>PAI-2: plasminogen activator inhibitor-2<BR/>PCV: packed cell volume<BR/>sTfR: Soluble transferrin receptor<BR/>UK: United Kingdom<BR/>UNIMMAP: United Nations International Multiple Micronutrient Preparation<BR/>USA: United States of America<BR/>WBC: white blood cell<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-04-18 11:33:53 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Baumslag-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were supplemented with either iron, iron and folic acid or iron, folic acid and vitamin B12 from "after the 24th week of pregnancy".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Biswas-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear of the gestational age at which women entered the trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blot-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Supplementation with either iron and folic acid or iron alone occurred "at the end of the 6th month of pregnancy". Unclear if women were randomised to the treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-24 09:16:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chanarin-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-24 09:16:24 +0100" MODIFIED_BY="[Empty name]">
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were given a folic acid supplement after the 20th week of pregnancy. Abortion was reported according to folic acid status at 15 weeks, prior to supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-02 06:17:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chelchowska-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-02 06:17:32 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant clinical outcomes, reports biochemical markers of antioxidant status only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-18 11:29:56 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Christian-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-18 11:29:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>Data for main outcomes of interest were not reported in a form that could be included in the analysis. Perinatal death was reported which included stillbirths (gestational age &gt;= 28 weeks) and death among infants in the first 7 days of life. Miscarriage data (defined as fetal loss &lt; 28 weeks' gestation age) was not provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-24 09:16:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colman-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-24 09:16:25 +0100" MODIFIED_BY="[Empty name]">
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were supplemented "during the final month of pregnancy". Outcomes reported included folic acid red cell and serum folic acid concentration and haemoglobin concentration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-13 10:28:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Correia-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-13 10:28:57 +0100" MODIFIED_BY="[Empty name]">
<P>No main outcomes of interest reported. Outcomes presented in the study were fetal weight (birthweight) and placental weight. Women's risk of spontaneous and recurrent miscarriage is unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coutsoudis-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were given vitamin A and beta-carotene "during the third trimester of pregnancy".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dawson-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were supplemented with folic acid "on or after the 28th week". Group allocation was not done randomly. Reported outcomes include incidence of folic acid deficiency and megaloblastic anaemia, and haemoglobin concentration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-24 09:16:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edelstein-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-24 09:16:53 +0100" MODIFIED_BY="[Empty name]">
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Supplementation was started at the 28th week of pregnancy. Outcomes reported included serum folate activity and serum folate, urinary formiminoglutamic acid, serum vitamin B12, mean haemoglobin and haematocrit values.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-07 03:43:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferguson-1955">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-07 03:43:14 +0000" MODIFIED_BY="[Empty name]">
<P>Only 24 (9%) of the 269 women in the trial began to participate before 15 weeks' gestation and outcomes not reported separately according to gestation at enrolment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-27 09:19:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feyi_x002d_Waboso-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-27 09:19:02 +0100" MODIFIED_BY="[Empty name]">
<P>Onset of supplementation was 20 or more weeks' gestation. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fletcher-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>No inclusion/exclusion criteria reported, unclear of gestational age at enrolment to the study, reports combined outcomes for "antepartum and threatened or complete abortion" and "stillbirth or neonatal death or congenital malformation" (not reported separately).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 14:36:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giles-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 14:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>Onset of supplementation was &gt; 20 weeks' gestation for a large proportion of the participants.<BR/>4 groups in the study, 2 of which involved supplementation after 20 weeks' gestation. Results were not reported separately between groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hampel-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear of the gestational age at which women entered the trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hankin-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported. <BR/>Supplementation was from "approximately 20 weeks", no clinically relevant outcomes, outcomes relating to vitamin C status in plasma and breast milk reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-28 06:16:41 +0100" MODIFIED_BY="Olukunmi Balogun" STUDY_ID="STD-Hekmatdoost-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-28 06:16:41 +0100" MODIFIED_BY="Olukunmi Balogun">
<P>The intervention assessed the effectiveness of different forms of the same vitamin - folate (folic acid vs 5-methylenetetrahydrofolate (MTHF)) against each other. There was no placebo or control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hibbard-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported.<BR/>Biochemical measures of blood folate status reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hunt-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>All women received a multivitamin in addition to the zinc supplement or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-27 09:19:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huybregts-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-27 09:19:22 +0100" MODIFIED_BY="[Empty name]">
<P>Both groups received a multivitamin supplement (same vitamin content in each group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-02 06:17:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaestel-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-02 06:17:14 +0000" MODIFIED_BY="[Empty name]">
<P>Women were recruited until late pregnancy and onset of supplementation occurred after 20 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laurence-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes or pregnancy loss outcomes reported. Miscarriage reported in those women where there was a neural tube defect, but not in all women according to treatment group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-06 00:03:52 +0000" MODIFIED_BY="Olukunmi Balogun" STUDY_ID="STD-Lin-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-06 00:03:52 +0000" MODIFIED_BY="Olukunmi Balogun">
<P>Intervention assessed effect of nutritional supplement besides vitamins. No main outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lira-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported. <BR/>Biochemical measures of iron and folate status reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lumeng-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear gestational age at enrolment, 5 women were excluded due to abortion, premature labour, inadequate dietary records or missing more than 3 prenatal visits. Exclusions were not reported by group allocation. Outcomes related to maternal and fetal plasma levels of pyridoxal 5'-phosphate and coenzyme saturation of aspartate aminotransferase and alanine aminotransferase in maternal erthrocytes were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marya-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were supplemented with vitamin D "throughout the 3rd trimester".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meirinho-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported.<BR/>Maternal plasma concentrations of trophoblastic protein SP1 were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Metz-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women were supplemented with either iron or iron and folic acid, or iron, folic acid and vitamin B12. Supplementation was started after the 24th week of pregnancy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-18 11:33:53 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mock-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-18 11:33:53 +0100" MODIFIED_BY="Heather Maxwell">
<P>No main outcomes reported.<BR/>Women were enrolled in either early or late pregnancy. Biochemical measures of biotin status reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-18 11:32:06 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Moldenhauer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-18 11:32:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>No main outcomes reported.<BR/>Unclear if this is a cohort study or randomised trial. Women in this study were participating in a randomised placebo-controlled trial of calcium supplementation, and completed a dietary assessment at 12-21 weeks' gestation and 29-31 weeks' gestation. Unclear whether all women took a standard prenatal multivitamin or just women in the placebo group. Results are presented according to "teens", "twins" and "singleton" pregnancies, not according to whether women took the supplement or not. Outcomes reported included dietary intakes of vitamin C and E (with and without the contribution of the prenatal vitamin supplement).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Owen-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Onset of supplementation was &gt; 20 weeks' gestation.<BR/>Women supplemented with oral vitamin K1 "several days before delivery".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-02 06:18:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potdar-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-02 06:18:13 +0000" MODIFIED_BY="[Empty name]">
<P>Study was a food intervention trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ross-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear about content of vitamin supplements.<BR/>Women were supplemented with high or low 'bulk' dietary supplements with vitamins added; however, the vitamin supplements added were not specified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schuster-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear of gestation at enrolment to the trial.<BR/>No pregnancy loss outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Semba-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported.<BR/>Women enrolled between 18 and 28 weeks' gestation, no clinical outcomes reported, only haemoglobin and plasma erythropoietin concentrations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-27 09:19:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-27 09:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>Both groups received a multivitamin (same vitamin content in both groups).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smithells-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study of periconceptional multivitamin supplementation for the prevention of neural tube defects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suharno-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported.<BR/>Anaemic pregnant women were enrolled between 16 and 24 weeks' gestation. The only clinical outcome reported was the percentage of women with anaemia following treatment with a combination of vitamin A and iron or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tanumihardjo-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported.<BR/>Mean gestation at enrolment was 17.6 weeks, no clinical outcomes reported, markers of vitamin A and iron status reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-18 11:32:59 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Taylor-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-18 11:32:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>No main outcomes reported. Haematological features and serum ferritin were determined. No reports on pregnancy loss.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-07 03:44:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thauvin-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-07 03:44:47 +0000" MODIFIED_BY="[Empty name]">
<P>No main outcomes reported.<BR/>Women were supplemented from 3 months' gestation, data on pregnancy outcomes including spontaneous abortion were collected but not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trigg-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear of gestation at enrolment to the trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ulrich-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study. <BR/>Observational cohort study of folic acid users, randomised to different doses of folic acid, but no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Villamor-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported.<BR/>Women enrolled between 12 and 27 weeks' gestation, no pregnancy loss or main outcomes reported, only reports measures of weight gain during pregnancy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vutyavanich-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No main outcomes reported.<BR/>Women were enrolled in the study if they were less than 17 weeks' gestation; however, no pregnancy loss or main outcomes were reported, only measures of nausea and vomiting.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-13 10:29:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wehby-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-13 10:29:47 +0100" MODIFIED_BY="[Empty name]">
<P>This trial involved only one vitamin compared at different doses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-03 01:15:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Young-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-03 01:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcomes were reported in this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-04-18 11:39:59 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-04-18 11:34:40 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Adu_x002d_Afarwuah-2015">
<CHAR_METHODS MODIFIED="2016-04-18 11:34:40 +0100" MODIFIED_BY="Heather Maxwell">
<P>Partially double-blind, individually-randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 15:16:26 +0000" MODIFIED_BY="[Empty name]">
<P>1320 pregnant women around 20 gestational weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:16:31 +0000" MODIFIED_BY="[Empty name]">
<P>Women received 1 of 3 supplements daily until delivery:</P>
<P>60 mg Fe + 400 &#956;g folic acid (IFA), or</P>
<P>1-2 recommended dietary allowances of 18 micronutrients including 20 mg Fe (MMN), or</P>
<P>SQ-LNS with the same nutrient levels as in MMN, plus 4 additional minerals as well as macronutrients contributing 118 kcal (LNS).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:16:35 +0000" MODIFIED_BY="[Empty name]">
<P>Haemoglobin concentration (g/L) and 2 markers of iron status, zinc protoporphyrin (ZPP, &#956;mol/mol heme) and transferrin receptor (TfR, mg/L) were assessed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 15:16:37 +0000" MODIFIED_BY="[Empty name]">
<P>Only study abstract available and the composition of the supplement is not clear. Need to see full text.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-04-18 11:36:10 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Agarwal-2012a">
<CHAR_METHODS MODIFIED="2016-04-18 11:35:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>Individually-randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 15:16:40 +0000" MODIFIED_BY="[Empty name]">
<P>50 women of recurrent of abortions (more than 2).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:16:44 +0000" MODIFIED_BY="[Empty name]">
<P>Women received Vitamin B12 1500 mcg, Vitamin B6 10 mg and folic acid 5 mg daily throughout pregnancy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-18 11:36:10 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Abortion.</LI>
<LI>Pre-eclampsia.</LI>
<LI>IUGR.</LI>
<LI>Preterm labour.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-03 13:18:34 +0000" MODIFIED_BY="[Empty name]">
<P>Only study abstract available, comparison group also received same intervention but duration is different.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-09-24 05:17:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frenzel-1956">
<CHAR_METHODS MODIFIED="2010-09-24 05:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-24 05:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-24 05:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-24 05:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-24 05:17:32 +0100" MODIFIED_BY="[Empty name]">
<P>A copy of the paper could not be located. </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-10 15:17:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prado-2015">
<CHAR_METHODS MODIFIED="2016-02-10 15:17:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised cohorts.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-10 15:17:07 +0000" MODIFIED_BY="[Empty name]">
<P>Pregnant women and infants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:17:10 +0000" MODIFIED_BY="[Empty name]">
<P>Various formulations of lipid-based nutrient supplements (LNS) during pregnancy and infancy or infancy alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:17:41 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Association between linear growth and language development</LI>
<LI>Association between 18-month language scores and</LI>
<LI>18-month length-for-age z-score (LAZ)</LI>
<LI>LAZ at age 6 or 9 months and</LI>
<LI>The change in LAZ between infancy (6 or 9 months) and 18 months</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-10 15:17:53 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only, no specification what LNS is in abstract.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>IFA: iron and folic acid<BR/>IUGR: Intrauterine growth restriction<BR/>MMN: multiple micronutrient</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-04-18 11:40:37 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-02-10 15:18:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johns-2004">
<CHAR_STUDY_NAME MODIFIED="2010-10-06 11:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>The effect of antioxidant supplementation on women with threatened miscarriage.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-10-06 11:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-06 11:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>580 women who present with first trimester bleeding.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-10 15:18:48 +0000" MODIFIED_BY="[Empty name]">
<P>Vitamin C 1000 mg and Vitamin E 400 IU versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-10 15:18:53 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Incidence of miscarriage.</LI>
<LI>Late miscarriage.</LI>
<LI>Preterm labour.</LI>
<LI>Preterm pre-labour rupture of the membranes.</LI>
<LI>Fetal growth restriction.</LI>
<LI>Pre-eclampsia.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-10-06 11:48:44 +0100" MODIFIED_BY="[Empty name]">
<P>01/03/2004.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-24 05:44:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Dr  Jemma  Johns </B>
</P>
<P>UCLH/UCL Research &amp; Development Governance Committee<BR/>Research and Development Directorate<BR/>University College London Hospitals NHS Trust<BR/>1st Floor, Maple House<BR/>149 Tottenham Court Road</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-24 05:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>Listed as completed. </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>IU: internation unit(s)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-04-19 10:28:27 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-04-18 18:16:27 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 13:47:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>"We randomly allocated the entire population of the urban and rural area." Pg S497.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:07:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>No methodological details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>Computer-generated random number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:16:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>Methodological details unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:18:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>Block randomisation using blocks of 20.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:20:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>Generation of sequence not reported, except that there were blocks of 20 in the sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:23:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>Quasi-randomised, alternate allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 02:48:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>A random number table was used but no details provided of how it was generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:11:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>"Patients presented to the health centre, those who met the inclusion criteria were randomly assigned...randomization was obtained by a computer-generated, block design sequence to receive vitamin C or not in a 1:1 ratio." pg 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:29:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>Methodological details unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:31:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>Containers 'given a random number'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 07:00:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:14:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>Cluster-randomised, unclear how sequence was generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:33:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>Block randomisation stratified by hospital site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>Computer-generated random number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 07:10:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>Third party randomisation, "randomisation was carried out through the Clinical Trials Service Unit in Oxford".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:43:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>Computer-generated randomisations by Victoria Pharmaceuticals using PRISYM ID software (version1.0009).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>Computer-generated in permuted blocks of 50.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:35:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>Quasi-randomistion using alternate separate lists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:11:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Computer-generated random sequence Pg 1146</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 17:42:11 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>Pregnant women were randomly allocated in a 1:1:1:1 ratio in blocks of 12 based on a list of treatment numbers derived from a computer-generated pseudo-random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>Computer-generated with permuted blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:50:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>"The simple urn method, with stratification according to clinical center, was used by the data coordinating center to create a randomization sequence." pg 1283, last pgh.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>Computer-generated random number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Computer-generated random number sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:38:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>No methodological details given beyond reporting of 'random assignment'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:38:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>No information provided about sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>Computer-generated sequence number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>Computer-generated sequence number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:42:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>Computer-generated number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:57:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>160 clusters were randomly assigned to 4 blocks of 40 clusters each. 2 of the 4 blocks received either MMN of IFA. No details of how blocks were selected. pg s489 pgh 5.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 18:05:25 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>A computerised tracking system assigned women to 1 of the 6 groups in blocks of 12 women were randomly allocated. "Computer generated register of study identity numbers with random assignment of food groups (&#8220;E&#8221; or &#8220;U&#8221;) and micronutrient groups (from 12 possible pill bottle number codes) was used for randomization.&#8221; Randomisation was probably done. Eneroth 2011 pg 221.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>Random-generation procedure used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 18:09:05 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>Randomisation sequence blocked by centre in groups of 2 to 10 individuals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:05:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>Sectors were randomised in blocks of 9. 3 sets of 3 identical coins on which the numbers 1, 2 or 3 were written were placed into a container, mixed and removed randomly, without replacement, and the 3-digit code of each sector was read aloud sequentially. Pg 7 (Labrique).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 18:16:27 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>"We used an in-house program (VBScript, Microsoft) that recognized 70 possible permutations for n = 8 sectors and k = 2 supplement allocations and 6 for the last block of n = 4sectors. Using this program, we randomised sectors within blocks to 1 of 2 codes such that each permutation had an equal probability of being chosen". Pg 2650.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:10:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>Participants were "..randomized according to a computer-generated random number sequence" pg 1153, pgh 2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:14:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>They [women] were randomly allocated at a ratio of 1:1 to antioxidant supplementation (vitamins C and E) group or to placebo group through an electronic data management platform.&#8221;Pg 239.e3</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:11:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>"Villages-not individuals-were randomly assigned to one treatment group or the other." No details on how randomisation was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:12:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>"Randomisation of villages was stratified by county with a fixed ratio of treatments (1:1:1) and blocking of 15 ....... The randomisation schedule was generated off site with a pseudo-random number generator....." pg 2, pgh 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-04-18 18:16:39 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 16:55:44 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>"cluster-based allocation strategy of supplements (either iron&#8211;folic acid or multiple micronutrients) by the community health workers was implemented. The allocation of either iron&#8211;folic acid or multiple micronutrient supplements and the distribution of the sealed, coded supplement bottles were independently controlled by the pharmacy at Aga Khan University, which maintained the allocation codes by individual community health workers." Pg S498.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:07:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>No methodological details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:11:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>Random number list used blocks of 10 and was held by the pharmacy department.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:16:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>Methodological details unclear, 'women agreed to their allocation on the basis of a random table'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:18:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>Women assigned the 'next numbered bottle of regimen'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:20:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>Identical coded bottles prepared according to the randomisation list, eligible women were assigned the next numbered bottle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:23:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>Quasi-randomised, alternate allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 02:04:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>No details provided about the allocation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 02:42:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>No description for allocation concealment in the text. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:29:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>Methodological details unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:31:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>'Key to random numbers were kept at the ICMR headquarters' but no other details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 07:00:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:32:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>Each ward was assigned to the treatment groups based on 'a random draw of numbered chits, blocked on subdistrict'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 06:58:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>Consequtively numbered, opaque sealed envelopes used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:34:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>Sequentially number opaque bottles used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 07:10:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>Third party randomisation, "randomisation was carried out through the Clinical Trials Service Unit in Oxford".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:17:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>Supplements were identical in appearance. The randomisation sequence was stratified by centre with balanced blocks of 8 patients, and was held by Victoria Pharmaceuticals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:34:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>1 of the authors allocated participants with sequential identification numbers, but unclear if this person was involved in the recruitment of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:35:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>No allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:11:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Although paper states that supplementation and placebo looked and tasted the same, (Pg 1146) there is no clear description of how women were allocated to treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 17:42:21 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>Treatment allocations was prepared and held at the University of Newcastle ....Supplements were coded with treatment numbers and women were assigned a treatment number in sequence based on date they consented to participate in the study. However, supplements were packed in plastic strips in identical opaque capsules..page 16 - 17.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:43:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>Randomisation numbers were kept in sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:50:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>Text says participants "were randomly assigned to receive capsules containing...". No details on how participants were allocated to groups. pg 1283 last pgh.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 09:35:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>Allocation occurred via a central telephone randomisation service. Tablets were provided in sealed opaque bottles.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:37:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Central allocation (randomisation by an independent third party who had no conflict of interest in the study).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:38:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>No methodological details given beyond reporting of 'random assignment'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:38:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>Women were 'randomly assigned on an individual basis' but no other details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:39:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>Central allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:40:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>Roche pharmaceuticals supplied numbered study containers and kept the study code until completion of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:41:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>Central allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 14:58:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>432 women in 40 clusters were allocated to the group receiving multiple micronutrients and 411 in the other 40 clusters were allocated to the iron&#8211;folic acid group. No further details on how allocation was done. pg s489, pgh 7.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 04:39:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>Micronutrient capsules looked identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>The vitamin A and placebo treatments allocated were prepared in identical capsules and packaged in bottles according to the randomisation schedule (sealed envelopes) by midwives who were not involved in the trial conduct.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:42:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>Central allocation (randomisation was performed by the statisticians of the British VIP Trial).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 18:13:15 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>Study supplements were identical in colour, taste and external appearance. Supplements were originally shipped in identically-labelled, 100-count white opaque plastic bottles distinguished only by the code number-1, 2 or 3-listed on the label. A senior administrative staff (not involved in field activities) recode the supplement bottles with sector-specific permanent stickers bearing codes from 001 to 596. Treatment codes were assigned by the Nutrilite Health Institute and were kept in a sealed envelope in a locked cabinet at both Nutrilite and Johns Hopkins University. Pg 7-8 (Labrique).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 18:16:39 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>"Supplements were identical in appearance. Tablets were packed into opaque plastic bottles, affixed with codes AorB representing supplement content, and shipped to the field where logistics staff, uninvolved in the study, relabeled bottles with sector numbers(001-596) according to the random allocation list." Pg 2652.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:10:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>"Participants were assigned on an individual basis to antioxidant or placebo supplementation." No details of how allocation was done. pg 1153, pgh 2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:14:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Although paper states that "Women in the placebo group were advised to take capsules that were identical in appearance to the active treatment capsules", no details were provided on how they were allocated to treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:11:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>"Packaged the supplements in boxes with identical labeling except for the supplement code."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 15:12:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>"A treatment colour code was assigned to each village based on the treatment allocation schedule. The treatment codes were opened only once all data had been collected." pg 2, pgh 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-01-20 03:40:37 +0000" MODIFIED_BY="Olukunmi Balogun" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-04-18 18:16:44 +0100" MODIFIED_BY="Heather Maxwell" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 13:48:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>All pregnant women were allocated a unique code and a uniquely labelled and numerically coded specific supplement supply for the duration of pregnancy. Blinding is unlikely to have been broken. Pg S498.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:53:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>Women and study investigators did not know the treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:54:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>Women, caregivers and researchers were blinded until the analyses were completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:55:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>Women were aware of the 'blind use of one of two kinds of tablets', but no other details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:56:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>Women and investigators were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:58:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>Women and outcome assessors were blinded to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:58:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>Women and investigators blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-13 03:43:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>Neither the researchers nor the patients were aware of the treatment allocation until after the completion of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-01 02:42:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>No information on participant or personnel blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 04:59:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>Methodological details unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-18 17:21:49 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>Double-blind mentioned in the text but no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-29 07:00:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 05:00:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>Women and investigators blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 05:02:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>Only participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 05:02:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>Not specifically stated but women were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 05:03:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>Women, caregivers and investigators blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-01 03:21:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>Treatment allocation was masked from all trial personnel and participants until trial completion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-18 17:31:40 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>Double-blind stated in the text but no other details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 05:04:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>No information about blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-03 01:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>&#8220;none of the trial staff or any other person involved in the trial knew the allocated treatment of any woman until after completion of the study&#8221; Pg 1146</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-03 01:11:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>All investigators, field and laboratory staff and participants were blinded to the treatment code until all field data had been collected and preliminary data analysis by coded groups had been completed page 17</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 02:17:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>Consulting physicians, pharmacist and women were blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 14:50:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>"Neither the participants nor the investigators were aware of the treatment assignments." pg 1283, last pgh.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 01:39:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>Women, caregivers and investigators were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 01:39:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Treatment allocations were blinded to both the investigator and the patient until the study was finished.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 14:54:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>No information provided about blinding of participants and personnel. Unlikely as participants were given canned beverages or multivitamins.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-18 17:57:05 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>Double-blind used in the text but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 01:36:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>All clinicians and clinical investigators were blinded to group assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-18 17:59:55 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>Authors claim the study had double-blind design, but it is unclear who was blinded. Allocation was double-blind and Roche Pharmaceuticals retained the code until completion of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 01:32:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>All study scientists and personnel, government staff, and enrollees were unaware of the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-18 18:03:13 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>Authors claim the study had a single-blind design, but it is unclear who was blinded. Probably not done. pg s489 pgh 8.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 15:01:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>Each micronutrient group had been given 4 different number codes to decrease the risk of unblinding. Pg 2054.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 01:31:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>Neither the women nor the midwives involved in treatment allocation revealed the randomisation schedule to anyone involved in the conduct of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-01-14 01:28:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>Women and investigators blinded to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 15:05:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>Study participants, interviewers, field supervisors and investigators remained masked to treatment assignments until the end of the trial. Pg 8 (Labrique).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-18 18:16:44 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>Double-blinded and blinding of the participants is unlikely to have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 15:10:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>"Treatment allocations were blinded to both investigator and the patient..." pg 1153, pgh 2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-04-03 01:14:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>None of the trial staff or any other person involved in the trial knew the treatment allocation for any women until after completion of the trial analysis.&#8221; Pg 239.e3 and 4</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-01 06:33:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>Health workers and midwives did not distinguish which supplement was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-10 15:12:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>"A treatment colour code was assigned to each village based on the treatment allocation schedule. The treatment codes were opened only once all data had been collected." pg 2, pgh 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-04-18 18:01:46 +0100" MODIFIED_BY="Heather Maxwell" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 13:48:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>"The field staff (medical officers, community health workers, social scientists, and data collection team) remained completely blinded as to the supplement allocation." Pg S498.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-05 14:41:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>Double-blind study, but it is unclear who was blinded and if the code was broken before or after outcome assessment pg289.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 13:41:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>"The code was revealed to the researchers once recruitment, data collection, and laboratory analyses were complete" pg811.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 04:55:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>No details are given if outcome assessment was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-02 05:46:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>Double-blinded study, but unclear if ocutome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 13:55:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>"Research assistants who assessed the study outcomes were unaware of the intervention groups." pg1424.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 13:56:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>"The identity of the tablets was not known to investigators until after the completion of the trial." pg426.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 13:59:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>"Neither the researchers nor the patients were aware of the treatment allocation until after the completion of the study." pg 214.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 02:42:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>No information on outcome assessor blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:00:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>No methodological details are given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:00:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>Unclear of outcome assessors were unaware of treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-29 07:00:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:28:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>"This committee and the data analysts were unmasked to the treatment codes, but the codes were made available to study investigators only at the end of the trial." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:02:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>Only participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:03:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>Unclear of outcome assessors were unaware of treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:03:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>No details are given if outcome assessment was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-05 14:36:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>Diagnosis were independently confirmed by 3 senior clinicians, who were unaware of treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 14:19:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>The allocation code was broken for the analysis. Pg 956.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-01-14 05:10:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>No information about blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-03 01:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Unclear from text if outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-03 01:11:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>All investigators, field and laboratory staff and participants were blinded to the treatment code until all field data had been collected and preliminary data analysis by coded groups had been completed page 17</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-18 17:48:41 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>Authors claim the study had double-blind design, but it is unclear if the assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 14:50:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>"Deidentified medical charts of all women with pregnancy-associated hypertension were reviewed centrally by at least three reviewers who were unaware of the treatment assignments." pg 1284.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 04:04:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>No information provided about blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-18 17:54:05 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>Authors claim the study had a double-blind design, but it is unclear if the assessors were blinded. Treatment allocations were blinded to both the investigator and the patient until the study was finished.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 04:06:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>No information provided about blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-18 17:57:10 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>Authors claim the study had double-blind design, but it is unclear who were blinded. No further information was available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-18 18:00:20 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>Authors claim the study had double-blind design, but it is unclear who was blinded. No further information was available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-18 18:00:06 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>Authors claim the study had double-blind design, but it is unclear who was blinded. allocation was double-blind and Roche Pharmaceuticals retained the code until completion of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-18 18:01:46 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>The code to indicate which strip was IFA or MMN was known only by the manufacturing production manager and a quality control officer from UNICEF. All study scientists and personnel. government staff, were unaware of the allocation. Blinding is unlikely to be broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 04:09:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>No details of blinded outcome assessment provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 15:01:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>Randomisation codes were safely kept at the administrative office of ICDDR,B and were not broken until after performing the intention-to-treat analyses. Pg 2054.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 04:40:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>No information provided about blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 04:41:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>Identifying characteristics and randomisation code were kept in a secure and separate database in the server unavailable to the research team, until all data analyses were completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 15:05:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>Investigators remained masked to treatment assignments until the end of the trial. Pg 8 (Labrique).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-10 15:09:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>At no time during the trial did study investigators or field or data management staff have access to the key. Pg 2651.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 06:11:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>"Investigators blinded to the sample background" but not sure if they blinded outcomes of interest in current review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-03 01:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>&#8220;None of the trial staff or any other person involved in the trial knew the treatment allocation for any women until after completion of the trial analysis.&#8221;Pg 239.e4</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 06:33:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>"Data collectors were informed that each supplement came in two sizes and colors, so that the code letter did not distinguish which supplement was used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-01 06:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>No information provided about blinding of outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-04-19 10:28:27 +0100" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 13:48:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>Approximately 16.5% of attrition with balanced number and similar reason for each group. S500 Figure1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 16:59:24 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>No losses to follow-up reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-13 05:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>123 (43.5%) women were excluded, of which, 70 women were withdrawn because their second Doppler scan was normal. Data were reported for all women randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 14:56:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>49 women (1%) excluded, partial intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-19 10:28:27 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>64 women (6%) were lost to follow-up and excluded, intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 17:09:15 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>49 (1%) women lost to follow-up, balanced across groups, analyses by intention-to-treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-13 06:49:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>21 women (28%) excluded from the analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-14 02:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>228 women met the entry criteria, but only 200 were included in the trial. 18 women were excluded and replaced by other women. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 17:18:37 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>Drop-out rates for each group were not clearly described and no information was provided on the reason of exclusion and attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-06 11:29:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>28 women (19%) in the control group excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-06 11:31:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>187 (40%) women excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-29 07:00:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 14:14:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>157 women (1%) were lost to follow-up and excluded, partial intention-to-treat analysis performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 14:15:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>3 women (1%) lost to follow-up and excluded. Intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 14:20:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>63 women (9%) lost to follow-up and 14 pairs of twins (2%) excluded. No intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:10:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>164 women (9%) excluded, intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 14:34:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>Only 1 loss to follow-up in placebo group, but the reason is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:12:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>61 women (5%) withdrew or were lost to follow-up, however data on miscarriage were reported for those who withdrew due to miscarriage. Intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 14:20:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>622 women (11%) excluded, intention-to-treat analyses not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-03 01:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Very low loss to follow-up rates. In the supplementation group 3 (0.25%) losses to follow-up and in the placebo group 6 (0.5%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 17:42:44 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>Drop-out rate appears balanced between groups and reasons for loss to follow-up were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-06 11:36:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>Data were reported for singletons only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-01 03:40:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>Vitamin C and E = 95/5088 missing and in placebo = 90/5066 missing. Reasons for missing similar between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>No losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-06 11:37:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>No missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 14:21:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>237 women (22%) excluded, no intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 14:21:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>42 women (17%) were lost to follow-up and excluded, no intention-to-treat analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:28:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>Small numbers of missing data, balanced across groups (32 women; treatment 16; placebo 16).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:30:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>No losses to follow-up reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:33:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>Loss to follow-up: 1748 loss to follow-up before delivery (IFA: 853; MMN: 895); 1128 loss to follow-up after delivery (IFA: 553; MMN: 575).</P>
<P>Post-randomisation exclusion: 10,549 pregnant women excluded because of trial termination (IFA group: 5057; MMN group: 5492).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 18:03:25 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>23/432 missing in MMN and 33/411 missing in IFA. Reasons for drop-out are similar, but IFA had 5 twin births while MMN cluster had none. Fig. 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-01 04:39:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>845 of 4436 losses to follow-up (19%) before birth; reasons were available. Numbers of women lost to follow-up did not differ among the treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:37:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>77 loss to follow-up before assessment at 26-28 weeks (5000 IU vitamin A: 26; 10,000 IU vitamin A: 26; placebo: 25). Additional 93 loss to follow-up before assessment at 36-38 weeks (5000 IU vitamin A: 34; 10,000 IU vitamin A: 28; placebo: 31).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-07 03:39:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>Small numbers of missing data, balanced across groups.</P>
<P>Women: 10 (treatment 6; placebo 4).</P>
<P>Infants: 29 (treatment 13; placebo 16).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 15:05:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>Number of missing data among each group are small and balanced with detailed reason.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 15:09:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>Numbers of missing outcome data in both group are small and balanced with similar reasons. Pg 2651, fig 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 18:18:10 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>3/52 drop-out from supplementation group and 3/58 drop-out from control group. drop-out rate balanced in both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 18:19:43 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>A higher loss to follow-up was seen in the Mexican centres although the loss was balanced between treatment and placebo groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-18 18:20:49 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>Proportion of women lost to follow-up was significantly different across groups 335/1777 in IFA and 290/L ,893 in MMN. Detailed reasons for missing data not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-10 15:12:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>121/1666 missing in folic acid, 67/1537 missing in iron-folic acid, 88/1494 missing in multiple micronutrients in birthweight analysis. No reasons for missing data. Amount of missing data from other outcomes unknown. Fig 1; table 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-04-03 01:14:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 01:51:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>No information about trial registration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-24 09:49:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>Limited information about selection bias, stated that 'unselected patients' were included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 13:44:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>Data reported for all outcomes in methods. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:16:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>Denominators vary with serial publications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:18:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>Figures change with serial publications, particularly for secondary outcomes, and results are not reported separately for the individual 4 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 07:52:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>All pre-specified outcomes appear to be reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 06:50:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>Results not reported as intention to treat; however, where possible, the review authors included data in the review as intention to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-10 13:59:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>Not all outcomes are reported by treatment group. In serial publications up to 70% of the data were excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 02:42:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>Although expected outcomes were reported, the study protocol was not available to see if all prespecified outcomes were reported as planned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:29:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>No details of exclusion of women in the control group given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 03:02:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>Difficult to assess given the high losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 07:00:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 05:47:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>Denominators vary in several publications of this trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:33:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>Compliance data not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 03:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>All pre-specified outcomes appear to be reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>No information provided about any women randomised that did not become pregnant in the study period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 03:21:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>Fewer outcomes were stated in the trial registration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 03:20:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>All pre-specified outcomes appear to be reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:36:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>Limited methodological details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>A large number of outcomes reported in the publication, but not pre-specified in the registered trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:11:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>Study protocol unavailable but outcomes predefined outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-24 09:47:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>As above - data only reported for singletons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 03:40:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>Relevant outcomes reported as pre-specified in the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:37:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>All pre-specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:37:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>All pre-specified outcomes were reported, no apparent evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:38:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>Unclear if all pre-specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 06:07:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>Serial publications of this study report different denominators. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:35:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>All pre-specified outcomes were reported, no apparent evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-24 09:47:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>Recruitment stopped after an interim analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:41:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>All pre-specified outcomes were reported, no apparent evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 04:10:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>All pre-specified outcomes were reported as described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 04:39:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>All the study's pre-specified outcomes have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:42:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>All pre-specified outcomes were reported, no apparent evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 03:40:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>Perinatal death was reported instead of pre-specified neonatal death.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 05:42:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>Registration of trial and outcomes reported as described previously.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 05:46:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>Study protocol was available and all of the study's pre-specified outcomes were reported in studies.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 06:11:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>Primary and secondary outcomes reported as planned in the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:14:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Outcomes reported according to the trial registration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:36:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>Many outcomes were assessed but report was limited to only 2 outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 06:14:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>Study protocol is available and all primary outcomes were reported as described in the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-04-18 18:23:18 +0100" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:18:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bhutta-2009">
<DESCRIPTION>
<P>The distribution of study participants across the urban and rural areas is unclear from the text and no adjustments were made for cluster design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 13:43:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Briscoe-1959">
<DESCRIPTION>
<P>Limited methodological details provided including patient compliance. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 13:48:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chappell-1999">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:01:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Czeizel-1994">
<DESCRIPTION>
<P>Limited methodological details provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:03:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-1998">
<DESCRIPTION>
<P>Limited methodological details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:08:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fawzi-2007">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:08:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fleming-1968">
<DESCRIPTION>
<P>Limited methodological details provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:09:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fleming-1986">
<DESCRIPTION>
<P>Limited methodological details provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-14 04:59:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hans-2010">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:11:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hemmi-2003">
<DESCRIPTION>
<P>No placebo control. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:13:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ICMR-2000">
<DESCRIPTION>
<P>Limited methodological details provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 07:00:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jauniaux-2004">
<DESCRIPTION>
<P>Could not be assessed because the trial was stopped.
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 13:58:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katz-2000">
<DESCRIPTION>
<P>Some women were pregnant more than once during the study period, however the denominators reported are the total number of pregnancies during the study period, not the total number of women randomised, which incorrectly assumes that each data point included is independent from the next.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:06:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kirke-1992">
<DESCRIPTION>
<P>The trial was stopped after there were poor recruitment rates and birth rates.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:19:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumwenda-2002">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of other bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:16:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MRC-1991">
<DESCRIPTION>
<P>The trial was stopped early after there were 1195 informative pregnancies, according to prespecified stopping rules.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-14 05:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCance-2010">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:21:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osrin-2005">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:22:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-People_x0027_s-League-1942">
<DESCRIPTION>
<P>Limited methodological details provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 17:42:53 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Prawirohartono-2011">
<DESCRIPTION>
<P>Overall, 70% of supplements were consumed, but it is unclear in text where there was more or less compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 13:59:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberfroid-2008">
<DESCRIPTION>
<P>Some women were pregnant more than once during the study period, however the denominators reported are the total number of pregnancies during the study period, not the total number of women randomised, which incorrectly assumes that each data point included is independent from the next.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 03:46:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2010">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:22:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumbold-2006">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 03:22:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumiris-2006">
<DESCRIPTION>
<P>At baseline, the control group appears to have a 2 mmHg higher systolic blood pressure than the intervention group, this figure was of borderline statistical significance, P = 0.059.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1980">
<DESCRIPTION>
<P>Limited methodological details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:35:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-2001">
<DESCRIPTION>
<P>Limited methodological details provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:04:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spinnato-2007">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:03:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Steyn-2003">
<DESCRIPTION>
<P>Results are from an interim analysis performed when 100 participants were recruited into each arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:04:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Summit-2008">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 04:10:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sunawang-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 04:39:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tofail-2008">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:01:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Broek-2006">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:04:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villar-2009">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 05:42:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2011">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 05:46:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-West-2014">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-01 06:11:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wibowo-2012">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:14:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-03 01:14:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zagre-2007">
<DESCRIPTION>
<P>There were differences in the baseline characteristics of participants. Women in control group tended to be poorer and less educated and more women in intervention group used more preventive measures against malaria and had larger households.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-18 18:23:18 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2008">
<DESCRIPTION>
<P>From the 531 clusters, 13 clusters were excluded due to no birth outcomes in the excluded clusters. The number of clusters excluded was unbalanced across the intervention groups which may have been due to important baseline differences.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-05-05 14:00:02 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-05-05 14:00:02 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-03-31 22:44:16 +0100" MODIFIED_BY="[Empty name]">Vitamin C and vitamin E versus placebo for preventing miscarriage</TITLE>
<TABLE COLS="7" ROWS="20">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Vitamin C plus vitamin E versus control</B> <B>for preventing miscarriage</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population:</B> pregnant women<BR/>
<B>Setting: </B>Australia, Brazil, Canada, Scotland, UK, USA<BR/>
<B>Intervention: </B>vitamin C and vitamin E<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Vitamin C plus vitamin E</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Total fetal loss</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 1.14<BR/>(0.92 to 1.40)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>18,949<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>17 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>20 per 1000<BR/>(16 to 24)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>14 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>16 per 1000<BR/>(13 to 20)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Early or late miscarriage</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.90<BR/>(0.65 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>13,346<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>9 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>9 per 1000<BR/>(7 to 12)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>8 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>8 per 1000<BR/>(6 to 11)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Stillbirth</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 1.31<BR/>(0.97 to 1.76)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>21,442<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>8 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>10 per 1000<BR/>(7 to 13)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>7 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>9 per 1000<BR/>(7 to 12)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Any adverse effects of vitamin supplementation sufficient to stop supplementation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.16<BR/>(0.39 to 3.41)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>739<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>2 3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>16 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>19 per 1000<BR/>(6 to 56)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Not effective but 95% CI is narrow and precise.</P>
<P>
<SUP>2</SUP> Non significant with wide 95% CI.</P>
<P>
<SUP>3</SUP> Small sample size.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-05-05 13:28:17 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-01-29 11:26:00 +0000" MODIFIED_BY="[Empty name]">Vitamin A plus iron plus folate versus iron plus folate for preventing miscarriage</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Vitamin A plus iron plus folate versus iron plus folate for preventing miscarriage</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population:</B> pregnant women<BR/>
<B>Settings: </B>Indonesia, Malawi<BR/>
<B>Intervention:</B> vitamin A plus iron plus folate<BR/>
<B>Comparison: </B>iron plus folate</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Vitamin A</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Total fetal loss (including miscarriages or combined miscarriages and stillbirths) - Vitamin A + iron + folate versus iron + folate</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 1.01<BR/>(0.61 to 1.66)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>1640<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>37 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>37 per 1000<BR/>(22 to 61)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>59 per 1,000</P>
</TD>
<TD>
<P>60 per 1,000</P>
<P>(36 to 98)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Early or late miscarriage - Vitamin A + iron + folate versus iron + folate</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.86<BR/>(0.46 to 1.62)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>1397<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>31 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>26 per 1000<BR/>(14 to 50)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>50 per 1,000</P>
</TD>
<TD>
<P>43 per 1,000</P>
<P>(23 to 80)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Stillbirth - Vitamin A + iron + folate versus iron + folate</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 1.29<BR/>(0.57 to 2.91)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>1640<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>13 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>16 per 1000<BR/>(7 to 37)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>21 per 1,000</P>
</TD>
<TD>
<P>27 per 1,000</P>
<P>(12 to 61)</P>
</TD>
</TR>
<TR>
<TD>
<P>Any adverse effects</P>
</TD>
<TD COLSPAN="2">
<P/>
</TD>
<TD>
<P>See comments.</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>No studies reported this outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> High and unclear risk of attrition bias.</P>
<P>
<SUP>2</SUP> Wide 95% CI.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-05-05 13:28:04 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2016-01-29 11:29:55 +0000" MODIFIED_BY="[Empty name]">Multivitamin plus iron plus folate versus iron plus folate for preventing miscarriage</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Multivitamin</B> <B>plus iron plus folate versus iron plus folate for preventing miscarriage</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Population:</B> pregnant women<BR/>
<B>Settings: </B>Bangladesh, Barkino Faso, Indonesia, Nepal, Niger, Pakistan, Tanzania<BR/>
<B>Intervention:</B> vitamin A plus iron plus folate<BR/>
<B>Comparison: </B>iron plus folate</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Multivitamin</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Total fetal loss (including miscarriages or combined miscarriages and stillbirths) - Multivitamins + iron + folic acid versus iron + folic acid</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.96<BR/>(0.93 to 1.00)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>94,948<BR/>(10 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>136 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>130 per 1000<BR/>(126 to 136)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>218 per 1,000</P>
</TD>
<TD>
<P>209 per 1,000</P>
<P>(202 to 218)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Early or late miscarriage - Multivitamin + iron + folic acid versus iron + folic acid</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.98<BR/>(0.94 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>94948<BR/>(10 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>84 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>83 per 1000<BR/>(79 to 87)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>134 per 1,000</P>
</TD>
<TD>
<P>132 per 1,000</P>
<P>(126 to 138)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Stillbirth - Multivitamin + iron + folic acid versus iron + folic acid</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>RR 0.92<BR/>(0.85 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>79,851<BR/>(10 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>29 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>26 per 1000<BR/>(24 to 28)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>46 per 1,000</P>
</TD>
<TD>
<P>43 per 1,000</P>
<P>(39 to 46)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Any adverse effects</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>No studies reported this outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Publication bias detected by funnel plot.</P>
<P>
<SUP>2</SUP> Wide confidence interval crossing the line of no effect.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-04-02 13:29:50 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-04-20 20:05:03 +0100" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2016-04-07 13:29:01 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Vitamin C plus vitamin E versus placebo</NAME>
<DICH_OUTCOME CHI2="8.464613937369379" CI_END="1.398807394138972" CI_START="0.9231903171657381" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1363826124369103" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="164" I2="29.116672722528534" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.14575791933728335" LOG_CI_START="-0.03470875923984085" LOG_EFFECT_SIZE="0.055524580048721246" METHOD="MH" MODIFIED="2016-04-02 13:43:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20600119142308704" P_Q="1.0" P_Z="0.22779713048400418" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9455" TOTAL_2="9494" WEIGHT="100.0" Z="1.206052862614158">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin C &amp; E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C &amp; E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.490609923107004" CI_START="0.04618042032887257" EFFECT_SIZE="0.5035460992907801" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7396205906298369" LOG_CI_START="-1.3355421185024463" LOG_EFFECT_SIZE="-0.29796076393630466" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="16495" O_E="0.0" SE="1.2189608475653815" STUDY_ID="STD-Chappell-1999" TOTAL_1="141" TOTAL_2="142" VAR="1.485865547897313" WEIGHT="1.2157336633749847"/>
<DICH_DATA CI_END="2.508973759863303" CI_START="0.5511194849647335" EFFECT_SIZE="1.175901495162709" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.39949611926352885" LOG_CI_START="-0.25875423411502957" LOG_EFFECT_SIZE="0.0703709425742496" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="1218" O_E="0.0" SE="0.38665951596636505" STUDY_ID="STD-McCance-2010" TOTAL_1="379" TOTAL_2="382" VAR="0.1495055812873437" WEIGHT="7.291410827444893"/>
<DICH_DATA CI_END="3.199591879555544" CI_START="1.057514493096367" EFFECT_SIZE="1.8394604601957154" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="0.5050945858947153" LOG_CI_START="0.02428632803634384" LOG_EFFECT_SIZE="0.2646904569655296" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="932" O_E="0.0" SE="0.28242915070526853" STUDY_ID="STD-Poston-2006" TOTAL_1="1393" TOTAL_2="1391" VAR="0.07976622516809927" WEIGHT="11.59875182374261"/>
<DICH_DATA CI_END="1.2949990047896451" CI_START="0.7349991944864095" EFFECT_SIZE="0.9756142810460962" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="95" LOG_CI_END="0.11226943466087563" LOG_CI_START="-0.13371313687539577" LOG_EFFECT_SIZE="-0.010721851107260082" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="0.14449138015377266" STUDY_ID="STD-Roberts-2010" TOTAL_1="4993" TOTAL_2="4976" VAR="0.020877758938742046" WEIGHT="58.05095181673239"/>
<DICH_DATA CI_END="1.893137275080997" CI_START="0.383879696609194" EFFECT_SIZE="0.8524886877828054" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.2771821066466418" LOG_CI_START="-0.41580485710314613" LOG_EFFECT_SIZE="-0.06931137522825215" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.4070639728474198" STUDY_ID="STD-Rumbold-2006" TOTAL_1="935" TOTAL_2="942" VAR="0.1657010779903249" WEIGHT="7.900716168409284"/>
<DICH_DATA CI_END="1.8491340821043452" CI_START="0.38095886178975996" EFFECT_SIZE="0.839311631764462" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.26696840332077226" LOG_CI_START="-0.4191219195010521" LOG_EFFECT_SIZE="-0.07607675809013992" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.4030128518274108" STUDY_ID="STD-Spinnato-2007" TOTAL_1="371" TOTAL_2="368" VAR="0.1624193587380626" WEIGHT="7.962484374818795"/>
<DICH_DATA CI_END="4.619938267231874" CI_START="1.0328974601198355" EFFECT_SIZE="2.184473049074819" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.6646361724436426" LOG_CI_START="0.014057209501694538" LOG_EFFECT_SIZE="0.33934669097266856" MODIFIED="2016-03-31 04:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="933" O_E="0.0" SE="0.38215330324990504" STUDY_ID="STD-Xu-2010" TOTAL_1="1243" TOTAL_2="1293" VAR="0.1460411471848139" WEIGHT="5.979951325477032"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4482531498869309" CI_END="1.2562385777178582" CI_START="0.6477876800823069" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9020952687436888" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.09907212598314558" LOG_CI_START="-0.1885673158552493" LOG_EFFECT_SIZE="-0.04474759493605186" METHOD="MH" MODIFIED="2016-04-07 13:29:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6942639350529494" P_Q="1.0" P_Z="0.5419832093546533" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6678" TOTAL_2="6668" WEIGHT="100.0" Z="0.609816747723515">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Vitamin C &amp; E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C&amp;E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.0007595165909695" CI_START="0.2539252325857575" EFFECT_SIZE="1.007915567282322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.602142446966" LOG_CI_START="-0.5952941410787272" LOG_EFFECT_SIZE="0.003424152943636391" MODIFIED="2016-03-31 04:50:49 +0100" MODIFIED_BY="[Empty name]" ORDER="1219" O_E="0.0" SE="0.7033801792241796" STUDY_ID="STD-McCance-2010" TOTAL_1="379" TOTAL_2="382" VAR="0.494743676525439" WEIGHT="5.452554143530959"/>
<DICH_DATA CI_END="1.3386241733011706" CI_START="0.6447632913651538" EFFECT_SIZE="0.9290294547960365" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" LOG_CI_END="0.12665866336620846" LOG_CI_START="-0.1905996964067041" LOG_EFFECT_SIZE="-0.031970516520247794" MODIFIED="2016-03-31 04:50:49 +0100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.18635913098481766" STUDY_ID="STD-Roberts-2010" TOTAL_1="4993" TOTAL_2="4976" VAR="0.03472972570141642" WEIGHT="80.88116980929469"/>
<DICH_DATA CI_END="1.6646829958838336" CI_START="0.1119936682640423" EFFECT_SIZE="0.4317799847211612" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.22133154340026848" LOG_CI_START="-0.9508065301487382" LOG_EFFECT_SIZE="-0.3647374933742348" MODIFIED="2016-03-31 04:50:49 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="0.6885197065797268" STUDY_ID="STD-Rumbold-2006" TOTAL_1="935" TOTAL_2="942" VAR="0.4740593863486332" WEIGHT="9.544008567684743"/>
<DICH_DATA CI_END="5.86820514087557" CI_START="0.29807119163851026" EFFECT_SIZE="1.3225516621743036" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7685052875149776" LOG_CI_START="-0.5256799961814342" LOG_EFFECT_SIZE="0.12141264566677172" MODIFIED="2016-03-31 04:50:49 +0100" MODIFIED_BY="[Empty name]" ORDER="425" O_E="0.0" SE="0.7602108419637463" STUDY_ID="STD-Spinnato-2007" TOTAL_1="371" TOTAL_2="368" VAR="0.577920524239228" WEIGHT="4.12226747948961"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.354857716263231" CI_END="1.7613185219826462" CI_START="0.972229717336936" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.308589396551683" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="76" I2="16.216406817149252" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.24583790215152565" LOG_CI_START="-0.012231108340471185" LOG_EFFECT_SIZE="0.11680339690552724" METHOD="MH" MODIFIED="2016-04-07 13:29:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.30234521323910934" P_Q="1.0" P_Z="0.07603336504245287" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10674" TOTAL_2="10768" WEIGHT="100.0" Z="1.7741800983413323">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Vitamin C &amp; E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C &amp; E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.490609923107004" CI_START="0.04618042032887257" EFFECT_SIZE="0.5035460992907801" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7396205906298369" LOG_CI_START="-1.3355421185024463" LOG_EFFECT_SIZE="-0.29796076393630466" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="16501" O_E="0.0" SE="1.2189608475653815" STUDY_ID="STD-Chappell-1999" TOTAL_1="141" TOTAL_2="142" VAR="1.485865547897313" WEIGHT="2.6258965310479794"/>
<DICH_DATA CI_END="3.1575513909958883" CI_START="0.5027104396795112" EFFECT_SIZE="1.2598944591029024" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4993504276816223" LOG_CI_START="-0.2986820957782366" LOG_EFFECT_SIZE="0.10033416595169282" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1222" O_E="0.0" SE="0.46876825460502225" STUDY_ID="STD-McCance-2010" TOTAL_1="379" TOTAL_2="382" VAR="0.21974367652543894" WEIGHT="10.499279008792579"/>
<DICH_DATA CI_END="6.449856012413493" CI_START="1.147261524209978" EFFECT_SIZE="2.7202337472607745" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.8095500194860777" LOG_CI_START="0.05966242886455233" LOG_EFFECT_SIZE="0.434606224175315" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="0.440487682734524" STUDY_ID="STD-Poston-2006" TOTAL_1="1369" TOTAL_2="1372" VAR="0.19402939864083069" WEIGHT="9.213134031608641"/>
<DICH_DATA CI_END="1.656673596035734" CI_START="0.6679790663258648" EFFECT_SIZE="1.0519616351781382" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.21923695054110748" LOG_CI_START="-0.17523714758675663" LOG_EFFECT_SIZE="0.02199990147717542" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="0.23171603791858547" STUDY_ID="STD-Roberts-2010" TOTAL_1="4993" TOTAL_2="4976" VAR="0.05369232222868734" WEIGHT="47.5146361004845"/>
<DICH_DATA CI_END="3.8565316295089103" CI_START="0.46790658743295466" EFFECT_SIZE="1.3433155080213903" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5861968975978947" LOG_CI_START="-0.3298408405405757" LOG_EFFECT_SIZE="0.12817802852865953" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="0.5380851018424722" STUDY_ID="STD-Rumbold-2006" TOTAL_1="935" TOTAL_2="942" VAR="0.28953557682482367" WEIGHT="7.876141778958621"/>
<DICH_DATA CI_END="1.8044616292173976" CI_START="0.2671752636707746" EFFECT_SIZE="0.6943396226415094" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2563476514848435" LOG_CI_START="-0.5732037533393863" LOG_EFFECT_SIZE="-0.1584280509272714" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="0.48728260153943276" STUDY_ID="STD-Spinnato-2007" TOTAL_1="371" TOTAL_2="368" VAR="0.2374443337630376" WEIGHT="13.229529769207023"/>
<DICH_DATA CI_END="4.755895914873957" CI_START="0.632004179628512" EFFECT_SIZE="1.7337087691069992" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6772323413018818" LOG_CI_START="-0.19928004959167045" LOG_EFFECT_SIZE="0.23897614585510565" MODIFIED="2016-03-31 04:59:26 +0100" MODIFIED_BY="[Empty name]" ORDER="937" O_E="0.0" SE="0.5148677172171828" STUDY_ID="STD-Xu-2010" TOTAL_1="1243" TOTAL_2="1293" VAR="0.26508876623243294" WEIGHT="7.74975666848628"/>
<DICH_DATA CI_END="51.7677683953485" CI_START="0.7524850039446094" EFFECT_SIZE="6.2413515687851975" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.714059443821431" LOG_CI_START="-0.12350215057664518" LOG_EFFECT_SIZE="0.7952786466223929" MODIFIED="2016-04-07 13:29:01 +0100" MODIFIED_BY="[Empty name]" ORDER="936" O_E="0.0" SE="1.0793927766260218" STUDY_ID="STD-Xu-2010" TOTAL_1="1243" TOTAL_2="1293" VAR="1.165088766232433" WEIGHT="1.29162611141438"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1760523932793028" CI_END="1.6194381558474298" CI_START="0.8388997514542624" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1655669291962423" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.20936436754407223" LOG_CI_START="-0.07628993427438525" LOG_EFFECT_SIZE="0.0665372166348435" METHOD="MH" MODIFIED="2016-04-06 10:47:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5288076828770516" P_Q="1.0" P_Z="0.36120808845605257" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4138" TOTAL_2="4196" WEIGHT="99.99999999999997" Z="0.9130655299475431">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Vitamin C &amp; E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C &amp; E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4731299181777255" CI_START="0.34543530769537556" EFFECT_SIZE="0.7133520074696545" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16824104980230256" LOG_CI_START="-0.46163327431463397" LOG_EFFECT_SIZE="-0.1466961122561657" MODIFIED="2016-03-31 05:00:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1227" O_E="0.0" SE="0.3699912959144782" STUDY_ID="STD-McCance-2010" TOTAL_1="378" TOTAL_2="382" VAR="0.13689355905247497" WEIGHT="26.316301720009708"/>
<DICH_DATA CI_END="4.638494946791151" CI_START="0.3358883688492542" EFFECT_SIZE="1.248205312275664" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6663770878103021" LOG_CI_START="-0.4738050346580235" LOG_EFFECT_SIZE="0.09628602657613933" MODIFIED="2016-03-31 05:00:09 +0100" MODIFIED_BY="[Empty name]" ORDER="935" O_E="0.0" SE="0.6697486227304258" STUDY_ID="STD-Poston-2006" TOTAL_1="1393" TOTAL_2="1391" VAR="0.4485632176493023" WEIGHT="6.229305136313119"/>
<DICH_DATA CI_END="5.445853803671943" CI_START="0.045167062696927524" EFFECT_SIZE="0.49595687331536387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7360659783350547" LOG_CI_START="-1.3451781515460735" LOG_EFFECT_SIZE="-0.3045560866055094" MODIFIED="2016-03-31 05:00:09 +0100" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="1.2225331042167713" STUDY_ID="STD-Spinnato-2007" TOTAL_1="371" TOTAL_2="368" VAR="1.4945871909058948" WEIGHT="3.1250516162452087"/>
<DICH_DATA CI_END="3.277456798555071" CI_START="0.7832992744995576" EFFECT_SIZE="1.6022576361221779" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.5155369757937625" LOG_CI_START="-0.10607227570555432" LOG_EFFECT_SIZE="0.20473235004410403" MODIFIED="2016-03-31 05:00:09 +0100" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.36513635134611905" STUDY_ID="STD-Villar-2009" TOTAL_1="753" TOTAL_2="762" VAR="0.1333245550743565" WEIGHT="18.563562197295216"/>
<DICH_DATA CI_END="2.063395517313573" CI_START="0.7976883483567521" EFFECT_SIZE="1.2829444891391795" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.31458248271040945" LOG_CI_START="-0.09816675153824575" LOG_EFFECT_SIZE="0.10820786558608185" MODIFIED="2016-03-31 05:00:09 +0100" MODIFIED_BY="[Empty name]" ORDER="938" O_E="0.0" SE="0.242450943339321" STUDY_ID="STD-Xu-2010" TOTAL_1="1243" TOTAL_2="1293" VAR="0.05878245992612664" WEIGHT="45.76577933013673"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4105664517993155" CI_START="0.3926583900548966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1572327044025157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5328265157843642" LOG_CI_START="-0.4059851184061942" LOG_EFFECT_SIZE="0.06342069868908497" METHOD="MH" MODIFIED="2016-04-02 13:45:15 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7911575878787762" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="368" WEIGHT="99.99999999999999" Z="0.26480772239714806">
<NAME>Any adverse effects of vitamin supplementation sufficient to stop supplementation</NAME>
<GROUP_LABEL_1>Vitamin C &amp; E</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C &amp; E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4105664517993164" CI_START="0.3926583900548965" EFFECT_SIZE="1.1572327044025157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5328265157843644" LOG_CI_START="-0.40598511840619433" LOG_EFFECT_SIZE="0.06342069868908497" MODIFIED="2016-03-31 05:00:32 +0100" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.5514626011160724" STUDY_ID="STD-Spinnato-2007" TOTAL_1="371" TOTAL_2="368" VAR="0.3041110004297043" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-04-02 13:47:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Vitamin C versus no supplement/placebo</NAME>
<DICH_OUTCOME CHI2="0.24204291876057926" CI_END="2.834364706134609" CI_START="0.5764786892544753" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2782608695652173" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="100.0" ID="CMP-002.01" LOG_CI_END="0.452455731469343" LOG_CI_START="-0.23921674268021423" LOG_EFFECT_SIZE="0.1066194943945644" METHOD="MH" MODIFIED="2016-04-02 13:46:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6227345175611136" P_Q="0.0" P_Z="0.5456797090948132" Q="4.6668547832501334E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="105" WEIGHT="100.0" Z="0.6042465961079483">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin C alone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin c alone]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.056470361864685" CI_START="0.10290955966455816" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.7822195962855812" LOG_CI_START="-0.9875442800798766" LOG_EFFECT_SIZE="-0.10266234189714771" MODIFIED="2016-03-31 04:42:56 +0100" MODIFIED_BY="[Empty name]" ORDER="16496" O_E="0.0" SE="1.039568061449545" STUDY_ID="STD-Hemmi-2003" TOTAL_1="19" TOTAL_2="5" VAR="1.080701754385965" WEIGHT="16.52173913043478"/>
<DICH_DATA CI_END="3.273846262800871" CI_START="0.5774935193146532" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5150582814336233" LOG_CI_START="-0.2384528851010604" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2016-03-31 04:42:56 +0100" MODIFIED_BY="[Empty name]" ORDER="16497" O_E="0.0" SE="0.4426161891629032" STUDY_ID="STD-Steyn-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.1959090909090909" WEIGHT="83.47826086956522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.16488103773912144" CI_END="2.646107429603935" CI_START="0.5207920956764255" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1739130434782608" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4226074721784177" LOG_CI_START="-0.283335615895629" LOG_EFFECT_SIZE="0.0696359281413944" METHOD="MH" MODIFIED="2016-04-02 13:46:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6847020868398763" P_Q="1.0" P_Z="0.6989996812849089" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="105" WEIGHT="100.0" Z="0.3866711452888009">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Vitamin C alone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C alone]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.056470361864685" CI_START="0.10290955966455816" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.7822195962855812" LOG_CI_START="-0.9875442800798766" LOG_EFFECT_SIZE="-0.10266234189714771" MODIFIED="2016-03-31 04:51:11 +0100" MODIFIED_BY="[Empty name]" ORDER="16499" O_E="0.0" SE="1.039568061449545" STUDY_ID="STD-Hemmi-2003" TOTAL_1="19" TOTAL_2="5" VAR="1.080701754385965" WEIGHT="16.52173913043478"/>
<DICH_DATA CI_END="3.0360428948092997" CI_START="0.5146501726544757" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.48230790320742845" LOG_CI_START="-0.2884878771913156" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2016-03-31 04:51:11 +0100" MODIFIED_BY="[Empty name]" ORDER="16500" O_E="0.0" SE="0.4527692569068708" STUDY_ID="STD-Steyn-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.205" WEIGHT="83.47826086956522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.77077883680238" CI_START="0.12367601589346236" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.8619570230280276" LOG_CI_START="-0.9077145135887024" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2016-04-02 13:47:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4995031318378703" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="0.6752717520081195">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Vitamin C alone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C alone]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.77077883680238" CI_START="0.12367601589346236" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8619570230280276" LOG_CI_START="-0.9077145135887024" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2016-03-31 04:59:50 +0100" MODIFIED_BY="[Empty name]" ORDER="16502" O_E="0.0" SE="1.626918770703887" STUDY_ID="STD-Steyn-2003" TOTAL_1="100" TOTAL_2="100" VAR="2.6468646864686467" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-04-02 13:48:44 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Vitamin C plus multivitamins versus placebo plus multivitamins or multivitamins alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7730245925707964" CI_START="0.6257183406966063" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3172442244224423" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.4429537211358973" LOG_CI_START="-0.20362111504550476" LOG_EFFECT_SIZE="0.11966630304519629" METHOD="MH" MODIFIED="2016-04-02 13:48:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.46815175767582395" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="303" TOTAL_2="103" WEIGHT="100.00000000000001" Z="0.7254895520426282">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [Vitamin C]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7730245925707964" CI_START="0.6257183406966063" EFFECT_SIZE="1.3172442244224423" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.4429537211358973" LOG_CI_START="-0.20362111504550476" LOG_EFFECT_SIZE="0.11966630304519629" MODIFIED="2016-03-31 04:41:29 +0100" MODIFIED_BY="[Empty name]" ORDER="16494" O_E="0.0" SE="0.37980125937001324" STUDY_ID="STD-Briscoe-1959" TOTAL_1="303" TOTAL_2="103" VAR="0.14424899661904805" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11302470598142948" CI_END="1.786528690322229" CI_START="0.7920043801009089" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1895118948170067" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.25200999504088134" LOG_CI_START="-0.1012724165817252" LOG_EFFECT_SIZE="0.07536878922957807" METHOD="MH" MODIFIED="2016-04-02 13:48:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7367265274691344" P_Q="1.0" P_Z="0.40300185227664176" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="300" WEIGHT="100.0" Z="0.8362721018003308">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin C]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin C]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7730245925707964" CI_START="0.6257183406966063" EFFECT_SIZE="1.3172442244224423" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.4429537211358973" LOG_CI_START="-0.20362111504550476" LOG_EFFECT_SIZE="0.11966630304519629" MODIFIED="2016-03-31 04:50:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16498" O_E="0.0" SE="0.37980125937001324" STUDY_ID="STD-Briscoe-1959" TOTAL_1="303" TOTAL_2="103" VAR="0.14424899661904805" WEIGHT="31.227996014372415"/>
<DICH_DATA CI_END="1.8367734463719405" CI_START="0.6970470835048397" EFFECT_SIZE="1.1315111903347197" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" LOG_CI_END="0.2640555923111405" LOG_CI_START="-0.1567378855810151" LOG_EFFECT_SIZE="0.053658853365062716" MODIFIED="2016-03-31 04:50:13 +0100" MODIFIED_BY="[Empty name]" ORDER="1216" O_E="0.0" SE="0.24717617187516133" STUDY_ID="STD-Hans-2010" TOTAL_1="187" TOTAL_2="197" VAR="0.0610960599428593" WEIGHT="68.77200398562759"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-04-20 19:53:07 +0100" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Vitamin A plus iron and folate versus iron and folate</NAME>
<IV_OUTCOME CHI2="1.5193783230251892" CI_END="1.6570279623963784" CI_START="0.6133760835907214" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.0081573894858895" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2193298372135328" LOG_CI_START="-0.21227316178534192" LOG_DATA="YES" LOG_EFFECT_SIZE="0.003528337714095404" MODIFIED="2016-04-20 19:52:23 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.4678119358430013" P_Q="1.0" P_Z="0.9744359583159171" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="930" TOTAL_2="710" WEIGHT="100.00000000000001" Z="0.0320452585406594">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin A]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="3.0610378196037686" CI_START="0.6680755485578791" EFFECT_SIZE="1.4300365451582704" ESTIMABLE="YES" ESTIMATE="0.3577" LOG_CI_END="0.48586869540712174" LOG_CI_START="-0.17517442305353534" LOG_EFFECT_SIZE="0.1553471361767932" MODIFIED="2016-03-31 14:13:28 +0100" MODIFIED_BY="[Empty name]" ORDER="16518" SE="0.3883" STUDY_ID="STD-Kumwenda-2002" TOTAL_1="340" TOTAL_2="357" WEIGHT="42.62941082657814"/>
<IV_DATA CI_END="4.859807182047935" CI_START="0.20165463699771416" EFFECT_SIZE="0.9899508337158773" ESTIMABLE="YES" ESTIMATE="-0.0101" LOG_CI_END="0.6866190385145972" LOG_CI_START="-0.6953917870490429" LOG_EFFECT_SIZE="-0.00438637426722283" MODIFIED="2016-03-31 14:13:28 +0100" MODIFIED_BY="[Empty name]" ORDER="16519" SE="0.8118" STUDY_ID="STD-Schmidt-2001" TOTAL_1="122" TOTAL_2="121" WEIGHT="9.753175016504498"/>
<IV_DATA CI_END="1.520426318028024" CI_START="0.36016581083363186" EFFECT_SIZE="0.7400037686696985" ESTIMABLE="YES" ESTIMATE="-0.3011" LOG_CI_END="0.18196537847606892" LOG_CI_START="-0.44349751547820715" LOG_EFFECT_SIZE="-0.13076606850106912" MODIFIED="2016-03-31 14:13:28 +0100" MODIFIED_BY="[Empty name]" ORDER="446" SE="0.3674" STUDY_ID="STD-Van-den-Broek-2006" TOTAL_1="468" TOTAL_2="232" WEIGHT="47.61741415691738"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.2361679943014179" CI_END="1.6194788480089959" CI_START="0.4564622695673991" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.8597854328136662" ESTIMABLE="YES" I2="19.104846217514385" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.2093752800689716" LOG_CI_START="-0.3405951147252677" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06560991732814805" MODIFIED="2016-04-20 19:52:47 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.2662109357497603" P_Q="1.0" P_Z="0.6400446646197842" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="808" TOTAL_2="589" WEIGHT="99.99999999999999" Z="0.4676363535529261">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin A]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="4.587132446073621" CI_START="0.4711140408039988" EFFECT_SIZE="1.4700552718768347" ESTIMABLE="YES" ESTIMATE="0.3853" LOG_CI_END="0.6615412798678684" LOG_CI_START="-0.32687395211322245" LOG_EFFECT_SIZE="0.16733366387732287" MODIFIED="2016-03-31 14:14:09 +0100" MODIFIED_BY="[Empty name]" ORDER="483" SE="0.5806" STUDY_ID="STD-Kumwenda-2002" TOTAL_1="340" TOTAL_2="357" WEIGHT="30.959915356884355"/>
<IV_DATA CI_END="1.4483630637794676" CI_START="0.315488200461244" EFFECT_SIZE="0.6759744496697476" ESTIMABLE="YES" ESTIMATE="-0.3916" LOG_CI_END="0.16087744088862252" LOG_CI_START="-0.5010168791152494" LOG_EFFECT_SIZE="-0.17006971911331345" MODIFIED="2016-03-31 14:14:09 +0100" MODIFIED_BY="[Empty name]" ORDER="482" SE="0.3888" STUDY_ID="STD-Van-den-Broek-2006" TOTAL_1="468" TOTAL_2="232" WEIGHT="69.04008464311563"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.1449038873080058" CI_END="2.907824714746395" CI_START="0.5701697383039828" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.2876154925445737" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.46356822346870785" LOG_CI_START="-0.24399583654664858" LOG_DATA="YES" LOG_EFFECT_SIZE="0.1097861934610296" MODIFIED="2016-04-20 19:53:07 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.930110458958407" P_Q="1.0" P_Z="0.5430421767755587" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="930" TOTAL_2="710" WEIGHT="100.0" Z="0.6082190923566547">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin A]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="3.992800013417024" CI_START="0.4909108467441132" EFFECT_SIZE="1.4000388692698706" ESTIMABLE="YES" ESTIMATE="0.3365" LOG_CI_END="0.6012775583174277" LOG_CI_START="-0.30899737199653915" LOG_EFFECT_SIZE="0.14614009316044427" MODIFIED="2016-03-31 14:14:44 +0100" MODIFIED_BY="[Empty name]" ORDER="488" SE="0.5347" STUDY_ID="STD-Kumwenda-2002" TOTAL_1="340" TOTAL_2="357" WEIGHT="60.42078540698141"/>
<IV_DATA CI_END="4.817788267719484" CI_START="0.2041878333338642" EFFECT_SIZE="0.9918335282934089" ESTIMABLE="YES" ESTIMATE="-0.0082" LOG_CI_END="0.6828477096968532" LOG_CI_START="-0.6899701392000666" LOG_EFFECT_SIZE="-0.0035612147516066645" MODIFIED="2016-03-31 14:14:44 +0100" MODIFIED_BY="[Empty name]" ORDER="489" SE="0.8064" STUDY_ID="STD-Schmidt-2001" TOTAL_1="122" TOTAL_2="121" WEIGHT="26.564747749754652"/>
<IV_DATA CI_END="14.224623420531168" CI_START="0.15548989916847078" EFFECT_SIZE="1.4872072018948332" ESTIMABLE="YES" ESTIMATE="0.3969" LOG_CI_END="1.1530407778052363" LOG_CI_START="-0.8082978180704349" LOG_EFFECT_SIZE="0.17237147986740065" MODIFIED="2016-03-31 14:14:44 +0100" MODIFIED_BY="[Empty name]" ORDER="487" SE="1.1521" STUDY_ID="STD-Van-den-Broek-2006" TOTAL_1="468" TOTAL_2="232" WEIGHT="13.014466843263936"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-04-20 19:54:02 +0100" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Vitamin A versus placebo</NAME>
<IV_OUTCOME CHI2="7.441259401754134" CI_END="1.2279473540176677" CI_START="0.9043219646612763" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.0537835468851624" ESTIMABLE="YES" I2="73.12282918764345" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.08917974762783844" LOG_CI_START="-0.04367692065129417" LOG_DATA="YES" LOG_EFFECT_SIZE="0.02275141348827216" MODIFIED="2016-04-20 19:53:31 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.024218800063428025" P_Q="1.0" P_Z="0.5020427634027862" Q="0.0" RANDOM="YES" SCALE="1.43" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.011256148967296473" TOTALS="YES" TOTAL_1="26422" TOTAL_2="26058" WEIGHT="100.0" Z="0.6712790801091633">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1727434021574046" CI_START="0.9222436828425078" EFFECT_SIZE="1.039978458543684" ESTIMABLE="YES" ESTIMATE="0.0392" LOG_CI_END="0.06920299828967816" LOG_CI_START="-0.03515431090846321" LOG_EFFECT_SIZE="0.017024343690607478" MODIFIED="2016-04-02 09:57:47 +0100" MODIFIED_BY="[Empty name]" ORDER="16513" SE="0.0613" STUDY_ID="STD-Katz-2000" TOTAL_1="6070" TOTAL_2="5653" WEIGHT="40.56487713906416"/>
<IV_DATA CI_END="3.041488265122976" CI_START="1.1366132910247295" EFFECT_SIZE="1.8592998646357508" ESTIMABLE="YES" ESTIMATE="0.6202" LOG_CI_END="0.4830861451776471" LOG_CI_START="0.05561273017514646" LOG_EFFECT_SIZE="0.2693494376763968" MODIFIED="2016-04-02 09:57:53 +0100" MODIFIED_BY="[Empty name]" ORDER="188" SE="0.2511" STUDY_ID="STD-Prawirohartono-2011" TOTAL_1="546" TOTAL_2="543" WEIGHT="8.196153672506629"/>
<IV_DATA CI_END="1.0214213074234966" CI_START="0.9257092338082209" EFFECT_SIZE="0.9723883668012469" ESTIMABLE="YES" ESTIMATE="-0.028" LOG_CI_END="0.009204913241401822" LOG_CI_START="-0.033525404227983925" LOG_EFFECT_SIZE="-0.01216024549329107" MODIFIED="2016-03-31 13:50:03 +0100" MODIFIED_BY="[Empty name]" ORDER="1233" SE="0.0251" STUDY_ID="STD-West-2011" TOTAL_1="19806" TOTAL_2="19862" WEIGHT="51.2389691884292"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.036990679380204" CI_START="0.9241111326467735" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.978925242940536" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.0157748529059775" LOG_CI_START="-0.03427579783505605" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.009250472464539285" MODIFIED="2016-04-20 19:53:49 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4687650949286376" Q="0.0" RANDOM="NO" SCALE="7.24" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19806" TOTAL_2="19862" WEIGHT="100.0" Z="0.7244897959183673">
<NAME>Early of late miscarriage</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.036990679380204" CI_START="0.9241111326467735" EFFECT_SIZE="0.978925242940536" ESTIMABLE="YES" ESTIMATE="-0.0213" LOG_CI_END="0.0157748529059775" LOG_CI_START="-0.03427579783505605" LOG_EFFECT_SIZE="-0.009250472464539285" MODIFIED="2016-03-31 13:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="481" SE="0.0294" STUDY_ID="STD-West-2011" TOTAL_1="19806" TOTAL_2="19862" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0591196616301708" CI_START="0.8570679672678935" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.952752609803211" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.024945030409484856" LOG_CI_START="-0.0669847362577196" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.021019852924117385" MODIFIED="2016-04-20 19:54:02 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3700945466004403" Q="0.0" RANDOM="NO" SCALE="24.08" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19806" TOTAL_2="19862" WEIGHT="100.0" Z="0.8962962962962963">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0591196616301708" CI_START="0.8570679672678935" EFFECT_SIZE="0.952752609803211" ESTIMABLE="YES" ESTIMATE="-0.0484" LOG_CI_END="0.024945030409484856" LOG_CI_START="-0.0669847362577196" LOG_EFFECT_SIZE="-0.021019852924117385" MODIFIED="2016-03-31 13:53:12 +0100" MODIFIED_BY="[Empty name]" ORDER="486" SE="0.054" STUDY_ID="STD-West-2011" TOTAL_1="19806" TOTAL_2="19862" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2016-04-20 19:55:00 +0100" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Beta-carotene versus placebo</NAME>
<IV_OUTCOME CHI2="0.02022995663701012" CI_END="1.068671155995882" CI_START="0.9768814365776327" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.0217460614547709" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.02884408770907847" LOG_CI_START="-0.01015814310282719" LOG_DATA="YES" LOG_EFFECT_SIZE="0.009342972303125611" MODIFIED="2016-04-20 19:54:29 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.8868967241308878" P_Q="1.0" P_Z="0.3477217553052423" Q="0.0" RANDOM="NO" SCALE="4.33" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25648" TOTAL_2="25515" WEIGHT="100.0" Z="0.9390175300994161">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Beta-carotene</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [beta-carotene]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1615389329988455" CI_START="0.9134325048115118" EFFECT_SIZE="1.0300424345653076" ESTIMABLE="YES" ESTIMATE="0.0296" LOG_CI_END="0.06503377126340691" LOG_CI_START="-0.03932353793473443" LOG_EFFECT_SIZE="0.012855116664336209" MODIFIED="2016-03-31 13:54:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16514" SE="0.0613" STUDY_ID="STD-Katz-2000" TOTAL_1="5650" TOTAL_2="5653" WEIGHT="13.967965419503729"/>
<IV_DATA CI_END="1.0710196197778634" CI_START="0.972183107153525" EFFECT_SIZE="1.0204054007001484" ESTIMABLE="YES" ESTIMATE="0.0202" LOG_CI_END="0.029797426651852626" LOG_CI_START="-0.012251929582961275" LOG_EFFECT_SIZE="0.008772748534445731" MODIFIED="2016-03-31 13:54:25 +0100" MODIFIED_BY="[Empty name]" ORDER="1234" SE="0.0247" STUDY_ID="STD-West-2011" TOTAL_1="19998" TOTAL_2="19862" WEIGHT="86.03203458049627"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.0566789759830775" CI_START="0.9423948335287995" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.99790220345731" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.023943066649877" LOG_CI_START="-0.025767103473870616" LOG_DATA="YES" LOG_EFFECT_SIZE="-9.120184119968471E-4" MODIFIED="2016-04-20 19:54:47 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9426673178372811" Q="0.0" RANDOM="NO" SCALE="3.46" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19998" TOTAL_2="19862" WEIGHT="100.0" Z="0.07191780821917809">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Beta-carotene</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [beta-carotene]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0566789759830775" CI_START="0.9423948335287995" EFFECT_SIZE="0.99790220345731" ESTIMABLE="YES" ESTIMATE="-0.0021" LOG_CI_END="0.023943066649877" LOG_CI_START="-0.025767103473870616" LOG_EFFECT_SIZE="-9.120184119968471E-4" MODIFIED="2016-03-31 14:07:43 +0100" MODIFIED_BY="[Empty name]" ORDER="485" SE="0.0292" STUDY_ID="STD-West-2011" TOTAL_1="19998" TOTAL_2="19862" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.2046850062831576" CI_START="0.9825361645674612" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.0879552314251637" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.0808735050716166" LOG_CI_START="-0.0076514554227283685" LOG_DATA="YES" LOG_EFFECT_SIZE="0.03661102482444412" MODIFIED="2016-04-20 19:55:00 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.10498464829609187" Q="0.0" RANDOM="NO" SCALE="11.26" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19998" TOTAL_2="19862" WEIGHT="100.0" Z="1.6211538461538462">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Beta-carotene</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [beta-carotene]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2046850062831576" CI_START="0.9825361645674612" EFFECT_SIZE="1.0879552314251637" ESTIMABLE="YES" ESTIMATE="0.0843" LOG_CI_END="0.0808735050716166" LOG_CI_START="-0.0076514554227283685" LOG_EFFECT_SIZE="0.03661102482444412" MODIFIED="2016-03-31 14:00:11 +0100" MODIFIED_BY="[Empty name]" ORDER="491" SE="0.052" STUDY_ID="STD-West-2011" TOTAL_1="19998" TOTAL_2="19862" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2016-04-20 19:55:14 +0100" MODIFIED_BY="Heather Maxwell" NO="7">
<NAME>Vitamin A or beta-carotene versus placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.205836428052044" CI_START="0.9143210990903474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.050010327672887" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.08128839966784751" LOG_CI_START="-0.03890125823409011" LOG_DATA="YES" LOG_EFFECT_SIZE="0.02119357071687869" MODIFIED="2016-04-20 19:55:14 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.48942847667126266" Q="0.0" RANDOM="NO" SCALE="16.44" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11720" TOTAL_2="5653" WEIGHT="100.0" Z="0.6912181303116148">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.205836428052044" CI_START="0.9143210990903474" EFFECT_SIZE="1.050010327672887" ESTIMABLE="YES" ESTIMATE="0.0488" LOG_CI_END="0.08128839966784751" LOG_CI_START="-0.03890125823409011" LOG_EFFECT_SIZE="0.02119357071687869" MODIFIED="2016-03-31 14:01:20 +0100" MODIFIED_BY="[Empty name]" ORDER="16516" SE="0.0706" STUDY_ID="STD-Katz-2000" TOTAL_1="11720" TOTAL_2="5653" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2016-04-20 19:56:04 +0100" MODIFIED_BY="Heather Maxwell" NO="8">
<NAME>Vitamin A (with/without multivitamins) versus multivitamins or placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.2088486952739608" CI_START="0.5294754840803308" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.0823719460884332" LOG_CI_START="-0.27615414391366416" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2016-04-20 19:55:32 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2894385034861393" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="538" TOTAL_2="536" WEIGHT="100.0" Z="1.0593542260208926">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin A]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2088486952739608" CI_START="0.5294754840803308" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="0.0823719460884332" LOG_CI_START="-0.27615414391366416" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2016-03-31 14:11:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16517" SE="0.2106" STUDY_ID="STD-Fawzi-1998" TOTAL_1="538" TOTAL_2="536" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.3346924160570625E-32" CI_END="1.5498449839631028" CI_START="0.373082794208074" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.7604081122701953" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.19028826205665653" LOG_CI_START="-0.4281947792432578" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11895325859330064" MODIFIED="2016-04-20 19:55:50 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.45089583845333314" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="539" TOTAL_2="536" WEIGHT="100.0" Z="0.7539223781998347">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin A]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.5498449839631028" CI_START="0.3730827942080739" EFFECT_SIZE="0.7604081122701953" ESTIMABLE="YES" ESTIMATE="-0.2739" LOG_CI_END="0.19028826205665653" LOG_CI_START="-0.4281947792432579" LOG_EFFECT_SIZE="-0.11895325859330064" MODIFIED="2016-03-31 14:11:59 +0100" MODIFIED_BY="[Empty name]" ORDER="484" SE="0.3633" STUDY_ID="STD-Fawzi-1998" TOTAL_1="539" TOTAL_2="536" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.7905484050800495" CI_START="0.5993425680134464" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.0359304413198107" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.25298606607677254" LOG_CI_START="-0.22232487565440304" LOG_DATA="YES" LOG_EFFECT_SIZE="0.015330595211184803" MODIFIED="2016-04-20 19:56:04 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8993894468969201" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="539" TOTAL_2="536" WEIGHT="100.0" Z="0.126432664756447">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Vitamin A</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin A]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no vitamin A]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.7905484050800495" CI_START="0.5993425680134464" EFFECT_SIZE="1.0359304413198107" ESTIMABLE="YES" ESTIMATE="0.0353" LOG_CI_END="0.25298606607677254" LOG_CI_START="-0.22232487565440304" LOG_EFFECT_SIZE="0.015330595211184803" MODIFIED="2016-03-31 14:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="490" SE="0.2792" STUDY_ID="STD-Fawzi-1998" TOTAL_1="539" TOTAL_2="536" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2016-04-20 19:56:48 +0100" MODIFIED_BY="Heather Maxwell" NO="9">
<NAME>Multivitamin plus iron and folic acid versus iron and folic acid</NAME>
<IV_OUTCOME CHI2="12.996849383112492" CI_END="1.0041339538912564" CI_START="0.9267721439240482" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.9646778618972921" ESTIMABLE="YES" I2="30.752448268776693" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.0017916526050740606" LOG_CI_START="-0.03302702831525473" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.01561768785509034" MODIFIED="2016-04-20 19:56:20 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.1627489295413258" P_Q="1.0" P_Z="0.07870368323543214" Q="0.0" RANDOM="NO" SCALE="2.68" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47778" TOTAL_2="47170" WEIGHT="100.0" Z="1.7582576311725824">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron/folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.28860035414868" CI_START="0.8931893946184979" EFFECT_SIZE="1.0728299819762876" ESTIMABLE="YES" ESTIMATE="0.0703" LOG_CI_END="0.11011824636838763" LOG_CI_START="-0.049056442212790444" LOG_EFFECT_SIZE="0.030530902077798645" MODIFIED="2016-04-02 09:19:54 +0100" MODIFIED_BY="[Empty name]" ORDER="553" SE="0.0935" STUDY_ID="STD-Bhutta-2009" TOTAL_1="947" TOTAL_2="1038" WEIGHT="4.784941258762452"/>
<IV_DATA CI_END="1.0370461902920025" CI_START="0.7062567277953657" EFFECT_SIZE="0.8558158966321436" ESTIMABLE="YES" ESTIMATE="-0.1557" LOG_CI_END="0.01579810040271954" LOG_CI_START="-0.15103740206739222" LOG_EFFECT_SIZE="-0.06761965083233631" MODIFIED="2016-04-02 09:48:17 +0100" MODIFIED_BY="[Empty name]" ORDER="554" SE="0.098" STUDY_ID="STD-Fawzi-2007" TOTAL_1="4214" TOTAL_2="4214" WEIGHT="4.355596909560188"/>
<IV_DATA CI_END="1.3690385061738977" CI_START="0.3990339918406603" EFFECT_SIZE="0.7391162967369511" ESTIMABLE="YES" ESTIMATE="-0.3023" LOG_CI_END="0.1364156634617192" LOG_CI_START="-0.3989901072204252" LOG_EFFECT_SIZE="-0.13128722187935304" MODIFIED="2016-04-02 09:48:17 +0100" MODIFIED_BY="[Empty name]" ORDER="555" SE="0.3145" STUDY_ID="STD-Osrin-2005" TOTAL_1="600" TOTAL_2="600" WEIGHT="0.4229203011762284"/>
<IV_DATA CI_END="2.2197422514064824" CI_START="0.8413133584792144" EFFECT_SIZE="1.3665646009204981" ESTIMABLE="YES" ESTIMATE="0.3123" LOG_CI_END="0.34630254864406246" LOG_CI_START="-0.0750422152472913" LOG_EFFECT_SIZE="0.13563016669838557" MODIFIED="2016-04-02 09:48:18 +0100" MODIFIED_BY="[Empty name]" ORDER="556" SE="0.2475" STUDY_ID="STD-Roberfroid-2008" TOTAL_1="714" TOTAL_2="712" WEIGHT="0.6828879129789376"/>
<IV_DATA CI_END="0.9256459018182813" CI_START="0.0034001474281223393" EFFECT_SIZE="0.05610109207867001" ESTIMABLE="YES" ESTIMATE="-2.8806" LOG_CI_END="-0.03355511731029877" LOG_CI_START="-2.4685022518307154" LOG_EFFECT_SIZE="-1.2510286845705072" MODIFIED="2016-04-02 09:48:18 +0100" MODIFIED_BY="[Empty name]" ORDER="550" SE="1.4303" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.020447751336726258"/>
<IV_DATA CI_END="1.0087761617518372" CI_START="0.8004846877481834" EFFECT_SIZE="0.8986155300503826" ESTIMABLE="YES" ESTIMATE="-0.1069" LOG_CI_END="0.0037948109342188854" LOG_CI_START="-0.0966469711651341" LOG_EFFECT_SIZE="-0.046426080115457645" MODIFIED="2016-04-02 09:19:51 +0100" MODIFIED_BY="[Empty name]" ORDER="552" SE="0.059" STUDY_ID="STD-Summit-2008" TOTAL_1="15804" TOTAL_2="15486" WEIGHT="12.016993024825064"/>
<IV_DATA CI_END="1.3695802545867595" CI_START="0.383696152409038" EFFECT_SIZE="0.7249156324016819" ESTIMABLE="YES" ESTIMATE="-0.3217" LOG_CI_END="0.13658748609926613" LOG_CI_START="-0.4160125557558183" LOG_EFFECT_SIZE="-0.13971253482827606" MODIFIED="2016-04-02 09:19:51 +0100" MODIFIED_BY="[Empty name]" ORDER="549" SE="0.3246" STUDY_ID="STD-Sunawang-2009" TOTAL_1="432" TOTAL_2="411" WEIGHT="0.39701123900363317"/>
<IV_DATA CI_END="1.2613736737159025" CI_START="0.6112792758169052" EFFECT_SIZE="0.8780954309205613" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.10084376253868259" LOG_CI_START="-0.21376032783352814" LOG_EFFECT_SIZE="-0.056458282647422746" MODIFIED="2016-04-02 09:48:19 +0100" MODIFIED_BY="[Empty name]" ORDER="551" SE="0.1848" STUDY_ID="STD-Tofail-2008" TOTAL_1="740" TOTAL_2="739" WEIGHT="1.2248866423809073"/>
<IV_DATA CI_END="1.020861769684316" CI_START="0.9299289042202581" EFFECT_SIZE="0.9743350896087494" ESTIMABLE="YES" ESTIMATE="-0.026" LOG_CI_END="0.008966940199029008" LOG_CI_START="-0.03155025325799812" LOG_EFFECT_SIZE="-0.011291656529484528" MODIFIED="2016-04-02 09:19:52 +0100" MODIFIED_BY="[Empty name]" ORDER="548" SE="0.0238" STUDY_ID="STD-West-2014" TOTAL_1="22405" TOTAL_2="22162" WEIGHT="73.8492209579409"/>
<IV_DATA CI_END="1.4353878391645565" CI_START="0.840603591489164" EFFECT_SIZE="1.0984498954351976" ESTIMABLE="YES" ESTIMATE="0.0939" LOG_CI_END="0.15696926249954318" LOG_CI_START="-0.0754087587981125" LOG_EFFECT_SIZE="0.04078025185071531" MODIFIED="2016-04-02 09:19:53 +0100" MODIFIED_BY="[Empty name]" ORDER="547" SE="0.1365" STUDY_ID="STD-Zagre-2007" TOTAL_1="1893" TOTAL_2="1777" WEIGHT="2.2450940020349686"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.787349194411586" CI_END="1.03248171456009" CI_START="0.9372477661293642" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.9837129563754156" ESTIMABLE="YES" I2="8.044560164065155" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.013882368961879485" LOG_CI_START="-0.0281455860185446" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.007131608528332548" MODIFIED="2016-04-20 19:56:33 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.3679734700919227" P_Q="1.0" P_Z="0.5059469911679257" Q="0.0" RANDOM="NO" SCALE="5.36" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47778" TOTAL_2="47170" WEIGHT="100.0" Z="0.6651618368717244">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron/folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.3070960999540686" CI_START="0.8419724718278685" EFFECT_SIZE="1.0490657435046165" ESTIMABLE="YES" ESTIMATE="0.0479" LOG_CI_END="0.11630751883187258" LOG_CI_START="-0.07470210746554104" LOG_EFFECT_SIZE="0.020802705683165747" MODIFIED="2016-04-02 09:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="545" SE="0.1122" STUDY_ID="STD-Bhutta-2009" TOTAL_1="947" TOTAL_2="1038" WEIGHT="4.841344719755547"/>
<IV_DATA CI_END="1.4142748249933481" CI_START="0.6536279922484403" EFFECT_SIZE="0.9614622272080772" ESTIMABLE="YES" ESTIMATE="-0.0393" LOG_CI_END="0.15053381072020738" LOG_CI_START="-0.1846693569978029" LOG_EFFECT_SIZE="-0.017067773138797798" MODIFIED="2016-04-02 09:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="546" SE="0.1969" STUDY_ID="STD-Fawzi-2007" TOTAL_1="4214" TOTAL_2="4214" WEIGHT="1.5720280410828849"/>
<IV_DATA CI_END="2.05377987719934" CI_START="0.07790369162901657" EFFECT_SIZE="0.3999962927668416" ESTIMABLE="YES" ESTIMATE="-0.9163" LOG_CI_END="0.3125538943534906" LOG_CI_START="-1.10844196188939" LOG_EFFECT_SIZE="-0.3979440337679496" MODIFIED="2016-04-02 09:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="547" SE="0.8347" STUDY_ID="STD-Osrin-2005" TOTAL_1="600" TOTAL_2="600" WEIGHT="0.08747639838583364"/>
<IV_DATA CI_END="2.0245247620624633" CI_START="0.4911847310568567" EFFECT_SIZE="0.9972039163438929" ESTIMABLE="YES" ESTIMATE="-0.0028" LOG_CI_END="0.30632309301419836" LOG_CI_START="-0.30875514211285654" LOG_EFFECT_SIZE="-0.0012160245493291176" MODIFIED="2016-04-02 09:48:37 +0100" MODIFIED_BY="[Empty name]" ORDER="548" SE="0.3613" STUDY_ID="STD-Roberfroid-2008" TOTAL_1="714" TOTAL_2="712" WEIGHT="0.46689131745664725"/>
<IV_DATA CI_END="1.0345188993333172" CI_START="0.0038000673562131465" EFFECT_SIZE="0.06269961322641546" ESTIMABLE="YES" ESTIMATE="-2.7694" LOG_CI_END="0.014738429077342732" LOG_CI_START="-2.420208705443074" LOG_EFFECT_SIZE="-1.2027351381828657" MODIFIED="2016-04-02 09:48:36 +0100" MODIFIED_BY="[Empty name]" ORDER="549" SE="1.4303" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.02979184799990082"/>
<IV_DATA CI_END="1.0563853982288558" CI_START="0.76870109423051" EFFECT_SIZE="0.9011351793974389" ESTIMABLE="YES" ESTIMATE="-0.1041" LOG_CI_END="0.023822389588596327" LOG_CI_START="-0.11424250072085332" LOG_EFFECT_SIZE="-0.045210055566128525" MODIFIED="2016-04-02 09:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="542" SE="0.0811" STUDY_ID="STD-Summit-2008" TOTAL_1="15804" TOTAL_2="15486" WEIGHT="9.266378002503707"/>
<IV_DATA CI_END="1.3981081558717303" CI_START="0.24519045439921788" EFFECT_SIZE="0.5854936157102331" ESTIMABLE="YES" ESTIMATE="-0.5353" LOG_CI_END="0.14554076917890676" LOG_CI_START="-0.6104964415045282" LOG_EFFECT_SIZE="-0.23247783616281073" MODIFIED="2016-04-02 09:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="550" SE="0.4441" STUDY_ID="STD-Sunawang-2009" TOTAL_1="432" TOTAL_2="411" WEIGHT="0.30902255178670174"/>
<IV_DATA CI_END="1.134127872562713" CI_START="0.472808913092554" EFFECT_SIZE="0.7322743794059348" ESTIMABLE="YES" ESTIMATE="-0.3116" LOG_CI_END="0.054662023884502635" LOG_CI_START="-0.32531434500660916" LOG_EFFECT_SIZE="-0.1353261605610533" MODIFIED="2016-04-02 09:48:36 +0100" MODIFIED_BY="[Empty name]" ORDER="541" SE="0.2232" STUDY_ID="STD-Tofail-2008" TOTAL_1="740" TOTAL_2="739" WEIGHT="1.2233855323240523"/>
<IV_DATA CI_END="1.0536907590404245" CI_START="0.9460129606249976" EFFECT_SIZE="0.9984012793176064" ESTIMABLE="YES" ESTIMATE="-0.0016" LOG_CI_END="0.02271317126736338" LOG_CI_START="-0.024102913609453762" LOG_EFFECT_SIZE="-6.948711710451821E-4" MODIFIED="2016-04-02 09:20:35 +0100" MODIFIED_BY="[Empty name]" ORDER="544" SE="0.0275" STUDY_ID="STD-West-2014" TOTAL_1="22405" TOTAL_2="22162" WEIGHT="80.59096074293873"/>
<IV_DATA CI_END="1.4564718915358728" CI_START="0.6797589706349532" EFFECT_SIZE="0.9950124791926823" ESTIMABLE="YES" ESTIMATE="-0.0050" LOG_CI_END="0.16330210759145172" LOG_CI_START="-0.16764505241048427" LOG_EFFECT_SIZE="-0.0021714724095162562" MODIFIED="2016-04-02 09:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="543" SE="0.1944" STUDY_ID="STD-Zagre-2007" TOTAL_1="1893" TOTAL_2="1777" WEIGHT="1.6127208457660012"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="10.239497060749162" CI_END="0.9923491972478339" CI_START="0.8502966467564974" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.9185810768959565" ESTIMABLE="YES" I2="12.105058025754985" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-0.003335477289471845" LOG_CI_START="-0.0704295336107618" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.03688250545011684" MODIFIED="2016-04-20 19:56:48 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.3314469468820559" P_Q="1.0" P_Z="0.031174580502733185" Q="0.0" RANDOM="NO" SCALE="14.05" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40191" TOTAL_2="39660" WEIGHT="99.99999999999999" Z="2.1548371437156075">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron/folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.7113267645558516" CI_START="0.7949556473539094" EFFECT_SIZE="1.1663742435220217" ESTIMABLE="YES" ESTIMATE="0.1539" LOG_CI_END="0.2333329426177363" LOG_CI_START="-0.09965710108791534" LOG_EFFECT_SIZE="0.06683792076491046" MODIFIED="2016-04-02 13:34:59 +0100" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.1956" STUDY_ID="STD-Bhutta-2009" TOTAL_1="743" TOTAL_2="832" WEIGHT="4.059808990225394"/>
<IV_DATA CI_END="1.028926346176008" CI_START="0.6568393071186772" EFFECT_SIZE="0.8220944400118526" ESTIMABLE="YES" ESTIMATE="-0.1959" LOG_CI_END="0.012384287693253941" LOG_CI_START="-0.18254086570294806" LOG_EFFECT_SIZE="-0.085078289004847" MODIFIED="2016-03-31 07:07:39 +0100" MODIFIED_BY="[Empty name]" ORDER="572" SE="0.1145" STUDY_ID="STD-Fawzi-2007" TOTAL_1="4214" TOTAL_2="4214" WEIGHT="11.847653072082517"/>
<IV_DATA CI_END="1.6375473194289771" CI_START="0.4240094291352339" EFFECT_SIZE="0.8332679665587854" ESTIMABLE="YES" ESTIMATE="-0.1824" LOG_CI_END="0.2141938584470077" LOG_CI_START="-0.37262448544531396" LOG_EFFECT_SIZE="-0.07921531349915312" MODIFIED="2016-03-31 07:07:39 +0100" MODIFIED_BY="[Empty name]" ORDER="571" SE="0.3447" STUDY_ID="STD-Osrin-2005" TOTAL_1="600" TOTAL_2="600" WEIGHT="1.307256274598168"/>
<IV_DATA CI_END="3.665230472615397" CI_START="0.911839566677488" EFFECT_SIZE="1.828141724791256" ESTIMABLE="YES" ESTIMATE="0.6033" LOG_CI_END="0.5641012886191842" LOG_CI_START="-0.040081566754720604" LOG_EFFECT_SIZE="0.26200986093223183" MODIFIED="2016-03-31 07:07:39 +0100" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.3549" STUDY_ID="STD-Roberfroid-2008" TOTAL_1="714" TOTAL_2="712" WEIGHT="1.2331937164070426"/>
<IV_DATA CI_END="8.374320585338136" CI_START="0.015101367893636251" EFFECT_SIZE="0.3556173449347521" ESTIMABLE="YES" ESTIMATE="-1.0339" LOG_CI_END="0.9229495825139327" LOG_CI_START="-1.8209837121934769" LOG_EFFECT_SIZE="-0.4490170648397721" MODIFIED="2016-03-31 07:07:39 +0100" MODIFIED_BY="[Empty name]" ORDER="573" SE="1.6118" STUDY_ID="STD-Rumiris-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.05978895997839771"/>
<IV_DATA CI_END="1.0638440827833637" CI_START="0.7543575331667278" EFFECT_SIZE="0.8958341352965282" ESTIMABLE="YES" ESTIMATE="-0.11" LOG_CI_END="0.026877982330585155" LOG_CI_START="-0.12242276834930058" LOG_EFFECT_SIZE="-0.04777239300935771" MODIFIED="2016-04-02 13:34:52 +0100" MODIFIED_BY="[Empty name]" ORDER="567" SE="0.0877" STUDY_ID="STD-Summit-2008" TOTAL_1="15804" TOTAL_2="15486" WEIGHT="20.195011979559972"/>
<IV_DATA CI_END="2.5117259882429233" CI_START="0.3603894014064216" EFFECT_SIZE="0.951419689411471" ESTIMABLE="YES" ESTIMATE="-0.0498" LOG_CI_END="0.39997225915553625" LOG_CI_START="-0.44322798955310017" LOG_EFFECT_SIZE="-0.021627865198781928" MODIFIED="2016-04-02 13:34:53 +0100" MODIFIED_BY="[Empty name]" ORDER="568" SE="0.4953" STUDY_ID="STD-Sunawang-2009" TOTAL_1="432" TOTAL_2="411" WEIGHT="0.6331500505652378"/>
<IV_DATA CI_END="2.801007089209322" CI_START="0.6825093671663622" EFFECT_SIZE="1.3826473071194796" ESTIMABLE="YES" ESTIMATE="0.324" LOG_CI_END="0.44731420800264476" LOG_CI_START="-0.1658913837293375" LOG_EFFECT_SIZE="0.1407114121366536" MODIFIED="2016-03-31 07:07:39 +0100" MODIFIED_BY="[Empty name]" ORDER="570" SE="0.3602" STUDY_ID="STD-Tofail-2008" TOTAL_1="740" TOTAL_2="739" WEIGHT="1.197170164334869"/>
<IV_DATA CI_END="0.9929073670720425" CI_START="0.8069592603838851" EFFECT_SIZE="0.8951177545787851" ESTIMABLE="YES" ESTIMATE="-0.1108" LOG_CI_END="-0.0030912669588144186" LOG_CI_START="-0.09314839023094619" LOG_EFFECT_SIZE="-0.04811982859488032" MODIFIED="2016-04-02 13:34:53 +0100" MODIFIED_BY="[Empty name]" ORDER="569" SE="0.0529" STUDY_ID="STD-West-2014" TOTAL_1="15022" TOTAL_2="14858" WEIGHT="55.50498093141098"/>
<IV_DATA CI_END="1.7926103773875053" CI_START="0.824916698765329" EFFECT_SIZE="1.2160403918813598" ESTIMABLE="YES" ESTIMATE="0.1956" LOG_CI_END="0.25348590621681755" LOG_CI_START="-0.08358990489626543" LOG_EFFECT_SIZE="0.08494800066027601" MODIFIED="2016-04-02 13:34:54 +0100" MODIFIED_BY="[Empty name]" ORDER="566" SE="0.198" STUDY_ID="STD-Zagre-2007" TOTAL_1="1893" TOTAL_2="1777" WEIGHT="3.9619858608374092"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.075900051377909" CI_START="0.14132477744725452" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.8497816897773104" LOG_CI_START="-0.8497816897773105" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2016-04-02 13:58:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="600" TOTAL_2="600" WEIGHT="100.0" Z="0.0">
<NAME>Congenital malformation</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron/folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.075900051377909" CI_START="0.14132477744725452" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8497816897773104" LOG_CI_START="-0.8497816897773105" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-03-31 07:08:35 +0100" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.9983319421247958" STUDY_ID="STD-Osrin-2005" TOTAL_1="600" TOTAL_2="600" VAR="0.9966666666666666" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2016-04-20 19:58:19 +0100" MODIFIED_BY="Heather Maxwell" NO="10">
<NAME>Multivitamin without folic acid versus no multivitamin/folic acid</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.6973564941540978" CI_START="0.34261720672738943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.4888009146066342" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-0.1565451503614943" LOG_CI_START="-0.46519082993120103" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.31086799014634764" MODIFIED="2016-04-20 19:57:49 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="7.875671926073671E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="454" WEIGHT="100.0" Z="3.94815223386652">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.6973564941540978" CI_START="0.34261720672738943" EFFECT_SIZE="0.4888009146066342" ESTIMABLE="YES" ESTIMATE="-0.7158" LOG_CI_END="-0.1565451503614943" LOG_CI_START="-0.46519082993120103" LOG_EFFECT_SIZE="-0.31086799014634764" MODIFIED="2016-03-31 14:22:02 +0100" MODIFIED_BY="[Empty name]" ORDER="545" SE="0.1813" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="454" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.3396500875377275" CI_START="0.5890710637033171" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8883406452797773" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.12699137680048875" LOG_CI_START="-0.22983231011517882" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.051420466657344996" MODIFIED="2016-04-20 19:58:08 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5721516520919014" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="454" WEIGHT="99.99999999999999" Z="0.5648854961832062">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.3396500875377275" CI_START="0.5890710637033171" EFFECT_SIZE="0.8883406452797773" ESTIMABLE="YES" ESTIMATE="-0.1184" LOG_CI_END="0.12699137680048875" LOG_CI_START="-0.22983231011517882" LOG_EFFECT_SIZE="-0.051420466657344996" MODIFIED="2016-03-31 14:22:27 +0100" MODIFIED_BY="[Empty name]" ORDER="551" SE="0.2096" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="454" WEIGHT="99.99999999999999"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="2.770925996306593" CI_START="0.007400693558584932" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.14320186511418675" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.4426249271446063" LOG_CI_START="-2.130727578302546" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.84405132557897" MODIFIED="2016-04-20 19:58:19 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.19853949420694023" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="454" WEIGHT="100.0" Z="1.285723736438211">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.770925996306593" CI_START="0.007400693558584932" EFFECT_SIZE="0.14320186511418675" ESTIMABLE="YES" ESTIMATE="-1.9435" LOG_CI_END="0.4426249271446063" LOG_CI_START="-2.130727578302546" LOG_EFFECT_SIZE="-0.84405132557897" MODIFIED="2016-03-31 06:52:55 +0100" MODIFIED_BY="[Empty name]" ORDER="557" SE="1.5116" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="454" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="8.650738969403063E-32" CI_END="4.8644474728152325" CI_START="0.5285934153286957" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6035320088300222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="100.0" I2_Q="100.0" ID="CMP-010.04" LOG_CI_END="0.6870335181635067" LOG_CI_START="-0.2768782511631129" LOG_EFFECT_SIZE="0.20507763350019687" METHOD="MH" MODIFIED="2016-04-06 10:48:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.40428851252980724" Q="9.611932188225623E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="454" WEIGHT="100.0" Z="0.8339866541434304">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.864447472815231" CI_START="0.5285934153286957" EFFECT_SIZE="1.603532008830022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6870335181635064" LOG_CI_START="-0.2768782511631129" LOG_EFFECT_SIZE="0.2050776335001968" MODIFIED="2016-03-31 06:54:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16602" O_E="0.0" SE="0.5662065447426672" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="454" VAR="0.32058985130943" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2016-04-20 19:59:05 +0100" MODIFIED_BY="Heather Maxwell" NO="11">
<NAME>Multivitamin with/without folic acid versus no multivitamin/folic acid</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.2735519424148194" CI_START="0.6486838586141523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.9089183616536712" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.10501666256551614" LOG_CI_START="-0.18796690860903728" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04147512302176054" MODIFIED="2016-04-20 19:58:44 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5789562678268048" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0" Z="0.5549099360836722">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2735519424148194" CI_START="0.6486838586141523" EFFECT_SIZE="0.9089183616536712" ESTIMABLE="YES" ESTIMATE="-0.0955" LOG_CI_END="0.10501666256551614" LOG_CI_START="-0.18796690860903728" LOG_EFFECT_SIZE="-0.04147512302176054" MODIFIED="2016-03-31 14:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="539" SE="0.1721" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.3415338523479539" CI_START="0.6703109128105441" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.948285179222792" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.12760163615996684" LOG_CI_START="-0.17372371013809218" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.023061036989062658" MODIFIED="2016-04-20 19:58:54 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7641771560338929" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0" Z="0.30000000000000004">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.3415338523479539" CI_START="0.6703109128105441" EFFECT_SIZE="0.948285179222792" ESTIMABLE="YES" ESTIMATE="-0.0531" LOG_CI_END="0.12760163615996684" LOG_CI_START="-0.17372371013809218" LOG_EFFECT_SIZE="-0.023061036989062658" MODIFIED="2016-03-31 14:23:26 +0100" MODIFIED_BY="[Empty name]" ORDER="539" SE="0.177" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.9754874521420067" CI_START="0.0554976179421914" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.3311115338803078" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.295674275484034" LOG_CI_START="-1.2557256571793625" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.4800256908476642" MODIFIED="2016-04-20 19:59:05 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.22517469513781518" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0" Z="1.2128826950510259">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.9754874521420067" CI_START="0.0554976179421914" EFFECT_SIZE="0.3311115338803078" ESTIMABLE="YES" ESTIMATE="-1.1053" LOG_CI_END="0.295674275484034" LOG_CI_START="-1.2557256571793625" LOG_EFFECT_SIZE="-0.4800256908476642" MODIFIED="2016-03-31 06:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="565" SE="0.9113" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.2596266994613154" CI_START="0.7505582026129846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.986870897155361" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.7209549213177693" LOG_CI_START="-0.12461562441529954" LOG_EFFECT_SIZE="0.2981696484512349" METHOD="MH" MODIFIED="2016-04-06 10:48:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.16688999487709966" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="914" TOTAL_2="454" WEIGHT="100.0" Z="1.3822661519997517">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.2596266994613154" CI_START="0.7505582026129846" EFFECT_SIZE="1.986870897155361" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.7209549213177693" LOG_CI_START="-0.12461562441529954" LOG_EFFECT_SIZE="0.2981696484512349" MODIFIED="2016-03-31 06:56:42 +0100" MODIFIED_BY="[Empty name]" ORDER="16603" O_E="0.0" SE="0.4966923242053112" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="454" VAR="0.24670326492447392" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2016-04-20 19:59:52 +0100" MODIFIED_BY="Heather Maxwell" NO="12">
<NAME>Multivitamin plus folic acid versus folic acid</NAME>
<IV_OUTCOME CHI2="0.007265135837296363" CI_END="1.230386080911134" CI_START="0.8759162140619691" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.0381305880409382" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.09004140940657536" LOG_CI_START="-0.05753743436939885" LOG_DATA="YES" LOG_EFFECT_SIZE="0.016251987518588255" MODIFIED="2016-04-20 19:59:24 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.9963740218817224" P_Q="1.0" P_Z="0.6659750648562244" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2453" TOTAL_2="2559" WEIGHT="100.0" Z="0.431678544141205">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.4062363951490546" CI_START="0.41558676529703764" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.3813382913602555" LOG_CI_START="-0.38133829136025543" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-03-31 06:06:56 +0100" MODIFIED_BY="[Empty name]" ORDER="542" SE="0.448" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="93" WEIGHT="3.74427193781059"/>
<IV_DATA CI_END="1.536994412654677" CI_START="0.7042451004819953" EFFECT_SIZE="1.0403945331364723" ESTIMABLE="YES" ESTIMATE="0.0396" LOG_CI_END="0.18667228873744665" LOG_CI_START="-0.15227616577070904" LOG_EFFECT_SIZE="0.017198061483368776" MODIFIED="2016-03-31 14:23:49 +0100" MODIFIED_BY="[Empty name]" ORDER="543" SE="0.1991" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="449" WEIGHT="18.957492417696226"/>
<IV_DATA CI_END="1.261059762593025" CI_START="0.8567985528428446" EFFECT_SIZE="1.039458599290056" ESTIMABLE="YES" ESTIMATE="0.0387" LOG_CI_END="0.10073566861064064" LOG_CI_START="-0.06712127571132896" LOG_EFFECT_SIZE="0.016807196449655882" MODIFIED="2016-04-02 13:35:17 +0100" MODIFIED_BY="[Empty name]" ORDER="544" SE="0.0986" STUDY_ID="STD-Zeng-2008" TOTAL_1="1899" TOTAL_2="2017" WEIGHT="77.29823564449318"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.17957200873032375" CI_END="1.1843365373145536" CI_START="0.796344289639257" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.9711537666618894" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.07347512766649794" LOG_CI_START="-0.0988991297954792" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.012712001064490644" MODIFIED="2016-04-20 19:59:37 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.9141268286066989" P_Q="1.0" P_Z="0.7725193676239068" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2453" TOTAL_2="2559" WEIGHT="99.99999999999999" Z="0.28908103361468973">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.4062363951490546" CI_START="0.41558676529703764" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.3813382913602555" LOG_CI_START="-0.38133829136025543" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-03-31 06:41:09 +0100" MODIFIED_BY="[Empty name]" ORDER="537" SE="0.448" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="93" WEIGHT="5.108154128639057"/>
<IV_DATA CI_END="1.5564890141787227" CI_START="0.6996097126082865" EFFECT_SIZE="1.0435204031965697" ESTIMABLE="YES" ESTIMATE="0.0426" LOG_CI_END="0.19214605974490914" LOG_CI_START="-0.1551441698867521" LOG_EFFECT_SIZE="0.01850094492907852" MODIFIED="2016-03-31 14:24:30 +0100" MODIFIED_BY="[Empty name]" ORDER="536" SE="0.204" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="449" WEIGHT="24.63540384069525"/>
<IV_DATA CI_END="1.1974133029763447" CI_START="0.7457508995650899" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.0566" LOG_CI_END="0.07824407874463052" LOG_CI_START="-0.12740621409607866" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2016-03-31 14:24:30 +0100" MODIFIED_BY="[Empty name]" ORDER="538" SE="0.1208" STUDY_ID="STD-Zeng-2008" TOTAL_1="1899" TOTAL_2="2017" WEIGHT="70.25644203066568"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.11582221224947581" CI_END="1.8766134187908734" CI_START="0.9259437851626265" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.3181951798888503" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.273374817438943" LOG_CI_START="-0.03341537890634699" LOG_DATA="YES" LOG_EFFECT_SIZE="0.11997971926629795" MODIFIED="2016-04-20 19:59:52 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.943733841038347" P_Q="1.0" P_Z="0.12527385812617553" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2086" TOTAL_2="2230" WEIGHT="100.0" Z="1.5330081041605668">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="50.00325549166778" CI_START="0.019998697888113176" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.6989982802568526" LOG_CI_START="-1.6989982802568526" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-03-31 06:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="563" SE="1.996" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="93" WEIGHT="0.8151491591022964"/>
<IV_DATA CI_END="6.8850477241862915" CI_START="0.13779998024341047" EFFECT_SIZE="0.9740428329225616" ESTIMABLE="YES" ESTIMATE="-0.0263" LOG_CI_END="0.8379069549457278" LOG_CI_START="-0.8607508446938388" LOG_EFFECT_SIZE="-0.011421944874055526" MODIFIED="2016-03-31 06:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="564" SE="0.9978" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="449" WEIGHT="3.2619038817148525"/>
<IV_DATA CI_END="1.9146471947541759" CI_START="0.9307790334063886" EFFECT_SIZE="1.3349582260308916" ESTIMABLE="YES" ESTIMATE="0.2889" LOG_CI_END="0.28208875977338294" LOG_CI_START="-0.03115340812968407" LOG_EFFECT_SIZE="0.12546767582184945" MODIFIED="2016-03-31 06:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="562" SE="0.184" STUDY_ID="STD-Zeng-2008" TOTAL_1="1532" TOTAL_2="1688" WEIGHT="95.92294695918285"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.019168988304390896" CI_END="4.043655485334321" CI_START="0.7235417519851506" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.710483432916893" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.6067741471188111" LOG_CI_START="-0.14053640285375263" LOG_EFFECT_SIZE="0.2331188721325292" METHOD="MH" MODIFIED="2016-04-06 10:48:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8898831186593837" P_Q="1.0" P_Z="0.22140635707748957" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="554" TOTAL_2="542" WEIGHT="100.0" Z="1.2227971183148154">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.67876755819227" CI_START="0.1845123339812934" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3360345888492646" LOG_CI_START="-0.7339745975213021" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2016-03-31 06:58:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16604" O_E="0.0" SE="1.2159336427848002" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="93" VAR="1.478494623655914" WEIGHT="12.357414448669202"/>
<DICH_DATA CI_END="4.2024463086145225" CI_START="0.6633688429997864" EFFECT_SIZE="1.6696622249767585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.623502173504395" LOG_CI_START="-0.17824493021030904" LOG_EFFECT_SIZE="0.222628621647043" MODIFIED="2016-03-31 06:58:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16605" O_E="0.0" SE="0.47095021743418714" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="449" VAR="0.22179410730130816" WEIGHT="87.6425855513308"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2016-04-20 20:05:03 +0100" MODIFIED_BY="Heather Maxwell" NO="13">
<NAME>Multivitamin without folic acid versus folic acid</NAME>
<IV_OUTCOME CHI2="0.047803179232114655" CI_END="1.2995939510633898" CI_START="0.6174031447891293" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.8957529750636983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.11380768126181492" LOG_CI_START="-0.20943116273684007" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04781174073751259" MODIFIED="2016-04-20 20:04:41 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.8269309736920785" P_Q="1.0" P_Z="0.5620396980876003" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="548" TOTAL_2="542" WEIGHT="99.99999999999999" Z="0.5798145341967694">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.3569109785343576" CI_START="0.40658923480516934" EFFECT_SIZE="0.978925242940536" ESTIMABLE="YES" ESTIMATE="-0.0213" LOG_CI_END="0.3723431793586806" LOG_CI_START="-0.39084412428775916" LOG_EFFECT_SIZE="-0.009250472464539285" MODIFIED="2016-03-31 14:25:05 +0100" MODIFIED_BY="[Empty name]" ORDER="537" SE="0.4483" STUDY_ID="STD-Kirke-1992" TOTAL_1="95" TOTAL_2="93" WEIGHT="17.93844594057983"/>
<IV_DATA CI_END="1.3248621961973606" CI_START="0.582568530718894" EFFECT_SIZE="0.8785345884162464" ESTIMABLE="YES" ESTIMATE="-0.1295" LOG_CI_END="0.12217070805136274" LOG_CI_START="-0.23465297886430497" LOG_EFFECT_SIZE="-0.056241135406471104" MODIFIED="2016-03-31 14:25:05 +0100" MODIFIED_BY="[Empty name]" ORDER="538" SE="0.2096" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="449" WEIGHT="82.06155405942016"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.12956819829868807" CI_END="1.3060983925614515" CI_START="0.6099640651120035" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.8925654513608716" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.11597589496119443" LOG_CI_START="-0.21469574987983014" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04935992745931783" MODIFIED="2016-04-20 20:04:51 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.7188802476270664" P_Q="1.0" P_Z="0.5584573412912626" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="548" TOTAL_2="542" WEIGHT="100.0" Z="0.585134417233045">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.959886622962703" CI_START="0.29579559337105255" EFFECT_SIZE="0.761397285639528" ESTIMABLE="YES" ESTIMATE="-0.2726" LOG_CI_END="0.2922309486800201" LOG_CI_START="-0.529008300213673" LOG_EFFECT_SIZE="-0.11838867576682643" MODIFIED="2016-03-31 14:25:33 +0100" MODIFIED_BY="[Empty name]" ORDER="553" SE="0.4824" STUDY_ID="STD-Kirke-1992" TOTAL_1="95" TOTAL_2="93" WEIGHT="16.212669034840676"/>
<IV_DATA CI_END="1.3951533778644674" CI_START="0.6072562872442794" EFFECT_SIZE="0.9204431869367559" ESTIMABLE="YES" ESTIMATE="-0.0829" LOG_CI_END="0.14462195492041285" LOG_CI_START="-0.21662798001997202" LOG_EFFECT_SIZE="-0.03600301254977957" MODIFIED="2016-03-31 14:25:33 +0100" MODIFIED_BY="[Empty name]" ORDER="552" SE="0.2122" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="449" WEIGHT="83.78733096515933"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.1508339282375823" CI_END="22.90397253010145" CI_START="0.042677572930245294" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9886788953172508" ESTIMABLE="YES" I2="53.50640573075712" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="1.3599108141424057" LOG_CI_START="-1.3698002868336345" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.004944736345614435" MODIFIED="2016-04-20 20:05:03 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.1424925432443721" P_Q="1.0" P_Z="0.99433446466359" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.7513549250000002" TOTALS="YES" TOTAL_1="548" TOTAL_2="542" WEIGHT="100.0" Z="0.007100755202252129">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="100.62980133738975" CI_START="0.2381990882451194" EFFECT_SIZE="4.895909203493641" ESTIMABLE="YES" ESTIMATE="1.5884" LOG_CI_END="2.0027266153097187" LOG_CI_START="-0.6230599051994685" LOG_EFFECT_SIZE="0.6898333550551252" MODIFIED="2016-03-31 06:59:35 +0100" MODIFIED_BY="[Empty name]" ORDER="558" SE="1.5424" STUDY_ID="STD-Kirke-1992" TOTAL_1="95" TOTAL_2="93" WEIGHT="50.114263737622075"/>
<IV_DATA CI_END="4.134821568516415" CI_START="0.009500183392986434" EFFECT_SIZE="0.19819576987963633" ESTIMABLE="YES" ESTIMATE="-1.6185" LOG_CI_END="0.6164567730226136" LOG_CI_START="-2.02226801094344" LOG_EFFECT_SIZE="-0.7029056189604131" MODIFIED="2016-03-31 17:37:18 +0100" MODIFIED_BY="[Empty name]" ORDER="559" SE="1.55" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="449" WEIGHT="49.88573626237792"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="1.5160061627417267" CI_END="3.847496845907449" CI_START="0.6699928839401241" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6055514653040752" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="34.037207461513184" I2_Q="100.0" ID="CMP-013.04" LOG_CI_END="0.5851782724786816" LOG_CI_START="-0.17392980995879892" LOG_EFFECT_SIZE="0.2056242312599413" METHOD="MH" MODIFIED="2016-04-06 10:49:07 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21822528653729878" P_Q="0.0" P_Z="0.28831979823504117" Q="1.5498084813530906E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="548" TOTAL_2="542" WEIGHT="100.0" Z="1.0618147716834834">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="41.10263394144678" CI_START="0.5828932712096476" EFFECT_SIZE="4.894736842105263" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6138696532527912" LOG_CI_START="-0.2344109580505789" LOG_EFFECT_SIZE="0.6897293476011062" MODIFIED="2016-03-31 07:00:22 +0100" MODIFIED_BY="[Empty name]" ORDER="16606" O_E="0.0" SE="1.085689180216181" STUDY_ID="STD-Kirke-1992" TOTAL_1="95" TOTAL_2="93" VAR="1.1787209960384832" WEIGHT="12.567501371293474"/>
<DICH_DATA CI_END="3.097538479755171" CI_START="0.4142509010594702" EFFECT_SIZE="1.1327656890570799" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.49101671018661086" LOG_CI_START="-0.38273653825025467" LOG_EFFECT_SIZE="0.054140085968178084" MODIFIED="2016-03-31 07:00:22 +0100" MODIFIED_BY="[Empty name]" ORDER="16607" O_E="0.0" SE="0.5132469832801496" STUDY_ID="STD-MRC-1991" TOTAL_1="453" TOTAL_2="449" VAR="0.2634224658461741" WEIGHT="87.43249862870653"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2016-04-20 20:00:50 +0100" MODIFIED_BY="Heather Maxwell" NO="14">
<NAME>Multivitamin with/without folic acid versus folic acid</NAME>
<IV_OUTCOME CHI2="0.001605426582345531" CI_END="1.3276274321956414" CI_START="0.6980752257689089" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9626961200020332" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.12307621746970085" LOG_CI_START="-0.15609777454592744" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.016510778538113304" MODIFIED="2016-04-20 20:00:16 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.9680390985860411" P_Q="1.0" P_Z="0.8166696212265083" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="542" WEIGHT="100.0" Z="0.23183055884093537">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.3569109785343576" CI_START="0.40658923480516934" EFFECT_SIZE="0.978925242940536" ESTIMABLE="YES" ESTIMATE="-0.0213" LOG_CI_END="0.3723431793586806" LOG_CI_START="-0.39084412428775916" LOG_EFFECT_SIZE="-0.009250472464539285" MODIFIED="2016-03-31 14:26:36 +0100" MODIFIED_BY="[Empty name]" ORDER="541" SE="0.4483" STUDY_ID="STD-Kirke-1992" TOTAL_1="188" TOTAL_2="93" WEIGHT="13.380971318208701"/>
<IV_DATA CI_END="1.3562799948438253" CI_START="0.6798074694415382" EFFECT_SIZE="0.9602131383963476" ESTIMABLE="YES" ESTIMATE="-0.0406" LOG_CI_END="0.13234935594918562" LOG_CI_START="-0.16761406787972968" LOG_EFFECT_SIZE="-0.017632355965272045" MODIFIED="2016-03-31 14:26:36 +0100" MODIFIED_BY="[Empty name]" ORDER="540" SE="0.1762" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="449" WEIGHT="86.61902868179129"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0646378413560687" CI_END="1.329356126873936" CI_START="0.699144841099278" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9640604120529116" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.12364134152780903" LOG_CI_START="-0.15543284260356943" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.015895750537880185" MODIFIED="2016-04-20 20:00:38 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.7993103606863031" P_Q="1.0" P_Z="0.8233217381498228" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="542" WEIGHT="99.99999999999999" Z="0.22327467270717938">
<NAME>Early of late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.9144104293961262" CI_START="0.4039720019752489" EFFECT_SIZE="0.879413562418416" ESTIMABLE="YES" ESTIMATE="-0.1285" LOG_CI_END="0.2820350515774084" LOG_CI_START="-0.39364873342654416" LOG_EFFECT_SIZE="-0.05580684092456784" MODIFIED="2016-03-31 14:26:56 +0100" MODIFIED_BY="[Empty name]" ORDER="534" SE="0.3969" STUDY_ID="STD-Kirke-1992" TOTAL_1="188" TOTAL_2="93" WEIGHT="17.0589514715478"/>
<IV_DATA CI_END="1.3980711228301315" CI_START="0.6903935254561968" EFFECT_SIZE="0.9824557248696747" ESTIMABLE="YES" ESTIMATE="-0.0177" LOG_CI_END="0.1455292654489865" LOG_CI_START="-0.1609032901083616" LOG_EFFECT_SIZE="-0.007687012329687568" MODIFIED="2016-03-31 14:26:56 +0100" MODIFIED_BY="[Empty name]" ORDER="535" SE="0.18" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="449" WEIGHT="82.94104852845219"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.7780560943400843" CI_END="4.098868788204462" CI_START="0.15320944499580824" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.7924553060907894" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.6126640160303736" LOG_CI_START="-0.8147144606621481" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1010252223158873" MODIFIED="2016-04-20 20:00:50 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.37773635785889526" P_Q="1.0" P_Z="0.7814424273757168" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="542" WEIGHT="99.99999999999999" Z="0.2774397968058259">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="51.27403030515789" CI_START="0.120611047774635" EFFECT_SIZE="2.4868080984936256" ESTIMABLE="YES" ESTIMATE="0.911" LOG_CI_END="1.7098974557376" LOG_CI_START="-0.9186129097098752" LOG_EFFECT_SIZE="0.39564227301386246" MODIFIED="2016-03-31 07:01:39 +0100" MODIFIED_BY="[Empty name]" ORDER="561" SE="1.544" STUDY_ID="STD-Kirke-1992" TOTAL_1="188" TOTAL_2="93" WEIGHT="29.488922194896634"/>
<IV_DATA CI_END="3.4768407067629514" CI_START="0.06939613958705847" EFFECT_SIZE="0.49120191673942887" ESTIMABLE="YES" ESTIMATE="-0.7109" LOG_CI_END="0.5411847937150119" LOG_CI_START="-1.1586646880850555" LOG_EFFECT_SIZE="-0.30873994718502173" MODIFIED="2016-03-31 07:01:39 +0100" MODIFIED_BY="[Empty name]" ORDER="560" SE="0.9985" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="449" WEIGHT="70.51107780510335"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.6284534795064627" CI_END="3.630468705776993" CI_START="0.7594287047062205" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.660446369716496" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="0.559962697540827" LOG_CI_START="-0.1195129915260686" LOG_EFFECT_SIZE="0.22022485300737918" METHOD="MH" MODIFIED="2016-04-06 10:49:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.42792337557205395" P_Q="1.0" P_Z="0.2039109577609587" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="542" WEIGHT="100.0" Z="1.270487781506472">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.731592036663862" CI_START="0.43238585293623166" EFFECT_SIZE="3.4627659574468086" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4429748026067526" LOG_CI_START="-0.3641285239977283" LOG_EFFECT_SIZE="0.5394231393045121" MODIFIED="2016-03-31 07:02:47 +0100" MODIFIED_BY="[Empty name]" ORDER="16608" O_E="0.0" SE="1.0615014393532067" STUDY_ID="STD-Kirke-1992" TOTAL_1="188" TOTAL_2="93" VAR="1.1267853057489297" WEIGHT="12.47486711825526"/>
<DICH_DATA CI_END="3.2946463927766256" CI_START="0.5979369506309226" EFFECT_SIZE="1.403563613629259" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.517808809550142" LOG_CI_START="-0.2233446077117097" LOG_EFFECT_SIZE="0.1472321009192161" MODIFIED="2016-03-31 07:02:47 +0100" MODIFIED_BY="[Empty name]" ORDER="16609" O_E="0.0" SE="0.43535718606819623" STUDY_ID="STD-MRC-1991" TOTAL_1="914" TOTAL_2="449" VAR="0.18953587946121803" WEIGHT="87.52513288174474"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2016-04-20 20:01:17 +0100" MODIFIED_BY="Heather Maxwell" NO="15">
<NAME>Multivitamin with/without vitamin A versus vitamin A or placebo</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.9150725996452868" CI_START="0.38842773878796677" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.5961875382017349" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-0.03854444869359434" LOG_CI_START="-0.4106897633871293" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22461710604036186" MODIFIED="2016-04-20 20:01:17 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.017983133067791132" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="537" TOTAL_2="537" WEIGHT="99.99999999999999" Z="2.3659652333028363">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9150725996452868" CI_START="0.38842773878796677" EFFECT_SIZE="0.5961875382017349" ESTIMABLE="YES" ESTIMATE="-0.5172" LOG_CI_END="-0.03854444869359434" LOG_CI_START="-0.4106897633871293" LOG_EFFECT_SIZE="-0.22461710604036186" MODIFIED="2016-03-31 14:27:49 +0100" MODIFIED_BY="[Empty name]" ORDER="535" SE="0.2186" STUDY_ID="STD-Fawzi-1998" TOTAL_1="537" TOTAL_2="537" WEIGHT="99.99999999999999"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2016-04-20 20:01:45 +0100" MODIFIED_BY="Heather Maxwell" NO="16">
<NAME>Multivitamin versus control</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.1683887186112358" CI_START="0.5844841380552758" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8263804651073235" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.0675873549871149" LOG_CI_START="-0.2332272703850152" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08281995769895013" MODIFIED="2016-04-20 20:01:30 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.28048507680051593" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2510" TOTAL_2="2511" WEIGHT="100.0" Z="1.0792303338992644">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1683887186112358" CI_START="0.5844841380552758" EFFECT_SIZE="0.8263804651073235" ESTIMABLE="YES" ESTIMATE="-0.1907" LOG_CI_END="0.0675873549871149" LOG_CI_START="-0.2332272703850152" LOG_EFFECT_SIZE="-0.08281995769895013" MODIFIED="2016-03-31 14:28:15 +0100" MODIFIED_BY="[Empty name]" ORDER="536" SE="0.1767" STUDY_ID="STD-People_x0027_s-League-1942" TOTAL_1="2510" TOTAL_2="2511" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.1683887186112358" CI_START="0.5844841380552758" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8263804651073235" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.0675873549871149" LOG_CI_START="-0.2332272703850152" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08281995769895013" MODIFIED="2016-04-20 20:01:45 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.28048507680051593" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2510" TOTAL_2="2511" WEIGHT="100.0" Z="1.0792303338992644">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1683887186112358" CI_START="0.5844841380552758" EFFECT_SIZE="0.8263804651073235" ESTIMABLE="YES" ESTIMATE="-0.1907" LOG_CI_END="0.0675873549871149" LOG_CI_START="-0.2332272703850152" LOG_EFFECT_SIZE="-0.08281995769895013" MODIFIED="2016-03-31 07:04:07 +0100" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.1767" STUDY_ID="STD-People_x0027_s-League-1942" TOTAL_1="2510" TOTAL_2="2511" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2016-04-20 20:02:30 +0100" MODIFIED_BY="Heather Maxwell" NO="17">
<NAME>Multivitamin plus vitamin E versus multivitamin without vitamin E or control</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="1.8345867344785456" CI_START="0.4576643410660396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.9163104981192898" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.2635382488883578" LOG_CI_START="-0.3394529243250462" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.03795733771834421" MODIFIED="2016-04-20 20:02:08 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8050991956559673" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="556" WEIGHT="100.0" Z="0.24675324675324675">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no or placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.8345867344785456" CI_START="0.4576643410660396" EFFECT_SIZE="0.9163104981192898" ESTIMABLE="YES" ESTIMATE="-0.0874" LOG_CI_END="0.2635382488883578" LOG_CI_START="-0.3394529243250462" LOG_EFFECT_SIZE="-0.03795733771834421" MODIFIED="2016-03-31 14:28:51 +0100" MODIFIED_BY="[Empty name]" ORDER="546" SE="0.3542" STUDY_ID="STD-Rush-1980" TOTAL_1="267" TOTAL_2="556" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="4.131525354140837" CI_START="0.2624101151858651" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.0412271817780303" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="0.6161104222575781" LOG_CI_START="-0.5810194281197953" LOG_DATA="YES" LOG_EFFECT_SIZE="0.017545497068891414" MODIFIED="2016-04-20 20:02:18 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.954185420476682" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="556" WEIGHT="100.0" Z="0.05745164960182025">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no or placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="4.131525354140837" CI_START="0.2624101151858651" EFFECT_SIZE="1.0412271817780303" ESTIMABLE="YES" ESTIMATE="0.0404" LOG_CI_END="0.6161104222575781" LOG_CI_START="-0.5810194281197953" LOG_EFFECT_SIZE="0.017545497068891414" MODIFIED="2016-03-31 14:29:11 +0100" MODIFIED_BY="[Empty name]" ORDER="540" SE="0.7032" STUDY_ID="STD-Rush-1980" TOTAL_1="267" TOTAL_2="556" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.9768270528808098" CI_START="0.38887665776876157" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8767792751377967" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.29596867575524466" LOG_CI_START="-0.4101881244957999" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05710972437027762" MODIFIED="2016-04-20 20:02:30 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7512282368298255" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="556" WEIGHT="100.0" Z="0.31702025072324014">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vitamin E]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no or placebo]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.9768270528808098" CI_START="0.38887665776876157" EFFECT_SIZE="0.8767792751377967" ESTIMABLE="YES" ESTIMATE="-0.1315" LOG_CI_END="0.29596867575524466" LOG_CI_START="-0.4101881244957999" LOG_EFFECT_SIZE="-0.05710972437027762" MODIFIED="2016-03-31 07:05:22 +0100" MODIFIED_BY="[Empty name]" ORDER="576" SE="0.4148" STUDY_ID="STD-Rush-1980" TOTAL_1="267" TOTAL_2="556" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2016-04-20 20:03:16 +0100" MODIFIED_BY="Heather Maxwell" NO="18">
<NAME>Multivitamin plus folic acid versus no multivitamin/folic acid</NAME>
<IV_OUTCOME CHI2="3.6943728099742117" CI_END="1.3358948788401626" CI_START="0.7536235314542461" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.0033752120932455" ESTIMABLE="YES" I2="45.8636119614046" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.12577228498396317" LOG_CI_START="-0.1228455494121292" LOG_DATA="YES" LOG_EFFECT_SIZE="0.0014633677859169697" MODIFIED="2016-04-20 20:02:48 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.15768027588155675" P_Q="1.0" P_Z="0.9815922448948192" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.03054429045844445" TOTALS="YES" TOTAL_1="3511" TOTAL_2="3372" WEIGHT="100.0" Z="0.023072746679660652">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.3347141335774593" CI_START="0.9773434662535159" EFFECT_SIZE="1.1421357790421207" ESTIMABLE="YES" ESTIMATE="0.1329" LOG_CI_END="0.12538825933052325" LOG_CI_START="-0.00995278604063887" LOG_EFFECT_SIZE="0.05771773664494215" MODIFIED="2016-03-31 17:36:25 +0100" MODIFIED_BY="[Empty name]" ORDER="557" SE="0.0795" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2819" TOTAL_2="2683" WEIGHT="57.85367317977366"/>
<IV_DATA CI_END="1.18354897734161" CI_START="0.2450930039307256" EFFECT_SIZE="0.5385903583947577" ESTIMABLE="YES" ESTIMATE="-0.6188" LOG_CI_END="0.07318623450767542" LOG_CI_START="-0.61066908531114" LOG_EFFECT_SIZE="-0.26874142540173224" MODIFIED="2016-04-01 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="558" SE="0.4017" STUDY_ID="STD-ICMR-2000" TOTAL_1="231" TOTAL_2="235" WEIGHT="11.113440729578192"/>
<IV_DATA CI_END="1.4443753763068499" CI_START="0.6714760281731651" EFFECT_SIZE="0.9848164503467863" ESTIMABLE="YES" ESTIMATE="-0.0153" LOG_CI_END="0.1596800759710631" LOG_CI_START="-0.17296948711730264" LOG_EFFECT_SIZE="-0.0066447055731197625" MODIFIED="2016-03-31 14:18:44 +0100" MODIFIED_BY="[Empty name]" ORDER="559" SE="0.1954" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" WEIGHT="31.032886090648145"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.128814191811999" CI_END="1.3755972731597073" CI_START="0.7157860090141596" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.9922868950891911" ESTIMABLE="YES" I2="51.559941739052526" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="0.13849130625082937" LOG_CI_START="-0.1452167947240674" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0033627442366190637" MODIFIED="2016-04-20 20:03:01 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.12689379903694575" P_Q="1.0" P_Z="0.9629418260023045" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.04265031289594282" TOTALS="YES" TOTAL_1="3511" TOTAL_2="3372" WEIGHT="100.0" Z="0.04646224461229709">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.33796938348523" CI_START="0.9736016143884665" EFFECT_SIZE="1.1413365637547765" ESTIMABLE="YES" ESTIMATE="0.1322" LOG_CI_END="0.12644617566233476" LOG_CI_START="-0.011618714647114928" LOG_EFFECT_SIZE="0.057413730507609916" MODIFIED="2016-03-31 14:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="556" SE="0.0811" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2819" TOTAL_2="2683" WEIGHT="56.417091728255535"/>
<IV_DATA CI_END="1.114853212869042" CI_START="0.17051657914570395" EFFECT_SIZE="0.43600568357307723" ESTIMABLE="YES" ESTIMATE="-0.8301" LOG_CI_END="0.04721768977202669" LOG_CI_START="-0.7682333886278053" LOG_EFFECT_SIZE="-0.3605078494278893" MODIFIED="2016-04-01 16:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="554" SE="0.479" STUDY_ID="STD-ICMR-2000" TOTAL_1="231" TOTAL_2="235" WEIGHT="10.207138350783481"/>
<IV_DATA CI_END="1.4947167835973447" CI_START="0.6787266929719948" EFFECT_SIZE="1.007225982320136" ESTIMABLE="YES" ESTIMATE="0.0072" LOG_CI_END="0.17455891107317542" LOG_CI_START="-0.16830507053376859" LOG_EFFECT_SIZE="0.0031269202697034567" MODIFIED="2016-03-31 14:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="555" SE="0.2014" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" WEIGHT="33.375769920960984"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.31826708155473055" CI_END="2.099576279041963" CI_START="0.5109255061136699" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.0357253849325945" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-018.03" LOG_CI_END="0.3221316574760916" LOG_CI_START="-0.29164241619046444" LOG_DATA="YES" LOG_EFFECT_SIZE="0.015244620642813603" MODIFIED="2016-04-20 20:03:16 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.8528824764604379" P_Q="1.0" P_Z="0.9224395115891866" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3511" TOTAL_2="3372" WEIGHT="100.0" Z="0.09736125620099995">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Multivitamin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.8031277291184984" CI_START="0.48280818347896853" EFFECT_SIZE="1.1633456094193282" ESTIMABLE="YES" ESTIMATE="0.1513" LOG_CI_END="0.4476428875524679" LOG_CI_START="-0.31622537732854383" LOG_EFFECT_SIZE="0.06570875511196198" MODIFIED="2016-03-31 14:21:14 +0100" MODIFIED_BY="[Empty name]" ORDER="580" SE="0.4487" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2819" TOTAL_2="2683" WEIGHT="64.56247103176561"/>
<IV_DATA CI_END="4.987460128311101" CI_START="0.20752015990533745" EFFECT_SIZE="1.0173487717339684" ESTIMABLE="YES" ESTIMATE="0.0172" LOG_CI_END="0.6978794367903057" LOG_CI_START="-0.6829397066128338" LOG_EFFECT_SIZE="0.007469865088735899" MODIFIED="2016-03-31 14:21:14 +0100" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.8111" STUDY_ID="STD-ICMR-2000" TOTAL_1="231" TOTAL_2="235" WEIGHT="19.758022709534433"/>
<IV_DATA CI_END="3.910820536737612" CI_START="0.11021225209327089" EFFECT_SIZE="0.6565213925581302" ESTIMABLE="YES" ESTIMATE="-0.4208" LOG_CI_END="0.592267887112238" LOG_CI_START="-0.9577701230820147" LOG_EFFECT_SIZE="-0.1827511179848884" MODIFIED="2016-03-31 14:21:14 +0100" MODIFIED_BY="[Empty name]" ORDER="579" SE="0.9105" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" WEIGHT="15.679506258699954"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.930433057024471" CI_END="3.5307747385757837" CI_START="0.8064704479360056" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6874434760845607" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-018.04" LOG_CI_END="0.5478700107054933" LOG_CI_START="-0.09341154214168655" LOG_EFFECT_SIZE="0.22722923428190336" METHOD="MH" MODIFIED="2016-04-06 10:49:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3347505729844703" P_Q="1.0" P_Z="0.16484121248290567" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2932" TOTAL_2="2845" WEIGHT="100.0" Z="1.3889721712711618">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [multivitamin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.354196413443027" CI_START="0.3799432649971882" EFFECT_SIZE="1.1288951841359773" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5255884902250203" LOG_CI_START="-0.4202812495364031" LOG_EFFECT_SIZE="0.05265362034430859" MODIFIED="2016-03-31 06:49:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16600" O_E="0.0" SE="0.5556085672665844" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2471" TOTAL_2="2391" VAR="0.30870088002002655" WEIGHT="54.76104744335498"/>
<DICH_DATA CI_END="6.654932140944615" CI_START="0.8394381581339405" EFFECT_SIZE="2.3635574837310194" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8231436314164708" LOG_CI_START="-0.07601129305834725" LOG_EFFECT_SIZE="0.37356616917906177" MODIFIED="2016-03-31 06:49:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16601" O_E="0.0" SE="0.5281680535251673" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" VAR="0.278961492764564" WEIGHT="45.23895255664502"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2016-04-06 10:49:48 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Folic acid plus multivitamin versus no folic acid/multivitamin</NAME>
<DICH_OUTCOME CHI2="3.695939459522034" CI_END="1.335921956635453" CI_START="0.7534921766705218" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0032979333015641" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="324" I2="45.886559509320435" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.12578108778580271" LOG_CI_START="-0.12292125250191847" LOG_EFFECT_SIZE="0.0014299176419421053" METHOD="MH" MODIFIED="2016-04-02 14:11:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15755680985288267" P_Q="1.0" P_Z="0.9820190540558736" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.030574608561759482" TOTALS="YES" TOTAL_1="3511" TOTAL_2="3372" WEIGHT="100.0" Z="0.022537681598192763">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3347395337938277" CI_START="0.9772758383193129" EFFECT_SIZE="1.14210713018801" ESTIMABLE="YES" EVENTS_1="312" EVENTS_2="260" LOG_CI_END="0.1253965240731881" LOG_CI_START="-0.009982838377265128" LOG_EFFECT_SIZE="0.057706842847961494" MODIFIED="2016-03-31 07:26:57 +0100" MODIFIED_BY="[Empty name]" ORDER="16616" O_E="0.0" SE="0.0795225076420482" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2819" TOTAL_2="2683" VAR="0.0063238292216796135" WEIGHT="57.839824796676204"/>
<DICH_DATA CI_END="1.1834878645813633" CI_START="0.2450953838723812" EFFECT_SIZE="0.5385790679908327" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.07316380905650813" LOG_CI_START="-0.6106648681752224" LOG_EFFECT_SIZE="-0.26875052955935713" MODIFIED="2016-04-02 13:35:05 +0100" MODIFIED_BY="[Empty name]" ORDER="16617" O_E="0.0" SE="0.40168435001246355" STUDY_ID="STD-ICMR-2000" TOTAL_1="231" TOTAL_2="235" VAR="0.16135031704493533" WEIGHT="11.11996875819411"/>
<DICH_DATA CI_END="1.444375538885891" CI_START="0.6714748178583909" EFFECT_SIZE="0.9848156182212582" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="47" LOG_CI_END="0.15968012485529195" LOG_CI_START="-0.17297026992038042" LOG_EFFECT_SIZE="-0.0066450725325442085" MODIFIED="2016-03-31 07:26:57 +0100" MODIFIED_BY="[Empty name]" ORDER="16618" O_E="0.0" SE="0.19540048853724087" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" VAR="0.038181350920592404" WEIGHT="31.040206445129687"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.131726517501505" CI_END="1.3757622531926215" CI_START="0.7155741179751427" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9921995065871606" ESTIMABLE="YES" EVENTS_1="352" EVENTS_2="309" I2="51.594085631557746" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="0.1385433895335254" LOG_CI_START="-0.14534537607539447" LOG_EFFECT_SIZE="-0.0034009932709345493" METHOD="MH" MODIFIED="2016-04-02 14:12:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12670915821853956" P_Q="1.0" P_Z="0.9625444557831216" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04272388773244452" TOTALS="YES" TOTAL_1="3511" TOTAL_2="3372" WEIGHT="100.0" Z="0.04696081796965162">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3380105174501158" CI_START="0.9735924886225228" EFFECT_SIZE="1.1413487589196247" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="251" LOG_CI_END="0.1264595272229828" LOG_CI_START="-0.011622785396699049" LOG_EFFECT_SIZE="0.057418370913141864" MODIFIED="2016-03-31 07:28:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16628" O_E="0.0" SE="0.08111023395127219" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2819" TOTAL_2="2683" VAR="0.006578870051630107" WEIGHT="56.40276626140851"/>
<DICH_DATA CI_END="1.1149791650135152" CI_START="0.17048706807873545" EFFECT_SIZE="0.4359925788497217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.04726675204408744" LOG_CI_START="-0.7683085578740924" LOG_EFFECT_SIZE="-0.36052090291500244" MODIFIED="2016-04-01 16:43:30 +0100" MODIFIED_BY="[Empty name]" ORDER="16629" O_E="0.0" SE="0.47907297420883344" STUDY_ID="STD-ICMR-2000" TOTAL_1="231" TOTAL_2="235" VAR="0.22951091461729758" WEIGHT="10.214755421922396"/>
<DICH_DATA CI_END="1.494789084794116" CI_START="0.6786558727551355" EFFECT_SIZE="1.0071977913626504" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" LOG_CI_END="0.1745799178964976" LOG_CI_START="-0.16835038838327349" LOG_EFFECT_SIZE="0.0031147647566120416" MODIFIED="2016-03-31 07:28:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16630" O_E="0.0" SE="0.20143895944113108" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" VAR="0.04057765438072565" WEIGHT="33.382478316669086"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.31818950934440426" CI_END="2.088545747782429" CI_START="0.5120062514642959" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0340930709243614" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-019.03" LOG_CI_END="0.319843992549127" LOG_CI_START="-0.29072473636816754" LOG_EFFECT_SIZE="0.014559628090479728" METHOD="MH" MODIFIED="2016-04-02 14:12:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8529155570625138" P_Q="1.0" P_Z="0.9255264942103697" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3511" TOTAL_2="3372" WEIGHT="100.0" Z="0.09347464203167005">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.80267646775063" CI_START="0.48281258065203514" EFFECT_SIZE="1.1632572622285287" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.44757296705025196" LOG_CI_START="-0.3162214220117782" LOG_EFFECT_SIZE="0.06567577251923684" MODIFIED="2016-03-31 07:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="16640" O_E="0.0" SE="0.448656604978239" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2819" TOTAL_2="2683" VAR="0.20129274919059958" WEIGHT="60.59571599933654"/>
<DICH_DATA CI_END="4.98849952769001" CI_START="0.20746356160666254" EFFECT_SIZE="1.0173160173160174" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6979699354354392" LOG_CI_START="-0.6830581706762552" LOG_EFFECT_SIZE="0.007455882379591995" MODIFIED="2016-03-31 07:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="16641" O_E="0.0" SE="0.8112227457293874" STUDY_ID="STD-ICMR-2000" TOTAL_1="231" TOTAL_2="235" VAR="0.6580823431887262" WEIGHT="19.542145394436375"/>
<DICH_DATA CI_END="3.9107484538296786" CI_START="0.11022178869824634" EFFECT_SIZE="0.6565437454808387" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5922598822709603" LOG_CI_START="-0.9577325454474113" LOG_EFFECT_SIZE="-0.1827363315882255" MODIFIED="2016-03-31 07:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="16642" O_E="0.0" SE="0.9104732246280305" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" VAR="0.828961492764564" WEIGHT="19.862138606227088"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.930433057024471" CI_END="3.5307747385757837" CI_START="0.8064704479360056" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6874434760845607" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-019.04" LOG_CI_END="0.5478700107054933" LOG_CI_START="-0.09341154214168655" LOG_EFFECT_SIZE="0.22722923428190336" METHOD="MH" MODIFIED="2016-04-06 10:49:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3347505729844703" P_Q="1.0" P_Z="0.16484121248290567" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2932" TOTAL_2="2845" WEIGHT="100.0" Z="1.3889721712711618">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.354196413443027" CI_START="0.3799432649971882" EFFECT_SIZE="1.1288951841359773" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5255884902250203" LOG_CI_START="-0.4202812495364031" LOG_EFFECT_SIZE="0.05265362034430859" MODIFIED="2016-03-31 07:29:58 +0100" MODIFIED_BY="[Empty name]" ORDER="16666" O_E="0.0" SE="0.5556085672665844" STUDY_ID="STD-Czeizel-1994" TOTAL_1="2471" TOTAL_2="2391" VAR="0.30870088002002655" WEIGHT="54.76104744335498"/>
<DICH_DATA CI_END="6.654932140944615" CI_START="0.8394381581339405" EFFECT_SIZE="2.3635574837310194" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8231436314164708" LOG_CI_START="-0.07601129305834725" LOG_EFFECT_SIZE="0.37356616917906177" MODIFIED="2016-03-31 07:29:58 +0100" MODIFIED_BY="[Empty name]" ORDER="16667" O_E="0.0" SE="0.5281680535251673" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="454" VAR="0.278961492764564" WEIGHT="45.23895255664502"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2016-04-06 10:50:03 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Folic acid without multivitamin versus no folic acid/multivitamin</NAME>
<DICH_OUTCOME CHI2="3.516153264390891E-31" CI_END="1.397963389147001" CI_START="0.6409628561698324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9465952708145761" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="47" I2="100.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.14549579794783696" LOG_CI_START="-0.19316713713933562" LOG_EFFECT_SIZE="-0.02383566959574932" METHOD="MH" MODIFIED="2016-04-02 14:12:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.7826316688958691" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="454" WEIGHT="100.0" Z="0.27589115379892404">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.397963389147001" CI_START="0.6409628561698326" EFFECT_SIZE="0.9465952708145762" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="47" LOG_CI_END="0.14549579794783696" LOG_CI_START="-0.19316713713933545" LOG_EFFECT_SIZE="-0.023835669595749273" MODIFIED="2016-03-31 07:31:19 +0100" MODIFIED_BY="[Empty name]" ORDER="16619" O_E="0.0" SE="0.19893228447877057" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="454" VAR="0.0395740538079425" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.443020702724468" CI_START="0.6455645734548379" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9651751366673416" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.1592725618727734" LOG_CI_START="-0.19006031034178583" LOG_EFFECT_SIZE="-0.01539387423450623" METHOD="MH" MODIFIED="2016-04-02 14:13:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.862857786087634" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="454" WEIGHT="100.0" Z="0.1727374746665129">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4430207027244677" CI_START="0.6455645734548379" EFFECT_SIZE="0.9651751366673416" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" LOG_CI_END="0.15927256187277333" LOG_CI_START="-0.19006031034178583" LOG_EFFECT_SIZE="-0.01539387423450623" MODIFIED="2016-03-31 07:32:33 +0100" MODIFIED_BY="[Empty name]" ORDER="16631" O_E="0.0" SE="0.2051998583644381" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="454" VAR="0.042106981872785464" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.015016794041636" CI_START="0.11317464461149909" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.674090571640683" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.6036873661886369" LOG_CI_START="-0.946250860592438" LOG_EFFECT_SIZE="-0.1712817472019005" METHOD="MH" MODIFIED="2016-04-02 14:13:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6648793825726722" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="454" WEIGHT="100.0" Z="0.43318636823612827">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.015016794041636" CI_START="0.11317464461149909" EFFECT_SIZE="0.674090571640683" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6036873661886369" LOG_CI_START="-0.946250860592438" LOG_EFFECT_SIZE="-0.1712817472019005" MODIFIED="2016-03-31 07:33:33 +0100" MODIFIED_BY="[Empty name]" ORDER="16643" O_E="0.0" SE="0.9104413867291635" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="454" VAR="0.8289035186693222" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.427105281766075" CI_START="0.4526424126054993" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4155902004454344" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="99.99999999999999" ID="CMP-020.04" LOG_CI_END="0.6461198501347933" LOG_CI_START="-0.34424475507075575" LOG_EFFECT_SIZE="0.1509375475320188" METHOD="MH" MODIFIED="2016-04-06 10:50:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.5502265410026344" Q="9.105316427818296E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="449" TOTAL_2="454" WEIGHT="99.99999999999999" Z="0.5974206984429936">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.427105281766075" CI_START="0.4526424126054993" EFFECT_SIZE="1.4155902004454344" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6461198501347933" LOG_CI_START="-0.34424475507075575" LOG_EFFECT_SIZE="0.1509375475320188" MODIFIED="2016-03-31 07:34:32 +0100" MODIFIED_BY="[Empty name]" ORDER="16668" O_E="0.0" SE="0.5817450714815999" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="454" VAR="0.33842732819313176" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2016-04-06 10:50:20 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Folic acid with/without multivitamin versus no folic acid/multivitamin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3484118206329072" CI_START="0.6919798349193182" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9659574468085106" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.12982255103755977" LOG_CI_START="-0.15990656119478694" LOG_EFFECT_SIZE="-0.015042005078613571" METHOD="MH" MODIFIED="2016-04-02 14:14:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.838734259597451" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="910" TOTAL_2="454" WEIGHT="100.0" Z="0.20351277772672308">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3484118206329072" CI_START="0.6919798349193182" EFFECT_SIZE="0.9659574468085106" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="47" LOG_CI_END="0.12982255103755977" LOG_CI_START="-0.15990656119478694" LOG_EFFECT_SIZE="-0.015042005078613571" MODIFIED="2016-03-31 07:40:34 +0100" MODIFIED_BY="[Empty name]" ORDER="16620" O_E="0.0" SE="0.1701883147075162" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="454" VAR="0.028964062462984573" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.392377457273809" CI_START="0.6988839870170249" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9864635364635365" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-021.02" LOG_CI_END="0.14375698339934975" LOG_CI_START="-0.15559491006246695" LOG_EFFECT_SIZE="-0.005918963331558592" METHOD="MH" MODIFIED="2016-04-02 14:14:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9382201093511631" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="910" TOTAL_2="454" WEIGHT="100.0" Z="0.07750714265749445">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.392377457273809" CI_START="0.6988839870170249" EFFECT_SIZE="0.9864635364635365" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="44" LOG_CI_END="0.14375698339934975" LOG_CI_START="-0.15559491006246695" LOG_EFFECT_SIZE="-0.005918963331558592" MODIFIED="2016-03-31 07:41:36 +0100" MODIFIED_BY="[Empty name]" ORDER="16632" O_E="0.0" SE="0.17584078403524217" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="454" VAR="0.030919981330128677" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9595572401724257" CI_START="0.1495132391088324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6652014652014652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="100.0" ID="CMP-021.03" LOG_CI_END="0.47122674398708475" LOG_CI_START="-0.8253203496984644" LOG_EFFECT_SIZE="-0.17704680285568974" METHOD="MH" MODIFIED="2016-04-02 14:14:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5924589300451384" Q="5.312619013519048E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="910" TOTAL_2="454" WEIGHT="100.0" Z="0.5352761328379086">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9595572401724257" CI_START="0.14951323910883246" EFFECT_SIZE="0.6652014652014652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.47122674398708475" LOG_CI_START="-0.8253203496984641" LOG_EFFECT_SIZE="-0.17704680285568974" MODIFIED="2016-03-31 07:42:26 +0100" MODIFIED_BY="[Empty name]" ORDER="16644" O_E="0.0" SE="0.7615981808425135" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="454" VAR="0.580031789062626" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.044616669760035" CI_START="0.712472233457212" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8958241758241758" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-021.04" LOG_CI_END="0.7028281706655013" LOG_CI_START="-0.14723205635986034" LOG_EFFECT_SIZE="0.27779805715282047" METHOD="MH" MODIFIED="2016-04-06 10:50:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.20018489681664292" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="910" TOTAL_2="454" WEIGHT="100.0" Z="1.281024966666234">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.044616669760035" CI_START="0.7124722334572119" EFFECT_SIZE="1.8958241758241758" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.7028281706655013" LOG_CI_START="-0.14723205635986042" LOG_EFFECT_SIZE="0.27779805715282047" MODIFIED="2016-03-31 07:43:18 +0100" MODIFIED_BY="[Empty name]" ORDER="16669" O_E="0.0" SE="0.4993295852206849" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="454" VAR="0.24933003467666118" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2016-04-06 10:50:33 +0100" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Folic acis plus multivitamin versus multivitamin</NAME>
<DICH_OUTCOME CHI2="0.08972146209124778" CI_END="1.6661147147064352" CI_START="0.7995507243458788" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.154185092169734" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="0.2217048999812525" LOG_CI_START="-0.09715397894123948" LOG_EFFECT_SIZE="0.062275460520006515" METHOD="MH" MODIFIED="2016-04-02 14:15:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7645315737202418" P_Q="1.0" P_Z="0.4439200221608063" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="554" TOTAL_2="548" WEIGHT="100.0" Z="0.765590471573655">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4592695821245374" CI_START="0.42430209420084286" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.39080613817828475" LOG_CI_START="-0.3723248247084594" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2016-03-31 13:06:32 +0100" MODIFIED_BY="[Empty name]" ORDER="16621" O_E="0.0" SE="0.44826690515886347" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="0.20094321826070552" WEIGHT="18.456093624474374"/>
<DICH_DATA CI_END="1.7741677296980538" CI_START="0.7904353952148443" EFFECT_SIZE="1.1842149174036376" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="39" LOG_CI_END="0.2489946756078103" LOG_CI_START="-0.10213362054300633" LOG_EFFECT_SIZE="0.07343052753240199" MODIFIED="2016-03-31 13:06:32 +0100" MODIFIED_BY="[Empty name]" ORDER="16622" O_E="0.0" SE="0.20625449927208755" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="453" VAR="0.042540918469979566" WEIGHT="81.54390637552562"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0782424867262251" CI_END="1.688860588576441" CI_START="0.7977089294317249" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1606977091701118" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-022.02" LOG_CI_END="0.22759380107435662" LOG_CI_START="-0.09815554649556796" LOG_EFFECT_SIZE="0.06471912728939433" METHOD="MH" MODIFIED="2016-04-02 14:15:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7796934271874346" P_Q="1.0" P_Z="0.43609623261061925" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="554" TOTAL_2="548" WEIGHT="99.99999999999999" Z="0.7788022265852586">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.380544484058473" CI_START="0.510250685913771" EFFECT_SIZE="1.3133640552995391" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5289866551231994" LOG_CI_START="-0.29221640280323813" LOG_EFFECT_SIZE="0.11838512615998069" MODIFIED="2016-03-31 13:10:42 +0100" MODIFIED_BY="[Empty name]" ORDER="16633" O_E="0.0" SE="0.482378741246686" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="0.23268925000673726" WEIGHT="14.968657124183597"/>
<DICH_DATA CI_END="1.7062783579004772" CI_START="0.7534257939572219" EFFECT_SIZE="1.1338227932588019" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.23204988230562443" LOG_CI_START="-0.12295951556156806" LOG_EFFECT_SIZE="0.054545183372028176" MODIFIED="2016-03-31 13:10:42 +0100" MODIFIED_BY="[Empty name]" ORDER="16634" O_E="0.0" SE="0.20853427763205007" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="453" VAR="0.04348654494752094" WEIGHT="85.03134287581639"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.118465854970455" CI_END="22.553145417220108" CI_START="0.044266109440392526" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9991696568970422" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="52.79602936937842" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="1.353207120142097" LOG_CI_START="-1.3539286465962297" LOG_EFFECT_SIZE="-3.607632270662547E-4" METHOD="MH" MODIFIED="2016-04-02 14:15:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14553231691598312" P_Q="1.0" P_Z="0.9995831974620704" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.670101171000669" TOTALS="YES" TOTAL_1="554" TOTAL_2="548" WEIGHT="100.0" Z="5.223845369589656E-4">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.198093304852494" CI_START="0.009937900940031552" EFFECT_SIZE="0.20425531914893616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6230520867790783" LOG_CI_START="-2.0027053365713763" LOG_EFFECT_SIZE="-0.6898266248961491" MODIFIED="2016-03-31 13:11:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16645" O_E="0.0" SE="1.542382908184927" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="2.378945035460993" WEIGHT="50.082492248075226"/>
<DICH_DATA CI_END="102.06088635302751" CI_START="0.23654208882808928" EFFECT_SIZE="4.913419913419913" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.008859335665401" LOG_CI_START="-0.6260915723914063" LOG_EFFECT_SIZE="0.6913838816369972" MODIFIED="2016-03-31 13:11:35 +0100" MODIFIED_BY="[Empty name]" ORDER="16646" O_E="0.0" SE="1.5477832066099217" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="453" VAR="2.395632854663692" WEIGHT="49.91750775192478"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8686898441699848" CI_END="3.1156894581984584" CI_START="0.2796478021862583" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9334322199710554" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="46.486571695145614" I2_Q="0.0" ID="CMP-022.04" LOG_CI_END="0.4935541648825277" LOG_CI_START="-0.5533885895384187" LOG_EFFECT_SIZE="-0.029917212327945527" METHOD="MH" MODIFIED="2016-04-06 10:50:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.17162540817569538" P_Q="1.0" P_Z="0.9108114944323277" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.38338654488923607" TOTALS="YES" TOTAL_1="554" TOTAL_2="548" WEIGHT="100.0" Z="0.1120150236161524">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.053804004366816" CI_START="0.0812909688894349" EFFECT_SIZE="0.40860215053763443" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31255899628007383" LOG_CI_START="-1.0899577001543237" LOG_EFFECT_SIZE="-0.38869935193712496" MODIFIED="2016-03-31 13:12:57 +0100" MODIFIED_BY="[Empty name]" ORDER="16670" O_E="0.0" SE="0.8238452500551807" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="0.6787209960384832" WEIGHT="35.60841009227939"/>
<DICH_DATA CI_END="3.57194211831467" CI_START="0.6082367524007848" EFFECT_SIZE="1.4739696312364425" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5529044127304469" LOG_CI_START="-0.21592734137271682" LOG_EFFECT_SIZE="0.168488535678865" MODIFIED="2016-03-31 13:12:57 +0100" MODIFIED_BY="[Empty name]" ORDER="16671" O_E="0.0" SE="0.45161557813875997" STUDY_ID="STD-MRC-1991" TOTAL_1="461" TOTAL_2="453" VAR="0.2039566304176064" WEIGHT="64.3915899077206"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2016-04-06 10:50:49 +0100" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Folic acid without multivitamin versus multivitamin</NAME>
<DICH_OUTCOME CHI2="0.047826465270190854" CI_END="1.6197005876067432" CI_START="0.7695984518408252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1164761818631979" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.20943473974743998" LOG_CI_START="-0.11373581461585545" LOG_EFFECT_SIZE="0.04784946256579226" METHOD="MH" MODIFIED="2016-04-02 14:16:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8268894934271758" P_Q="1.0" P_Z="0.5616485445728161" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="548" WEIGHT="99.99999999999999" Z="0.5803946061442405">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4592695821245374" CI_START="0.42430209420084286" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.39080613817828475" LOG_CI_START="-0.3723248247084594" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2016-03-31 13:14:47 +0100" MODIFIED_BY="[Empty name]" ORDER="16623" O_E="0.0" SE="0.44826690515886347" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="0.20094321826070552" WEIGHT="18.65495836218156"/>
<DICH_DATA CI_END="1.7165432139003731" CI_START="0.7547882307653795" EFFECT_SIZE="1.1382559534007195" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="0.2346547412439917" LOG_CI_START="-0.12217488030559785" LOG_EFFECT_SIZE="0.056239930469196904" MODIFIED="2016-03-31 13:14:47 +0100" MODIFIED_BY="[Empty name]" ORDER="16624" O_E="0.0" SE="0.20960348603334267" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="453" VAR="0.04393362135732967" WEIGHT="81.34504163781843"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12947097925705495" CI_END="1.6396995538625045" CI_START="0.7661862495347959" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1208546968888475" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="0.21476427850308227" LOG_CI_START="-0.115665646407689" LOG_EFFECT_SIZE="0.04954931604769663" METHOD="MH" MODIFIED="2016-04-02 14:16:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7189812584003844" P_Q="1.0" P_Z="0.5566603711092968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="548" WEIGHT="100.0" Z="0.5878092000190519">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.380544484058473" CI_START="0.510250685913771" EFFECT_SIZE="1.3133640552995391" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5289866551231994" LOG_CI_START="-0.29221640280323813" LOG_EFFECT_SIZE="0.11838512615998069" MODIFIED="2016-03-31 13:17:23 +0100" MODIFIED_BY="[Empty name]" ORDER="16635" O_E="0.0" SE="0.482378741246686" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="0.23268925000673726" WEIGHT="15.13692009063561"/>
<DICH_DATA CI_END="1.6467796875116842" CI_START="0.7168653470351729" EFFECT_SIZE="1.0865170464279597" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="39" LOG_CI_END="0.21663550147823274" LOG_CI_START="-0.14456241271641274" LOG_EFFECT_SIZE="0.03603654438090999" MODIFIED="2016-03-31 13:17:23 +0100" MODIFIED_BY="[Empty name]" ORDER="16636" O_E="0.0" SE="0.21216944275644584" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="453" VAR="0.04501587243958075" WEIGHT="84.86307990936439"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.872862260135314E-4" CI_END="42.292236589947635" CI_START="0.5839553093876699" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.96958510366604" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.03" LOG_CI_END="1.6262606530586494" LOG_CI_START="-0.23362038855369371" LOG_EFFECT_SIZE="0.6963201322524778" METHOD="MH" MODIFIED="2016-04-02 14:16:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9890810865488383" P_Q="1.0" P_Z="0.14221826461900725" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="544" TOTAL_2="546" WEIGHT="100.0" Z="1.4675802918469478">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.62487098979125" CI_START="0.23820337648144205" EFFECT_SIZE="4.895833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0027053365713763" LOG_CI_START="-0.6230520867790783" LOG_EFFECT_SIZE="0.689826624896149" MODIFIED="2016-03-31 13:20:05 +0100" MODIFIED_BY="[Empty name]" ORDER="16647" O_E="0.0" SE="1.542382908184927" STUDY_ID="STD-Kirke-1992" TOTAL_1="95" TOTAL_2="93" VAR="2.378945035460993" WEIGHT="50.37264052378631"/>
<DICH_DATA CI_END="104.77868069962116" CI_START="0.24285875316598093" EFFECT_SIZE="5.044444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.020272925811854" LOG_CI_START="-0.614646238976296" LOG_EFFECT_SIZE="0.702813343417779" MODIFIED="2016-03-31 13:20:05 +0100" MODIFIED_BY="[Empty name]" ORDER="16648" O_E="0.0" SE="1.5477645604567807" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="453" VAR="2.3955751346059717" WEIGHT="49.6273594762137"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5160061627417265" CI_END="1.4925531658174567" CI_START="0.2599092449065142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6228389569627468" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="34.03720746151318" I2_Q="0.0" ID="CMP-023.04" LOG_CI_END="0.17392980995879898" LOG_CI_START="-0.5851782724786816" LOG_EFFECT_SIZE="-0.2056242312599413" METHOD="MH" MODIFIED="2016-04-06 10:50:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21822528653729878" P_Q="1.0" P_Z="0.2883197982350413" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="542" TOTAL_2="548" WEIGHT="100.0" Z="1.0618147716834831">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.715579934427366" CI_START="0.024329341069104265" EFFECT_SIZE="0.20430107526881722" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23441095805057893" LOG_CI_START="-1.6138696532527912" LOG_EFFECT_SIZE="-0.6897293476011062" MODIFIED="2016-03-31 13:22:09 +0100" MODIFIED_BY="[Empty name]" ORDER="16672" O_E="0.0" SE="1.085689180216181" STUDY_ID="STD-Kirke-1992" TOTAL_1="93" TOTAL_2="95" VAR="1.1787209960384832" WEIGHT="38.31369676065061"/>
<DICH_DATA CI_END="2.413995956176422" CI_START="0.3228369902539645" EFFECT_SIZE="0.8827951002227171" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3827365382502547" LOG_CI_START="-0.4910167101866108" LOG_EFFECT_SIZE="-0.05414008596817807" MODIFIED="2016-03-31 13:22:09 +0100" MODIFIED_BY="[Empty name]" ORDER="16673" O_E="0.0" SE="0.5132469832801496" STUDY_ID="STD-MRC-1991" TOTAL_1="449" TOTAL_2="453" VAR="0.2634224658461741" WEIGHT="61.686303239349385"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2016-04-02 14:17:51 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Folic acid with or without multivitamin versus multivitamin</NAME>
<DICH_OUTCOME CHI2="0.08966426995842132" CI_END="1.5694956254366677" CI_START="0.8214624559287548" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1354654248547782" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="0.19576010955414747" LOG_CI_START="-0.08541228074452491" LOG_EFFECT_SIZE="0.05517391440481127" METHOD="MH" MODIFIED="2016-04-02 14:17:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7646044171838127" P_Q="1.0" P_Z="0.4417746652411466" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1096" TOTAL_2="548" WEIGHT="100.0" Z="0.769199884844002">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.186493017976816" CI_START="0.4772360237698856" EFFECT_SIZE="1.021505376344086" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.3397480948713708" LOG_CI_START="-0.3212667814015456" LOG_EFFECT_SIZE="0.009240656734912641" MODIFIED="2016-03-31 13:25:21 +0100" MODIFIED_BY="[Empty name]" ORDER="16625" O_E="0.0" SE="0.38828341039912" STUDY_ID="STD-Kirke-1992" TOTAL_1="186" TOTAL_2="95" VAR="0.15076400679117147" WEIGHT="18.619197490001916"/>
<DICH_DATA CI_END="1.6611865362981404" CI_START="0.8121734484073585" EFFECT_SIZE="1.1615384615384616" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="39" LOG_CI_END="0.2204184025515421" LOG_CI_START="-0.0903512125788767" LOG_EFFECT_SIZE="0.0650335949863327" MODIFIED="2016-03-31 13:25:21 +0100" MODIFIED_BY="[Empty name]" ORDER="16626" O_E="0.0" SE="0.18254761026201283" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="453" VAR="0.033323630012371735" WEIGHT="81.38080250999808"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05957135118077176" CI_END="1.5093511083403683" CI_START="0.7868578405251337" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0897911514152239" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="0.17879027799810715" LOG_CI_START="-0.10410372336172911" LOG_EFFECT_SIZE="0.037343277318189025" METHOD="MH" MODIFIED="2016-04-02 14:17:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8071747269806969" P_Q="1.0" P_Z="0.6048434074585347" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1096" TOTAL_2="546" WEIGHT="100.0" Z="0.5174480777713182">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1392385502744573" CI_START="0.46745604872897567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.3302592162177503" LOG_CI_START="-0.3302592162177503" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-03-31 13:28:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16637" O_E="0.0" SE="0.3879917968315853" STUDY_ID="STD-Kirke-1992" TOTAL_1="186" TOTAL_2="93" VAR="0.15053763440860216" WEIGHT="18.727672437482823"/>
<DICH_DATA CI_END="1.5924645676715965" CI_START="0.7743782251825735" EFFECT_SIZE="1.1104818258664413" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="39" LOG_CI_END="0.20206977806490922" LOG_CI_START="-0.11104686749719404" LOG_EFFECT_SIZE="0.0455114552838576" MODIFIED="2016-03-31 13:28:25 +0100" MODIFIED_BY="[Empty name]" ORDER="16638" O_E="0.0" SE="0.1839262675555723" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="453" VAR="0.03382887189692396" WEIGHT="81.27232756251718"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.117263416052017" CI_END="28.38931001119408" CI_START="0.016942693491290035" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6935354193902954" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="67.92058076161912" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="1.453154837331335" LOG_CI_START="-1.7710175458697448" LOG_EFFECT_SIZE="-0.15893135426920493" METHOD="MH" MODIFIED="2016-04-02 14:17:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07746706980747764" P_Q="1.0" P_Z="0.8467806347950365" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.873048617765749" TOTALS="YES" TOTAL_1="1096" TOTAL_2="548" WEIGHT="100.0" Z="0.19322771450113913">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1173732642455056" CI_START="0.004978767194988247" EFFECT_SIZE="0.10267379679144385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3257974250069771" LOG_CI_START="-2.302878180672876" LOG_EFFECT_SIZE="-0.9885403778329493" MODIFIED="2016-03-31 13:30:22 +0100" MODIFIED_BY="[Empty name]" ORDER="16649" O_E="0.0" SE="1.5440970629304511" STUDY_ID="STD-Kirke-1992" TOTAL_1="186" TOTAL_2="95" VAR="2.3842357397504457" WEIGHT="49.42396362333925"/>
<DICH_DATA CI_END="83.12539562754893" CI_START="0.24200606233730204" EFFECT_SIZE="4.485181119648738" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9197337253000635" LOG_CI_START="-0.6161737546532023" LOG_EFFECT_SIZE="0.6517799853234305" MODIFIED="2016-03-31 13:30:22 +0100" MODIFIED_BY="[Empty name]" ORDER="16650" O_E="0.0" SE="1.4896046066690254" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="453" VAR="2.218921884209582" WEIGHT="50.57603637666075"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.635522063630551" CI_END="2.5067405079398735" CI_START="0.18634713634358344" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6834646407906229" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="62.05685341057419" I2_Q="0.0" ID="CMP-024.04" LOG_CI_END="0.39910937911073974" LOG_CI_START="-0.7296772768019348" LOG_EFFECT_SIZE="-0.16528394884559755" METHOD="MH" MODIFIED="2016-04-02 14:17:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.10449775902179714" P_Q="1.0" P_Z="0.565981212715307" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5656909742154684" TOTALS="YES" TOTAL_1="1096" TOTAL_2="548" WEIGHT="100.0" Z="0.5739801852955169">
<NAME>Congenital malformations</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [multivitamin]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2550290362766046" CI_START="0.07482901856167931" EFFECT_SIZE="0.3064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.09865377374440973" LOG_CI_START="-1.1259299508352596" LOG_EFFECT_SIZE="-0.5136380885454249" MODIFIED="2016-03-31 13:32:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16674" O_E="0.0" SE="0.7193265416052977" STUDY_ID="STD-Kirke-1992" TOTAL_1="186" TOTAL_2="95" VAR="0.5174306734578381" WEIGHT="40.59024769778269"/>
<DICH_DATA CI_END="2.6798862282314113" CI_START="0.5215842759884747" EFFECT_SIZE="1.1822802197802198" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.42811635690188055" LOG_CI_START="-0.28267550959663323" LOG_EFFECT_SIZE="0.07272042365262366" MODIFIED="2016-03-31 13:32:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16675" O_E="0.0" SE="0.41752266085771145" STUDY_ID="STD-MRC-1991" TOTAL_1="910" TOTAL_2="453" VAR="0.17432517232970351" WEIGHT="59.40975230221732"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2016-04-02 14:18:43 +0100" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Folic acid plus iron versus iron</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.589618196995962" CI_START="0.011304364289679139" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22777777777777777" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="100.0" ID="CMP-025.01" LOG_CI_END="0.6617765587759157" LOG_CI_START="-1.9467538555430568" LOG_EFFECT_SIZE="-0.6424886483835706" METHOD="MH" MODIFIED="2016-04-02 14:18:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.33429960939553005" Q="2.0999716773428274E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" WEIGHT="100.0" Z="0.9654896905899251">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron]</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.589618196995962" CI_START="0.011304364289679139" EFFECT_SIZE="0.22777777777777777" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6617765587759157" LOG_CI_START="-1.9467538555430568" LOG_EFFECT_SIZE="-0.6424886483835706" MODIFIED="2016-03-31 13:35:08 +0100" MODIFIED_BY="[Empty name]" ORDER="16627" O_E="0.0" SE="1.5322636778047645" STUDY_ID="STD-Fleming-1968" TOTAL_1="35" TOTAL_2="40" VAR="2.347831978319783" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.030314868023677" CI_START="0.01595942752816445" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37962962962962965" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.9557028935096487" LOG_CI_START="-1.796982691044077" LOG_EFFECT_SIZE="-0.4206398987672142" METHOD="MH" MODIFIED="2016-04-02 14:18:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5491681785688495" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" WEIGHT="100.0" Z="0.5990070618094038">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron]</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.030314868023677" CI_START="0.01595942752816445" EFFECT_SIZE="0.37962962962962965" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9557028935096487" LOG_CI_START="-1.796982691044077" LOG_EFFECT_SIZE="-0.4206398987672142" MODIFIED="2016-03-31 13:36:06 +0100" MODIFIED_BY="[Empty name]" ORDER="16639" O_E="0.0" SE="1.6169411383802597" STUDY_ID="STD-Fleming-1968" TOTAL_1="35" TOTAL_2="40" VAR="2.61449864498645" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.030314868023677" CI_START="0.01595942752816445" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37962962962962965" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="0.9557028935096487" LOG_CI_START="-1.796982691044077" LOG_EFFECT_SIZE="-0.4206398987672142" METHOD="MH" MODIFIED="2016-04-02 14:18:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5491681785688495" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" WEIGHT="100.0" Z="0.5990070618094038">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [iron]</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.030314868023677" CI_START="0.01595942752816445" EFFECT_SIZE="0.37962962962962965" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9557028935096487" LOG_CI_START="-1.796982691044077" LOG_EFFECT_SIZE="-0.4206398987672142" MODIFIED="2016-03-31 13:36:49 +0100" MODIFIED_BY="[Empty name]" ORDER="16651" O_E="0.0" SE="1.6169411383802597" STUDY_ID="STD-Fleming-1968" TOTAL_1="35" TOTAL_2="40" VAR="2.61449864498645" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2016-04-02 14:19:57 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Folic acid plus iron and antimalarials versus iron and antimalarials</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="226.97843946948691" CI_START="0.7445641110010317" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="2.355984605809261" LOG_CI_START="-0.1280979011955873" LOG_EFFECT_SIZE="1.1139433523068367" METHOD="MH" MODIFIED="2016-04-02 14:19:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07877760744550256" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="1.7578231360533085">
<NAME>Total fetal loss</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="226.97843946948672" CI_START="0.7445641110010319" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3559846058092604" LOG_CI_START="-0.12809790119558717" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2016-03-31 13:38:38 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="1.459162361021371" STUDY_ID="STD-Fleming-1986" TOTAL_1="80" TOTAL_2="80" VAR="2.1291547958214623" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="226.97843946948691" CI_START="0.7445641110010317" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="2.355984605809261" LOG_CI_START="-0.1280979011955873" LOG_EFFECT_SIZE="1.1139433523068367" METHOD="MH" MODIFIED="2016-04-02 14:19:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.07877760744550256" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="1.7578231360533085">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [folic acid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no folic acid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="226.97843946948672" CI_START="0.7445641110010319" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3559846058092604" LOG_CI_START="-0.12809790119558717" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2016-03-31 13:38:43 +0100" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="1.459162361021371" STUDY_ID="STD-Fleming-1986" TOTAL_1="80" TOTAL_2="80" VAR="2.1291547958214623" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2016-04-02 14:20:32 +0100" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Antioxidant vitamin supplementation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.2862685660799205" CI_START="0.23534234492350947" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1153846153846154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="0.7231492234577519" LOG_CI_START="-0.6282999236014756" LOG_EFFECT_SIZE="0.047424649928138135" METHOD="MH" MODIFIED="2016-04-02 14:20:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8905905874248202" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="58" WEIGHT="100.0" Z="0.13755694180699682">
<NAME>Early or late miscarriage</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [antioxidant]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [no antioxidant]</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.286268566079919" CI_START="0.23534234492350953" EFFECT_SIZE="1.1153846153846154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7231492234577518" LOG_CI_START="-0.6282999236014756" LOG_EFFECT_SIZE="0.047424649928138135" MODIFIED="2016-03-31 13:43:31 +0100" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.7938479187637595" STUDY_ID="STD-Wibowo-2012" TOTAL_1="52" TOTAL_2="58" VAR="0.6301945181255525" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-04-20 19:56:49 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-04-19 10:28:28 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-04-19 10:28:28 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWcAAAYFCAIAAAB1QY8FAABWaUlEQVR42u3dzW4cxd/F8ZGQEAsv
vPAVcA1eIYsVrLgnsvQiElnmLhCXgAgsQ1bsEOAg4kUWDuwgRP2Msf48g90v1S9V07/qz9EImcnk
uFJT/e166zq7HRHRWDVERGlCDSJCDSJCDSJCDSJCDSJCDSIi1CAi1CAi1CAi1CDqbX/2KKMGUWLL
S3mTUIOo6W9yGiRqEBFqEC3d6dAOUYNoHDKMTVCDCDVQgwg1CDVoJe0PMlCDiFCDiAg1aEXtz6Zy
1CBKbHyHP2iHqEE0jhrAgRpEqIEaRDnBoR2iBhGhBhERatARByYih1GDiFCDiAg1aI3tz/AENYgS
G9/gO4QaRKiBGkQLgUM7RA2ioWZn5RU1iAg1iIhQg4hQg4hQg4hQg6in/TkBEDWIEhtf1w+EGkSo
gRpEqIEaREdrfzaGogYRoQYREWrQOtpf68+EGkQDyAAO1CBCDdQgytf+rKGgBhGhBhERatD6Riia
ImoQDTQ+lYAaRGuhhi4MahBwjGvTKW8SalDMxrdop6DfQVNHDSJCDaKlxz5aOGpQ5YOUxZFhbIIa
VGd3YNkLGzVQgzZBjQWvbdRADUKNiS0bMlCDagaHdogaRIQaROFatk3lqEGu7bEDn8a8BmpQTY0v
t7MJUdSgEfdt1EAN1KCBbzHlzW2CQwtHDRpx4a38yzVniRpEq+hoEGpQnX3yTEfyNHlO7iDUqBkZ
ge7k2h5qEGqMb3x6BKhBqLFCJGkhqEGd36XhSSNBFjVoC10k1EANotGDiGWb4qGVFo4alHoRqgRT
G6hBw7dWT3kSatAUajRxJkR1B1CDUGPK1IMJCNSgI4Mj6MqrpogaRKiBGkQ52l+GeQ1rKKhBA3fs
WGuNucumSaMGVUs61EANoukjiHx7Qwk1qPQcQbgegb2hqEFTrsAtHzVMqEF1UgM4UINWdAVG3E6+
+LyG4Qlq0Ihrb+Nfq/1jqEGEGqhB9N+O0rIXNmqgBlXeI8jxnK7BGmoQahBqkMaHGqhBK5kjiLU9
dNkCS2xEDRp93yZCDUKNBWpD/aAGVQKOHCMUe95Qg6ZfLZvtEWjSqEHGEYQaRA8wsfi5oWCEGlR6
juAoo6pFCq8XgxrkOllRbZhkRQ3XySpKu3jJc1zbrVYbvIJQAzVcgWshHWpQDfMaua9tvX3UoMr7
L4HurplO7mgC5umiBtG4C3tZxnlOFzXquULKJBKFS1pBDdSgqq5A1EANWtccxMavk9xp9ZtFBmpU
9BVmG6HkoIYnU1GD1tjX2PLd1U5Z1CBaUS9G/wg16uxuRPlOi+WhLO6cYycIalA9ffJAMybF6tka
CmqgxhHurmVSlAKVGTXoyEP69V8nQXdV2FGOGrSKHkEU0hFqUJ13V9RADTrmSN547ZA7dqahhnHE
uq5tTRE1KDY1ct9dNTzUIH2N41Oj/N5Q1CAj+fDgeOicddepeQ2icjwqOfZZvzNqUIVjn0DXSe79
9VtGBmpU2BEIdN+O1T9yJghq0Crurq5A1CC9mFm9mNyemjpqUPtF3oQ9cWvBekh5k1DDIKL9hw2C
owm7Dh2izKiBGusaAW357h2lf4QaqEFzYZe1w7XC7xE1qm3NKiTWkCpeS1MRVPLuGpd0uRMkVj42
QQ068nUSdN93vqWfKGNM1Kjw8s50ml4IahTYY+LEdtSoEBnh7q4F+hob/wZRg4q2OWdVFL4a1w8+
3xZq1HwFIh1qUA13qpIMDTSqQg2q+b6dqYu02RncAv0j1KARrTbHzsVYCWlRqBEodxo1ahub9L+5
EWpEnMG1hkL1jCOC9jXi9hlRg/AotZekHdpRTrQK0i3FI4mNqEErurVuubePGlThVZ17ZjEWNTI9
OxOrF4MadPxBRIgnwSQboMYmLsLV3l3L18b6R1WoQTXMEbi71kE61KDS98Dcp1dFSWPIPfsQqE+H
GsBx/AJn2lEeq3+EGnT8SY315yGXXOmI0vMKcQ9ADTraPTAiNXKYh5s/Qg06Zs+5wDP4gfp0wTq2
ro36BikhnEsO2bQQ1KByPYIKakM9owZV0poD7cWyewU1UGPKBdNkPm4r4lleRihkXqPzOgnxJFhP
vyBimWXKU+xeTO7TPde/NzT3hd1aGzLlCTVizxSUn2dFDcrV2iSk9cAuaFo9ahDVM6oqSWfUoNJ3
KtRYfFS18o4AatAxZwfi7lAoRo3GLi+qqa+hQrIu+mz56X7UoKr6R4U7Mts8WxA1ar4UF3devHEH
2q+ht4ga1ba5fPu+A+0NzdEjyJ3CHQgcqFEnNZqYZ+esvMy5U7jNaxBqjL5U1l8bTcw9b6hBhfrk
ca8T66OoQTRrNLHxzATUoNQ5gkh3Lef06WtQZeCwQ+EoX5++BpW+acsfCJTqJtmA6rwH5j6VJ1CZ
y5wSZoRCqFFV/6jAKaqoQeU6uk2Gfd+xljDj7l5BDapkHBGaoYHOXjavQeGpUebJC8+8RiWyqw41
Bscm/W+uao6AUIOO2Sdvwj4tkqNHEDQrGzVI/+g447Wsuyrs8iJaRY8g0M401KDjj1CcUd6EWlFC
DTp+m1MhmZAhrQo1UKOee2D5XoyVVwKOgZuqsY/ddKhR86TGBp+q6rq8nS2IGlTnrdtOkCi8Rg2a
0pFZ+bVtDQU1aNy13QR5EBM1eqraCIWKdvUzXYGBytxkWHktsDc0ytwzaqDGkcERbjFCyiRqoMaU
e6B63jI4UKPCeY1wB1XkuAIjPmMW5YRk1KDjAy736oxzA1CDjnaRN5tfnYk4xkQNGnf3dgUqM2pQ
0q07x+mhgbJFmpine9pRTkdDxrJD+qDZa4QadDRqNPnn/6iRokTr6d+uP+I0bj03GVZnUINoBOZC
NEW76VCDJjZo4win8qAG1Tb7kHuPSayMO9SgeqgR7uSOJs/ccNaMO9SgesCRb9933PM17NegGvrk
jbO8CDXq7g44lSf3fdvcMGqgxpHnNVY+hi9ZG6hBlVDDpaIqUKP+eY2sMYKBOgU2wqMGId1aRlUl
TxtGDaK+azvQDG5u8zWv/qBGnRdhlLP8812TufeYFGMoalC8+3Ys0sWd10ANQo1j9mVyB7iUmXg2
QqHSF2GI+3bE2QdCDUq9Atef0wEcqEFrpEaz3LPhhTNT9elQgwq1OU+C9XdhNnj2MmpU25ozdTc2
3lpQAzVQY0XFjpWrmKPYThsm4FjRfXv98xpOG6bjT2qsP+s8KDUINWjEpEag+zZqoAbVSY1ina9M
A6sF87eNUOiY10nj5N78DN1yLwY19AiOcN8Od3ctQI1APEIN1Ki/U7DyNd3cJxKgBtVDDfftoCMd
1KhwXiPE/F/Q837sDUUNqvY6iTiOsDeUUKOeu2uBMpvXoCMPTwI9Gx6LdIQaG+ogbIR0BWZMJDai
BnD4t6/lF8mUp3quHHfXAvVslxcdv7cf4r5dwTgCNYjKUaPYOcYhul2oQcAxmhpN2KRF8xpUyQgl
66oEamhsKrS2HkG41JLcp+ltsEeAGlTPqFg9G6GQ1qyet8V97aDaqY2N8yhcbaAGubtWewUGOpEA
NQg1Krxvd8FozUNC1KhwhNLEeT4i093V3DBq0IjrJNYJgPnurmZwUYMqpAYV6y2iBpWmRsT9Y75B
1KCj9cnNEZTpEaAGVXgPXJAacZ83yXdtowbpxQxfITkaXrGH7gNlZaMGJTXouAsoa3ZuzDqjRq3I
iNKag45Tgp6ZtuAdBTVQgyrH6OJtAzVQY0XjlIg9gvWfdYoaNPBdxkJGvitwcedwye+oQSvqEchw
3vgdBTXoaNeJZ15j30VUBB3l7hrxdM8oT4ugBlULjqBVEXrW2bwGlW5wEmSbzHtDm5xPuJjXoFz3
EypMjUDOmpdBBM2i8wZ5hBqocbTrhEqOfQ6/SiMUyguOwrsh1/8AGzqjhnmNo1Gj6TglbMGH8Rd0
jrs3FDWo9Ail/F6sHKf+RDmMM8d3tzjpUAM1jtZzRo2eqtbXoPDgKMmjfMkGgTIT1nxhoka1kxq+
1ljjtax9jWUbhuZFpUfFqFG4c7F4mVGD1tVFCuEca1SIGlR6vB3xrIrc0w3L9r8K9OmWJR1q6DkX
vUKiUyN6V87KK8XuEQBHmW8wF4xcdaixkjvhyp1zzJiE23WKGuY1jnCd1ETnDXaOUINSW/OWz7yL
O/BBDTo+NZrldnzn6JMXXo/Ih6Q1Fxg1ahuYSDYtX+GZru3VggM16uw8L95KDpuLSi7jvNq5YdSo
tjUHONYlzwgl6B6Txqk8hBor6R9ldd70GM1VV994e/1XYNDExojr0MtmJqAG1XltB+15FchDaTy9
RqHHPhETG3PXs2QDOtoIJcS1bSSIGrSiHgEFHa9lzYJ0lheFp0a4U3mCjteyfGuuOuA4Yp88VlXo
5aFGtZMaEVc6QvS8Is7y2BtKlYzkGw+edxN/zftZUYOO2deIeCqPoStq1DxI2XKfvMxFGGiEghrU
2SycnRN6vLbs3lCnDdMIajSrf+a1iXkqT9D9GkYoVKjNhTsF9ygjwfVzX4oSJTU73ynuG6FQzbfr
LacElOzFGKFQ4Gu7smrZaA24Qupox1nvMBS0VhdnHGpU1Y4PVxCyNsFlSZdpi9fizvmocVjI9S/6
oEZt1MjarHM05cXjzjM5Z50mKFAbC/4TUKPCvkYmWGS68GJRI98eE9SgGqiRb6IkdF+j2DeIGqSv
gRpHKLN5DUrtM+c7vHflZQ66E+Se1cofPkQNmtJi1IM2oBEQEWoQEWoQEWoQEWoQEWrQWr4korJC
jdjU4Mx5Pc6ogRqcOaMGanDmjBqowZkzapDWzBk1CDU4owZFocbN25vLq8uLFxen357uvt6dPDs5
f37+6OdHr/96zTmE87t3N2/eXF5fX7x8efrLL7urq5NXr85vbh69ezfX+e3NzdXl5YuLi29PT7/e
7Z6dnDw/P//50aO/Xr9Gje1S4+lvT8++O9s34oevfeN+8usTzit3/uOPpy9fnu1h8fC1h8jvv093
/u3p0+/OztqKvNtD5NcnT1Bji9TY3+ha2/Hha/8Zzqt13ncoWnlx+Np/ZoLzvkMxVOTd/jOosS1q
7O9+g0357tV1J+R8XOd9L2MQGXevrh5Hl/O+l5FW5F1Xj2Nb1OjaFZv+z5wQmdeVSDLnzf6S78fY
XR3m1i709Z/XnFfl/O7dzeHA5Jtvdh9/vPvgg9vXZ5/tvv/+/lDl779Tnd/e3HQNTFqHKn9eX6PG
bj4CRv2VVjbNfHPw+7u8ukxsyj39Z85HdH7z5vKQCx9+eHslfvXV7ssvb3/46KOkcUqr89Xl5Zgi
t49TUOP/f+jpgNzL3Wk9ynGwropR4+LFRcv3f6e2pnH+/Jzzqpyvry9aByM//njr/f77999/9SrV
+cXFxShqPD8/R41OavTHdvf8afpIpxg17hb/0lvzybMTzqtyvltkvff64YfdJ5/cen/xxf0/urpK
db5bZE1/PTs5QY3heY2x1EivzZm/Lv03trfjQz1oHZxX5dza0fj001vLzz9vnxNNdH7IhbOBIu9Q
Y3heYwI1Es8dmECNQ17oa2y8r/Hee7fGP/3Uggx9jWDUSBmh9CSVzRyMmCPY1LxG18u8xuqo0T/r
MWEQYQ2F86g1lLvXndL3ellDOcK8Ruvo4PCd1jfTf6P9GpybtP0a/dSwX4Nm9Z7+lX2W0Z3tDaXS
1Gg80xHf2XMoVJoad3fC9nn+fzrMj18+5rxy53+eeT3tfuZ1uvO+x9G1nrJ//+Xjic6oEZ4aTfe5
D61jbM4rdO46X6N1LmOUc9f5Gq1zGaixIWpw5lzSGTVQgzNn1EANzpxRAzU4c0YN0po5owahBmfU
oPVQg0imPLkHctbXINTgjBqEGpw5owZqcOaMGqjBmTNqkNbMGTUob8vIl0iezzliPnvEMudwRo3w
1MiXSJ7POWI+e8QyZ3JGjdjUyHcSVD7niOdiRSxzPmfUCEyNfKdO5nOOeAZnxDLncw5PjZQNsMX+
dT1nl3eVuf+T/f+EfInk+Zwj5rNHLHM+50qocRRAdNVjV2H6E0+m5aHkSyTP5xwxnz1imfM510yN
w+CSxICS9D5CVzHGZq/NpEa+RPJ8zhHz2SOWOZ9z5dRYNj5+wcTG9Hin/jfzJZLnc46Yzx6xzPmc
a57XmHafz0SNVoQ1szPl8yWS53OOmM8escz5nOsfobT+3MOXxD5C+pxlelL8hEz5fInk+Zwj5rNH
LHM+5y1SI6UDkt5PGVXLi7+ZL5E8n3PEfPaIZc7nvDlqrGReYw7jeubJF0wkz+ccMZ89YpnzOW9u
XiPfGkr/CCVTpny+RPJ8zhHz2SOWOZ9zDdTYiOwNVWZ7Q2kZajSeQ1Fmz6HQ2O+vyZlIns85Yj57
xDJnckaN8NRociaS53OOmM8escw5nFGjBmpw5lzSGTVQgzNn1EANzpxRAzU4c0YN0po5owahBmfU
oPVQg0imPLkHctbXINTgjBqEGpw5owZqcOaMGqjBmTNqkNbMGTUob8vIl3XOmTNqVEiNfFnnnDmj
RoXUyHfGFGfOqFEhNfKdZ8mZcyXU6Drdu/ClOzZFKdMZ5fnOzubMuRJqjApGLU+NxEz5BfNQ8uV0
cOZcAzV6EtL+DTocvHu3fnLsX+8pTGFq5MsE48y5Tmq03uQHL87+QOaxKW39hcxNjXz5o5w510+N
xEtu5mU8mRqjaDUi/DVb1jlnzhulxsNjAkYBouevz8yUT3/TPZCzvkbGeY18b85ZQ5kw7jCvwdm8
RtE1lMGBQE3zGub2OVtDSQJH4gJna58/3xpK/wjFfg3O9mtEVfptPMq0jj2LnO0NRY3Rk8Gej+Bc
3tlzKE1oajQ5s845c0aNOqnR5Mw658wZNeqkBmfOJZ1RAzU4c0YN1ODMGTVQgzNn1CCtmTNqEGpw
Rg1aDzWIZMqTeyBnfQ1CDc6oQajBmTNqoAZnzqiBGpw5owZpzZxRg/K2jHfvbt68uby+vnj58vSX
X3ZXVyevXp3f3Dx69+415wWd8yW/x6oN1AhPjT/+ePry5dm+QTx87RvK778/4byIc77k93C1gRqx
qbG/abS2icPX/jOcZzrnOxcrYm2gRmBq7O8kg83i7tV1V+Gc4pzvDM6ItVEbNQZ3wi4ypZTjjPKx
znfj1cPO5zff7D7+ePfBB7evzz7bff/9/e7o339fc57gnO+874i1URs1igXNL54p3+XQ/xvfvLk8
/O4//PD2r3/11e7LL29/+OijpL4o50HnfNkiEWujKmr05Ly3Zi/2pKIkfrj1d5WkxvX1RWuH88cf
b33ef//++69enXOe4JwvxyxibVROja4PpAQjTchznEmNnpDXrvfvFtLuvX74YffJJ7df6Bdf3P+j
q6sTzhOc82WmRqwN1ChEjZT4+AnUaL2ZfPrpre3nn7fPe3Ge4Jwvnz1ibWyIGl1Z8yldgP4Pp8yG
NmlRkov0Nd5779b8p59amsXMO9VmnQv3NVZeG5uY1+gfOMz88Kha7v+l/UehjBq7dr3mj4q36Vx+
XmPNtbGVNZRR0w1j5yaWmteYwKN78+R3rzul7+fhvJ41lBC1URs1utY7Cqyh9I9QyuzX6G8Zc1b7
N+5cbL9GiNqokBq1yg7O4zrbG4oaVc31elqkjLPnUFCjqhWif55rPO1+rvEx50Wc8yW/h6sN1AhP
jab7DIXW8Srnyc75kt9j1QZq1EANzpxLOqMGanDmjBqowZkzaqAGZ86oQVozZ9Qg1OCMGrQeahDJ
lCf3QM76GoQanFGDUIMzZ9RADc6cUQM1OHNGDdKaOaMG5W0Z8tnLlPntzc3V5eWLi4tvT0+/3u2e
nZw8Pz//+dGjv17LlKdQ1JDPXqbMvz19+t3ZWeuJPHuI/PpEpjwFoYZzscqUed+hGDwAcP+ZjXyD
qBGYGs7gLFPmfS8j8Yjyrh6Hc0ODXW8pO2QXuYbnnFHeX0L57Ecs89ubm66BSetQ5c9rmfK1zyMu
i6euX50eAZmeeCCfvUyZry4vxxS5fZwiU74GakxLbOxKY52ZKT+NGvLZy5T5xcXFKGo8P5cpXyM1
+mOZB39ePHttGjXks5cp890ia/rr2YlM+YrmNfov9UN89PcdMmXKj53XkM9epswPuXA2UGSZ8rWP
UBKpMSexsUnOlJ/f15DPvniZC/c1ZMqHGaH0UyMlaL6Zlym/4LyGfPZly1x+XkOm/Kqp0RP7nJhK
f8R5DfnsZcpcbA1FpnyMEUri3OfgGkr/CKXMfg357JnKXGy/hkx5KsE+e0PLlNneUNSohxqN51BK
ldlzKKhRDzUa+eylyrzvcXStp+zff/lYpjzFoUYjn71UmbvO12idy6j4G0SNGqjBmXNJZ9RADc6c
UQM1OHNGDdTgzBk1SGvmjBqEGpxRg9ZDDSKZ8uQeyFlfg1CDM2oQanDmjBqowZkzaqAGZ86oQVoz
Z9SgvC0jYvI757jOqBGeGhGT3zmHdkaN2NSIeOIW5+jOqBGYGhFP9+Qc3bmRKb/UNTznOPLBQlaT
/M45uvNWqFH4t+SIPqkm+Z1zdOdNU2PZTPnW3ziBGqPyUCImv3OO7rxdamTKlJ9JjbGBjxGT3zlH
d97cvEbKRT4nU34scWZSI2LyO+fozkYoC2fKF6ZGxOR3zvoa9YxQmgyZ8qOokTjqSZnXWHPyO2fz
GuGpsWCmfP/UZg5qREx+52wNJfwIpVkoU75rw8WoTRxj/xURk985R3feBDXqZp+9oZztDaVm7Pfn
ORTO5Z1RIzY1mpjJ75xDO6NGeGo0MZPfOcd1Ro0aqMGZc0ln1EANzpxRAzU4c0YN1ODMGTVIa+aM
GoQanFGD1kMNIpny5B7IWV+DUIMzahBqcOaMGqjBmTNqoAZnzqhBWjNn1KC8LePtzc3V5eWLi4tv
T0+/3u2enZw8Pz//+dGjv16/Xq1zxHz2fLXR9dTyu3drdEaN8NT47enT787OWk9d2TfuX588WaFz
xHz2fLXxzwkpZ90npKzOGTViU2N/oxs85G3/mVU5Rzy9Kl9t5DuNLZ8zagSmxv7ul3gMddedsLxz
xJMy89VGvpNf8zlHpUbrvteZ/4r5ldBzdvm0N/vLth9jd3WYW7vQf15fH9054qnc+Wrj3inz33yz
+/jj3Qcf3L4++2z3/ffTT5nP5xybGiUnk9NB1lWeHEHzV5eXYyIv2vvPhZ0jJoDkq417iTYffnjb
hL76avfll7c/fPTR9ESbfM41U6M1muTetd0VofTwk/c+3xWYNJYa/Z8c/Pe+uLgY1Zqfn58f3Tli
2li+2uhKz/vxx9tSv//+9PS8fM7VUqMnDKn15/5P9vxpf6nSkTSNGneLf+mvZycnR3eOmGyarzZa
T5b/4YfdJ5/clvqLL6Yn9eZzrmReY+YooAcQowYRTW8GfT+Sps1rPGyvZwOx4bujO0dMUc9XG63d
gU8/vfX8/PP2mcujO9fc1+ifKy1DjdZBzYLzGvoaVfY13nvvtsg//dRyYc/sayzivIkRyuAoICs1
ss6GmteodV6j6zV/XmO+8+bmNRahxiLzGtZQrKE8XOnoz/ees4ayoPMW11AmU6N/DaV/hGK/xr+y
X+NQ93ZV9F/bc/ZrLOgcmBorZNZRfqO9oWWc7Q1FjcVWbdbAKc+hlHH2HApqVNW72d8Ju+b59++/
fPx4hc4R89nz1cY/T6aedj+Zujpn1KhhTNR17kPrGHslzhHz2fPVRtcpGK0zDkd3Ro1Nz6Rw5owa
qMGZM2qQ1swZNUhr5owahBqcUYNQgzNn1AhNDSKZ8uQeyFlfg1CDM2oQanDmjBqowZkzaqAGZ86o
QVozZ9SgvC0jViL5nWTKl3GWKY8aLQqXSN7IlC/lLFMeNdruqwFPgnKWVxlnZ3mhRvudJNypk84N
LePs3NCOQm87Uz5iIrkzyss4y5RPvYq2likfMZFcHkoZZ5nyU6gRIlM+vZdUTSK57LUyzjLlR1Nj
/ZnyiZzq//dGTCSX81rGWab8wLzGzFFA4Uz5rn5Qekjtv4qYSC5TvoyzTPkpfY0tZMpHTCTX1zhi
X0OmvEz5kInk5jWOO68hU36ZKzNupnzERHJrKEdZQ5EpP2sNZTI1mvVlykdMJLdfo4yzTPkYzDrK
b7Q3tIyzvaGosdiqzRo45TmUMs6eQ0GNqno34RLJG5nypZxlyqNGp2Ilkv87EyFTvoCzTHnU4Mz5
+M6ogRqcOaMGanDmjBqowZkzapDWzBk1CDU4owathxpEMuXJPZCzvgahBmfUINTgzBk1UIMzZ9RA
Dc6cUYO0Zs6oQXlbRr4U9Yhp9Zxztw3UCE+NfCnqEdPqORdoG6gRmxr5Tq+KeEoY5zJtAzUCUyPf
SZkRTyTlXKZtbIIaXbGsi/+W9JPHE08z7y9wvlO5I6bVcy7TNlAjy69IT0jo/+uDBc6XABIxrZ5z
mbaBGu03+f5M+fT89/4g6PnUyJc2FjGtnnOZtoEaSenziRd2el9jKWrkSzaNmFbPuUzb2BA1Uh4B
Tg9VHDtUyUSNfCnqEdPqOZdpG/oa95mSMh+R2NGor6+x8rR6zvoaRx6hTLiGR7Eg6LzGmtPqOZvX
KE2Nwb7GhAs7NzWKraGESKvnbA2l9AglfcW066punTSpY79GiLR6zmXaxlaoUSX47mRvKGd7Q6kZ
+/15DoVz+baBGrGp0eRMUY+YVs+5QNtAjfDUaHKmqEdMq+ecu22gRg3U4My5pDNqoAZnzqiBGpw5
owZqcOaMGqQ1c0YNQg3OqEHroQaRTHlyD+Ssr0GowRk1CDU4c0YN1ODMGTVQgzNn1CCtmTNqUN6W
IUW9jPPbm5ury8sXFxffnp5+vds9Ozl5fn7+86NHf73eVplRIzw1pKiXcf7t6dPvzs5aT7fZX5C/
PtlQmVEjNjWcXlXGeX9zHjxMb/+ZjZQZNQJTw0mZZZz3d+zE47677t41lbkGapSJjB/0T8+UH5U+
3/MbpaiXcX57c9PVyW/t9v95XXOZUSNLGSbkqkzLQ5GiXsb56vJyTLRIe5+/mjJvghopkfHTPjBY
ngUBIUX9iM4vLi5GXYHPz2suc/3USImMH8xh68+XPyI1pKiXcb5bsEx/PTupucz1UKPrCd9R1+20
D6QMVRKpMXZeQ4p6GeeH19jZQDx7zWXeRF9jVGT8camxSF9DPvvizoX7Gisv87ZGKPMv7EFqpGQ+
F5jXkM++rHP5eY01l3m78xo5qJGYKZ9vDUU+eybnYmsoIcq86TWUZakxKlM+034N+eyZnIvt1whR
5kqosQXZwXlcZ3tDUaMeajSeFinl7DkU1KiHGo0U9VLO+7t319rE/v2XjzdUZtQIT41Ginop566z
KlrnBSouM2rUQA3OnEs6owZqcOaMGqjBmTNqoAZnzqhBWjNn1CDU4IwatB5qEMmUJ/dAzvoahBqc
UYNQgzNn1EANzpxRAzU4c0YN0po5owblbRmS38s4R8yUz+GMGuGpIfm9jHPETPlMzqgRmxpO3Crj
HPEsr3zOqBGYGk73LOMc8dzQfM6boEbiEeFdfytxm61M+VqdI2bK53PeIjV6fu7635TMepnyFTtH
zJTP57w5agx2KCZTY/DX5aCG5PcyzhEz5fM5o8b9zzz875qpIfm9jHPETPl8zqiRSo3Ex4ebqcFu
06gh+b2Mc8RM+XzOqDG6rzFYUSWpIfm9jHPETPl8zqhx/49SRiiD6ClGDcnvZZwjZsrnc7aG0ncB
j6WGTPlanSNmyudz3iI1mqH9GoPUaGTKy5RffaZ8PuetUKM+8P0rOzjLONsbihr1UKPxtEgpZ8+h
oEY91Ggkv5dyjpgpn8kZNcJTo5H8Xso5YqZ8DmfUqIEanDmXdEYN1ODMGTVQgzNn1EANzpxRg7Rm
zqhBqMEZNWg91CCSKU/ugZz1NQg1OKMGoQZnzqiBGpw5owZqcOaMGqQ1c0YNytsyJL9zLumMGuGp
Ifmdc2Fn1IhNDSducS7vjBqBqeF0T87ODS06/bPsv3qR48hlynOWKR9s0niRIk2OPhmbbCD5nXMj
U37aJfowgqTrWu3/5KBPYnRjMWpIfufcyJQfS41Rd/jEnKSUNxfPlB90lvzOWab88iOUyQiY4JMY
9ZqbGpLfOTcy5eeMUGZSI9EnvaMxrSTz+xoy5Tk3MuUXmW5Mv1bTRzqDtTzWduzaiuR3zo1M+cnU
6Jq2GEuNRJ/EC3tCfPycNRSZ8pwLOAcbofTsfWgdbkwYofS/Obj8MSdTfgI1JL9zbmTK06gJ4Mae
Rc72htJYajSej+DsORQa+/01kt85F3dGjfDUaCS/cy7rjBo1UIMz55LOqIEanDmjBmpw5owaqMGZ
M2qQ1swZNQg1OKMGrYcaRDLlyT2Qs74GoQZn1CDU4MwZNVCDM2fUQA3OnFGDtGbOqEF5W0bErPOb
tzeXV5cXLy5Ovz3dfb07eXZy/vz80c+PXv8l+X1J57c3N1eXly8uLr49Pf16t3t2cvL8/PznR4/+
ei1TfsPUiJh1/vS3p2ffne1h8fC1h8iTXyW/L+P829On352dtVXzbg+RX5/IlN8kNSKeBLXvULTy
4vC1/8xGaiOf875DMVTNu/1nUGNb1Ih46uS+lzGIjLtXV4/D6Z4pzvteRlo177p6HKgxXCPpQSd9
9Tg1U75/D281ieQ3b2+6BiatQ5XrPyW/T3F+e3PTNTBpHar8ee2M8vHUSE9UG/zAUiFPgwWImEh+
eXWZiIyecYrk90Hnq8vLMdXcPk5BjaTrvPW2P+HBnjLUiJhIfvHioqXN3qmtOZ8/l/w+xfnFxcUo
ajw/P0eNEdQYG7PYZMiUn0aNiInkd4us6dQ4eSb5fYrz3SJr+uvZyQlqpFJjwvXfZMiUn0aNiInk
7bw41IMWXXFt5HN+yIWzgWreoUYSNbrAkZ4vf1xqREwkL9zX2Gzyu75G0XmN9PT5UTOsJec11pxI
Xn5eY5vJ7+Y1iq6hDObLp6+zFF5DCZFIXmwNZePJ79ZQSlCjlRf9yyhdg5ppmfLz92uESCQvtl9j
48nv9muQvaHV1oa9oVSaGo3nUOLXhudQqDQ1mphZ5/seR/t6yj8Dk8cvJb8v47zvcXStp+zff/lY
pvxWqdHEzDrvOl+jdS6j+trI59x1vkbrXAZqbIganDmXdEYN1ODMGTVQgzNn1EANzpxRg7RmzqhB
qMEZNWg91CCSKU/ugZz1NQg1OKMGoQZnzqiBGpw5owZqcOaMGqQ1c0YNytsy8uWzR3TOkaKeu8wy
5akoNfLls0d0zpSinrXMMuWpKDXynYsV0Tnf6VURzx9zlhdqtN/9Mp3BGdE530mZEc86dW5olguv
J35tWoX0BDJNe7O/PPnO+47onO9U7mLnqsuUXzs1ZobId9Vjl0mOPJR82SIRnfMlgBTLcJEpv2pq
9Fy6DzsgD1NRuswnU2PwqyqcYxbROV/aWPm8OJnyq6NGT+paT9haStRrYWrky0yN6Jwv2bRwNq1M
+dVRoz9yrefDc6jRxaP+kMdhlGTLZ4/onC9FPV+ZZcoHoEb/OKI/aTHl3IGu2dBW82YoGlZfY5t9
DZny8eY1UkYoE+ZQU8YdY/+6eY1a5zVkyq99DWUCNXLMa0xY07GGUtkaikz5tVPj4eRFSmdk8Fi0
9sod2poxOPyxX2PQuYL9GjLlKS/y7mRv6KHsDS1TG6gRmxqN51D+K8+hlKkN1IhNjSZnPntE50wp
6lnLLFOeSlOjyZnPHtE5R4p67jLLlKfS1ODMuaQzaqAGZ86ogRqcOaMGanDmjBqkNXNGDUINzqhB
66EGkUx5cg/krK9BqMEZNQg1OHNGDdTgzBk1UIMzZ9QgrZkzalDelhEx+T1finpE51j1jBrhqREx
+T1finpE53D1jBqxqRHxxK18p1dFdI5Yz6gRmBoRT/fMd1JmROeI9Xx8aqQnCa18GnJmfPxGMuXz
pahHdI5Yz2ukxtp6PYnlmRkfv51M+Xwp6hGdI9bz6qiRHvveH6HaJAeaPDS8Z9sf49j/L5Ip//DN
fCnqEZ0j1vO6qJEYXNbDi35qpBim/GmTnJMmU/7hm/lS1CM6R6znFVGjf3ZjVG+i9b8FxgujSjh2
Tqea5Pd8KeoRnSPW81qo0R/1viA1Hh4cMPa3jAptzE2Navoai6SoR3SOWM9R5zXm9zWWmsVMn9lN
8dlCpny+FPWIzhHredVrKNPmOxfB0OCsR+KwRab84Nz+ginqEZ0j1vMaqdF6fS5CjZ41lK7BSMqb
PcOfRqb8A+VLUY/oHLGeV0ENmsbWO9kbGt3Z3lAqTY3GcyjxnT2HQqWp0cRMfs+Xoh7ROVw9o0Z4
ajQxk9/zpahHdI5Vz6hRAzU4cy7pjBqowZkzaqAGZ86ogRqcOaMGac2cUYNQgzNq0HqoQSRTntwD
OetrEGpwRg1CDc6cUQM1OHNGDdTgzBk1SGvmjBqUt2VEzJTnfKi3NzdXl5cvLi6+PT39erd7dnLy
/Pz850eP/nq9xjKjRnhqRMyU53yo354+/e7srPVEnj1Efn2yujKjRmxqRDzLi/Oh9h2KwQMA959Z
VZlRIzA1Ip4byvleLyPxiPKuHkf5MsegxoTc+cRM1mULmZ4U33PKefr3F/GMcs735jK6BiatQ5U/
r49f5kjUaE0YSKFMmX/ahAy3UQWuJg+F86GuLi/HGLePUwqXuRJq9EScdF2xo2Llx/ZfUiKaFqFG
xOw1zod6cXExihrPz49f5mAjlP4cxv5kxv7LOMVtqUz5wf+tO1Oe86HuFlnTX89Ojl/mqqgxdkiS
nuo6ihrpKXDzqRExU57zoR5ev2cDxscv8xapMSFW/uFfXAk13Lf1NfQ1clFjQlj8tC5MOgvMa3A2
r1FohWLCvEP6XMbMeY1RgxprKJytoRyNGl0LsT0bJdJz6tPXUEZlyjf2a3D+R/ZrUAlu3pN9ltGd
7Q2l0tRoPNMR39lzKFSaGk3MTHnO93ocXesp+/dfPl5dmVEjPDWamJnynO/NcbSer9E6l3H0MqNG
DdTgzLmkM2qgBmfOqIEanDmjBmpw5owapDVzRg1CDc6oQeuhBpFMeXIP5KyvQajBGTUINThzRg3U
4MwZNVCDM2fUIK2ZM2pQ3pYhn/1Q797dvHlzeX198fLl6S+/7K6uTl69Or+5efTu3RbLnCOtHjXC
U0M++6H++OPpy5dn+wvv4Wt/Qf7++7bKnCmtHjViU8O5WP/pC9w8ar32Dl/7z2ykzPlOCUONwNRw
Bue9O/bg5Xf36rp711TmfCeSbosa/VEp/XtpU0JeE/9W+sHl/X/kvO978wKHnfxvvtl9/PHugw9u
X599tvv++/vd/r//rrnM+U4/3yI1urIL0tNMesIHUlJO0oMUBr8/2SKHevPm8vAa+/DD2/r86qvd
l1/e/vDRR0l9/mrKnC9pBTWSqJEe7zaZGq1/ffD7k2N2qOvri9aO/Y8/3nq///7991+9qrnM+VLd
NjpCGZv8mF45c/oaE6ghM/VQdwuW914//LD75JNb7y++uP9HV1c1lzlfgixqJM1rzKdGa6emf0ST
8v3JZz9U6037009vLT//vH1+seIy50urR425XYDE2dCuKQx9jdz37ffeuzX+6aeWy2+1fY1Fyqyv
cYQRSn9fY1Qaa99NbB41zGukzBF0vdY8rzG/zOY1FqZGMxQ33YzPfD/KvIY1lJ71iLvXndL3TVVT
ZmsoR6BG6yVtv0ag/Rr9V+A692ssWGb7Ncje0CRne0MPZW8oangOJcnZcyiH8hwKanRKPvu9u3fr
2sT/nh/dVpkzpdWjRnhqNPLZH8wXtJ5V0TovUH2Zc6TVo0YN1ODMuaQzaqAGZ86ogRqcOaMGanDm
jBqkNXNGDUINzqhB66EGkUx5cg/krK9BqMEZNQg1OHNGDdTgzBk1UIMzZ9QgrZkzalDelhEx6zxW
inrueo7ljBrhqREx6zxcinrWeg7njBqxqRHxjKmIp1c5Mw01KqFGxPMsI56U6XzWjVIj5ZDxOVNN
6ceR97+5S07Biph1HjFF3VnwG6XGtATGmf5jM+XHwiti1nnEFHW5M1ukRn/ySFewa2s4W0pdTaBG
uuehImadR0xRl3GHGknXcH+Yc2K/YBQ1+gdQ1WSdR0xRl6eLGsM3+bFJiylDoWnDloE3A2adR0xR
z1fPEZ1Ro2+EUpIaw42glqzziCnq+hqoMXxlTqbGzHTosW9GzDqPmKJuXsMaSrlBRO4RSsSs84gp
6tZQNkqNpjfJff4IpevctJmbOPq/v4hZ5xFT1O3X2C41Khtk3cne0EPZG1rGGTViU6PxHMp/5TmU
Ms6oEZsaTcys83Ap6lnrOZwzaoSnRhMz6zxWinrueo7ljBo1UIMz55LOqIEanDmjBmpw5owaqMGZ
M2qQ1swZNQg1OKMGrYcaRDLlyT2Qs74GoQZn1CDU4MwZNVCDM2fUQA3OnFGDtGbOqEF5W0a+FPV8
zhHT6jmjRiXUyJeins85Ylo9Z9SohBr5Tq/K5xzxlDDOqFEJNfKdlJnPOeKJpJynUCNxn+myHe+U
X7Qq3qUcgN714QlnlOc7lTufc8S0es7TqZHjWq2JGq1hBf2MSPlkz5v5EkDyOUdMq+e8PDUS0z1a
M9kTkxPT79hjS3VYpMHok8FiTKbG4L+ocNpYPueIafWcF6bG2Nj0rk/2X2D9Q4D+0iYWtSsyfvHE
xi7ETKBGvmTTfM4R0+o5LzyvMTOUcCw1JlxjS0W6zqFGV7drVNfp4Zv5UtTzOUdMq+e8TF+jnyaT
b/XpoYqDUOjPT5zcVxo7Z9kz/JlPjWr6GitPq+e8PDWWGiBMXqTIV6qxJeyv5UH6pPz1Wuc11pxW
zzkjNaLMa3SVZMJkx7R5jaUGYhWsoYRIq+e8MDWyrqGM+qOHQ4+U5ZIJb47qESSOrQaHP7Xu1wiR
Vs95IjVyb81YyYaLcGWzN5TzeveG1npN5tjwWrj2PIfCubyz51AC6Fgp6vmcI6bVc0aNeqjR5ExR
z+ccMa2eM2rUQw3OnEs6owZqcOaMGqjBmTNqoAZnzqhBWjNn1CDU4IwatB5qEMmUJ/dAzvoahBqc
UYNQgzNn1EANzpxRAzU4c0YN0po5owblbRk3b28ury4vXlycfnu6+3p38uzk/Pn5o58fvf5rvVnn
yhy3zKgRnhpPf3t69t1Z67E5+4by5Nc1Zp0rc+gyo0ZsauxvGoOn9O0/M8E530lQyhy9zKgRmBr7
O0niOeJdd5Xyp04qc/Qy10ON+an3MythbLLs/Ez5/Xi1q/PZ2h29/vP4ieTKHL3MtVFjJgLmVMKC
EU3pyQaXV5cjMks6+qKFE8mVOXqZt0KNlHv7YJxKa55Lf0kWDHZr/cDFi4uWFtAVxPr17vz58RPJ
lTl6mTdBjaWiqrty2BakxtgRyt1CWnrLOHl2/ERyZY5e5k3Ma6Tf2+dnyvd8bCaS2t9sbRO90e+J
zvkSyZU5eplr7mukXMZdfDkKNSbMaxS+By6SSK7M0cu8aWpMGKGM+l0FqFF+vD0/kVyZo5d5u9SY
Nq8x9sKuZg1lwURyZY5e5k1QoxmTej+4htIDiK5ZlQr2ayyYSK7M0ctcFTXqlj2LymxvKC3Wk/J8
hDKXLzNqxKbG3V2lfc78n87n45drzDpX5tBlRo3w1Gi6z1BoHa+Ocs6Xda7MccuMGjVQgzPnks6o
gRqcOaMGanDmjBqowZkzapDWzBk1CDU4owathxpEMuXJPZCzvgahBmfUINTgzBk1UIMzZ9RADc6c
UYO0Zs6oQXlbhqxzziW/QdQITw1Z55wLf4OoEZsazpjiXP4bRI3A1HCeJefy3+AC1Jgf5j5nguco
8fH99TD4ZjMmvqDnj2Sdcy7/DS5GjTIzumumxqiUky6OjKWGrHPO5b/BvNT4N/G49a7bHzWSaNJ0
5yr3f3JafHxifyoxCPrhXxlLDVnnnMt/g9mp0XP9pFNjQq5ysU9OoMaCIxRZ55zLf4N55zUGY8QO
AdHaxWimhi2PvfNPfjNxqJKJGrLOOZf/BrP0NXquk9ZBSiZqdP26mqgh65xz+W+wHDUGR/jLUqPY
m+kTwzmoIeucc/lv8AjUSIxcXooaJfsaiZnyC1JD1jnn8t/gEUYoiX341mu1GRP1/vDXzY+P71lD
GZUp30TbrxEi65xzmW9wGWpQAdkbyrmqvaF0RGo0nkPh7DkUGvv9NbLOORf/BlEjPDUaWeecy36D
qFEDNThzLumMGqjBmTNqoAZnzqiBGpw5owZpzZxRg1CDM2rQeqhBJFOe3AM562sQanBGDUINzpxR
AzU4c0YN1ODMGTVIa+aMGpS3ZUhRP1SOFPU7vb25ubq8fHFx8e3p6de73bOTk+fn5z8/evTX622V
GTXCU0OK+qEypajv9dvTp9+dnbWem7O/IH99sqEyo0Zsaji96j/9l2ynV+1vzoPH9O0/s5Eyo0Zg
ajgp894dO9NJmfs7duJB4l1375rKvDpqpO9pnTkVlPivTj9MPD1TflT6fM9vdCr3vXmBTCnqb29u
ujr5rd3+P69rLvNKqTGKC0fJlE+MPskattJIAPmv8qWoX11ejilye5+/mjLHo8bimfKJmfX3uidz
0qEXpIa0sUPlS1F/cXEx6gp8fl5zmYNRI1NSfHqMW+LQphg1JJseKl+K+t2CZfrr2UnNZQ42r1Ey
vTU9cTZlqNKMibMeMb0iRf1A+VLUH15jZwNFrrnMa+9rpIQt93QrJmfKl6eGvsaaU9QL9zVWXuYA
I5T5F+HkO/8EaszBnHmN1aaol5/XWHOZK6FG+rzGItToCYhedmHFGspKUtSLraGEKPMW11D6eyWT
11BGZcrbrxErRb3Yfo0QZV4jNSidGo29of+VvaFlyowasanReA7lXl/GcyhFyowasanRSFF/cPfO
kaJ+d/fuWpvYv//y8YbKjBrhqdFIUX8wX7B4ivq/8wWtZ1W0zgtUXGbUqIEanDmXdEYN1ODMGTVQ
gzNn1EANzpxRg7RmzqhBqMEZNWg91CCSKU/ugZz1NQg1OKMGoQZnzqiBGpw5owZqcOaMGqQ1c0YN
ytsyIuazR0yr54walVAjYj57xLR6zqhRCTUinovl/LHozqgRmBoRz+B01ml058DUKJM+n/63Rp08
3nPKeXoxIuazO1c9unN4aoy6wrNSY0I44+BfHyxGxHx2GS7RnWumxuLp84PdgURqtCaqrC17LV/W
uby46M7VUiNT+vzYTk1iZm2zvpzXfFnnsmmjO1c7r5E7fX7sUCUTNSLms0dMq+dcZ1+jQPp84gil
JDUi5rO7b+trrGiEkjt9PqU201kQdF5jfta5OQLzGsGokSN9Pn12dnFqRMxntx5hDaXmNZRW1nTV
1ahM+Sbafo0Fs87tfYjuHJsam5K9oZztDaVlqNF4DoWz51Bo7PfXxMxnj5hWzxk16qFGEzOfPWJa
PWfUqIcanDmXdEYN1ODMGTVQgzNn1EANzpxRg7RmzqhBqMEZNWg91CCSKU/ugZz1NQg1OKMGoQZn
zqiBGpw5owZqcOaMGqQ1c0YNytsyZJ0fqus53XfvZMrLlEeNfyTr/FD/nAly1n0miEx5mfKbp4Yz
pv5zX3X+WBFn1AhMDedZ3utlOOu0gHMMaoyNj19wAmlEElpypvyo9Pme3+js7HtzGYcDk2++2X38
8e6DD25fn322+/5756pv7IzysfHx5amRIyNysBhyOg51L8Plww9vW/VXX+2+/PL2h48+kuGysTyU
CUHQTVuUyb1PTs5GmZMOPS1EVibYoHNXXtyPP956v/++vLiNZa/NjI9vjVwbm8PWBaAFqTF2hCJ/
9FCtZ6n/8MPuk09uvb/4QjbtxnJeF4mPn9kLGBxEzPzV6dGz//+mrPMDtXY0Pv301vLzz9vnRNVz
zZnyi8THr5waE+Y13AMH+xrvvXdr/NNPLcjQ16i/rzH/yixAjclEW1umfE3zGl0v8xrbmtcY1clf
Kl9+cF5j8YUVc/tz1lD6E62toWx6DaV1aSOxr7HgGsqoTHn7NQrs1+inhv0aMuXrlz2LKc72hpZx
Ro3Y1Gg8H3HvHus5lCLOqBGbGo2s8wc9jtb1lP898ypTXqY8avxvHCvr/HCOo/V8jda5DPWMGhul
BmfOJZ1RAzU4c0YN1ODMGTVQgzNn1CCtmTNqEGpwRg1aDzWIZMqTeyBnfQ1CDc6oQajBmTNqoAZn
zqiBGpw5owZpzZxRg/K2DFnnh5Ipn7s2UCM8NWSdH0qmfIHaQI3Y1HDG1H/u2M7yKlIbqBGYGs6z
vHdfdW5ogdoITI0yQfOjcqRlyh/RWaZ8mdoIT41ik8mjCiNT/ijOMuXL1Ea11JgTNH/4yaYtDyU9
/12mfElnmfJlamNz1EjMXktPZluWGjLlZcqvvzaqndeYGf46rTsw9rc0MuVlygesjXr6GssGzfcn
NiZ2NBqZ8jLla6yNqkYoufsaKbUpU36FI/ltZsrnq436qTE2aH7ZC9sayhFXDTaeKZ+vNmpeeZ0c
ND9thCJT/ujOMuXL1EZsamxK9oamONsbWqY2UCM2NRrPody7e3sOpUhtoEZsajSyzh/cY2XK564N
1AhPjUbW+YNRvUz5rLWBGjVQgzPnks6ogRqcOaMGanDmjBqowZkzapDWzBk1CDU4owathxpEMuXJ
PZCzvgahBmfUINTgzBk1UIMzZ9RADc6cUYO0Zs6oQXlbRr4Udc6cUaNCauRLUefMGTUqpEa+85o4
c0aNCqmR72xIzpw3TY1F0udT/lbrsen5zijPlxvOmTNqLJA+nxLgXDhFKV9uOGfOqDEuR7r1zt8f
4PwwgL4ANfLlhnPmjBqj0+db3xxMii5MjXy54Zw5o8b09Pn+TyZSYzCQbRo18uWGc+aMGuPS56dd
2D2zoSX7GovkhnPmjBrj0udHzYCk13KxeY35ueGcOaPGAunzc0YoZdZQFswN58wZNcalzy8+Qimz
X2PB3HDOnBt7Q+sD353sWeRsbyg1Y78/z0dwLu+MGrGp0eRMUefMGTXqpEaTM0WdM2fUqJManDmX
dEYN1ODMGTVQgzNn1EANzpxRg7RmzqhBqMEZNWg91CCSKU/ugZz1NQg1OKMGoQZnzqiBGpw5owZq
cOaMGqQ1c0YNytsyZJ1zLumMGuGpIeucc2Fn1IhNDWdMcS7vjBqBqeE8S87ODR13IaVkxC+YID8Y
zjbzOPKUOJV741VZ55xlyk+8qsdebzN/6WBUwtg3m+7c6Z5/haxzzo1M+UWokZIF//DN/vSTw8CU
lAd7pqFkLDVknXNuZMrPH+c/vDhbQ9W6eNH/w2Cm/Jy+xgRqyDrn3MiUnz+vMWfs0E+NwXmNsc7z
qSHrnHMjU/64Mw7hqCHrnHMjU37+vMZxqTE5HXoaNWSdc25kyi9IjckLGZPnNWYCawI1ZJ1zbmTK
z5/XGFwNmTaOuLfG0bMF4+FvL7ZfQ4o65wLO9cxrVC97FjnbG0rLUKPxfARnz6HQ2O+vkXXOubgz
aoSnRiPrnHNZZ9SogRqcOZd0Rg3U4MwZNVCDM2fUQA3OnFGDtGbOqEGowRk1aD3UIJIpT+6BnPU1
CDU4owahBmfOqIEanDmjBmpw5owapDVzRg3K2zJu3t5cXl1evLg4/fZ09/Xu5NnJ+fPzRz8/ev3X
6w0658tnV8+oUQk1nv729Oy7s32DePjaN5Qnvz7ZlHO+fHb1jBqVUGN/02htE4ev/Wc24pzv9Cr1
jBqVUGN/JxlsFnevrrtKTc75TspUz4GpkZgjv+AUUbrPnEz5wW28rW/ux6tdnc/W7uj1n9cVO+dL
UVfPgamRnh5SfoJ6fqb8hDcvry4Tm0VPX7Qa53wp6uq5Qmr0pMY3yZnyrb2A/v8dLOcEaiSmut3p
4sVFSwu4U1vLOH9+XrFzvhR19VwPNe79A7ouzpRM+ZSLfLCPMJ8aY1OU7hbS0lvGybOTip3zpair
5wrnNWYGtfaPCMZSo2Q6dHubONSDxlGxc74UdfVczxrKnD5Cz7X9cFSyWmq4Bw72NRZJUVfP1c5r
zKfG/BHKnEz5xFGP8XZTPEVdPddJjUUy5SfMevRXcW5qmNvvWUNZMEVdPVc7r9G/hjJqhNJDkJ79
FDMz5SdQwz6CQ+VLUVfP9cxrJF5vdciexRRne0PLOKNG+H+j5yP+c4/1HEoRZ8+hhCfj/q7SPmf+
T+fz8cvHm3LOl8+unlGjqv5U1xkKrePV6p3z5bOrZ9QwCuPMGTVQgzNn1CCtmTNqkNbMGTUINTij
BqEGZ86oEZsaRDLlyT2Qs74GoQZn1CDU4MwZNVCDM2fUQA3OnFGDtGbOqEF5W4bk9zLOEWvj7c3N
1eXli4uLb09Pv97tnp2cPD8///nRo79ey5TfMDUkv5dxjlgbvz19+t3ZWeuJPHuI/PpEpvwmqeHE
rTLOEWtj36EYPABw/xnU2BY1nO5Zxjlibex7GYlHlHf1OLZOjcHQtgV/xYJv9hdV8nsZ54i18fbm
pmtg0jpU+fP6GjX6/vGt+QYL/oqlApwGvz/J72WcI9bG1eXlmCK3j1NQ4/7/DsbHP/x80xZD3/Pr
FgSE5PcjOkesjRcXF6Oo8fz8HDWS/vGDjHhImZROSjFqSH4v4xyxNu4WWdNfz05OUGPcvEbPm4XT
oUfNa0h+L+McsTYecuFsoMg71Bg3gmg9U6A8NTbb11gk+T1ipny+MutrZJ8N7blQi2XKb3xeY37y
e8RM+XxlNq9RlBpjf+550xrK4KrBgsnvETPl85XZGkrGeY3+vPh0aiySKb/B/RoLJr9HzJTPV2b7
NVa3+LKektgbWsbZ3lDUCIaMxnMoK3D2HApqVIUwye9lnCPWxr7H0bWesn//5WOZ8hvu+Eh+L+Mc
sTa6ztdonctADcMlzpyzOKMGanDmjBqowZkzaqAGZ86oQVozZ9Qg1OCMGrQeahDJlCf3QM76GoQa
nFGDUIMzZ9RADc6cUQM1OHNGDdKaOaMG5W0ZETPlIzrnyGePWBuoEZ4aETPlIzpnymePWBuoEZsa
Ec/yiuic71ysiLWBGoGpEfHc0IjO+c7gjFgb4amRsvt18Uu3K3xApnyVzvnO+45YG+Gp0RNEUPjO
L1O+Yud82SIRa6NaavTntt7LQLn3ycQPpIQ25qZGxOy1iM75cswi1kZt1Bi883f9nP6BlE5NMWpE
zHmN6JwvMzVibVQ7rzHqypzwgRzp0BPmNSJmykd0zpfPHrE2altDmXY/XwM19DX0NfQ11juvkZUa
kzPlzWuY1zCvsRZqtE5PZKKGTHlrKNZQAs9rHPIiEzW6dlvIlK/P2X6Nmuc1KpYdnMd1tjcUNeqh
RuNpkVLOnkNBjXqo0cTMlI/onCmfPWJtoEZ4ajQxM+UjOufIZ49YG6hRAzU4cy7pjBqowZkzaqAG
Z86ogRqcOaMGac2cUYNQgzNq0HqoQSRTntwDOetrEGpwRg1CDc6cUQM1OHNGDdTgzBk1SGvmjBqU
t2W8e3fz5s3l9fXFy5env/yyu7o6efXq/Obm0bt3r1frnC+fPZ9zvtqQKU9FqfHHH09fvjzbN+KH
r33j/v33Jyt0zpfPns85X23IlKei1Njf6Frb8eFr/5lVOec7Fyufc77acJYXFaXG/u432JTvXl13
wvLO+c7gzOecrzacG7rM5VEsIz5TyRd8s//724+xDzvM33yz+/jj3Qcf3L4++2z3/ff3u9B//319
dOd8533nc85XG84oX/6OGggcR8mUf/Pm8rC9fvjh7ff41Ve7L7+8/eGjj5L6z4Wd82WL5HPOVxvy
UDJSIzEjvvWmnZJyMhguf/jJZjXp0NfXF62d5B9/vC3n++/ff//Vq/OjO+fLMcvnnK82ZK9lHL2n
ZMR3fbKfGhOcB6urGDXuFv/uvX74YffJJ7cl/OKL+390dXVydOd8man5nPPVhpzXjPMaM6+0Q0D0
dBZmXtjpXZueN7u+i9Y3W2+An3566/D55+1zdUd3zpfPns85X23IlM/Y9RgbsNg6SOmiRtfnS1Jj
cPiTfg98771bn59+amnKM/saizhX09dYpDb0NY4zrzFqBuQhNRYcRDQzMuWHbx1jxttdr/nzGvOd
a5rXmF8b5jVKUCO9R5AyxlnEuaeKC6+h3L3ulL4HqbBzBWsoC9aGNZSM8xrNyIz4lHnQpZwfFrtY
pvy9fQT9rXnOfo0FnSvYr7FgbdivsSGVry57Q4/rbG8oaizZCTo6pzyHUsbZcyioUVXv5p9nMU+7
n8V8vELnfPns+Zzz1YZMeTrCmKjr3IfWMfZKnPPls+dzzlcbMuUpzEwKZ86ogRqcOaMGac2cUYO0
Zs6oQajBGTUINThzRo3Q1CCSKU/ugZz1NQg1OKMGoQZnzqiBGpw5owZqcOaMGqQ1c0YNytsyYiWS
c47ujBrhqREukZxzdGfUiE2NiCdBcY7ujBqBqRHx1EnO0Z3rp8aofbJNbyBj6yHmD3/Rgm/2f38R
T7jmHN15W32NlH9jYj0sHn0yLQ8lYpoG5+jOW6fGw6DGnv8d7GuUp0bE5C7O0Z03TY3BgLXEPz0i
NSKmhHKO7owaqRMW6dSYmQ49al4jYiI55+jOqDFwSXdlzS9ODX0NzvoaGx2hTM6UN6/B2bxGPdRI
72uUz5Q3t8/ZGsqR11CaoQT5HmocJVPePgLOjf0alI68O9mzyNneUGrGfn+ej+Bc3hk1YlOjCZhI
zjm6M2qEp0YTLZGcc3Rn1KiBGpw5l3RGDdTgzBk1UIMzZ9RADc6cUYO0Zs6oQajBGTVoPdQgkilP
7oGc9TUINTijBqEGZ86ogRqcOaMGanDmjBqkNXNGDcrbMmSdH+rdu5s3by6vry9evjz95Zfd1dXJ
q1fnNzeP3r2b6/z25ubq8vLFxcW3p6df73bPTk6en5///OjRX69lylMoasg6P9Qffzx9+fJsD4uH
rz1Efv99uvNvT59+d3bWerrNHiK/PpEpT0Go4Yyp/9xXbx618uLwtf/MBOd9h2LwML39ZzZSz6gR
mBrOs7zXyxhExt2rq8fR5bzvZSQe993V43BuaGrLzmQ76u8mRsnPL4lM+eM6v3t3czgw+eab3ccf
7z744Pb12We777+/P1T5++9U57c3N10Dk9ahyp/XzigPTo0FyzM2ck0eSknnN28uD7nw4Ye3rfqr
r3Zffnn7w0cfJY1TWp2vLi/HFLl9nCIPpRl18TTdySP9d9d7cSQTfLqo8TDoJOXmP3htL0KNdGDJ
BDvU9fVF62Dkxx9vvd9///77r16lOr+4uBhFjefnstdmU6Przf5Qov6PjfWZYNvzZqZM+bEjFPmj
h7pbZL33+uGH3Sef3Hp/8cX9P7q6SnW+W2RNfz07kfO6RF9jbJ98qb59TyTa5N+ViIwFGdrIOk9w
bu1ofPrpreXnn7fPiSY6P7zKzgaKLFN+Eji6evszqTHHJ4U1g79rsK5kyq+qr/Hee7fGP/3Uggx9
jRVlyrdORize10js3cyhRmJHKXHyVab8seY1ul7mNdaVKT95NmGpCYhlqSFTPuIayt3rTul7vayh
rIUaTW8+e891kr6GMmdeY5E1FJnyR3e+t1+jnxr2a8iUr1/2hqY42xtaxhk1YlOj8RzKvXus51CK
OKNGbGo0ss4f9Dha11P+98zrdOd9j6NrPWX//svHMuUpDjUaWecP5jhaz9doncsY5dx1vkbrXEbF
9YwaNVCDM+eSzqiBGpw5owZqcOaMGqjBmTNqkNbMGTUINTijBq2HGkQy5ck9kLO+BqEGZ9Qg1ODM
GTVQgzNn1EANzpxRg7RmzqhBeVuGTPnozl3P6b57J1OeMlBDpnx053/OBDnrPhNEpjwtSg1neUV3
znf+mLO8UKP9TuLc0NDO+c46dW5olguv69j0abUhU57zzHPVv/lm9/HHuw8+uH199tnu+++nn6vu
jPK81Hj4vxNqQ6Y85/kZLh9+eHslfvXV7ssvb3/46KPpGS7x8lBCgKOni5GYYj/4W2Svce537sqL
+/HHW+/335+eFxcve60aagwmOR+XGnJeozu3nqX+ww+7Tz659f7ii+nZtMFyXivra4wdv8zPgpQp
vx3n1o7Gp5/eWn7+efuc6NHLvMU1lJ7w6v4RSlZqNB0Jle7bG+xrvPferfFPP7UgQ18jADXS4+b7
p1fnD0bMEWxqXqPrZV5jLYspiRMcg9SQKc955hpKf6K1NZQY1GgdOHRd1TLlOc/cr9FPDfs1aBbp
/pV9ltGd7Q2l0tRoPNMR39lzKFSaGo1M+fjO/zzzetr9zKtMeVqaGo1M+fjOXedrtM5lHL3MqFED
NThzLumMGqjBmTNqoAZnzqiBGpw5owZpzZxRg1CDM2rQeqhBJFOe3AM562sQanBGDUINzpxRAzU4
c0YN1ODMGTVIa+aMGpS3Zchn51zSGTXCU0M+O+fCzqgRmxrOxeJc3hk1AlPDGZycnRta6Krr/99p
1/Cok8fT4wt6/sh535wbZ5SXoUZPkNJkakyLWXv4NYyihmwRzo08lKNQY2x8ScqDPYMoae3sjKWG
HDPOjey1MuDoosa0qLSx1FhwhCIzlXMj57UANdI7HfMv79zUkM/OuZEpf3RqJKYuroQa7oGc9TVW
1NdIH3okLs3koIbxNmfzGkXnRBO7BnOGLbmpYW6fszWUI1OjSd5z0fOZlEz5xn4NzmGdN0eNmnh3
J3sWOdsbSs3Y78/zEZzLO6NGbGo08tk5F3dGjfDUaOSzcy7rjBo1UIMz55LOqIEanDmjBmpw5owa
qMGZM2qQ1swZNQg1OKMGrYcaRDLlyT2Qs74GoQZn1CDU4MwZNVCDM2fUQA3OnFGDtGbOqEF5W4as
c84lnVEjPDVknXMu7IwasanhjCnO5Z1RIzA1nGfJ2bmhha66dWbKj33f2dmcG2eUl6HGOjPlm95Y
eTkdnOWhrIgaa8iUn0YNmWCcG9lrZcCxzkz5Hpo08kc5y3k9IjVWmyk/gRqyzjk3MuWPTo1jZcqP
zZ12D+Ssr7G6vkb60CNxaWaQGv1HoRhvczavcfw50cSuQclM+bHvm9vnbA3lyNRojp0p39ivwdl+
DcrHuzvZs8jZ3lBqxn5/no/gXN4ZNWJTo5F1zrm4M2qEp0Yj65xzWWfUqIEanDmXdEYN1ODMGTVQ
gzNn1EANzpxRg7RmzqhBqMEZNWg91CCSKU/ugZz1NQg1OKMGoQZnzqiBGpw5owZqcOaMGqQ1c0YN
ytsy8iWSv3t38+bN5fX1xcuXp7/8sru6Onn16vzm5tG7d6+VWaY8RaVGvkTyP/54+vLl2f7Ce/ja
X5C///5EmWXKUzxq5DuvaX9zbr32Dl/7zyizs7woEjXynQ25v2MPXn53r667tzLX6hyVGimhROlB
J0sVaU6mfP8e3sLnUL97d3PYyf/mm93HH+8++OD29dlnu++/v9/t//vva2V2RnkkagxmxBf4183M
lB8MdiucefHmzeXhNfbhh7cF/uqr3Zdf3v7w0UdJfX5lrtK5Tmp0/ZASFj9IgZS6mpwpP5Ya+fK1
rq8vWjv2P/546/3++/fff/XqXJllr0UCRwo1UhLk+6mRmPPaTM2Un0CNfFmedwuW914//LD75JNb
7y++uP9HV1cnyiznNQw1RnU6RnUEUhLnE4cqTZ7Exny54a037U8/vbX8/PP2+UVllimPGgGoUfi+
/d57t8Y//dRy+a22r7HyMutroMb0TPlpw5bycwRdrzXPa6y5zOY1jr/+2j+Lmb7AMbbjMKowKR9e
23rE3etO6fumlNkaSmxqpKyhpFzqXXU1M1N+8Ni14+596L8C17lfI0SZ7degony8k32W0ctsbyiV
pkbjmY74ZfYcCpWmRpMzkfyf50dPu58ffazMMuUpJDWanInkXWdVtM4LKPNGnFGjBmpw5lzSGTVQ
gzNn1EANzpxRAzU4c0YN0po5owahBmfUoPVQg0imPLkHctbXINTgjBqEGpw5owZqcOaMGqjBmTNq
kNbMGTUob8uQz642SjqjRnhqyGdXG4WdUSM2NZyLpTbKO6NGYGo4g1NtODd0jddnYuXIlD9umdVG
GWfUGAZHOjIe/ixTvmSZ1UYZZ9QYQMCoFKXEv96aKT+NGvLZ1UYje21t4MhBjcH/lSm/tmRTtYEa
Eyc4sqZDT6OGfHa10ciUr6CvUZIa8tnVhr5G+HmNyZnyUeY1tpnPrjZQY+6CSHqAc25qyGdXG9ZQ
1jid0cqLnt0W0zLlm3Xv19h4PrvaQI1KWHYnuyHVhr2h1Iz9/jx5oTbKO6NGbGo08tnVRnFn1AhP
jUY+u9oo64waNVCDM+eSzqiBGpw5owZqcOaMGqjBmTNqkNbMGTUINTijBq2HGkQy5ck9kLO+BqEG
Z9Qg1ODMGTVQgzNn1EANzpxRg7RmzqhBeVuGrPMytRHR+e3NzdXl5YuLi29PT7/e7Z6dnDw/P//5
0aO/XsuU3zA1ZJ2XqY2Izr89ffrd2VnriTx7iPz6RKb8JqnhjKkytRHRed+hGDwAcP8Z1NgWNZxn
WaY2IjrvexmJR5R39Tg2So30HbIL/q4Jbw4WUtb5EWsjovPbm5uugUnrUOXPa2eUl51qbsZkyk8M
Z5R1frzaiOh8dXk5pprbxylbp0Z6F6Dpzn9P7LDMocaoPBRZ52VqI6Lzi4uLUdR4fi57La0v0AxF
q937ObHbMpkaifGx/0rWeZnaiOh8t8ia/np2Iud1zD9+whU+Jx16QWrIOi9TGxGdH3LhbKCaZcon
TBPcG26kXOGJ5w4Uo4as8zK1EdFZX2Nhaiw4czk4e7JI/6WRdX7U2ojobF5j+Y5Gz7RFylzGnEz5
Bakh67xMbUR0toYyHRld+zVa0+G71lD6V176xy+jNnGMpYas8zK1EdHZfo0VzZ6urUj2hpapDXtD
UaNJmR+NAjLPoZSpDc+hoEZV3R9Z52VqI6LzvsfRtZ6yf//lY5nyGx40yTovUxsRnbvO12idy0AN
Uy2cOWdxRg3U4MwZNVCDM2fUQA3OnFGDtGbOqEGowRk1aD3UIJIpT+6BnPU1CDU4owahBmfOqIEa
nDmjBmpw5owapDVzRg3K2zIiJr9HzJTPkc8esTZQIzw1Iia/R8yUz5TPHrE2UCM2NSKeuBXxLK98
52JFrA3UCEyNiKd7Rjw3NN8ZnBFro9lUOnTWfPk5mfLNUIhsNSeJR8yUz3fed8Ta2G5fIwcyHv6c
O2g+YmpJxEz5fNkiEWtjo9QYvMn/m4oyGDrf75+bGhET0iJmyufLMYtYG6jReQ23ZrI9/NPjUiNi
GmvETPl8makRa2OL1JgcxZo7U37CvEbE5PeImfL58tkj1sbmqNEaxTotX35ZauhrrDlTvpq+xiK1
gRrDl+goauTryJjXmDySX3M+e8Ta2BY1ZgJicF5jTqa8NZQ1Z8pXsIayYG1siBqD+fKDI4v+NZRF
MuXt11hnpnwF+zUWrI2NrqFk6rYc5TfaG3ooe0PL1AZqTOmtrIpTnkP5z93bcyhFagM1wvduIia/
R8yUz5TPHrE2UKOGMVHE5PeImfI58tkj1gZqbHomhTNn1EANzpxRg7RmzqhBWjNn1CDU4IwahBqc
OaNGaGoQyZQnouC3MRVBRKhBRKhBRKhBRKhBRKhBRIQaRDSXGkRE6fo/Q3rZDv4e74UAAAAASUVO
RK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-04-20 19:56:21 +0100" MODIFIED_BY="Heather Maxwell" NO="3" REF_ID="CMP-009.01" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 9 Multivitamin plus iron and folic acid versus iron and folic acid, outcome: 9.1 Total fetal loss.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAATNElEQVR42u2dDXRT53mAP1uShcE2XNfO6JzQneAFAicdPiEwWrLR
juyQUZSeBNYmXhvYOjhp2oZlJxAOkJ5A2FACHLymS7GDMeSQNDMkVJCYDnKatkoDiolgKXb4bUJx
Q2K4N9gGZAnwJMs2sizZ+rlX0tV9nhMsRbpcoU+P3u993/vd6xxJAKhPLkMAiAWIBcbGHOuGiv+P
FLzpviMUSZEGbCP1Pd97J/AYeRxiRfVK6vkhhT4QTu/zyo07EmYxFSaAoijBm54QBRDfVNg7A/YP
WIEb/5/Af4P9PUIWYkV1oze1CjOs3wahz0fbEBArPFqF5liDbBeMT1KUPAzIscKKwpgdVMLvAGIl
nMUzljDkVKgMmPLCc6yefFwKbikp/aJTX7Lec4cpEbFCa71IFaEU9lD4w1LvT0mQvCNWAvRrISgh
2f3A4EfAIseKx6zQ+366byJsJmVL2Ppt11cV00iUiQ1TfoQHPfnBP4qnh3zDj9O52zwvVNzZct5k
/dSONcmKle/HI/l/GH6YHlty7vjRtWf++J2GtZuuYE2yYvXeNzTOEnutWL9iYeeYlxpPf3FcwZ33
rVtH0BqSHGmIqtDYmXdpyz+cslVO8d/76tq/Kgo88smYDRtu2f/n51EngapQUmgUCCF7R4vn3BW2
4qrA/+15+/aWwK31sx+Klyoq5gvnhGL0iTNihUcvoxk1pvjITY/kuCuqQnOGt+/uvvUNuxZ8YLF7
kq1wCgbFk2OF51vGwrcx94+7N3/W9ez3Qh8t2vxuTXc0z7kafOBA/bXqR4/UoBARK8Z4dd+wNy1C
7vqzgs/7PT7CM+KYtfALl69YQrYtFr5vzppK3EKsodi0c8eXN1cEsqcir6f/U2XnpeaSvF+HW+Tc
4T5zLA+TECt6Y2GqRdSNrTwWnPx91uv9n24rivYXS9bNF76DJPOIFWECbKp3lM9bGHjDJ4IxSS4J
E6usZbAdVNeftM3DrT44rzDgkBBNy59rfzXglSi9I/hgYU7YVs2D7KDAPO9Xpydub+reF1AVBqa8
zTdXH8vd9v6o3FVBoWYcN3V/5fJ9/Te8tT3aLlzjcy42byzY+1/ThHh/7Iet6/DK8GLJbZ+OnDT3
Zetb25zXmz4LHKrpPJd77aazz+Ra/7C+/6ZRvZLHF3RYaiwe06v+dL9x4qgldzVyzMfIOZZzijxa
OMtH+4YPvxiIO9OKek7fvuIVOdYRrbHup+D65e7bvjrSOV34nphj7O6pYcUqbZktbMEOVNfw4IKF
kd+qTmhX5vaeOnLGOzdmR/cOb8Wcv2MqNNRU6Fq9Tmz8y++vaAj2zc1FwYhTeKJjsL9VFm0uvNAc
3M/FyhtjVbPn9PbOtt3i3D8atDdvvIglux2rn9rY7y0WBJvp8uCDEbWP1Rexeg8jhrDp5QJbxRTE
yn6xnMutew73/6TNv7o7qhihEStaH2ukp6PbzK4RlyN4fHj9K/83nakwm6dC1+Sug/Za90JT2OxU
uLm1u4rrO74cmRZrlCc6rbkFRYE6cu3+C4UFnf2ftG89canULv/+R8uNtTzQOBHLO3vnQ49Pitga
H+EZkXe80Gz53ZSEIlagjvSdL7F4h/1yYv43ftcS6TUCRxRtVYiVZWIFjgJWj62IesCleG5ta0le
myWp3G3O0cByCF/+3pmRN/Btny98W+YWI1Z2iCU7HhpXXjlf89epWhbWzYpo+NNNtooFFgOIlf05
1mrPCfmjXdq/zv79W4JiXeqKvlHtaXlR0zsmIdsRS79inbvt5tHHhem0yaTK7qL2sYJc+GlQlrNL
Bx0x056DpkC+/y17LWLpswY0LyuYusak3g6jVoVBxq0L9u8feLlr6H29Ofzs2rt+XoNYekvWf3bd
ZL+0Yd4uFb0aZHVDN11XPN2v9orZN/S+7LsOnrZOs8tH/31blk6KWZi8l7bckzehMqFutzzG01o6
vC3yk9FXkAYZ3vn8yuOFL/7ocuy5uVy/Y+fKbQpiZX4J6B0tFo8ttCVW07u+YpE/uGNUzm8iWjn4
ClI/o+58+3zJsM/jq/lck0Se8LmnIFYGW1XftHpYEqc1yDcVBDtRYefnaE9dbWG2HVHMIrGqv/2A
LakzsQasq0rhd6Jph7tyIWJlXAXoXpAn5JNJfucjratKpVzF4jGRNedjZEFVKN989dEJz24V9mSr
90jrqkJzrHZt34e/PFy/4KPnHm7IijpR7xErcGkO77UrqnzNB1tXFUNVqA6Bo4nyDv0f9dF1xHIW
fnZoco0wWdT5jheaPZHPzwlya3tKPpDddvFAw6d//WSNvs/10XPEWtxZlaPqN3u4d7j1WKHZ+vEX
0xexeqZ3h1tUCVkUI1ZK8W2pfyMvkO2qTPe6KuupiF4N3cdSnSUrhjm/jlipmwG3751ljLUnTveG
MWumI1YKKF2z0B+vbKOzTyKf2dJaUnAxfE5sKh8tvL/V3zmKuhKr5E+zTz7+w+wMTp/cYhnxyYGZ
prMR5ve3NnRMsunsHEXdVIUuu118bc73V8xI279A0z6Wb2dXx2XTltb/HPeLgU9uO3HyuwcOCPkB
Ha2z0UnEesux+rX5af43aFoV9p2N7emMnnEtP/PkRL105nUhVvX2vDcOpz3L0LQq7D23sUQZ5NxG
+bBj1TCdXDww06+P5dq0SYgFr+/LS3/22qzlzlsnBG+PD3YB+eKvbyzqEML7mDPzr8KV0TmW66ez
9pq/slWYMuLomaad94Ke3OqZsR2Db+gfiutf+/nah3+S4flWxkYs2SlE+YonX9+YMR1CTfujBYuC
QegLF4fe1vLsvuMTy/0Zgi+DxcrMHEt2uB3lawx1LY0Rk6bVHR/3cFXsC5td2x3l8zK2T5yZYs32
vlHWKoyFdPnq+dK8i/GIIjfVZ+wRxUwT65zDPXW+BkcBM70qTKZm/vZTtkkZN2CZlbw7rcuKJ9vs
IiOXug1xXmHa2H3k8uaXn96FWNGk+ptd4p/Nte/tUs8q+fmugdcVysyqMBlqGk5vv9ckvC8+lUGV
YoZMhb6u2cKm9lFA34z3/3di/qjcFnXmiVSux0qE4u+4KybMy5Q5MQMilrzULh/55t9vaFBVqqWu
C97JzVvsFs9N69U56SZjI1YPVw7WX2+aYRfOjLgoRLojllw+7ZUP1e8rfHKLuWDlEtG9ViANZ3Ol
E9fyk49XpP+IYprF8nqSPBcwSrwae/GisLRdKR0pD3lp0ezDOeWewj3GnQp9L87dJa7/flmDBhln
rq9DiAu+4qIrfqcuLjXY7/KsNX18wC42jX2kNo3VdZoilu9njp0r79PsaE33WgFze36pfE29iJWp
faxoQ7zF7Zg7L23rmtMRsVw14vr47/33/Vu1e1ubTEIUWDx/CgSrkWZ1jqllah8r2ie7u/HjtntN
oq7eZASxfC996eyVRmE6uFXLMJ3r3BK4al7OT8rOPDPS267OyGZ6VTgQe+D6YF86f9eH76b+UuAp
Xt0g37Z9wkcvaP4yBS8F1gpc/qW3OWfG9UsqHadtFrqk6g+Vm572j3yKl3ClLseSd7grp6fqKOAI
z7/FuVYg63KsMOruXzlx0pTsE6vO7bBNTOEaj+JLca8VyHJcBx07U7iuORViOcV04Tw5azQfbpoJ
fBDVXam5wpvWYsnjHjp85slFfKiZQknlak160ilN3l1CNBWIBYeyw6uyrHgX56uuLjvl9UcvjZN5
7SKW7HYcfj2bfnFMpq9uiO/TWb7XpunVAzUTa/Gqh17ryKpfSKTvqnAAgZVK+7TbvRYNUtfk103i
VOu/mLLr2vg667wP+cmbTjfahdP6A20686qL5ZrcufejrbXictb9xgX9dd6Hwv8R/Udb46f/9AMN
1jWrOhUGrltc/N05FQb5lXzZkm45nmjt/o2OmSpWndsx6wU+J33iHTdmn0vNZF41sXy3zVL5iqCQ
2mS+dsebFvUOuanRx5K9j/iE5dALedntVVl2i2VZtM8ifOZvVKvT4Eo+YlW7HbapNgOkVVnVx4oa
JOodr6xU45eiJ1cV+g7ViMXW5+ftshtgzLOvKoxUKO45cWR8raj7n3eTPNcn8YglH919MO+QLAyD
ISJWD6UtM63JHVFMPMc6vOqWNa8ayCtxu4Hea2veb358qkMIV8IfcCIRSz78Cy99BUPwiH1lRWL5
c/w5lty58d2/vbeGQTcCjbn/2rik1aS5WK4vP11jP/nOoj14ZRBMuxtPrxNy28LXTJqJ5ay4+ugd
47PxKGBslLUb8337P+6lilt5cOFuLcSS7WLqsc3e+2uN++XNstUNcbnlj1uX/mKbcFZujDWqxJK8
y031DluVMDpZth4rETatPbJyrjWmLkQMEauk7oM6+T3SDQNHrF72fP6et/ru2sD8FU/EUoSQ+u71
3ZVkL+fXELFCcT2RN3eoc31CxAp0rHq6Vkr/RwH6Idc3rX7wjfjFCpUJsSCiW0fvFk53xfT4xLox
EyIWRMXXdU+eLYpbkY8VSpIUkEvxE/wBWb8eKwEseb/+8aKmyEcUI+dYIZGKiNWLkVY3xMdjjlkD
VuSFtBsCrdAbffbee558Bi7Ire2MQWQOth7wrPrYPvRUyNQXiWaGIPqcuO+D4qhTYU8fq3tGJHmP
kGPRx4oDXf0We9APuQwBIBYgVhbmWAwBYlEVIpZuuJ0hQCwiFmIRsRDL2NAfRSxALEAsg0MfC7Go
ChGLqhCxiFiAWEQsxNIJ9LEQCxALEMvg0MdCLKpCxKIqRCwiFiAWEQuxdAJ9LMQCxALEMjj0sRCL
qhCxqAoRi4gFiEXEQiydQB8LsQCxALEMDn0sxKIqRCyqQsQiYgFiEbEQSyfQx0IsQCxALINDHwux
qAoRi6oQsYhYgFhELMTSCfSxEAsQCxDL4NDHQiyqQsSiKkQsIhYgFhELsXQCfSzEAsQCxDI49LEQ
i6oQsagKEYuIBYhFxEIsnUAfC7EAsQCxDA59LMSiKkQsqkLEImIBYhGxEEsn0MdCLEAsQCyDQx8L
sagKEYuqELGIWJCsWAojQ8TSQCy8igB9rKTFUiQGBjQQC68gWcyDPan0/sA0P2XMhWqJJTEthlaF
RYxB0lUhUBUiVqoiFkOAWESsDBWLxGog5O5ELEAsQCyDw3osxKIqRCyqQsQiYgFiEbEQSyfQx0Is
QCxALINDHwuxqAoRi6oQsYhYgFhELMTSCfSxEAsQCxDL4NDHQiyqQsSiKkQsIhYgFhELsXQCfSzE
AsQCxDI49LEQi6oQsagKEYuIBYhFxEIsnUAfC7EAsQCxDA59LMSiKkQsqkLEImIBYhGxEEsn0MdC
LEAsQCyDQx8LsagKEYuqELGIWIBYRCzE0gn0sRALEAsQy+DQx0IsqkLEoipELCIWIBYRC7F0An0s
xALEAsQyOPSxEIuqELGoChGLiAWIRcRCLJ1AHwuxIDPE8jAOoIFYnucYhxigjxWnWMc85YwDVaHK
mPI9ZQ3bh0XfwJPPIAW5tZ0xiCNiefzxqoFxIGKpLZZT3CtOMg4xQB8rLrFmNjYIcqxYoI8VX/I+
s9QfswDUJUcSYn/rg9E3UCQGCRKJWCIQs2Bo6GPFG7EGhYjVS1sRYxBfxAKqQsRKH/SxEhZL6bvj
h7EhYiWBOZJXQpBYDYQ+VoIR60aaTsIOKkYsqV/swi1Qayrs51ggaim9EySW+SljLkxWLCnklmmx
ryqkj5VoVQhUhZqKRashYsRiCJISK5C4KwozIBErKThWCORYgFiAWBAbrMdCLKpCxKIqRCwiFiAW
EQuxdALHoBELEAsQy+DQx0IsqkLEoipELCIWIBYRC7F0An0sxALEAsQyOPSxEIuqELGoChGLiAWI
RcRCLJ1AHwuxALEAsQwOfSzEoipELKpCxCJiAWIRsRBLJ9DHQixALEAsg0MfC7GoChGLqhCxiFiA
WEQsxNIJ9LEQCxALEMvg0MdCLKpCxKIqRCwiFiAWEQuxdAJ9LMQCxALEMjj0sRCLqhCxqAoRi4gF
iEXEQiydQB8LsQCxALEMDn0sxKIqRCyqQsQiYgFiEbEQSyfQx0IsQCxALINDHwuxqArTjpkhiLkq
JHu/gdL9Uwq5g1gJR6wixuAG3SopUsgdpsJEIxZDQI6lBcyE5FiQmiRLCr2DWKBOjhVMrKRIGRZT
YRzQxwp3Swm/g1gJVYUMAck7VWG6Q1aONFSSJjGAQdroYyUdsRRF0bacEDrc/e2pegspeFPavwNz
tChFpAqHPlbSEQungOQdMpJoybsipSOXAB2XiDHkWJpOiRonb6nIDVOef6r+gtq/g9wMGTowRI6F
V5AkkdsNgewKt0CD5B1A/YilVQraFwYVLSqDvt0rmhUeacgU+l5LzTFLwYRkTu0Q9Q6TpOXute6U
KKn9Mqpfo6fiyEpaGqTaf+O1fIW0xCtVXzUVbyA9K0i1DsWafvapzEqllE5f+heLg9zpHjPNhz83
TWMEWT5mWXkQmmiY/hFKT/LOJ5veMUvBNy+FOZak9CYKkhaJ6I3dZ2WAUXPMUnFkhc47kGMBYgFi
ASAWIBYgFgBiAWIBYgEgFiAWIBYAYgFiAWIBIBZkMP8Pzl6iT7GhjkwAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-04-20 19:56:34 +0100" MODIFIED_BY="Heather Maxwell" NO="4" REF_ID="CMP-009.02" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 9 Multivitamin plus iron and folic acid versus iron and folic acid, outcome: 9.2 Early or late miscarriage.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-04-20 19:56:49 +0100" MODIFIED_BY="Heather Maxwell" NO="5" REF_ID="CMP-009.03" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 9 Multivitamin plus iron and folic acid versus iron and folic acid, outcome: 9.3 Stillbirth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-12-07 12:06:56 +0000" MODIFIED_BY="Lynn Hampson">
<APPENDIX ID="APP-01" MODIFIED="2010-12-07 12:06:56 +0000" MODIFIED_BY="Lynn Hampson" NO="1">
<TITLE MODIFIED="2010-12-07 12:06:21 +0000" MODIFIED_BY="Lynn Hampson">Additional searching carried out for the initial version of the review</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-07 12:06:56 +0000" MODIFIED_BY="Lynn Hampson">
<P>For the initial version of the review, authors carried out a separate search of CENTRAL <I>(The Cochrane Library,</I> 2003, Issue 2) for the following terms: miscarriage*, spontaneous abortion, recurrent abortion, spontaneous pregnancy loss, recurrent pregnancy loss, fetal death, vitamin*, folate, folic acid; and also MEDLINE (1966 to May 2003), Current Contents (1998 to May 2003) and EMBASE (1980 to May 2003) using the search strategy given below:</P>
<OL>
<LI>miscarriage*</LI>
<LI>spontaneous abortion</LI>
<LI>recurrent abortion</LI>
<LI>habitual abortion</LI>
<LI>spontaneous pregnancy loss</LI>
<LI>recurrent pregnancy loss</LI>
<LI>early pregnancy loss</LI>
<LI>early pregnancy bleeding</LI>
<LI>fetal death</LI>
<LI>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9</LI>
<LI>vitamin*</LI>
<LI>retinol*</LI>
<LI>carotenoid*</LI>
<LI>thiamin*</LI>
<LI>riboflavin</LI>
<LI>niacin or nicotinamide or nicotinic acid</LI>
<LI>pantothenic acid or pantothenate</LI>
<LI>pyridox*</LI>
<LI>cyanocobalamin or cobalamin</LI>
<LI>ascorb*</LI>
<LI>calciferol</LI>
<LI>tocopherol* or alpha-tocopherol</LI>
<LI>folate*</LI>
<LI>folic acid</LI>
<LI>phylloquinone</LI>
<LI>menaquinone</LI>
<LI>#13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #11 or #12</LI>
<LI>#10 and #27</LI>
<LI>random*</LI>
<LI>controlled-clinical-trial</LI>
<LI>#29 or #30</LI>
<LI>#28 and #31</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>